10-K

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001193125-20-056695.txt : 20200228 0001193125-20-056695.hdr.sgml : 20200228 20200228165018 ACCESSION NUMBER: 0001193125-20-056695 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 98 CONFORMED PERIOD OF REPORT: 20191130 FILED AS OF DATE: 20200228 DATE AS OF CHANGE: 20200228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CRYO CELL INTERNATIONAL INC CENTRAL INDEX KEY: 0000862692 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 223023093 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23386 FILM NUMBER: 20671434 BUSINESS ADDRESS: STREET 1: 700 BROOKER CREEK BLVD STREET 2: SUITE 1800 CITY: OLDSMAR STATE: FL ZIP: 34677 BUSINESS PHONE: 813-749-2104 MAIL ADDRESS: STREET 1: 700 BROOKER CREEK BLVD STREET 2: SUITE 1800 CITY: OLDSMAR STATE: FL ZIP: 34677 10-K 1 d807043d10k.htm 10-K 10-K

U.S.

Securities and Exchange Commission

Washington, D.C. 20549

FORM 10-K

☒	ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the fiscal year ended November 30, 2019

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from to

Commission File Number 000-23386

CRYO-CELL INTERNATIONAL, INC.

(Exact Name of registrant as specified in its charter)


DELAWARE		22-3023093
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

700 Brooker Creek Blvd, Suite 1800, Oldsmar, FL 34677

(Address of principal executive offices) (Zip Code)

(813) 749-2100

Registrant’s telephone number:

Securities registered pursuant to Section 12 (b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.01 per value

CCEL

OTCQB

Securities registered pursuant to Section 12 (g) of the Act:

Common Stock, par value $0.01 per share

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes ☐ No ☒

The aggregate market value of the Registrant’s Common Stock held by non-affiliates of the Registrant is computed by reference to the price at which the common stock was last sold as of the last business day of the Registrant’s most recently completed second fiscal quarter (May 31, 2019) was $30,374,581.

As of February 15, 2020, there were 7,545,613 shares of Common Stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

None.

TABLE OF CONTENTS


		Page
	PART I
	FORWARD-LOOKING STATEMENTS	3
ITEM 1.	BUSINESS	3
ITEM 1A.	RISK FACTORS	12
ITEM 1B.	UNRESOLVED STAFF COMMENTS	12
ITEM 2.	PROPERTIES	12
ITEM 3.	LEGAL PROCEEDINGS	13
ITEM 4.	MINE SAFETY DISCLOSURES	13

	PART II
ITEM 5.	MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	13
ITEM 6.	SELECTED FINANCIAL DATA	15
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	15
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	26
ITEM 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	26
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	67
ITEM 9A.	CONTROLS AND PROCEDURES	67
ITEM 9B.	OTHER INFORMATION	68

	PART III
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	68
ITEM 11.	EXECUTIVE COMPENSATION	71
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	79
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	82
ITEM 14.	PRINCIPAL ACCOUNTANT FEES AND SERVICES	82

	PART IV
ITEM 15.	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	84
ITEM 16.	FORM 10-K SUMMARY	85
	SIGNATURES	86

PART I

Forward-Looking Statements

This Form 10-K, press releases and certain information provided periodically in writing or orally by the Company’s officers or its agents may contain statements which constitute “forward-looking statements”. The terms “Cryo-Cell International, Inc.,” “Cryo-Cell,” “Company,” “we,” “our” and “us” refer to Cryo-Cell International, Inc. The words “expect,” “believe,” “goal,” “plan,” “intend,” “estimate” and similar expressions and variations thereof, if used, are intended to specifically identify forward-looking statements. Those statements appear in a number of places in this Form 10-K and in other places, and include statements regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things, our future performance and operating results, our future operating plans, our liquidity and capital resources; and our legal proceedings. Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

ITEM 1.

BUSINESS.

Introduction

Cryo-Cell International, Inc. (the “Company” or “Cryo-Cell”) is a Delaware corporation that was incorporated in 1989. The Company is organized in three reportable segments, cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use, the manufacture of PrepaCyte^® CB Processing System (“PrepaCyte CB”) units, the processing technology used to process umbilical cord blood stem cells and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company, in combination with its global affiliates, currently stores nearly 500,000 cord blood and cord tissue specimens worldwide for the exclusive benefit of newborn babies and possibly other members of their families. Founded in 1989, the Company was the world’s first private cord blood bank to separate and store stem cells in 1992. All aspects of its U.S.-based business operations, including the processing and storage of specimens, are handled from its headquarters facility in Oldsmar, Florida. The specimens are stored in commercially available cryogenic storage units at this technologically and operationally advanced facility.

In recent years, utilizing its infrastructure, experience and resources derived from its umbilical cord blood stem cell business, the Company has expanded its research and development activities to develop technologies related to stem cells harvested from sources beyond umbilical cord blood stem cells. During fiscal 2011, the Company introduced the advanced new cord tissue service, which stores a section of the umbilical cord tissue. The Company offers the cord tissue service in combination with the umbilical cord blood service. This service is growing; however, the umbilical cord blood service continues to be the Company’s main focus.

Consistent with its fiduciary duties, the board of directors and management has reviewed and will continue to review strategic options and opportunities for the Company, in order to maximize shareholder value. These options may include, but are not limited to, strategic mergers or acquisitions, investments in other public and/or private companies, repurchases of RSA interests, a deregistration of the Company’s common stock under the Securities Exchange Act of 1934 or a going-private transaction. These options may or may not be related to the Company’s current business. In order to undertake any of the aforementioned activities, the Company may take on substantial debt or equity capital which could increase the risk of investment in the Company.

Cord Blood Stem Cell Processing and Storage Business

Background of Business

Nearly fifty years ago researchers discovered that cells could be cryopreserved at extremely low temperatures and all cellular activity would cease until the specimens were thawed. Historically, cryopreservation was required for organ transplants, blood banking and medical research. Today, cryopreservation of umbilical cord blood stem cells gives individuals the opportunity to potentially take advantage of evolving cellular therapies and other medical technologies.

Hematopoietic stem cells are the building blocks of our blood and immune systems. They form the white blood cells that fight infection, red blood cells that carry oxygen throughout the body and platelets that promote healing. Stem cells are found in bone marrow where they continue to generate cells throughout our lives. Stem cells can be stored in a cryogenic environment, and upon thawing, infused into a patient. They can be returned to the individual from whom they were taken (autologous) or donated to someone else (allogeneic). An individual’s own bone marrow may be used for a transplant if the cancer has not entered the marrow system (metastasized). Otherwise, a marrow donor needs to be identified to provide the needed bone marrow. The availability of a marrow donor or matched stem cell specimen allows physicians to administer larger doses of chemotherapy or radiation in an effort to eradicate the disease. Stem cell therapies and transplants are used for both cancerous and non-cancerous diseases.

Stem cells are found in umbilical cord blood (“cord blood stem cells”) and can be collected and stored after a baby is born. Over 35,000 cord blood stem cell transplants have been performed to date. The Company believes that parents will want to save and store these cells for potential future use by their family, either for the donor or for another family member. Moreover, researchers believe they may be utilized in the future for treating diseases that currently have no cure.

The Company believes that the market for cord blood stem cell preservation is enhanced by global discussion on stem cell research developments and the current focus on reducing prohibitive health care costs. With the increasing costs of bone marrow matches and transplants, a newborn’s umbilical cord blood cells can be stored as a precautionary measure. Medical technology is constantly evolving which may provide new uses for cryopreserved cord blood stem cells.

Our Cord Blood Stem Cell Storage Services

The Company enters into storage agreements with its clients under which the Company charges a fee for the processing and testing and first year of storage of the umbilical cord blood. Thereafter, the client is charged an annual fee to store the specimen, unless the client has entered into a 18-year pre-paid storage plan or a lifetime pre-paid storage plan.

The Company’s corporate headquarters are located in a nearly 18,000 square-foot state-of-the-art current Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Food and Drug Administration (“FDA”) 21 CFR Part 1271, effective in May 2005, requires human cellular and tissue-based products to be manufactured in compliance with good tissue practices (cGTPs). The Company’s laboratory processing facility contains a Class 10,000 clean room and Class 100 environments for the processing of cord blood stem cells and other cellular tissues. In addition, the cellular products cryogenic storage area has been designed as a “bunker,” with enhanced provisions for security, building fortification for environmental element protection and back-up systems for operational redundancies. The Company believes that it was the first private bank to process cord blood in a technologically and operationally advanced cGMP/cGTP-compliant facility. The Company’s facility, which also currently houses the Company’s client services, marketing and administrative operations, is designed to accommodate a broad range of events such as client tours and open houses, as well as educational workshops for clinicians and expectant parents.

Competitive Advantages

The Company believes that it provides several key advantages over its competitors, including:

•

The world’s first private cord blood bank, that in combination with its global affiliates, currently stores nearly 500,000 cord blood and cord tissue specimens worldwide,

•

our status as a cGMP- and cGTP-compliant private cord blood bank with International Organization for Standardization (“ISO”) certification, AABB accreditation and FACT (the Foundation for the Accreditation for Cellular Therapy) accreditation,

•

a state-of-the-art laboratory processing facility,

•

utilization of a processing method using superior technology that yields the maximum recovery of healthy stem cells and provides superior red blood depletion over all other methods,

•

a safe, secure and monitored storage environment,

•

since inception, 100% viability rate of the Company’s specimens upon thaw for therapeutic use,

•

a state-of the-art, insulated collection kit that protects cord blood specimens thirty times longer under extreme conditions than competitor’s kits,

•

7 day per week processing capability, and

•

a payment warranty under which the Company agrees to pay $50,000 (effective February 1, 2012 this payment was increased to $75,000 for new clients, effective June 1, 2017 this payment was increased to $100,000 for new clients that choose the premium cord blood processing method, Prepacyte CB) to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions.

Cord Tissue

In August 2011, the Company introduced its advanced new cord tissue service, which stores a section of the umbilical cord tissue. Approximately six inches of the cord tissue is procured and transported to the Company’s laboratory for processing, testing and cryopreservation for future potential use. Umbilical cord tissue is a rich source of mesenchymal stem cells (MSCs). MSCs have many unique functions including the ability to inhibit inflammation following tissue damage, to secrete growth factors that aid in tissue repair, and to differentiate into many cell types including neural cells, bone cells, fat cells and cartilage. MSCs are increasingly being researched in regenerative medicine for a wide range of conditions including heart and kidney disease, ALS, wound healing and auto-immune diseases. MSCs from several different tissues are being tested in clinical trials for efficacy. Specifically, cells derived from cord tissue are currently being used in many clinical trials. Disorders being treated include cardiomyopathy, ulcerative colitis, diabetes, anemia, autism and cirrhosis of the liver.

Public Banking

In June 2018, the Company acquired substantially all of the assets (the “Cord Purchase”) of Cord:Use Cord Blood Bank, Inc., a Florida corporation (“Cord:Use”), in accordance with the definitive Asset Purchase Agreement between Cryo-Cell and Cord:Use (the “Purchase Agreement”), including without limitation Cord:Use’s inventory of public cord blood units existing as of the closing date (the “Public Cord Blood Inventory”). The Public Cord Blood Inventory creates a large, ethnically diverse, high quality inventory of available cord blood stem cell units for those in need of life saving therapy. The Company collects cord blood units at hospitals in Florida, Arizona, California and Michigan. The Company’s public inventory is stored in North Carolina, and the cord blood units are sold through the National Marrow Donor Program (“NMDP”) located in Minnesota, who ultimately distributes the cord blood units to transplant centers located in the United States, and around the world.

Marketing

Marketing Approach

It is the Company’s mission to inform expectant parents and their prenatal care providers of the potential medical benefits from preserving stem cells and to provide them the means and processes for collection and storage of these cells. Today, stem cell transplants are known and accepted treatments for approximately 80 diseases, a number of them life-threatening. With continued research in this area of medical technology, other therapeutic uses for cord blood stem cells are being explored. A vast majority of expectant parents are simply unaware that umbilical cord blood contains a rich supply of non-controversial stem cells and that they can be collected, processed and stored for the potential future use of the newborn and possibly related family members. A baby’s stem cells are a perfect match for the baby throughout its life and have a 1-in-4 chance of being a perfect match and a 3-in-4 chance of being an acceptable match for a sibling. There is no assurance, however, that a perfect match means the cells could be used to treat certain diseases of the newborn or a relative. Today, it is still common for the cord blood (the blood remaining in the umbilical cord and placenta) to be discarded at the time of birth as medical waste.

Despite the potential benefits of umbilical cord blood stem cell preservation, the number of parents of newborns participating in stem cell preservation is still relatively small compared to the number of births (four million per annum) in the United States. Some reasons for this low level of market penetration are the misperception of the high cost of stem cell storage and a general lack of awareness of the benefits of stem cell preservation programs. However, evolving medical technology could significantly increase the utilization of the umbilical cord blood for transplantation and/or other types of treatments. The Company believes it offers the highest quality, highest value service targeted to a broad base of the market. We intend to maximize our growth potential through our superior quality, value-driven competitive leadership position, product differentiation, an embedded client base, increased public awareness and accelerated market penetration.

Umbilical Cord Blood and Cord Tissue Services

The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives and other related healthcare professionals. The Company believes that its revenues have been facilitated by a variety of referral sources, resulting from high levels of customer satisfaction. New expectant parent referrals during fiscal 2019 were provided by physicians, midwives and childbirth educators, and by client-to-client referrals and repeat clients storing the stem cells of their additional children.

The Company has a national sales force to increase its marketing activities with its clinical referral sources, including physicians, midwives and hospitals. Promotional activities also include advertisements in clinical journals and telemarketing activities. In addition, the Company exhibits at conferences, trade shows and other meetings attended by medical professionals. Significant portions of client referrals to the Company are from medical caregiver professionals.

To increase awareness among expectant parent audiences, the Company continues to promote its service through internet marketing. Expectant parents have also received information via emails and internet marketing campaigns.

The Company’s client support team advisors are available by telephone to enroll clients and educate both expectant parents and the medical community on the life-saving potential of cord blood stem cell preservation.

The Company continues to use its website, www.cryo-cell.com, to market its services and to provide resource information to expectant parents. The site, which is frequently updated and improved, is divided into areas of interest, including sections for expectant parents, medical caregivers and investors. Expectant parents may request and receive information about the umbilical cord blood and cord tissue service and enroll online. Viewers may read about successful transplants using Cryo-Cell stored cord blood stem cells and access other topical information. Information on our website is not incorporated into this Annual Report on Form 10-K and should not be considered part of this Annual Report on Form 10-K.

Competition

Growth in the number of families banking their newborn’s cord blood stem cells has been accompanied by an increasing landscape of competitors. The Company competes against approximately 25 other national private cord blood banks.

Some of these competitors may have access to greater financial resources. Nevertheless, the Company believes it is currently well positioned to compete in the industry. Importantly, the Company believes that some competitors charge more for comparable (or even inferior) quality service. In addition, the Company possesses an industry-recognized AABB accreditation, and believes that it was the first private cord blood bank to process in a cGMP- and cGTP-compliant facility exceeding current FDA requirements. In November 2005, the Company was granted ISO 9001:2008 certification from BSI America’s, Inc., a leading quality management systems registrar. ISO (International Organization for Standardization) standards are internationally recognized as an effective framework for a quality management system. During 2014, the Company was granted FACT (the Foundation for the Accreditation for Cellular Therapy) accreditation. These achievements position Cryo-Cell as an industry quality leader as a cGMP- and cGTP-compliant private cord blood bank with ISO certification, AABB and FACT accreditations.

The Company believes that its longevity and experience; value-based pricing strategy; superior customer service; premier technical and operational expertise; state-of-the-art facilities; innovative marketing programs and its expansive client base will continue to provide a competitive advantage.

Government Regulation

The Company is required to register with the FDA under the Public Health Service Act because of its ongoing cellular storage business and is subject to FDA inspection. This requirement applies to all establishments engaged in the recovery, processing, storage, labeling, packaging, or distribution of any Human Cells, Tissues, and Cellular and Tissue-Based Products (“HCT/Ps”) or the screening or testing of a cell or tissue donor. In addition, with the purchase of the manufacturing rights to the PrepaCyte CB Processing System on June 30, 2015, Cryo-Cell is required to register this product as a Medical Device under the Federal Food, Drug, and Cosmetic Act which is also subject to FDA inspection. At November 30, 2019 and November 30, 2018, the Company was in compliance with these requirements.

The division of FDA which regulates HCT/Ps is the Center for Biologics Evaluation and Research (“CBER”). The section of FDA Code of Federal Regulations (“CFR”) pertaining to cord blood is 21 CFR 1271. Since 2004, the FDA has formulated a “Tissue Action Plan” which consists of these three rules:

As of January 21, 2004, all cord blood banks are required to register with the FDA. Any cord blood bank which has a laboratory should be on the web page of FDA Registered Establishments.

The second rule was published May 20, 2004, and became effective May 25, 2005. It pertains to donor eligibility. This rule requires more screening of donors for communicable diseases.

The final rule establishes FDA standards of current Good Tissue Practice (“GTP”) for laboratories which process HCT/Ps. This rule was published November 19, 2004, became effective May 25, 2005, and is intended to prevent contamination or cross-contamination during the handling of HCT/Ps.

These three FDA rules apply only to cord blood processed on or after the effective date of May 25, 2005. The final rule allows the FDA to inspect cord blood laboratories to determine compliance with the provisions of 21 CFR Part 1271. As part of this oversight authority, the FDA conducts unannounced inspections of cord blood banks.

Upon execution of the acquisition of all of the assets of Cord:Use, the Company acquired the cord blood operations which included both public (PHS 351) and private (PHS 361) banks. The Company closed the Cord:Use location and maintains its operations in Oldsmar, FL. The new PHS 351 product is distributed under an IND (10-CBA) maintained by the National Marrow Donor Program (NMDP). The Company has continued the contract with Duke University initiated by Cord:Use to manufacture, test, cryopreserve, store and distribute the public cord blood units. The units are listed on the NMDP Single Point of Access Registry and are available to transplant centers worldwide. The Company is reimbursed via cost recovery for public cord blood units distributed for transplant through the NMDP. The donation of cord blood units in the public cord blood banking program functions under The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and the Company adheres to HIPAA rules. The FDA does not require establishments that manufacture drugs (including biological products) and devices that are HCT/Ps for use under an investigational new drug application (IND) (21 CFR Part 312) to register and list their HCT/Ps until the HCT/P is approved through a biologics license application (BLA), new drug application (NDA), or premarket approval application (PMA); or cleared through a premarket notification submission (510(k)).

The PrepaCyte CB (Cord Blood) Processing System is intended for use in cell processing laboratories to process and store total nucleated cells (TNC) from human umbilical cord blood, prior to banking. The device is composed of three integrally-attached processing and storage containers (or a single processing container) with separation media. The system is 510K cleared as a Class II device. The division of the FDA which regulates this product is the Center of Biologics Evaluation and Research (“CBER”). Approval to market the device was determined by the Office of Cellular, Tissue and Gene Therapies. The section of FDA Code of Federal Regulations (“CFR”) pertaining to medical device is 21 CFR 800s. The requirements for compliance to this section include annual registration of the device, listing of devices with the FDA, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

Currently, the states of California, Illinois, Maryland, New Jersey and New York require cord blood banks to be registered or licensed. The Company is currently registered or licensed to operate in these states. If the Company identifies other states with licensing requirements or if other states adopt such requirements, the Company would have to obtain licenses or registration to continue providing cord blood services in those states.

Federal and state laws govern the Company’s ability to obtain and, in some cases, to use and disclose data that we may need to conduct certain activities. The HIPAA requires the Department of Health and Human Services to issue a series of regulations establishing standards for the electronic transmission of certain health information. The Company’s private cord blood bank operation is not subject to HIPAA because the Company does not engage in certain electronic transactions related to the reimbursement of healthcare providers and because blood and tissue procurement and banking activities are exempt. However, the healthcare providers that collect umbilical cord blood for the Company’s customers are subject to HIPAA. The identifiable information shared is only what is permitted by HIPAA. In 2009, a portion of the American Recovery and Reinvestment Act of 2009 modified HIPAA under the Health Information Technology for Economic and Clinical Health Act (“HITECH Act”). While the Company is still not subject to HIPAA for the reasons stated above the Company may incur material expenses associated with compliance efforts. In addition, compliance may require management to spend substantial time and effort on compliance measures. If the Company fails to comply with HIPAA, it could suffer criminal and civil penalties. The civil penalties could include monetary penalties ranging from $100 per violation to $1.5 million depending on the level of violation.

The Company is also subject to local, state and federal laws and regulations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances. These laws include the Occupational Safety and Health Act (“OSHA”), cGTPs, cGMPs, Environmental Protection Act and those of the local Department of Health.

OSHA requires all employers to assure safe and healthful working conditions for working men and women through development and implementation of work standards, education, and training. OSHA enforces the standards developed under the Act, applicable to all employers in the U.S. and its territories. cGTPs are laws, enforced by the FDA, that define and govern methods used in the manufacture of Human Cells, Tissues, and cellular and tissue-based Products (HCT/Ps). Current Good Manufacturing Practices (cGMPs) are laws, enforced by the FDA, that define and govern methods used in the manufacture of drugs and finished pharmaceuticals. Both of the latter federal practices, or laws, govern the Company’s products.

The Environmental Protection Agency (EPA) governs the management and proper disposal of products and by-products or waste. These products must be disposed in a manner that does not adversely affect the environment from which it came or where disposed of. The Department of Health on the local level primarily regulates systems and associated equipment employed in recovery activities such as back-up generators; therefore, governing specific internal processes.

Evolving legislation and regulations governing private cord blood banking in various jurisdictions throughout the world may impact the Company’s international licensees.

In addition, as the organization grows and evolves, other legislation and regulations are expected to impact the Company. One such evolution involves activities that may be designated as or involve medical research or cooperative agreements associated with medical research. These types of activities are also governed by the FDA, specifying oversight by an Institutional Review Board (IRB). The IRB is a board or committee that approves the initiation of, and conducts periodic review of, biomedical research involving human subjects. The primary purpose of such review is to assure the protection of the rights and welfare of the human subjects. Governance of biomedical research is codified as laws by Title 21 of the Code of Federal Regulations (CFR) Part 56, and enforced by the FDA. Other medical research associated with clinical trials may require an Investigational New Drug Application (IND). Current Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. Because a sponsor will likely want to ship the investigational drug to clinical investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the sponsor technically obtains this exemption from the FDA. This approval would be required in the case of a clinical trial.

Subsidiaries and Joint Ventures

Since its inception, Cryo-Cell has entered into a number of business activities through subsidiaries and joint ventures, including the following activities and those described under “International” below. The Company continues to evaluate and pursue, certain opportunities for global expansion, on a selective basis, in which operational synergies and economic potential align with Cryo-Cell’s strategic direction.

Saneron CCEL Therapeutics, Inc. (“Saneron”). Saneron is the owner and/or exclusive licensee of certain technology developed by and/or in collaboration with the University of South Florida and the University of Minnesota. The technology covers various patents, patent applications and trade secrets for the therapeutic use of umbilical cord blood stem cells (U-CORD-CELL^®) and Sertoli cells (SERT-CELL^™). As of November 30, 2019, and November 30, 2018, the Company had an ownership interest of approximately 33% in Saneron which is accounted for under the equity method. As of November 30, 2019, and November 30, 2018, the net Saneron investment, which represents underlying goodwill, is reflected on the consolidated balance sheets at $0.

Revenue Sharing Agreements (“RSAs”)

The Company entered into RSAs prior to 2002 with various third and related parties. The Company’s RSAs provide that in exchange for a non-refundable up-front payment, the Company would share for the duration of the RSA a percentage of its future revenue derived from the annual storage fees related to a certain number of specimens that originated from specific geographical areas. The RSAs have no definitive term or termination provisions. The sharing applies to the storage fees collected for all specified specimens in the area covered by the RSA up to the number covered in the RSA. When the number of specimens is filled, any additional specimens stored in that area are not subject to the RSA. As there are empty spaces resulting from attrition, the Company agrees to fill them as soon as possible. The Company reflects these up-front payments as long-term liabilities on the accompanying consolidated financial statements. The Company does not intend to enter into additional RSAs.

In the future, the Company could reverse the liability relating to the RSAs up-front payments over an appropriate period of time, based on the Company’s expectations of the total amount of payments it expects to pay to the other party under the particular RSA. However, the RSAs do not establish a finite term or time frame over which to estimate the total payments and the Company had not previously estimated and has concluded that it is not currently practicable to estimate the projected cash flows under the RSAs. At present, the Company intends to defer the reversal of the liability, until such time as these amounts can be determined. During the periods when the Company defers the reversal of the liability, the quarterly payments made during these periods are treated as interest expense, which is recognized as the payments become due. In future periods, if a portion of the liability can be de-recognized based on the effective interest method, the payments will be allocated between interest and amortization of the liability. As cash is paid out to the other party during any period, the liability would be de-recognized based on the portion of the total anticipated payouts made during the period, using the effective interest method. That is, a portion of the payment would be recorded as interest expense, and the remainder would be treated as repayment of principal, which would reduce the liability.

Florida. On February 9, 1999, the previous Arizona RSAs were modified and replaced by an RSA for the state of Florida for a price of $1,000,000. The RSA applies to net storage revenues originating from specimens from within the state of Florida less a deduction for billing and collection fees. The RSA entitles the investors to revenues of up to a maximum of 33,000 storage spaces.

Illinois. In 1996, the Company entered into an RSA with a group of investors entitling them to an on-going 50% share of the Company’s 75% share of the annual storage fees (“net storage revenues”) less a deduction for 50% of billing and collection expenses generated by specimens stored in the Illinois Masonic Medical Center for a price of $1,000,000. The RSAs were modified in 1998 to broaden the covered specimens to those originating in Illinois and its contiguous states and stored in Oldsmar, Florida for a maximum of up to 33,000 storage spaces.

Texas. On May 31, 2001, the Company entered into an RSA with Red Rock Partners, an Arizona general partnership, entitling them to on-going shares in a portion of the Company’s net storage revenue generated by specimens originating from within the State of Texas for a price of $750,000. The investors are entitled to a 37.5% share of net storage revenues less a deduction for billing and collection fees for specimens originating in the State of Texas to a maximum of 33,000 storage spaces. During fiscal 2008, Red Rock assigned 50% of their interest in the agreement to SCC Investments, Inc., an Arizona corporation. Subsequent to November 30, 2009, SCC Investments, Inc. assigned its interest to SCF Holdings, LLC, an Arizona limited liability company.

The Company made total payments to all RSA holders of $832,587 and $671,245 for the fiscal years ended November 30, 2019 and 2018, respectively. The Company recorded an RSA accrual of $909,765 and $798,292 as of November 30, 2019 and 2018, respectively, related to interest owed to the RSA holders, which is included in accrued expenses. The Company also recorded interest expense of $944,060 and $848,024 for the fiscal years ended November 30, 2019 and 2018, respectively, which is reflected in interest expense on the accompanying consolidated statements of comprehensive income (loss).

International

The Company enters into two types of licensing agreements and in both types, the Company earns revenue on the initial license fees. Under the technology agreements, the Company earns processing and storage royalties from the affiliates that process in their own facility. Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Company’s facility in Oldsmar, Florida.

Technology Agreements

The Company has entered into a definitive License and Royalty Agreement with LifeCell International Private Limited, formerly Asia Cryo-Cell Private Limited, (“LifeCell”) to establish and market its umbilical cord blood and menstrual stem cell programs in India.

Per the License and Royalty Agreement with Lifecell, there is a $1,000,000 cap on the amount of royalties due to the Company per year and a $10,000,000 cap on the amount of royalties due to the Company for the term of the License and Royalty Agreement. The cap(s) are calculated based on Lifecell’s fiscal year end, March 31^st. As of the end of the Company’s fiscal years ended November 30, 2019 and November 30, 2018, Lifecell had reached the $1,000,000 cap. Since inception of the License and Royalty Agreement, the Company has recorded $9,300,000 in royalty income due under the terms of the License and Royalty Agreement, of which, Lifecell has paid the Company $8,400,000 as of November 30, 2019. The balance of $900,000 is reflected as Accounts Receivable on the accompanying consolidated balance sheets.

The following table details the processing and storage royalties earned for the technology agreements for fiscal years 2019 and 2018. The initial license fees and processing and storage royalties are reflected in licensee income in the accompanying consolidated statements of comprehensive income (loss).


	For the fiscal years ended November 30,
	2019						2018
	License Fee		Process and		Total		License Fee		Process and		Total
			Storage Royalties						Storage Royalties

India	$	—	$	1,000,000	$	1,000,000	$	—	$	1,000,000	$	1,000,000

Total	$	—	$	1,000,000	$	1,000,000	$	—	$	1,000,000	$	1,000,000

Marketing Agreements

The Company has definitive license agreements to market the Company’s umbilical cord blood stem cell programs in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and Pakistan.

Employees

At November 30, 2019, the Company had 87 full-time employees and 10 part-time employees on the staff of the Company. Additional employees and staff will be hired on an “as needed” basis. The Company believes its relationship with its employees is good. None of our employees are members of any labor union, and we are not a party to any collective bargaining agreement.

ITEM 1A.

RISK FACTORS.

Not applicable.

ITEM 1B.

UNRESOLVED STAFF COMMENTS.

None.

ITEM 2.

PROPERTIES.

The Company entered into a ten-year lease in April 2004 for its 17,600-square foot cGMP/cGTP compliant corporate headquarters in Oldsmar, Florida. The lease effectively commenced during October 2004, and the Company moved into this facility in November 2004. This facility contains the Company’s executive offices, its conference and training center, its laboratory processing and cryogenic storage facility and its scientific offices. In July 2018, the Company extended the main lease through December 31, 2021 for the 17,600 square foot space.

The Company entered into a one-year lease in November 2013 for an additional 800 square feet of office space in Miami, Florida for annual rent of approximately $38,000. The lease commenced during December 2013. In December 2016, the Company extended the lease through December 31, 2019.

Rent charged to operations was $322,984 and $312,307 for the fiscal years ended November 30, 2019 and 2018, respectively, and is included in cost of sales and selling, general and administrative expenses in the consolidated statements of comprehensive income (loss).

The future minimum rental payments under the operating lease are as follows:


Fiscal Year Ending November 30,	Rent
2020	$	228,148
2021	$	224,928
2022	$	18,744

ITEM 3.

LEGAL PROCEEDINGS.

On December 3, 2015, a complaint styled Gary T. Brotherson, M.D., et al. v. Cryo-Cell International, Inc., Case No. 15-007461-CI, Circuit Court, Sixth Judicial Circuit, Pinellas County, Florida, was served on the Company, naming it as defendant and alleging, among other things, that the Company breached certain agreements with plaintiffs and seeking damages in excess of $15,000, the jurisdictional amount of the court in which the action is pending. On January 12, 2016, the Company served its answer, affirmative defenses, and counterclaim against the plaintiffs. The Company believes the plaintiffs’ claims are without merit and it intends to contest the action vigorously. At this time, it is not possible for the Company to estimate the loss or the range of possible loss in the event of an unfavorable outcome, as the ultimate resolution of the complaint is uncertain at this time. No amounts have been accrued as of November 30, 2019.

In addition, from time to time the Company is subject to proceedings, lawsuits, contract disputes and other claims in the normal course of its business. The Company believes that the ultimate resolution of current matters should not have a material adverse effect on the Company’s business, consolidated financial position or results of operations. It is possible, however, that there could be an unfavorable ultimate outcome or resolution which could be material to the Company’s results of operations for a particular quarterly reporting period. Litigation is inherently uncertain and there can be no assurance that the Company will prevail. The Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies.

ITEM 4.

MINE SAFETY DISCLOSURES

Not Applicable

PART II

ITEM 5.

MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

The Company’s common stock is quoted on the OTC Pink Marketplace under the symbol “CCEL”. The following table shows, for the fiscal quarters indicated, the high and low closing bid quotations for the Company’s common stock as reported by Yahoo Finance. The quotations represent inter-dealer prices without retail mark-up, markdown or commission and may not necessarily represent actual transactions.


Quarter Ended	Low Closing Bid		High Closing Bid
February 28, 2018		7.16		9.95
May 31, 2018		7.20		7.56
August 31, 2018		7.49		9.30
November 30, 2018		6.03		8.37
February 28, 2019		6.67		7.99
May 31, 2019		6.40		8.04
August 31, 2019		7.45		8.23
November 30, 2019		7.08		8.90

The Company has not declared any cash dividends on its common stock and has no plans to do so in the immediate future.

As of November 30, 2019, the Company had 170 shareholders of record, and management believes there are approximately 1,500 additional beneficial holders of the Company’s common stock.

The following table sets forth as of November 30, 2019, the Company’s equity compensation plans approved by shareholders. At such date the Company had no equity compensation plans that had not been approved by shareholders.


Equity Compensation plans approved by stockholders	Number of securities to be issued upon exercise of outstanding options, warrants, rights and issued restricted shares		Weighted-average exercise price of outstanding options, warrants and rights		Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in the first column)
Cryo-Cell International, Inc. 2006 Stock Incentive Plan		325,000	$	2.74		—
Cryo-Cell International, Inc. 2012 Stock Incentive Plan		763,274	$	3.54		667,479
Total		1,088,274	$	3.30		667,479

As discussed in further detail in the 2019 Proxy Statement, on or about March 26, 2018, the Company received a letter from counsel for a purported stockholder. Among other things, the letter identified equity awards allegedly made in violation of the 2012 Plan. The Board formed a committee of directors (the “Demand Review Committee”) to (among other things) conduct an investigation of the allegations in that letter. After completing its investigation, the Demand Review Committee determined that 1,129,247 restricted stock performance based awards were granted in violation of the 2012 Plan and the Delaware General Corporation Law (“DGCL”). The Demand Review Committee also determined that 70,270, 75,000 and 77,500 stock option awards were granted in violation of the 2012 Plan, the 2006 Plan, the 2000 Stock Incentive Plan, respectively, as amended (the “2000 Plan”) and the DGCL. Annex II attached to the 2019 Proxy Statement describes each of these awards and the applicable Plan that the awards were purportedly granted under, and Annexes I and II of the 2019 Proxy Statement describe each defective award and defective stock issuance identified by the Demand Review Committee (the “Defective Awards and Issuances”).

Based on the recommendation of the Demand Review Committee, the Board of Directors approved that 776,798 restricted stock performance based awards be ratified that were in violation of the 2012 Plan and that 352,449 restricted stock performance based awards be surrendered for cash in the amount of $1,436,244 that were in violation of the 2012 Plan. The Board of Directors also approved the recommendation that 45,000 stock option awards not be ratified and 177,770 stock options be ratified under the 2012 Plan, the 2006 Plan and the 2000 Stock Incentive Plan. The proposed treatment of each award and issuance is listed on Annexes I and II in the manner identified in the column entitled “Recommended Disposition” in each of those Annexes and recommended to the Company’s stockholders that such awards and issuances be ratified as proposed by the Recommended Dispositions.

On November 21, 2019, the Company held its Annual Meeting of Stockholders. At the 2019 Annual Meeting, the Company’s stockholders considered various matters presented to them, including the ratification of certain equity-based awards and stock issuances made pursuant to the Company’s incentive Plans, as well as the approval of certain amendments to those incentive Plans. All such matters presented to the stockholders were duly approved by the stockholders at the 2019 Annual Meeting. Accordingly, all references contained herein to the number of options or shares of common stock granted under the Company’s incentive Plans, the value thereof, and the number of securities that remain available for future issuance under the Company’s 2012 Plan for all periods presented in this Annual Report on Form 10-K have been calculated and are being presented after taking into account the ratification and surrender of the Defective Awards and Issuances in accordance with the Recommended Disposition, as further described in the 2019 Proxy Statement.

Under the DGCL, any claim that the defective corporate acts, or the shares of stock or awards, listed as having been purportedly issued or granted on Annexes I and II, are void or voidable due to the failures of authorization listed on Annex III, or that the Delaware Court of Chancery should declare in its discretion that the ratification not be effective or be effective only on certain conditions, must be brought within 120 days from the date of the 2019 Annual Meeting, which was on November 21, 2019.

ITEM 6.

SELECTED FINANCIAL DATA

Not Applicable.

ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of the financial condition and results of operations of the Company for the two years ended November 30, 2019, should be read in conjunction with the consolidated financial statements and related notes as well as other information contained in this Annual Report on Form 10-K. This section of the Form 10-K contains forward-looking statements that involve substantial risks and uncertainties, such as statements about our plans, objectives, expectations and intentions. We use words such as “expect”, “anticipate”, “plan”, “believe”, “seek”, “estimate”, “intend”, “future” and similar expressions to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Form 10-K.

Overview

The Company is engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use. The Company’s principal sources of revenues are service fees for cord blood processing and preservation for new customers and recurring annual storage fees. Effective April 2016, the Company offers two pricing models, a standard plan and premium plan. The Company charges fees of $1,675 for the standard plan and $2,025 for the premium plan to new clients for the collection kit, processing, testing and return medical courier service, with discounts in the case of multiple children from the same family and in other circumstances. The Company charges an annual storage fee of $175 for new clients that enroll in the standard and premium plans; storage fees for existing customers depend on the contracts with such customers. The Company continues to offer a one-time payment plan for 18 years of storage and a life-time payment plan, pursuant to which the client is charged $4,650 for the standard plan and $5,000 for the premium plan and approximately $5,800 for the standard plan and approximately $6,100 for the premium plan, respectively, less discounts in the case of multiple children from the same family and in other circumstances. The one-time plan includes the collection kit, processing and testing, return medical courier service and 18 years of pre-paid storage fees. The life-time plan includes the collection kit, processing and testing, return medical courier service and pre-paid storage fees for the life of the client. The Company also receives other income from licensing fees and royalties from global affiliates.

On June 11, 2018, Cryo-Cell completed its acquisition of substantially all of the assets (the “Cord Purchase”) of Cord:Use Cord Blood Bank, Inc., a Florida corporation (“Cord:Use”), in accordance with the definitive Asset Purchase Agreement between Cryo-Cell and Cord:Use (the “Purchase Agreement”), including without limitation Cord:Use’s inventory of public cord blood units existing as of the closing date (the “Public Cord Blood Inventory”) and Cord:Use’s shares of common stock of Tianhe Stem Cell Biotechnologies, Inc., an Illinois corporation (the “Tianhe Capital Stock”). Cord:Use was in the business of public and private cord blood and tissue, collection, processing, storage and banking. The aggregate consideration payable at closing under the Purchase Agreement was $14,000,000, with $10,500,000 paid in cash and the balance paid through the delivery to Seller of 465,426 shares of Cryo-Cell’s common stock, par value $0.01 per share (“Common Stock”), at $7.52 per share. In addition, Cryo-Cell assumed certain limited liabilities incurred by Cord:Use in connection with its business that were unpaid as of the closing date and that directly relate to the services to be provided after closing by Cryo-Cell. Cryo-Cell also assumed certain of Cord:Use’s contracts and the obligations arising therefrom after the closing. Additionally, Cord:Use is entitled to an earnout from Cryo-Cell’s sale of the Public Cord Blood Inventory from and after closing. Each calendar year after the closing, Cryo-Cell is required to pay to Cord:Use 75% of all gross revenues, net of any returns, received from the sale of public cord blood inventory in excess of $500,000. Such payments are to be made quarterly, within 30 days of the end of the last month of each calendar quarter, until the public cord blood inventory is exhausted. In addition, each calendar year after closing, until the public cord blood inventory is exhausted, for every $500,000 of retained gross revenues, net of any returns, received and retained by Cryo-Cell in excess of the initial $500,000 retained by Cryo-Cell during such year, Cryo-Cell is to deliver $200,000 worth of Cryo-Cell Common stock to Cord:Use, up to an aggregate value of $5,000,000. Cord:Use is also entitled to a portion of the gross profits generated, or deemed to have been generated, by Cryo-Cell from its ownership of the Tianhe Capital Stock.

During the fiscal year ended November 30, 2019, the Company’s total revenue increased 9% as compared to fiscal 2018. The Company reported net income of approximately $2,291,000, or $0.29 per basic common share and $0.27 per diluted share for fiscal 2019 compared to a net loss of approximately ($855,000), or ($0.11) per basic and diluted common share for fiscal 2018. Net income for the twelve months ended November 30, 2019 principally resulted from a 9% increase in total revenues and a 5% decrease in selling, general and administrative expenses, which were offset by a 18% increase in cost of sales. Also included in the net income for the twelve months ended November 30, 2019 was an impairment charge of $2,332,763. Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge was recognized during the second quarter of fiscal 2019 to reduce inventory from cost to net realizable value. Included in the net loss for the twelve months ended November 30, 2018 was approximately $3,078,100 of income tax expense related to the reduction of the federal tax rate to 21% as of January 1, 2018 as a result of the Tax Cuts and Jobs Act that was signed into law on December 22, 2017. The decrease in the federal tax rate caused a decrease in the Company’s deferred tax asset which resulted in an increase in the income tax expense.

As of November 30, 2019, the Company had cash and cash equivalents of $6,541,037. The Company’s cash increased by approximately $501,000 during fiscal 2019. Cash provided by operations was approximately $6,323,000 which was offset by approximately $662,000 that was used for the purchase of property and equipment, approximately $4,100,000 used to repay the note payable and approximately $992,000 to repurchase the Company’s common stock. On May 20, 2016, the Company entered into a Credit Agreement (“Agreement”) with Texas Capital Bank, National Association (“TCB”) for a term loan of $8.0 million in senior credit facilities. The proceeds of the term loan were used by the Company to fund repurchases of the Company’s common stock. Subject to the terms of the Agreement, on May 20, 2016, TCB advanced the Company $100.00. On July 1, 2016, TCB advanced the remaining principal amount of $7,999,900 per a promissory note dated May 20, 2016 between the Company and TCB.

On August 26, 2016, the Company entered into a First Amendment to Credit Agreement with TCB. Pursuant to terms of the First Amendment to Credit Agreement, on August 26, 2016, TCB made an additional advance to the Company in principal amount of $2,133,433 per an Amended and Restated Promissory Note dated August 26, 2016 between the Company and TCB. The proceeds of the term loan were used by the Company to fund the extinguishment of some of the revenue sharing agreements.

On June 11, 2018, the Company entered into a Second Amendment to Credit Agreement with TCB. Pursuant to the terms of the Second Amendment to Credit Agreement, TCB made an additional advance to the Company in principal amount of $9,000,000 per an Amended and Restated Promissory Note dated June 11, 2018 between the Company and TCB in the principal amount of $15,500,000. The proceeds were used to finance a portion of the purchase price of the Cord:Use purchase. See Note 5.

Results of Operations

Revenue. For the fiscal year ended November 30, 2019, the Company had revenue of $31,816,571 compared to $29,218,490 for the fiscal year ended November 30, 2018. The 9% increase in revenue was primarily attributable to an 8% increase in processing and storage fees.

Processing and Storage Fees. For the fiscal year ended November 30, 2019, processing and storage fees were $29,991,972 compared to $27,817,872 for the fiscal year ended November 30, 2018. The increase in processing and storage fee revenue was primarily attributable to a 12% increase in recurring annual storage fee revenue. The Company had a 7% increase in the number of new domestic cord blood specimens processed year-over-year. Also, the Company’s cord tissue service continues to increase year-over-year.

Product Revenue. For the twelve months ended November 30, 2019, revenue from the product sales was $172,395 compared to $104,323 for the twelve months ended November 30, 2018.

Public Cord Blood Banking Revenue. On June 11, 2018, the Company entered into an Asset Purchase Agreement as described in Note 2. For the twelve months ended November 30, 2019, revenue from the public cord blood banking sales was $652,204 compared to $296,295 for the twelve months ended November 30, 2018.

Licensee Income. For the fiscal year ended November 30, 2019, licensee income was $1,000,000 as compared to $1,000,000 for fiscal 2018. Licensee income for the twelve months ended November 30, 2019 and November 30, 2018 consists of royalty income earned on the processing and storage of cord blood stem cell specimens in India where the Company has a definitive License and Royalty Agreement.

2019 and November 30, 2018, Lifecell had reached the $1,000,000 cap. Since inception of the License and Royalty Agreement, the Company has recorded $9,300,000 in royalty income due under the terms of the License and Royalty Agreement, of which, Lifecell has paid the Company $8,400,000 as of November 30, 2019. The balance of $900,000 is reflected as Accounts Receivable on the accompanying consolidated balance sheets.

Cost of Sales. For the fiscal year ended November 30, 2019, cost of sales was $10,036,175, as compared to $8,539,662 for the fiscal year ended November 30, 2018, representing an 18% increase. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and quality systems in the processing of cord blood specimens at the Company’s facility in Oldsmar, Florida and depreciation expense of $195,073 for the year ended November 30, 2019 compared to $137,062 for the 2018 period. Also, included in Cost of Sales is $249,847 and $169,396 related to the costs associated with production of the PrepaCyte CB processing and storage system for the twelve months ended November 30, 2019 and November 30, 2018, respectively. Also included in Cost of Sales is $1,295,864 and $626,057 for the twelve months ended November 30, 2019 and November 30, 2018, respectively, related to the public banking due to the Purchase Agreement with Cord:Use. The increase in cost of sales for the twelve months ended November 30, 2019 versus November 30, 2018 is due to the increased costs due to the public cord blood bank and the increased costs associated with the 7% increase in the number of new domestic cord blood specimens processed in fiscal year 2019 versus fiscal year 2018.

Selling, General and Administrative Expenses. Selling, general and administrative expenses during the fiscal year ended November 30, 2019 were $14,891,462 as compared to $15,632,696 for the fiscal year ended November 30, 2018 representing a 5% decrease. These expenses are primarily comprised of selling and marketing expenses, salaries and wages for personnel and professional fees. The decrease in selling, general and administrative expenses is in part due to costs in fiscal 2018 associated with the Purchase Agreement with CordUse. As of the twelve months ended November 30, 2019 and November 30, 2018, $0 and $580,000, respectively, of selling, general and administrative expenses are associated with the CordUse purchase. These expenses were non-recurring expenses related to the acquisition of CordUse. Also for the twelve months ended November 30, 2019, bonuses decreased approximately $657,000. Bonuses are calculated per the criteria set forth in the employment agreements.

Research, Development and Related Engineering Expenses. Research, development and related engineering expenses for the fiscal year ended November 30, 2019, were $30,145 as compared to $91,845 in 2018.

Depreciation and Amortization. Depreciation and amortization (not included in Cost of Sales) for the fiscal year ended November 30, 2019 was $206,238 compared to $180,264 for fiscal 2018.

Change in the Fair Value of Contingent Consideration. Change in the fair value of the contingent consideration for the fiscal year ended November 30, 2019 was $742,918 compared to $415,280 for fiscal 2018. The contingent consideration is the earnout that Cord:Use is entitled to from the Company’s sale of the public cord blood inventory from and after closing, described above. The contingent consideration was remeasured to fair value as of November 30, 2019. The estimated fair value of the contingent earnout was determined using a monte carlo analysis examining the frequency and mean value of the resulting earnout payments. The resulting value captures the risk associated with the form of the payout structure. The risk-neutral method is applied, resulting in a value that captures the risk associated with the form of the payout structure and the projection risk. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different from the estimated value of the liability.

Impairment of Public Inventory. The impairment of public inventory for the twelve months ended November 30, 2019 was $2,332,763 compared to $0 for the 2018 period. Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of $2,332,763 was recognized during the twelve months ended November 30, 2019 to reduce inventory from cost to net realizable value.

Interest Expense. Interest expense during the fiscal year ended November 30, 2019 was $1,703,446 compared to $1,546,900 in fiscal 2018, of which $759,386 and $698,876, respectively, related to the credit and subordination agreements with Texas Capital Bank, National Association and CrowdOut Capital LLC as described in Note 5. The remaining interest expense is comprised of amounts due to the parties to the Company’s revenue sharing agreements based on the Company’s storage revenue collected.

Income Taxes. U.S. income tax expense for the twelve months ended November 30, 2019 was $992,491, net of foreign taxes, compared to $4,364,190, net of foreign income taxes, for the twelve months ended November 30, 2018. Included in the $4,472,504 tax expense for the twelve months ended November 30, 2018 is approximately $3,078,100 of expense related to the reduction of the federal tax rate to 21% as of January 1, 2018 as a result of the Tax Cuts and Jobs Act that was signed into law on December 22, 2017. The decrease in the federal tax rate caused a decrease in the Company’s deferred tax asset which resulted in an increase in the income tax expense.

Deferred tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The ultimate realization of our deferred tax assets depends upon generating sufficient future taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, we must project future levels of taxable income. This assessment requires significant judgment. We examine the evidence related to the recent history of tax losses, the economic conditions in which we operate and our forecasts and projections to make that determination.

The Company records foreign income taxes withheld from installment payments of non-refundable up-front license fees and royalty income earned on the processing and storage of cord blood stem cell specimens in certain geographic areas where the Company has license agreements. The Company recorded approximately $108,000 and $108,000 for the years ended November 30, 2019 and 2018, respectively, of foreign income tax expense, which is included in income tax expense in the accompanying consolidated statements of comprehensive income (loss).

There was approximately $2,801,000 and $2,204,000 of U.S. income taxes paid for fiscal years ended November 30, 2019 and November 30, 2018, respectively.

Liquidity and Capital Resources

On August 26, 2016, the Company entered into a First Amendment to Credit Agreement with TCB. Pursuant to terms of the First Amendment to Credit Agreement, on August 26, 2016, TCB made an additional advance to the Company in principal amount of $2,133,433 per an Amended and Restated Promissory Note dated August 26, 2016 between the Company and TCB. The additional proceeds of the term loan were used by the Company to fund the extinguishment of revenue sharing agreements.

Prior to the loans, the Company’s principal source of cash has been from sales of its umbilical cord blood program to customers and royalties from licensees.

At November 30, 2019, the Company had cash and cash equivalents of $6,541,037 as compared to $6,040,033 at November 30, 2018. The increase in cash and cash equivalents during the twelve months ended November 30, 2019 was primarily attributable to the following:

Net cash provided by operating activities in fiscal 2019 was $6,323,207 which was attributable to the Company’s operating activities and an increase in the Company’s new clients choosing the prepaid storage plans versus the annual storage fee plan.

Net cash provided by operating activities in fiscal 2018 was $5,333,330 which was attributable to the Company’s operating activities and an increase in the Company’s new clients choosing the prepaid storage plans versus the annual storage fee plan.

Net cash used in investing activities in fiscal 2019 was $690,659 which was primarily attributable to cash used to purchase property and equipment.

Net cash used in investing activities in fiscal 2018 was $11,282,411 which was primarily attributable to cash used to purchase CordUse in the amount of $10,500,000 and purchases of property, equipment and sales and purchases of marketable securities and other investments and intangibles of $782,411.

Net cash used in financing activities in fiscal 2019 was $5,131,544, which was primarily attributable to the payments of $4,100,000 to repay the note payable described above and $45,000 to Cord Use and $992,244 used to repurchase common stock which was offset by the receipt of $5,700 from the exercise of stock options.

Net cash provided by financing activities in fiscal 2018 was $5,709,960, which was primarily attributable to the payments of $3,291,665 to repay the note payable described above offset by the receipt of $170,925 from the exercise of stock options and $9,000,000 received as part of the Second Amendment to Credit Agreement with TCB described above.

The Company does not have a line of credit.

The Company anticipates making discretionary capital expenditures of approximately $500,000 over the next twelve months for software enhancements and purchases of property and equipment. The Company anticipates funding future property and equipment purchases with cash-on-hand and cash flows from future operations.

The Company anticipates that its cash and cash equivalents, marketable securities and cash flows from future operations will be sufficient to fund its known cash needs for at least the next 12 months. Cash flows from operations will depend primarily upon increasing revenues from sales of its umbilical cord blood and cord tissue cellular storage services and managing discretionary expenses. If expected increases in revenues are not realized, or if expenses are higher than anticipated, the Company may be required to reduce or defer cash expenditures or otherwise manage its cash resources during the next 12 months so that they are sufficient to meet the Company’s cash needs for that period. In addition, the Company may consider seeking equity or debt financing if deemed appropriate for its plan of operations, and if such financing can be obtained on acceptable terms. There is no assurance that any reductions in expenditures, if necessary, will not have an adverse effect on the Company’s business operations, including sales activities and the development of new services and technology.

Critical Accounting Policies and Estimates

The preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of the company’s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. The Company believes that its estimates and assumptions are reasonable under the circumstances; however, actual results may vary from these estimates and assumptions. We have identified the following critical accounting policies that affect the more significant judgments and estimates used in the preparation of the consolidated financial statements. For further discussion of the Company’s significant and critical accounting policies, refer to Note 1 – “Description of Business and Summary of Critical and Significant Accounting Policies” to the Consolidated Financial Statements contained in Item 8 of this document.

Revenue Recognition

Effective December 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. The Company recognized the cumulative effect of applying the new revenue standard to all contracts with customers that were not completed as of December 1, 2018 as an adjustment to the opening balance of stockholders’ deficit at the beginning of fiscal year 2019. The reported results for 2019 reflect the application of ASC 606 guidance while the reported results for 2018 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. ASC 606 also requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

The adoption of ASC 606 did not have an impact on the amount of reported revenues with respect to the Company’s product or service revenues. In connection with the adoption of ASC 606, the Company is required to capitalize certain contract acquisition costs consisting primarily of commissions paid when contracts are signed and amortize these costs on a systematic basis, consistent with the pattern of transfer of the storage services provided over time for which the asset relates. As of December 1, 2018, the Company capitalized in deposits and other assets, net, $329,231 in incremental contract acquisition costs related to sales commissions on prepaid storage contracts and reversed $18,408 of its variable consideration that the Company determined to be fully constrained, with a corresponding change in the opening balance of stockholders’ deficit of $253,447, net of tax, of $94,192.

Under ASC 606, revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised services are transferred to the customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring services to a customer (“transaction price”).

as) each performance obligation is satisfied. The Company evaluates its contracts for legal enforceability at contract inception and subsequently throughout the Company’s relationship with its customers. If legal enforceability with regards to the rights and obligations exist for both the Company and the customer, then the Company has an enforceable contract and revenue recognition is permitted subject to the satisfaction of the other criteria. If, at the outset of an arrangement, the Company determines that a contract with enforceable rights and obligations does not exist, revenues are deferred until all criteria for an enforceable contract are met. The Company only applies the five-step model to contracts when it is probable that collection of the consideration that the Company is entitled to in exchange for the goods or services being transferred to the customer, will occur.

Income Taxes

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The Company records a valuation allowance when it is “more likely than not” that all future income tax benefits will be realized. When the Company changes its determination as to the amount of deferred income tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to income tax expense in the period in which such determination is made. The ultimate realization of the Company’s deferred income tax assets depends upon generating sufficient taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, the Company projects future levels of taxable income. This assessment requires significant judgment. The Company examines the evidence related to the recent history of losses, the economic conditions in which the Company operates and forecasts and projections to make that determination.

Long-Lived Assets

The Company evaluates the realizability of its long-lived assets, which requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment, such as reductions in demand or when significant economic slowdowns are present. Reviews are performed to determine whether the carrying value of an asset is impaired, based on comparisons to undiscounted expected future cash flows. If this comparison indicates that there is impairment and carrying value is in excess of fair value, the impaired asset is written down to fair value, which is typically calculated using: (i) quoted market prices or (ii) discounted expected future cash flows utilizing a discount rate. The Company did not note any impairment for the twelve months ended November 30, 2019 and 2018.

Goodwill

Goodwill represents the excess of the purchase price of the assets acquired from Cord:Use (Note 2) over the estimated fair value of the net tangible and identifiable assets acquired. The annual assessment of the reporting unit is performed as of September 1st, and an assessment is performed at other times if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below its carrying value. The Company first performs a qualitative assessment to test goodwill for impairment and concludes if it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment concludes that it is not more likely than not that the fair value is less than the carrying value, the two-step goodwill impairment test is not required. If the qualitative assessment concludes that it is more likely than not that the fair value of the reporting unit is less than the carrying value, then the two-step goodwill impairment test is required. Step one of the impairment assessment compares the fair value of the reporting unit to its carrying value

and if the fair value exceeds its carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, the implied fair value of goodwill is compared to the carrying value of goodwill. If the implied fair value exceeds the carrying value then goodwill is not impaired; otherwise, an impairment loss would be recorded by the amount the carrying value exceeds the implied fair value.

Stock Compensation

As of November 30, 2019, the Company has two stock-based employee compensation plans, which are described in Note 11 to the consolidated financial statements.

The Company recognizes stock-based compensation based on the fair value of the related awards. Under the fair value recognition guidance of stock-based compensation accounting rules, stock-based compensation expense is estimated at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the award. The fair value of service-based vesting condition and performance-based vesting condition stock option awards is determined using the Black-Scholes valuation model. For stock option awards with only service-based vesting conditions and graded vesting features, the Company recognizes stock compensation expense based on the graded-vesting method. To value awards with market-based vesting conditions the Company uses a binomial valuation model. The Company recognizes compensation cost for awards with market-based vesting conditions on a graded-vesting basis over the derived service period calculated by the binomial valuation model. The use of these valuation models involves assumptions that are judgmental and highly sensitive in the determination of compensation expense and include the expected life of the option, stock price volatility, risk-free interest rate, dividend yield, exercise price, and forfeiture rate. Forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period.

The estimation of stock awards that will ultimately vest requires judgment and to the extent that actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period they become known. The Company considered many factors when estimating forfeitures, including the recipient groups and historical experience. Actual results and future changes in estimates may differ substantially from current estimates.

The Company issues performance-based equity awards which vest upon the achievement of certain financial performance goals, including revenue and income targets. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the required performance targets and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance goals are not met, the award does not vest, so no compensation cost is recognized and any previously stock-recognized stock-based compensation expense is reversed.

The Company issues equity awards with market-based vesting conditions which vest upon the achievement of certain stock price targets. If the awards are forfeited prior to the completion of the derived service period, any recognized compensation is reversed. If the awards are forfeited after the completion of the derived service period, the compensation cost is not reversed, even if the awards never vest.

License and Royalty Agreements

The Company has entered into licensing agreements with certain investors in various international markets in an attempt to capitalize on the Company’s technology. The investors typically pay a licensing fee to receive Company marketing programs, technology and know-how in a selected area. The investor may be given a right to sell sub-license agreements as well. As part of the accounting for the up-front license revenue, revenue from the up-front license fee is recognized based on such factors as when the payment is due, collectability and when all material services or conditions relating to the sale have been substantially performed based on the terms of the agreement. The Company has twelve active licensing agreements. The following areas each have one license agreement: El Salvador, Guatemala, Panama, Honduras, China, and Pakistan. The following areas each have two license agreements: India, Nicaragua and Costa Rica. In October 2012, the Company sent a notice of termination to the Company’s Venezuelan affiliate for failure to meet its payment obligation in accordance with the contract. Subsequent to the notice of termination, payment was received for outstanding processing and storage fees due from Venezuela. The Company is in the process of discussing a new agreement with Venezuela. In December 2012, the Company sent notice of termination to the Company’s affiliate in Ecuador for failure to meet its payment obligation in accordance with the contract. Subsequent to the notice of termination, payment was received for outstanding processing and storage fees due from Ecuador. In August 2013, the Company was notified that its affiliate in Ecuador was closed by the National Institute of Organic Donation (INDOT). As a result, the Company recorded an allowance for uncollectible receivables for the $150,000 processing and storage fee receivable due from Ecuador in the third quarter of fiscal 2013. During the fourth quarter of fiscal 2013, the Company began to bill the Ecuadorian clients directly for cord blood specimens that are stored at the Company’s facility in Oldsmar, Florida. In the future, if the Company loses revenue due to lack of payment from the foreign affiliates or the foreign affiliates are closed, the Company’s overall revenue will decrease.

In addition to the license fee, the Company earns a royalty on processing and storage fees on subsequent processing and storage revenues received by the licensee in the licensed territory and a fee on any sub-license agreements that are sold by the licensee where applicable. The Company processes and stores specimens sent directly from customers of licensees in Mexico, El Salvador, Guatemala, Ecuador, Panama, Honduras, Nicaragua, Costa Rica, Pakistan and Venezuela. The Company also processes and stores specimens from sub-licenses of Venezuela, who are Chile, Colombia and Peru. These fees are included in processing and storage fees revenue on the consolidated statements of comprehensive income (loss). As part of the accounting for royalty revenue from India, the Company uses estimates and judgments based on historical processing and storage volume in determining the timing and amount of royalty revenue to recognize. The Company periodically reviews license and royalty receivables for collectability and, if necessary, will record an expense for an allowance for uncollectible accounts. If the financial condition of the Company’s sub-licensees were to deteriorate beyond the estimates, the Company may have to increase the allowance for doubtful accounts which could have a negative impact on earnings. If the licensee’s customer base were to decrease, it would negatively impact the Company’s ongoing license income.

Accounts Receivable

Accounts receivable consist of uncollateralized amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs and amounts due from license affiliates, and sublicensee territories. Accounts receivable are due within 30 days and are stated at amounts net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering the length of time accounts receivable are past due, the Company’s previous loss history, and the client’s current ability to pay its obligations. Therefore, if the financial condition of the Company’s clients were to deteriorate beyond the estimates, the Company may have to increase the allowance for doubtful accounts which could have a negative impact on earnings. The Company writes-off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.

Inventories

As part of the Asset Purchase Agreement, (see Note 2), the Company has an agreement with Duke University (“Duke”) expiring on January 31, 2025 for Duke to receive, process, and store cord blood units for the Public Cord Blood Bank (“Duke Services”). As of November 30, 2019, the Company had approximately 6,000 cord blood units in inventory. These units are valued at the lower of cost or net realizable value. Costs include the cost of collecting, transporting, processing and storing the unit. Costs charged by Duke for their Duke Services are based on a monthly fixed fee for processing and storing 12 blood units per month. The Company computes the cost per unit for these Duke Services and capitalizes the unit cost on all blood units shipped and stored in a year at Duke. If the Company ships and stores less than 144 blood units with Duke in a one-year period, a portion of these fixed costs are expensed and included in facility operating costs. Certain costs of collection incurred, such as the cost of collection staff and transportation costs incurred to ship Public Bank units from hospitals to the stem cell laboratory are allocated to banked units based on an average cost method. The change in the number of expected units to be sold could have a significant impact on the estimated net realizable value of banked units which could have a material effect on the value of the inventory. Costs incurred related to cord blood units that cannot be sold are expensed in the period incurred and are included in facility operating costs in the accompanying statements of operations. The Company records a reserve against inventory for units which have been processed and frozen but may not ultimately become distributable (see Note 3).

Patents and Trademarks

The Company incurs certain legal and related costs in connection with patent and trademark applications. If a future economic benefit is anticipated from the resulting patent or trademark or an alternate future use is available to the Company, such costs are capitalized and amortized over the expected life of the patent or trademark. The Company’s assessment of future economic benefit involves considerable management judgment. A different conclusion could result in the reduction of the carrying value of these assets.

Revenue Sharing Agreements

The Company has entered into Revenue Sharing Agreements (“RSAs”) with various parties whereby these parties contracted with the Company for a percentage of future storage revenues the Company generates and collects from clients in specific geographical areas. The RSAs have no definitive term or termination provisions. The sharing applies to the storage fees collected for all specified specimens in the area up to the number covered in the contract. When the number of specimens is filled, any additional specimens stored in that area are not subject to revenue sharing. As there are empty spaces resulting from attrition, the Company agrees to fill them as soon as possible. The parties typically pay the Company a non-refundable up-front fee for the rights to these future payments. The Company recognized these non-refundable fees as a long-term liability. Given the criteria under which these RSAs are established, cash flows related to these contracts can fluctuate from period to period. All payments made to the other parties to the RSAs are recognized as interest expense. At such time as the total payments can be determined, the Company will commence amortizing these liabilities under the effective interest method. The Company does not intend to enter into additional RSAs.

Contingent Consideration

The contingent consideration is the earnout that Cord:Use is entitled to from the Company’s sale of the public cord blood inventory from and after closing. See Note 2. The estimated fair value of the contingent earnout was determined using a monte carlo analysis examining the frequency and mean value of the resulting earnout payments. The resulting value captures the risk associated with the form of the payout structure. The risk-neutral method is applied, resulting in a value that captures the risk associated with the form of the payout structure and the projection risk. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different from the estimated value of the liability.

Recently Issued Accounting Pronouncements

See Note 1 to the Consolidated Financial Statements.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable, as the Company is a smaller reporting company.

ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

The consolidated financial statements and supplementary data listed in the accompanying Index to Consolidated Financial Statements are attached as part of this report.

The following consolidated financial statements of Cryo-Cell International, Inc. are included in Item 8:

Reports of Independent Registered Public Accounting Firms

Consolidated Balance Sheets as of November 30, 2019 and 2018

Consolidated Statements of Comprehensive Income (Loss)

For the Fiscal Years Ended November 30, 2019 and 2018

Consolidated Statements of Cash Flows

For the Fiscal Years Ended November 30, 2019 and 2018

Consolidated Statements of Stockholders’ Deficit

For the Fiscal Years Ended November 30, 2019 and 2018

Notes to Consolidated Financial Statements

All other schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under the related instructions, are already included in the Notes to Consolidated Financial Statements included under this Item 8 or are inapplicable, and therefore have been omitted.

LOGO

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Cryo-Cell International, Inc.

Oldsmar, Florida

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Cryo-Cell International, Inc. and subsidiaries (the “Company”), as of November 30, 2019, and the related consolidated statements of comprehensive income, changes in stockholders’ deficit, and cash flows for the year then ended and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of November 30, 2019, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ Wipfli LLP

We have served as the Company’s auditor since 2019.

Atlanta, Georgia

February 28, 2020

LOGO

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Cryo-Cell International, Inc.

Oldsmar, Florida

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Cryo-Cell International, Inc. and subsidiaries (the “Company”), as of November 30, 2018, and the related consolidated statements of comprehensive loss, changes in stockholders’ deficit, and cash flows for the year then ended and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of November 30, 2018, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

/s/ Porter Keadle Moore, LLC

We have served as the Company’s auditor since 2016.

Atlanta, Georgia

February 28, 2019

CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS


	November 30,			November 30,
	2019			2018
ASSETS
Current Assets
Cash and cash equivalents	$	6,541,037		$	6,040,033
Marketable securities		904,053			875,689
Accounts receivable (net of allowance for doubtful accounts of $2,584,091 and $2,264,848, respectively)		6,097,331			5,867,335
Prepaid expenses		500,260			461,815
Inventory, current portion		1,084,533			1,260,557
Other current assets		260,397			254,465

Total current assets		15,387,611			14,759,894

Property and Equipment-net		1,846,467			1,493,401

Other Assets
Investment - Tiahne Stock		308,000			308,000
Intangible assets, net		1,249,254			1,341,336
Inventory, net of current portion		12,646,000			14,775,316
Goodwill		1,941,411			1,941,411
Deferred tax assets		9,079,994			7,656,897
Deposits and other assets, net		427,423			113,888

Total other assets		25,652,082			26,136,848

Total assets	$	42,886,160		$	42,390,143

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable	$	1,369,111		$	1,261,653
Accrued expenses		2,085,180			2,702,788
Current portion of note payable		3,100,000			3,100,000
Deferred revenue		8,875,138			8,365,284

Total current liabilities		15,429,429			15,429,725

Other Liabilities
Deferred revenue, net of current portion		23,633,373			20,317,231
Contingent Consideration		3,495,057			4,282,975
Note payable, net of current portion and debt issuance costs		5,856,152			9,843,510
Long-term liability - revenue sharing agreements		1,425,000			1,425,000

Total other liabilities		34,409,582			35,868,716

Total liabilities		49,839,011			51,298,441

Commitments and contingencies (Note 13)		—			—
Stockholders’ Deficit
Preferred stock ($.01 par value, 500,000 authorized and none issued and outstanding)		—			—
Series A Junior participating preferred stock ($.01 par value, 20,000 authorized and none issued and outstanding)		—			—
Common stock ($.01 par value, 20,000,000 authorized; 13,598,909 issued and 7,510,884 outstanding as of November 30, 2019 and 13,596,409 issued and 7,800,833 outstanding as of November 30, 2018)		135,989			135,964
Additional paid-in capital		35,918,827			35,515,382
Treasury stock, at cost		(20,563,357	)		(19,571,113	)
Accumulated other comprehensive income		—			340,984
Accumulated deficit		(22,444,310	)		(25,329,515	)

Total stockholders’ deficit		(6,952,851	)		(8,908,298	)

Total liabilities and stockholders’ deficit	$	42,886,160		$	42,390,143

The accompanying notes are an integral part of these consolidated financial statements.

CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)


	November 30,			November 30,
	2019			2018
Revenue:
Processing and storage fees	$	29,991,972		$	27,817,872
Public banking revenue		652,204			296,295
Licensee and royalty income		1,000,000			1,000,000
Product revenue		172,395			104,323

Total revenue		31,816,571			29,218,490

Costs and Expenses:
Cost of sales		10,036,175			8,539,662
Selling, general and administrative expenses		14,891,462			15,632,696
Impairment of public inventory		2,332,763			—
Change in fair value of contingent consideration		(742,918	)		(415,280	)
Research, development and related engineering		30,145			91,845
Depreciation and amortization		206,238			180,264

Total costs and expenses		26,753,865			24,029,187

Operating Income		5,062,706			5,189,303

Other Expense:
Other income (expense)		32,155			(24,723	)
Interest expense		(1,703,446	)		(1,546,900	)

Total other expense		(1,671,291	)		(1,571,623	)

Income before income tax expense		3,391,415			3,617,680
Income tax expense		(1,100,641	)		(4,472,504	)

Net Income (Loss)	$	2,290,774		$	(854,824	)

Net income (loss) per common share—basic	$	0.29		$	(0.11	)

Weighted average common shares outstanding—basic		7,794,828			7,463,051

Net income (loss) per common share—diluted	$	0.27		$	(0.11	)

Weighted average common shares outstanding—diluted		8,412,414			7,463,051

Other Comprehensive Income
Unrealized gain on marketable securities (net of tax)	$	—		$	300,119

Comprehensive Income (Loss)	$	2,290,774		$	(554,705	)

The accompanying notes are an integral part of these consolidated financial statements.

CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS


	November 30,			November 30,
	2019			2018
Cash flows from operating activities:
Net income (loss)	$	2,290,774		$	(854,824	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization expense		401,311			317,326
Impairment of public inventory		2,332,763			—
Loss on disposal of property and equipment		—			162,307
Change in fair value of contingent consideration		(742,918	)		(415,280	)
Compensatory element of stock options		397,770			478,378
Provision for doubtful accounts		767,128			727,483
Deferred income tax expense		(1,517,289	)		2,378,491
Amortization of debt issuance costs		112,642			109,292
Changes in assets and liabilities:
Accounts receivable		(997,124	)		(1,347,773	)
Prepaid expenses		(38,445	)		(20,796	)
Inventory		(27,423	)		316,650
Other current assets		(5,932	)		(48,329	)
Goodwill		—			66,565
Deposits and other assets, net		15,696			(85,000	)
Accounts payable		107,458			(666,889	)
Accrued expenses		(599,200	)		120,313
Deferred revenue		3,825,996			4,095,416

Net cash provided by operating activities		6,323,207			5,333,330

Cash flows used in investing activities:
Purchases of property and equipment		(662,295	)		(446,163	)
Purchase of intangible asset		—			(200,000	)
Purchases of marketable securities and other investments, net		(28,364	)		(136,248	)
Purchase of Cord Use		—			(10,500,000	)

Net cash used in investing activities		(690,659	)		(11,282,411	)

Cash flows from financing activities:
Treasury stock purchases		(992,244	)		—
Repayments of note payable		(4,100,000	)		(3,291,665	)
Proceeds from the exercise of stock options		5,700			170,925
Proceeds from note payable		—			9,000,000
Issuance costs associated with the proceeds from the note payable		—			(169,300	)
Payment of Cord Use earnout		(45,000	)		—

Net cash (used in) provided by financing activities		(5,131,544	)		5,709,960

Increase (decrease) in cash and cash equivalents		501,004			(239,121	)
Cash and cash equivalents - beginning of period		6,040,033			6,279,154

Cash and cash equivalents - end of period	$	6,541,037		$	6,040,033

Supplemental non-cash investing activities:
Unrealized gain on marketable securities, net of tax	$	—		$	300,119
Cumulative-effect adjustment due to the adoption of ASU 2016-01	$	(340,984	)	$	—

Assets acquired and liabilities assumed in acquisitions:
Assets acquired in acquisition	$	—		$	20,103,661

Liabilities assumed in acquisition	$	—		$	1,405,406

The accompanying notes are an integral part of these consolidated financial statements.

CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT


					Additional					Other						Total
	Common Stock				Paid-In		Treasury			Comprehensive			Accumulated			Stockholders’
	Shares		Amount		Capital		Stock			Income			Deficit			Deficit
Balance at November 30, 2017		12,899,517	$	128,995	$	31,373,048	$	(19,571,113	)	$	40,865		$	(24,474,691	)	$	(12,502,896	)
Common stock issued		696,892	$	6,969	$	3,663,956										$	3,670,925
Compensatory element of stock options						478,378											478,378
Unrealized loss on available for sale securities											300,119						300,119
Net loss														(854,824	)		(854,824	)

Balance at November 30, 2018		13,596,409	$	135,964	$	35,515,382	$	(19,571,113	)	$	340,984		$	(25,329,515	)	$	(8,908,298	)

Common stock issued		2,500		25		5,675											5,700
Compensatory element of stock options						397,770											397,770
Cumulative-effect adjustment due to the adoption of ASU 2016-01											(340,984	)		340,984			—
ASC 606 adoption adjustment, net of tax ($94,192)														253,447			253,447
Treasury Stock								(992,244	)								(992,244	)
Net income														2,290,774			2,290,774

Balance at November 30, 2019		13,598,909	$	135,989	$	35,918,827	$	(20,563,357	)	$	—		$	(22,444,310	)	$	(6,952,851	)

The accompanying notes are an integral part of these consolidated financial statements.

CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOVEMBER 30, 2019 and 2018

NOTE 1 – DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business.

Cryo-Cell International, Inc. (“the Company” or “Cryo-Cell”) was incorporated in Delaware on September 11, 1989 and is headquartered in Oldsmar, Florida. The Company is organized in three reportable segments, cellular processing and cryogenic cellular storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use, the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Revenues for the cellular processing and cryogenic cellular storage represent sales of the umbilical cord blood stem cells program to customers and income from licensees selling the umbilical cord blood stem cells program to customers outside the United States. Revenues for the manufacture of PrepaCyte CB units represent sales of the PrepaCyte CB units to customers. Revenue for the cryogenic storage of umbilical cord blood stem cells for public use, stored at Duke University (see below), is generated from the sale of the cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States and around the world. The Company’s headquarters facility in Oldsmar, Florida handles all aspects of its U.S.-based business operations including the processing and storage of specimens, including specimens obtained from certain of its licensees’ customers. The specimens are stored in commercially available cryogenic storage equipment.

On October 10, 2001, Saneron Therapeutics, Inc. merged into one of the Company’s wholly owned subsidiaries, CCEL Bio-Therapies, Inc. (”CCBT”), which then changed its name to Saneron CCEL Therapeutics, Inc. (“SCTI” or ”Saneron”). As part of the merger, the Company contributed 260,000 shares of its common stock, whose fair value was $1,924,000 and 195,000 common shares of another of its subsidiaries, Stem Cell Preservation Technologies, Inc., whose fair value was $3,900. At the conclusion of the merger, the Company retained a 43.42% non-controlling interest in the voting stock of SCTI. As of November 30, 2019 and 2018, the Company had an interest of approximately 33% in the voting stock of SCTI. The accompanying consolidated financial statements as of November 30, 2019 and 2018 reflect the investment in SCTI under the equity method of accounting.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements as of November 30, 2019 and November 30, 2018 and for the years then ended includes the accounts of the Company and all of its subsidiaries, which are inactive. All intercompany balances have been eliminated upon consolidation.

Concentration of Risks

Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit. The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.

The Company depends on one supplier for the source of its collection kits, a critical component of the umbilical cord blood stem cell collection process. However, the Company believes that alternative sources of supply are available.

The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units. However, the Company believes that alternative sources of supply and manufacturing are available.

The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for transplant.

During fiscal 2019 and 2018, there were no concentration of risks.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition

At contract inception, if the contract is determined to be within the scope of ASC 606, the Company evaluates its contracts with customers using the five-step model: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to separate performance obligations; and (5) recognize revenue when (or as) each performance obligation is satisfied. The Company evaluates its contracts for legal enforceability at contract inception and subsequently throughout the Company’s relationship with its customers. If legal enforceability with regards to the rights and obligations exist for both the Company and the customer, then the Company has an enforceable contract and revenue recognition is permitted subject to the satisfaction of the other criteria. If, at the outset of an arrangement, the Company determines that a contract with enforceable rights and obligations does not exist, revenues are deferred until all criteria for an enforceable contract are met. The Company only applies the five-step model to contracts when it is probable that collection of the consideration that the Company is entitled to in exchange for the goods or services being transferred to the customer, will occur.

Contract modifications exist when the modification either creates new or changes in the existing enforceable rights and obligations. The Company’s contracts are occasionally modified to account for changes in contract terms and conditions, which the Company refers to as an upgrade or downgrade. An upgrade occurs when a customer wants to pay for additional years of storage. A downgrade occurs when a customer originally entered into a long-term contract (such as twenty-one year or life-time plan) but would like to change the term to a one-year contract. Upgrade modifications qualify for treatment as a separate contract as the additional services are distinct and the increase in contract price reflects the Company’s stand-alone selling price for the additional services and will be accounted for on a prospective basis. Downgrade modifications do not qualify for treatment as a separate contract as there is no increase in price over the original contract, thus failing the separate contract criteria. As such, the Company separately considers downgrade modifications to determine if these should be accounted for as a termination of the existing contract and creation of a new contract (prospective method) or as part of the existing contract (cumulative catch-up adjustment). ASC 606 requires that an entity account for the contract modification as if it were a termination of the existing contract, and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. As the services after the modification were previously determined to be distinct, the Company concluded that downgrade modifications qualify under this method and will be accounted for on a prospective basis. Although contract modifications do occur, they are infrequent.

Performance Obligations

At contract inception, the Company assesses the goods and services promised in the contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good or service (or bundle of goods or services) that is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. The Company determined that the following distinct goods and services represent separate performance obligations involving the sale of its umbilical cord blood product:

•

Collection and processing services

•

Storage services

•

Public cord blood banking

•

License and royalties

•

Sale of PrepaCyte CB product

a)	Processing

Processing and storage fees include the Company providing umbilical cord blood and tissue cellular processing and cryogenic cellular storage for private use. Revenues recognized for the cellular processing and cryogenic cellular storage represent sales of the umbilical cord blood stem cells program to customers and income from licensees who are selling the umbilical cord blood stem cells program to customers outside the United States.

The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period as well as other income from royalties paid by licensees related to long-term storage contracts which the Company has under license agreements. Contracted storage periods are annual, twenty-one years and life-time. The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual, the twenty-one-year and the life-time storage fees that are being recognized over the contractual storage period as well as royalties received from foreign licensees relating to long-term storage contracts for which the Company has future obligations under the license agreement. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.

Significant financing

When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. For all plans being annual, twenty-one years and life-time, the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans (including a stated service fee) for customers to pay over time for a period of one to twenty-four plus months. The one-time plan includes the collection kit, processing and testing, return medical courier service and twenty-one years of pre-paid storage fees. The life-time plan includes the collection kit, processing and testing, return medical courier service and pre-paid storage fees for the life of the customer. The Company concluded that a significant financing component is not present within either the prepaid or overtime payment plans. The Company has determined that the twenty-one year and life-time prepayment options do not include a significant financing component as the payment terms were structured primarily for reasons other than the provision of financing and to maximize profitability.

The Company has determined that the majority of plans that are paid over time are paid in less than a year. When considered over a twenty-four-month payment plan, the difference between the cash selling price and the consideration paid is nominal. As such, the Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when considered in the context of all contracts entered into nor significant at the individual contract level.

The Company elected to apply the practical expedient where the Company does not need to assess whether a significant financing component exists if the period between when it performs its obligations under the contract and when the customer pays is one year or less.

As of November 30, 2019, the total aggregate transaction price allocated to the unsatisfied performance obligations was recorded as deferred revenue amounting to $32,508,511, which will be recognized ratably on a straight-line basis over the contractual period of which $8,875,138 will be recognized over the next twelve months.

Variable consideration

In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. In the processing and storage agreements, the Company provides limited rights which are offered to customers automatically upon contract execution. The Company has determined that the payment warranty represents variable consideration payable to the customer.

Based on the Company’s historical experience to date, the Company has determined the payment warranty to be fully constrained under the most likely amount method. Consequently, the transaction price does not currently reflect any expectation of service level credits. At the end of each reporting period, the Company will update the estimated transaction price related to the payment warranty including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.

Allocation of transaction price

As the Company’s processing and storage agreements contain multiple performance obligations, ASC 606 requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the stand-alone selling prices of the processing services and storage services and concluded that the published list price is the price that a customer in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage.

Costs to Obtain a Contract

Prior to the adoption of ASC 606, the Company expensed in the period, all commissions paid to its internal and external sales representatives the Company employs and to its customers for generating new contracts. With the adoption of ASC 606 as of December 1, 2018, the Company capitalizes commissions that are incremental in obtaining customer contracts and the costs incurred to fulfill a customer contract if those costs are not within the scope of another topic within the accounting literature and meet the specified criteria. These costs are deferred in other current or long-term assets and are expensed to selling, general and administrative expenses as the Company satisfies the performance obligations by transferring the service to the customer. These assets will be periodically assessed for impairment. As a practical expedient, the Company elected to recognize the incremental costs of obtaining its annual contracts as an expense when incurred, as the amortization period of the asset recognized would have been one year.

The Company has determined that payments under the Company’s refer-a-friend program (“RAF program”) are incremental costs of obtaining a contract as they provide an incentive for existing customers to refer new customers to the Company and is referred to as commission. The amount paid under the RAF program (either through issuance of credits to customers or check payments) which exceeds the typical commission payment to a sales representative is recorded as a reduction to revenue under ASC 606. During the twelve months ended November 30, 2019, the Company recorded $35,300, in commission payments to customers under the RAF program as a reduction to revenue. As of December 1, 2018, the Company capitalized $329,231 in incremental contract acquisition costs related to contracts that were not completed, net of the cumulative amortization expense of $66,533 through the adoption date. The Company did not record any impairment losses in relation to costs capitalized. For the twelve months ended November 30, 2019, the Company capitalized additional contract acquisition costs of $87,518, net of amortization expense.

b)	Public banking revenue

The Company sells and provides units not likely to be of therapeutic use for research to qualified organizations and companies operating under Institutional Review Board approval. Control is transferred at the point in time when the shipment has occurred, at which time, the Company records revenue.

c)	Licensee and royalty income

Licensee and royalty income consist of royalty income earned on the processing and storage of cord blood stem cell specimens by an affiliate where the Company has a License and Royalty Agreement. The Company records revenue from processing and storage of specimens and pursuant to agreements with licensees. The Company records the royalty revenue in same period that the related processing and storage is being completed by the affiliate.

d)	Product Revenue

The Company records revenue from the sale of the PrepaCyte CB product line upon shipment of the product to the Company’s customers.

e)	Shipping and handling

The Company elected to apply the practical expedient to account for shipping and handling activities performed after the control of a good has been transferred to the customer as a fulfillment cost. Shipping and handling costs that the Company incurs are therefore expensed and included in cost of sales.

The adoption of ASC 606 did not have an impact on the timing of revenue recognition for any of the Company’s revenue streams.

Disaggregation of Revenue

The following table provides information about disaggregated revenue by products and services:


	Twelve months ended
	November 30, 2019		November 30, 2018
Processing and storage fees	$	29,991,972	$	27,817,872
Public banking revenue		652,204		296,295
Licensee and royalty income		1,000,000		1,000,000
Product revenue		172,395		104,323

	$	31,816,571	$	29,218,490

The following table provides information about assets and liabilities from contracts with customers:


	November 30, 2019		At Adoption
Contract assets (sales commissions)	$	398,535	$	329,231
Accounts receivables	$	6,097,331	$	5,867,335
Short-term contract liabilities (deferred revenue)	$	8,875,138	$	8,365,284
Long-term contract liabilities (deferred revenue)	$	23,633,373	$	20,317,231

The Company, in general, requires the customer to pay for processing and storage services at the time of processing. Contract assets include deferred contract acquisition costs, which will be amortized along with the associated revenue. Contract liabilities include payments received in advance of performance under the contract and are realized with the associated revenue recognized under the contract. Accounts receivable consists of amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs related to renewals of annual plans and amounts due from license affiliates, and sublicensee territories. The Company did not have asset impairment charges related to contract assets in the twelve months ended November 30, 2019.

The following table presents changes in the Company’s contract assets and liabilities during the twelve months ended November 30, 2019:


	Balance at December 1, 2018		Additions		Deductions			Balance at November 30, 2019
Contract assets (sales commissions)	$	329,231	$	88,569	($	19,265	)	$	398,535
Accounts receivables	$	5,867,335	$	36,579,504	($	36,349,508	)	$	6,097,331
Contract liabilities (deferred revenue)	$	28,682,515	$	18,759,963	($	14,933,967	)	$	32,508,511

Revenue Sharing Agreements

The Company entered into Revenue Sharing Agreements (“RSAs”) prior to 2002 with various third and related parties. The Company’s RSAs provide that in exchange for a non-refundable up-front payment, the Company would share for the duration of the contract a percentage of its future storage revenue collected from the annual storage fees charged related to a certain number of specimens that originated from specific geographical areas. The RSAs have no definitive term or termination provisions. The sharing applies to the storage fees collected for all specified specimens in the area up to the number covered in the contract. When the number of specimens is filled, any additional specimens stored in that area are not subject to revenue sharing. As there are empty spaces resulting from attrition, the Company agrees to fill them as soon as possible. The Company has reflected these up-front payments as long-term liabilities on the accompanying consolidated balance sheets. The Company does not intend to enter into additional RSAs.

In the future, the Company could reverse the liability relating to the RSAs over an appropriate period of time, based on the Company’s expectations of the total amount of payments it expects to pay to the other party under the particular RSA. However, the RSAs do not establish a finite term or time frame over which to estimate the total payments and the Company had not previously estimated and has concluded that it is not currently practicable to estimate the projected cash flows under the RSAs. At present, the Company intends to defer the reversal of the liability, until such time as these amounts can

be determined. During the periods when the Company defers the reversal of the liability, the quarterly payments made during these periods will be treated as interest expense, which will be recognized as the payments become due. In future periods, if a portion of the liability can be de-recognized based on the effective interest method, the payments will be allocated between interest and amortization of the liability. As cash is paid out to the other party during any period, the liability would be de-recognized based on the portion of the total anticipated payouts made during the period, using the effective interest method. That is, a portion of the payment would be recorded as interest expense, and the remainder would be treated as repayment of principal, which would reduce the liability.

License and Royalty Agreements

In addition to the license fee, the Company earns processing and storage fees on subsequent processing and storage revenues received by the licensee in the licensed territory and a fee on any sub-license agreements that are sold by the licensee where applicable. These fees are included in processing and storage fees revenue on the consolidated statements of comprehensive income (loss). As part of the accounting for royalty revenue from India, the Company uses estimates and judgments based on historical processing and storage volume in determining the timing and amount of royalty revenue to recognize. The Company periodically reviews license and royalty receivables for collectability and, if necessary, will record an expense for an allowance for uncollectible accounts.

Cash and Cash Equivalents

Cash and cash equivalents consist of highly liquid investments with a maturity date of three months or less at the time of purchase.

Accounts Receivable

Inventory

Property and Equipment

Property and equipment are stated at cost. Depreciation is provided primarily by the straight-line method over the estimated useful lives of the related assets. Estimated useful lives of property and equipment are as follows:


Furniture and equipment		3-10 years

Leasehold improvements		Lesser of 8-10 years or the lives of the leases

Computer software – internal use		1-5 years

Leasehold improvements are amortized over the shorter of the respective life of the lease or the estimated useful lives of the improvements. Upon the sale or retirement of depreciable assets, the cost and related accumulated depreciation is removed from the accounts and the resulting profit or loss is reflected in earnings. Expenditures for maintenance, repairs and minor betterments are expensed as incurred.

The Company capitalizes external direct costs of materials and services consumed in developing or obtaining internal-use computer software. Capitalized internal-use software costs, which are included in property and equipment, are depreciated over the estimated useful lives of the software.

Long-Lived Assets

The Company evaluates the realizability of its long-lived assets, which requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment, such as reductions in demand or when significant economic slowdowns are present. Reviews are performed to determine whether the carrying value of an asset is impaired, based on comparisons to undiscounted expected future cash flows. If this comparison indicates that there is impairment and carrying value is in excess of fair value, the impaired asset is written down to fair value, which is typically calculated using: (i) quoted market prices or (ii) discounted expected future cash flows utilizing a discount rate. The Company did not note any indicators of impairment as of November 30, 2019 and November 30, 2018, respectively.

Goodwill

Goodwill represents the excess of the purchase price of the assets acquired from Cord:Use (Note 2) over the estimated fair value of the net tangible, intangible and identifiable assets acquired. The annual assessment of the reporting unit is performed as of September 1st, and an assessment is performed at other times if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below its carrying value. The Company first performs a qualitative assessment to test goodwill for impairment and concludes if it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment concludes that it is not more likely than not that the fair value is less than the carrying value, the two-step goodwill impairment test is not required. If the qualitative assessment concludes that it is more likely than not that the fair value of the reporting unit is less than the carrying value, then the two-step goodwill impairment test is required. Step one of the impairment assessment compares the fair value of the reporting unit to its carrying value and if the fair value exceeds its carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, the implied fair value of goodwill is compared to the carrying value of goodwill. If the implied fair value exceeds the carrying value then goodwill is not impaired; otherwise, an impairment loss would be recorded by the amount the carrying value exceeds the implied fair value.

Income Taxes

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The Company records a valuation allowance when it is “more likely than not” that all of the future income tax benefits will not be realized. When the Company changes its determination as to the amount of deferred income tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to income tax expense in the period in which such determination is made. The ultimate realization of the Company’s deferred income tax assets depends upon generating sufficient taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, the Company projects future levels of taxable income. This assessment requires significant judgment. The Company examines the evidence related to the recent history of losses, the economic conditions in which the Company operates and forecasts and projections to make that determination.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management’s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions.

The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. For fiscal 2019 and 2018 the Company had no uncertain tax provisions and therefore no material provisions for interest or penalties related to uncertain tax positions.

Research, Development and Related Engineering Costs

Research, development and related engineering costs are expensed as incurred.

Cost of Sales

Cost of sales represents the associated expenses resulting from the processing, testing, storage and delivery of the umbilical cord blood. Cost of sales related to PrepaCyte CB represents the associated expenses resulting from the manufacturing of the PrepaCyte CB units. Cost of sales related to the Public Cord Blood Bank represents the associated expenses resulting from the collection, shipping, processing and storage of the cord blood stem cell units.

Advertising

Advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). Total advertising expense for the fiscal years ended November 30, 2019 and 2018 was approximately $981,448 and $986,664, respectively.

Rent Expense

Rent is expensed on a straight-line basis over the term of the lease and is included in cost of sales and selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). All leases include provisions for escalations and related costs.

Legal Expense

Legal fees are expensed as incurred and are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss).

Fair Value of Financial Instruments

Management uses a fair value hierarchy, which gives the highest priority to quoted prices in active markets. The fair value of financial instruments is estimated based on market trading information, where available. Absent published market values for an instrument or other assets, management uses observable market data to arrive at its estimates of fair value. Management believes that the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments. The Company believes that the fair value of its Revenue Sharing Agreements (”RSA”) liability recorded on the balance sheet is between the recorded book value and up to the Company’s previous settlement experience, due to the various terms and conditions associated with each RSA.

The Company uses an accounting standard that defines fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The three levels of inputs used to measure fair value are as follows:


Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3		Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of November 30, 2019 and November 30, 2018, respectively, segregated among the appropriate levels within the fair value hierarchy:


	Fair Value at			at November 30, 2019 Using
Description	November 30, 2019			Level 1		Level 2		Level 3
Assets:
Marketable securities	$	904,053		$	904,053		—		—

Total	$	904,053		$	904,053		—		—

Liabilities:
Contingent consideration	$	3,495,057		$	—		—	$	3,495,057

Total	$	3,495,057		$	—		—	$	3,495,057

Contingent Consideration:
Beginning Balance as of November 30, 2018	$	4,282,975
Subtractions – Cord:Use earnout payment		(45,000	)
Fair value adjustment as of November 30, 2019		(742,918	)

Ending balance as of November 30, 2019	$	3,495,057


			Fair Value Measurements
	Fair Value at		at November 30, 2018 Using
Description	November 30, 2018		Level 1		Level 2		Level 3
Assets:
Trading securities	$	68,816	$	68,816		—		—
Available-for-sale securities		806,873		806,873		—		—

Total	$	875,689	$	875,689		—		—

Liabilities:
Contingent consideration	$	4,282,975	$	—		—	$	4,282,975

Total	$	4,282,975	$	—		—	$	4,282,975

The following is a description of the valuation techniques used for these items, as well as the general classification of such items pursuant to the fair value hierarchy:

Trading securities – Fair values for these investments are based on quoted prices of identical securities in active markets and are therefore classified within Level 1 of the fair value hierarchy. For trading securities, there was approximately ($28,000) in unrealized holding losses, respectively, recorded in other income and expense on the accompanying consolidated statements of comprehensive income (loss) for the twelve months ended November 30, 2018.

Available-for-sale securities – These investments are classified as available for sale and consist of marketable equity securities that we intend to hold for an indefinite period of time. Investments are stated at fair value and unrealized holding gains and losses are reported as a component of accumulated other comprehensive income until realized. Realized gains or losses on disposition of investments are computed using the first in, first out (FIFO) method and reported as income or loss in the period of disposition in the accompanying consolidated statements of comprehensive income (loss). For available-for-sale securities, there was approximately $300,000 in unrealized holding gains (loss), net of tax, respectively, reported as comprehensive income on the accompanying statements of comprehensive income (loss) for the year ended November 30, 2018.

Marketable securities - Effective December 1, 2018, the Company adopted ASU 2016-01, which requires equity securities with readily determinable fair values to be measured at fair value with the changes in fair value recognized through net income. Such securities are no longer reflected as trading or available-for-sale but are noted as marketable securities. As a result of this accounting change, in the first quarter of 2019, the Company recognized a cumulative-effect adjustment from accumulated other comprehensive income to retained earnings of approximately $341,000 in the consolidated statements of stockholders’ deficit as of the date of adoption. Prior periods have not been restated for the impact of this accounting change. There was $28,000 in unrealized holding gain recorded in other income and expense on the accompanying consolidated statements of comprehensive income (loss) for the twelve months ended November 30, 2019.

Contingent consideration - The contingent consideration is the earnout that Cord:Use is entitled to from the Company’s sale of the public cord blood inventory from and after closing. See Note 2. The estimated fair value of the contingent earnout was determined using a monte carlo analysis examining the frequency and mean value of the resulting earnout payments. The resulting value captures the risk associated with the form of the payout structure. The risk-neutral method is applied, resulting in a value that captures the risk associated with the form of the payout structure and the projection risk. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different from the estimated value of the liability.

Product Warranty and Cryo-Cell Cares^TM Program

In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.

As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. Upon the adoption of ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits at November 30, 2019. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.

Income (Loss) per Common Share

Basic income (loss) per common share was computed by dividing net income by the weighted average number of common shares outstanding for the fiscal year ended or as of the date indicated. Diluted income per common share includes the effect of all dilutive stock options. The composition of basic and diluted net (loss) income per share is as follows:


	November 30, 2019		November 30, 2018
Numerator:
Net income (loss)	$	2,290,774	($	854,824	)
Denominator:
Weighted-average shares outstanding-basic		7,794,828		7,463,051
Dilutive common shares issuable upon exercise of stock options		617,586		—

Weighted-average shares-diluted		8,412,414		7,463,051

Income(Loss) per share:
Basic	$	0.29	($	0.11	)

Diluted	$	0.27	($	0.11	)

For the year ended November 30, 2019, the Company excluded the effect of 70,136 outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.

For the year ended November 30, 2018, the Company excluded the effect of all outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.

Stock Compensation

As of November 30, 2019, the Company has two stock-based employee compensation plans, which are described in Note 11 to the consolidated financial statements. The Company’s stock-based employee compensation plan became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting. The Company recognized approximately $398,000 and $478,000 for the fiscal years ended November 30, 2019 and November 30, 2018, respectively, of stock compensation expense. The Company reversed $444,000 of stock compensation expense during the twelve months ended November 30, 2018 as the Co-CEOs each opted to receive a lump sum cash payment in lieu of 30,000 shares of earned common stock pursuant to the terms of their Employment Agreements. The reversal had no impact on the accompanying consolidated statements of comprehensive income (loss) as other compensation expense was recognized to offset the reversal.

Reclassifications

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no material effect on the reported results of operations.

Recently Issued Accounting Pronouncements

In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles – Goodwill and Other Internal-Use Software (Topic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. This update addresses how a customer should account for the costs of implementing a cloud computing service arrangement (also referred to as a “hosting arrangement”). Entities should account for costs associated with implementing a cloud computing arrangement that is considered a service contract in the same way as accounting for implementation costs incurred to develop or obtain software for internal use using the guidance in Topic 350-40. The amendments address when costs should be capitalized rather than expensed, the term to use when amortizing capitalized costs, and how to evaluate the unamortized portion of these capitalized implementation costs for impairment. The ASU also includes guidance on how to present

implementation costs in the financial statements and creates additional disclosure requirements. The guidance is effective for annual periods beginning after December 15, 2019, and interim periods within that reporting period. The Company is currently evaluating the effect that the updated standard will have on our financial statements.

In June 2018, the FASB issued Accounting Standards Update No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This update simplifies the accounting for nonemployee share-based payment transactions by expanding the scope of Topic 718, Compensation-Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within that reporting period. The Company is currently evaluating the effect that the updated standard will have on our financial statements.

In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The update removes Step 2 from the goodwill impairment test. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, although early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on our financial statements.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842). This update requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. It also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated balance sheets and related disclosures.

Note 2 – Acquisition

The aggregate consideration payable at closing under the Purchase Agreement was $14,000,000, with $10,500,000 paid in cash and the balance paid through the delivery to Seller of 465,426 shares of Cryo-Cell’s common stock, par value $0.01 per share (“Common Stock”), at $7.52 per share. In addition, Cryo-Cell assumed certain limited liabilities incurred by Cord:Use in connection with its business that were unpaid as of the closing date and that directly relate to the services to be provided after closing by Cryo-Cell. Cryo-Cell also assumed certain of Cord:Use’s contracts and the obligations arising therefrom after the closing.

revenues, net of any returns, received and retained by Cryo-Cell in excess of the initial $500,000 retained by Cryo-Cell during such year, Cryo-Cell will deliver $200,000 worth of Cryo-Cell Common stock to Cord:Use, up to an aggregate value of $5,000,000. Cord:Use is also entitled to a portion of the gross profits generated, or deemed to have been generated, by Cryo-Cell from its ownership of the Tianhe Capital Stock.

The Company incurred $580,000 in costs associated with the acquisition of Cord:Use.

The following summarizes the fair value of the consideration of the Acquisition as of the purchase date:


Consideration
Cash	$	10,500,000
Cryo-Cell common stock		3,500,000
Cord blood inventory earnout		4,698,255

Consideration	$	18,698,255

The following summarizes the allocation of the total purchase price for the Acquisition:


Accounts receivable	$	188,019
Inventory		16,037,957
Prepaid expenses		68,867
Property and equipment		568,407
Other asset—Tianhe capital stock		308,000
Brand		31,000
Customer relationships		960,000

Total identifiable net assets acquired		18,162,250

Less: Deferred revenue		(1,405,406	)

Goodwill		1,941,411

Total	$	18,698,255

The Company has assigned goodwill to the segment reporting unit for cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. Goodwill includes the fair value of the assembled workforce. The fair value of the assembled workforce was estimated by applying a cost approach, representing a level 2 measurement. The goodwill is not deductible for income tax purposes.

The property and equipment are stated at an estimate of fair value.

The Tianhe capital stock is an investment that is valued based on fair value. Cord:Use had a supply and equity participation agreement with Tianhe who is engaged in medical and life science research that involves the use of stem cells derived from umbilical cord blood units in clinical trials for humans.

The fair value of the company brand and customer relationships were estimated by applying an income approach, representing a level 3 measurement. The fair value estimates are based on (1) an assumed discount rate of 19%, (2) long-term sustainable growth rate of 3%, (3) market royalty rate of 1% and (4) one and thirty-year lives for the brand and customer relationships, respectively.

The fair values of the assets acquired includes public cord blood banking inventory of $16,037,957 which the Company expects to sell to outside customers. The Company also acquired accounts receivable of $188,019 and prepaid expenses of $68,867.

The fair values of the license agreement and customer relationships reflect the anticipated cash flows over their expected lives.

The fair value of deferred revenue is valued based on the cost method. Deferred revenues are pre-payment fees for future storage of umbilical cord blood and/or cord tissue specimens. The short- and long-term deferred revenue is $330,508 and $1,074,898, respectively.

Unaudited Pro forma Results

The following table provides the Company’s consolidated unaudited pro forma revenues, net income per basic and diluted common share had the results of the acquired businesses’ operations been included in its operations commencing on December 1, 2016, based on available information related to the respective operations. This proforma information presented is not necessarily indicative either of the combined results of operations that actually would have been realized by the Company had the acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results, and does not account for any operation improvements to be made by the Company post-acquisition.


	Twelve months ended November 30, 2018
Revenue	$	31,388,278
Net income (loss)	($	2,658,679	)
Earnings (loss) per share:
Basic	($	0.36	)
Diluted	($	0.36	)

Note 3 – Inventory

Inventory is comprised of public cord blood banking specimens, collection kits, finished goods, work-in-process and raw materials. Collection kits are used in the collection and processing of umbilical cord blood and cord tissue stem cells, finished goods include products purchased or assumed for resale and for the use in the Company’s processing and storage service. Inventory in the Public Cord Blood Bank includes finished goods that are specimens that are available for resale. The Company considers inventory in the Public Cord Blood Bank that has not completed all testing to determine viability to be work in process. Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of $2,332,763 was recognized during the second quarter of fiscal 2019 to reduce inventory from cost to net realizable value and is included in the accompanying consolidated statements of comprehensive income (loss).

The components of inventory at November 30, 2019 and November 30, 2018 are as follows:


	As of November 30, 2019			As of November 30, 2018
Raw materials	$	—		$	—
Work-in-process		149,972			188,085
Work-in-process – Public Bank		—			—
Finished goods		52,451			5,262
Finished goods – Public Bank		13,491,375			15,831,081
Collection kits		44,453			19,163
Inventory reserve		(7,718	)		(7,718	)

Total inventory	$	13,730,533		$	16,035,873

Note 4– Intangible Assets

Intangible assets were as follows as of November 30, 2019 and 2018:


	Useful lives	November 30, 2019			November 30, 2018
Patents	10-20 years	$	234,570		$	234,570
Less: Accumulated amortization			(35,526	)		(23,663	)
License agreement	10 years		470,000			470,000
Less: Intangible asset impairment			(185,000	)		(185,000	)
Less: Accumulated amortization			(155,194	)		(123,528	)
Customer relationships – Prepacyte^®CB	15 years		41,000			41,000
Less: Intangible asset impairment			(26,267	)		(26,267	)
Less: Accumulated amortization			(6,329	)		(5,276	)
Brand	1 year		31,000			31,000
Less: Accumulated amortization			(31,000	)		(15,500	)
Customer relationships – Cord:Use	30 years		960,000			960,000
Less: Accumulated amortization			(48,000	)		(16,000	)

Net Intangible Assets		$	1,249,254		$	1,341,336

Expected amortization related to these intangible assets for each of the next five fiscal years and for periods thereafter is as follows:

Fiscal years ending November 30:


2020	$	67,667
2021	$	67,667
2022	$	67,667
2023	$	67,667
2024	$	67,667
Thereafter	$	910,919

Total	$	1,249,254

Amortization expense of intangibles was approximately $92,000 and $76,000 for the twelve months ended November 30, 2019 and November 30, 2018, respectively.

Note 5– Note Payable

On May 20, 2016, the Company entered into a Credit Agreement (“Agreement”) with Texas Capital Bank, National Association (“TCB”) for a term loan of $8.0 million in senior credit facilities. The proceeds of the term loan were used by the Company to fund repurchases of the Company’s common stock. Subject to the terms of the Agreement, on May 20, 2016, TCB advanced the Company $100.00. On July 1, 2016, TCB advanced the remaining principal amount of $7,999,900 per a promissory note dated May 20, 2016 between the Company and TCB, at a rate of 3.75% per annum plus LIBOR, payable monthly with a maturity date of July 2021. On August 26, 2016, the Company entered into a First Amendment to Credit Agreement with TCB. Pursuant to terms of the First Amendment to Credit Agreement, on August 26, 2016, TCB made an additional advance to the Company in principal amount of $2,133,433 per an Amended and Restated Promissory Note dated August 26, 2016 between the Company and TCB. The additional proceeds of the term loan were used by the Company to fund the extinguishment of revenue sharing agreements. On June 11, 2018, the Company entered into a Second Amendment to Credit Agreement with TCB. Pursuant to the terms of the Second Amendment to Credit Agreement, TCB increased the current outstanding principal amount of the loan from TCB by $9,000,000 to finance a portion of the purchase price of the Cord:Use Purchase. In connection therewith, Cryo-Cell executed and delivered to TCB a Second Amended and Restated Promissory Note, in the principal amount of $15,500,000. As of November 30, 2019, and November 30, 2018, the Company paid interest of $646,744 and $589,583, respectively, which is reflected in interest expense on the accompanying consolidated statements of comprehensive income (loss).

Collateral of the term and subordinated loans includes all money, securities and property of the Company.

The Company incurred debt issuance costs related to the term and subordinated loans in the amount of $548,085 which is recorded as a direct reduction of the carrying amount of the note payable and amortized over the life of the loan. As of November 30, 2019, and November 30, 2018, $112,642 and $109,293, respectively, of the debt issuance costs were amortized and are reflected in interest expense on the accompanying consolidated statements of comprehensive income (loss).

As of November 30, 2019, and November 30, 2018, the note payable obligation was as follows:


	November 30, 2019			November 30, 2018
Note payable	$	9,108,433		$	13,208,433
Unamortized debt issuance costs		(152,281	)		(264,923	)

Net note payable	$	8,956,152		$	12,943,510

Current portion of note payable	$	3,100,000		$	3,100,000
Long-term note payable, net of debt issuance costs		5,856,152			9,843,510

Total	$	8,956,152		$	12,943,510

Future principal payments under the note payable obligation are as follows:


Years ending November 30:	Amount
2020		3,100,000
2021		3,100,000
2022		2,908,433

Total	$	9,108,433

Interest expense on the note payable for the years ended November 30, 2019 and November 30, 2018 was as follows:


	November 30, 2019		November 30, 2018
Interest expense on notes payable	$	646,744	$	589,583
Debt issuance costs		112,642		109,293

Total interest expense	$	759,386	$	698,876

Note 6– Segment Reporting

During the third quarter of fiscal 2018, the Company purchased the assets and assumed contracts that Cord:Use used in the operation of its cord blood business (See Note 2). The Company evaluated and determined that this acquisition qualifies as a separate segment.

The Company is organized in three reportable segments:

The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. Revenue is generated from the initial processing and testing fees and the annual storage fees charged each year for storage (the “Umbilical cord blood and cord tissue stem cell service”).

The manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells. Revenue is generated from the sales of the PrepaCyte CB units (the “PrepaCyte CB”).

The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Revenue is generated from the sale of the cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States, and around the world.

The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax (expense) benefit, other comprehensive loss, and assets for the years ended November 30, 2019 and 2018:


	For the years ended November 30,
	2019		2018
Net revenue:
Umbilical cord blood and cord tissue stem cell service	$	30,991,972	$	28,817,872
PrepaCyte CB		172,395		104,323
Public cord blood banking		652,204		296,295

Total net revenue	$	31,816,571	$	29,218,490

Cost of sales:
Umbilical cord blood and cord tissue stem cell service	$	8,490,824	$	7,744,208


PrepaCyte CB		249,487			169,397
Public cord blood banking		1,295,864			626,057

Total cost of sales	$	10,036,175		$	8,539,662

Operating profit:
Umbilical cord blood and cord tissue stem cell service	$	8,152,475		$	5,620,394
PrepaCyte CB		(113,346	)		(101,329	)
Public cord blood banking		(2,976,423	)		(329,762	)

Total operating profit	$	5,062,706		$	5,189,303

Depreciation and amortization:
Umbilical cord blood and cord tissue stem cell service	$	365,057		$	281,072
PrepaCyte CB		36,254			36,254
Public cord blood banking		—			—

Total depreciation and amortization	$	401,311		$	317,326

Interest expense:
Umbilical cord blood and cord tissue stem cell service	$	1,703,446		$	1,546,900
PrepaCyte CB		—			—
Public cord blood banking		—			—

Total interest expense	$	1,703,446		$	1,546,900

Income tax (expense) benefit:

Umbilical cord blood and cord tissue stem cell service	$	(1,100,641	)	$	(4,472,504	)

PrepaCyte CB		—			—
Public cord blood banking		—			—

Total income tax (expense) benefit	$	(1,100,641	)	$	(4,472,504	)

Other comprehensive income (loss):
Umbilical cord blood and cord tissue stem cell service	$	—		$	300,119
PrepaCyte CB		—			—
Public cord blood banking		—			—

Total other comprehensive income (loss)	$	—		$	300,119

The following table shows the assets by segment as of November 30, 2019 and November 30, 2018:


	2019		2018
Assets:
Umbilical cord blood and cord tissue stem cell service	$	28,975,002	$	26,239,260
PrepaCyte CB		289,804		319,802
Public cord blood banking		13,621,354		15,831,081

Total assets	$	42,886,160	$	42,390,143

NOTE 7—ALLOWANCE FOR DOUBTFUL ACCOUNTS

The activity in the allowance for doubtful accounts is as follows for the years ended November 30, 2019 and 2018:


December 1, 2017	$	2,098,991
Bad Debt Expense		727,483
Write-offs		(907,263	)
Recoveries		345,637

November 30, 2018		2,264,848
Bad Debt Expense		767,128
Write-offs		(756,688	)
Recoveries		308,803

November 30, 2019	$	2,584,091

NOTE 8—PROPERTY AND EQUIPMENT

The major classes of property and equipment are as follows:


	2019			2018
Furniture and equipment	$	6,568,205		$	5,905,910
Leasehold improvements		1,200,934			1,200,934
Computer software – internal use		1,194,039			1,194,039

		8,963,178			8,300,883
Less: Accumulated Depreciation		(7,116,711	)		(6,807,482	)

Total Property and Equipment	$	1,846,467		$	1,493,401

Depreciation expense was approximately $309,000 in fiscal 2019 and approximately $241,000 in fiscal 2018 of which approximately $195,000 and $137,000 is included in cost of sales, respectively, in the accompanying consolidated statements of comprehensive income (loss).

NOTE 9—ACCRUED EXPENSES

Accrued expenses are as follows:


	November 30,
	2019		2018
Professional fees	$	115,000	$	14,867
Payroll and payroll taxes (1)		513,108		1,021,004
Interest expense		950,300		864,676
General expenses		330,726		478,449
Federal and state taxes		176,046		323,792

	$	2,085,180	$	2,702,788

(1)	– Payroll and payroll taxes includes accrued vacation and wages due as of November 30, 2019 and November 30, 2018.

NOTE 10—INCOME TAXES

The Company recorded the following income tax provision for the years ended November 30, 2019 and 2018.


	2019			2018
Current:
Federal	$	1,637,000		$	1,467,000
State		769,000			622,000
Foreign		108,000			108,000

Subtotal		2,514,000			2,197,000
Deferred:
Federal		(1,106,000	)		2,716,000
State		(307,000	)		(441,000	)
Foreign		—			—

Subtotal		(1,413,000	)		2,275,000

Income Tax Expense	$	1,101,000		$	4,472,000

As of November 2019 and 2018, the tax effects of temporary differences that give rise to the deferred tax assets are as follows:


	2019			2018
Tax Assets:
Deferred income (Net of Discounts)	$	6,256,000		$	5,157,000
Tax over book basis in unconsolidated affiliate		1,224,000			1,214,000
Accrued payroll		82,000			257,000
Reserves and other accruals		1,589,000			868,000
Stock compensation		411,000			330,000
Depreciation and Amortization		450,000			428,000
Transaction costs		18,000			18,000
RSA Buy-out		1,095,000			1,210,000

Total Assets:		11,125,000			9,482,000
Tax Liabilities:
Unrealized gains on marketable securities		(117,000	)		(112,000	)
NOL’s credits, and other carryforward items		(282,000	)		(79,000	)

Total Liabilities:		(399,000	)		(191,000	)
Less: Valuation Allowance		(1,646,000	)		(1,634,000	)

Net Deferred Tax Asset	$	9,080,000		$	7,657,000

A valuation allowance covering the deferred tax assets of the Company for November 30, 2019 and November 30, 2018, has been provided as the Company does not believe it is more likely than not that all of the future income tax benefits will be realized. The valuation allowance changed by approximately ($12,000) and ($711,000) during the years ended November 30, 2019 and 2018, respectively. The change for year ended November 30, 2019 was primarily due to changes in statutory rates. The change for year ended November 30, 2018 was a result of the revaluation impact of the Tax Cuts and Jobs Act of 2017 which reduced the federal tax rate from 34% to 21%.

The Company evaluates the recoverability of our deferred tax assets as of the end of each quarter, weighing all positive and negative evidence, and are required to establish and maintain a valuation allowance for these assets if we determine that it is more likely than not that some or all of the deferred tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed.

The positive evidence that weighed in favor of releasing the allowance as of November 30, 2017 and ultimately outweighed the negative evidence against releasing the allowance was the following:

•

Identifiable sources of future income relating to the Company’s deferred revenue accounts;

•

Certainty as to the amount available of deferred tax assets and nature in which the deferred tax assets reverse;

•

Profitability for years ended November 30, 2015 and 2016 and our expectations regarding the sustainability of these profits;

•

The Company’s three-year cumulative position as of November 30, 2017; and

•

The Company’s taxable income projection for fiscal years ending November 30, 2018, 2019 and 2020.

The Tax Cuts and Jobs Act (the “Tax Act”) was signed into law on December 22, 2017. The Tax Act makes significant changes to provision of the Internal Revenue Code, including changing the corporate tax rate to a flat 21% rate as of January 1, 2018. This requires the Company’s net deferred tax assets and liabilities to be revalued at the newly enacted U.S. corporate rate. The impact will be recognized in tax expense in the year of enactment. Based on evaluation, the Company’s discrete expense for the rate impact will be approximately $3.1 million. Based on the Company’s evaluation, the Tax Act is not expected to impact the recoverability of its deferred tax asset.

A reconciliation of the income tax provision with the amount of tax computed by applying the federal statutory rate to pretax income follows:


	For the Years Ended November 30
	2019		%		2018		%
Tax at Federal Statutory Rate		733,198		21.00		799,507		22.10
State Income Tax Effect		220,527		6.32		216,608		5.99
Valuation Allowance Release		—		0.00		—		0.00
Tax Compensation Differences		26,330		0.75		260,845		7.21


Permanent Disallowances		76,775		2.20			149,141		4.12
Impact of Tax Reform		—		0.00			3,078,094		85.08
Deferred Repricing		24,533		0.70			(28,337	)	(0.78	)
Other		19,278		(0.10	)		(3,354	)	(0.09	)
Foreign tax credits		(108,150	)	(3.10	)		(108,314	)	(2.99	)
Foreign tax withholding		108,150		3.10			108,314		2.99

Total income taxes	$	1,100,641		30.87		$	4,472,504		123.63

The Company adopted the accounting standard for uncertain tax positions, ASC 740-10, on December 1, 2007. As required by the standard, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management’s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions. There were no uncertain tax positions as of November 30, 2019 and 2018.

There was approximately $2,801,000 and $2,204,000 of U.S. income taxes paid for the fiscal years ended November 30, 2019 and November 30, 2018, respectively.

The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. For the years ended November 30, 2019 and 2018, the Company had no material provisions for interest or penalties related to uncertain tax positions.

The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. The table below summarizes the open tax years and ongoing tax examinations in major jurisdictions as of November 30, 2019:


Jurisdiction	Open Tax Years	Examinations in Process
United States – Federal Income Tax	2015 – 2018	N/A
United States – Various States	2013 – 2018	N/A

NOTE 11—STOCKHOLDERS’ EQUITY.

Common Stock Issuances

During the year ended November 30, 2019, the Company issued 2,500 common shares to option holders who exercised options for $5,700. During the year ended November 30, 2018, the Company issued 63,750 common shares to option holders who exercised options for $170,925.

Employee Stock Incentive Plan

The Company maintains the 2006 Stock Incentive Plan (the “2006 Plan”) under which it has reserved 1,000,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, stock-appreciation rights (commonly referred to as “SARs”) and stock awards (i.e. performance options to purchase shares and performance units). As of November 30, 2019, and November 30, 2018, there were 325,000 and 380,000 options issued, but not yet exercised, under the 2006 Plan, respectively. As of November 30, 2019, there were 0 shares available for future issuance under the 2006 Plan.

The Company maintains the 2012 Equity Incentive Plan (the “2012 Plan”) which became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting on July 10, 2012. The 2012 Plan originally reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, SARs, and other stock awards (i.e. performance shares and performance units). In May 2012, the Board of Directors approved an amendment to the 2012 Plan to increase the number of shares of the Company’s common stock reserved for issuance to 2,500,000 shares. In October 2019, the Board of Directors approved amendments to the plan, subject to ratification by the stockholders, which occurred at the Company’s 2019 Annual Meeting of Stockholders on November 21, 2019. See the Company’s Proxy Statement filed with the Securities and Exchange Commission on October 29, 2019 in connection with the Company’s 2019 Annual Meeting (the “2019 Proxy Statement”). As of November 30, 2019, there were 763,274 service-based options issued, 129,729 service-based restricted common shares granted, 530,851 performance-based and 116,218 market-based restricted common shares granted under the 2012 Plan. As of November 30, 2018, there were 621,365 service-based options issued, 129,729 service-based restricted common shares granted, 823,415 performance-based and 116,240 market-based restricted common shares granted under the 2012 Plan. As of November 30, 2019, there were 667,479 shares available for future issuance under the 2012 Plan.

The Company granted 1,500 options to an optionee during the second fiscal quarter of 2019 as approved by the Board of Directors. These options were not issued under either the 2006 or 2012 Plan.

ratification of certain equity-based awards and stock issuances made pursuant to the Company’s incentive Plans, as well as the approval of certain amendments to those incentive Plans. All such matters presented to the stockholders were duly approved by the stockholders at the 2019 Annual Meeting. Accordingly, all references contained herein to the number of options or shares of common stock granted under the Company’s incentive Plans, the value thereof, and the number of securities that remain available for future issuance under the Company’s 2012 Plan for all periods presented in this Annual Report on Form 10-K have been calculated and are being presented after taking into account the ratification and surrender of the Defective Awards and Issuances in accordance with the Recommended Disposition, as further described in the 2019 Proxy Statement.

Service-based vesting condition options

The fair value of each option award is estimated on the date of the grant using the Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatility is based on the historical volatility of the Company’s stock over the most recent period commensurate with the expected life of the Company’s stock options. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected term of options granted to employees is based upon historical exercise data. Expected dividends are based on the historical trend of the Company not issuing dividends.

Variables used to determine the fair value of the options granted for the years ended November 30, 2019 and November 30, 2018 are as follows:


	2019		2018
Weighted average values:
Expected dividends		0%		0%
Expected volatility		64.02%		50.85%
Risk free interest rate		1.55%		2.67%
Expected life		8.4 years		5.0 years

Stock option activity for options with only service-based vesting conditions for the year ended November 30, 2019, was as follows:


				Weighted		Weighted Average
				Average		Remaining		Aggregate
	Options			Exercise Price		Contractual Term (Years)		Intrinsic Value
Outstanding at November 30, 2018		1,001,365		$	2.77		3.97	$	4,580,967
Granted		143,409			7.55				4,851
Exercised		(2,500	)		2.28				14,175
Expired/forfeited		(52,500	)		4.82				143,450

Outstanding at November 30, 2019		1,089,774			3.30		3.91	$	4,648,111

Exercisable at November 30, 2019		964,540			2.75		3.33	$	4,644,277

The weighted average grant date fair value of options granted during the years ended November 30, 2019 and November 30, 2018 was $5.02 and $3.23, respectively.

The aggregate intrinsic value represents the total value of the difference between the Company’s closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of in-the-money stock options that would have been received by the option holders had all option holders exercised their options on either November 30, 2019 or November 30, 2018, as applicable. The intrinsic value of the Company’s stock options changes based on the closing price of the Company’s stock.

Significant option groups outstanding and exercisable at November 30, 2019 and related price and contractual life information are as follows:


	Outstanding						Exercisable
			Weighted Average
			Remaining		Weighted				Weighted
Range of Exercise Prices	Outstanding		Contractual Life (Years)		Average Exercise Price		Outstanding		Average Exercise Price
$1.01 to $2.00		422,500		2.10	$	1.73		422,500	$	1.73
$2.01 to $3.00		265,000		2.11	$	2.72		265,000	$	2.72
$3.01 to $4.00		204,729		6.23	$	3.14		204,729	$	3.14
$6.01 to $7.00		2,500		4.65	$	6.50		1,667	$	6.50
$7.01 to $8.00		195,045		7.84	$	7.63		70,644	$	7.67

		1,089,774		3.91	$	3.30		964,540	$	2.75

A summary of the status of the Company’s non-vested options as of November 30, 2019, and changes during the fiscal year then ended, is presented below:


				Weighted Average
				Grant-Date
	Options			Fair Value
Non-vested at November 30, 2018		40,254		$	3.06
Granted		143,409			5.02
Vested		(58,429	)		4.36
Forfeited		—			—

Non-vested at November 30, 2019		125,234		$	4.70

As of November 30, 2019, there was approximately $519,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 Plan and the 2012 Plan. The cost is expected to be recognized over a weighted-average period of 1.16 years as of November 30, 2019. The total fair value of options vested during the fiscal year ended November 30, 2019 was approximately $255,000.

During the second fiscal quarter of 2018, the Company entered into Amended and Restated Employment Agreements (“2018 Employment Agreements”) with each of the Company’s Co-CEOs. Per the Employment Agreements, each of the Co-CEOs is to receive base grant equity awards in the form of qualified stock options of the Company’s common stock. As of March 8, 2018, David Portnoy and Mark Portnoy were granted 23,636 and 20,000 stock options of the Company’s common stock, respectively. The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019. The fair value of the options that vested through the twelve months ended November 30, 2019 and November 30, 2018 was approximately $77,000 and $62,000, respectively, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss).

During the second fiscal quarter of 2018, the Company entered into an Amendment Agreement (“CIO Agreement”) with the Company’s CIO. Per the CIO Agreement, the CIO is to receive a base grant equity award in the form of qualified stock options of the Company’s common stock. As of May 21, 2018, Oleg Mikulinsky was granted 8,000 stock options of the Company’s common stock. The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019. The fair value of the options that vested through the twelve months ended November 30, 2019 and November 30, 2018 was approximately $18,000 and $10,000, respectively, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss).

Performance and market-based vesting condition options

Per the 2018 Employment Agreements, based upon certain performance criteria, the Company shall grant David Portnoy and Mark Portnoy a percentage of up to 47,273 and 40,000, respectively, of qualified stock options of the Company’s common stock. For market-based vesting condition options, accounting principles do not require that the market condition be met in order for the compensation cost to be recognized. Fair value of these options has been determined using a Monte Carlo valuation approach and is being recognized over the requisite service period, regardless if the market condition will be met. During fiscal 2019 and 2018, 15,756 and 13,332, respectively, of qualified stock options were forfeited as certain market conditions were not met by the end of the requisite service period. The fair value of these options as of November 30, 2019 and November 30, 2018 was approximately $182,00 and $144,300, respectively, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss). For performance-based vesting condition options, the Company estimates the fair value of qualified stock options that met certain performance targets by the end of the fiscal 2018 requisite service period using a Black-Scholes valuation model. As of August 30, 2019, the Company granted David Portnoy and Mark Portnoy 26,243 and 22,222 of non-qualified stock options of the Company’s common stock based upon certain performance criteria met by the end of the fiscal 2018 service period and per the 2018 Employment Agreements. These options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon date of grant, 1/3 on December 1, 2019 and 1/3 on November 30, 2020. The fair value of these options as of November 30, 2019 was approximately $86,000 and is reflected as selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). As of November 30, 2019, there was approximately $172,000 of total unrecognized compensation cost related to the non-vested options of common stock.

Per the Amendment Agreement, based upon certain performance criteria, the Company shall grant Oleg Mikulinsky a percentage of up to 8,000 of qualified stock options of the Company’s common stock. For market-based vesting condition options, accounting principles do not require that the market condition be met in order for the compensation cost to be recognized. Fair value of these options has been determined using a Monte Carlo valuation approach and is being recognized over the requisite service period, regardless if the market condition will be met. During fiscal 2019

and 2018, 2,666, respectively, of qualified stock options were forfeited as certain market conditions were not met by the end of the requisite service period. The fair value of these options as of November 30, 2019 and November 30, 2018 was approximately $19,200 and $13,500, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss). For performance-based vesting condition options, the Company estimated the fair value of the qualified stock options that met certain performance targets by the end of the fiscal 2018 requisite service period using a Black-Scholes valuation model. As of September 4, 2019, the Company granted Oleg Mikulinsky 4,444 of qualified stock options of the Company’s common stock based upon certain performance criteria met by the end of the fiscal 2018 service period and the per the Amendment Agreement. These options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon date of grant, 1/3 on December 1, 2019 and 1/3 on November 30, 2020. The fair value of these options as of November 30, 2019 was approximately $8,000 and is reflected as selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). As of November 30, 2019, there was approximately $15,000 of total unrecognized compensation cost related to the non-vested options of common stock.

Restricted common shares

Based upon performance measures being obtained during prior fiscal years, David Portnoy and Mark Portnoy earned 304,946 and 265,172 shares of common stock, respectively. Pursuant to the terms of the Employment Agreements, the Co-CEOs each opted to receive a lump sum cash payment in lieu of 30,000 shares of earned common stock which amounted to approximately $444,000 each paid in fiscal 2018. Per the recommendation of the DCCL, as described above, David Portnoy and Mark Portnoy surrendered 157,472 and 134,977 commons shares, respectively, for cash which amounted to $534,917 and $457,327, respectively in 2019.

Based upon performance measures being obtained during prior fiscal years, Oleg Mikulinsky was granted 34,349 shares of common stock.

NOTE 12—LICENSE AGREEMENTS

Technology Agreements

Per the License and Royalty Agreement with Lifecell, there is a $1,000,000 cap on the amount of royalties due to the Company per year and a $10,000,000 cap on the amount of royalties due to the Company for the term of the License and Royalty Agreement. The cap(s) are calculated based on Lifecell’s fiscal year end, March 31^st. As of the end of the Company’s fiscal years ended November 30, 2019 and November 30, 2018, Lifecell had reached the $1,000,000. Since inception of the License and Royalty Agreement, the Company has recorded $9,300,000 in royalty income due under the terms of the License and Royalty Agreement, of which, Lifecell has paid the Company $8,400,000 as of November 30, 2019. The balance of $900,000 is reflected as Accounts Receivable on the accompanying consolidated balance sheets.


	For the years ended November 30,
	2019						2018
	License Fee		Processing and Storage Royalties		Total		License Fee		Processing and Storage Royalties		Total
India		—		1,000,000		1,000,000		—		1,000,000		1,000,000

Total	$	—	$	1,000,000	$	1,000,000	$	—	$	1,000,000	$	1,000,000

Marketing Agreements

The Company has definitive license agreements to market the Company’s umbilical cord blood stem cell programs in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and Pakistan. `

NOTE 13 – COMMITMENTS AND CONTINGENCIES

Employment Agreements

The Company has employment agreements in place for certain members of management. These employment agreements which include severance arrangements, are for periods ranging from one to two years and contain certain provisions for severance payments in the event of termination or change of control.

Leases

The Company entered into a ten-year lease in April 2004 for its 17,600-square foot cGMP/cGTP compliant corporate headquarters in Oldsmar, Florida. This facility contains the Company’s executive offices, its conference and training center, its laboratory processing and cryogenic storage facility and its scientific offices. In July 2018, the Company extended the main lease through December 31, 2021 for the 17,600 square foot space.

The future minimum rental payments under the operating lease are as follows:


Fiscal Year Ending November 30,	Rent
2020	$	228,148
2021	$	224,928
2022	$	18,744

Legal Proceedings

In addition, from time to time the Company is subject to proceedings, lawsuits, contract disputes and other claims in the normal course of its business. The Company believes that the ultimate resolution of current matters should not have a material adverse effect on the Company’s business, consolidated financial position or results of operations. It is possible, however, that there could be an unfavorable ultimate outcome for or resolution which could be material to the Company’s results of operations for a particular quarterly reporting period. Litigation is inherently uncertain and there can be no assurance that the Company will prevail. The Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies.

NOTE 14—RETIREMENT PLAN

The Company maintains a 401(k)-retirement plan (the “401(k) Plan”), which allows eligible employees to defer up to 15% of their eligible compensation. In fiscal 2008, the Company implemented an employer match up to certain limits. In fiscal 2010, the Company implemented a Safe Harbor provision with matching contributions up to certain limits. For the years ended November 30, 2019 and November 30, 2018, the Company made matching contributions of approximately $205,000 and $158,000, respectively, to the 401(k) Plan.

NOTE 15—REVENUE SHARING AGREEMENTS (“RSAs”)

Florida. On February 9, 1999, the previous agreements with the Company’s Arizona Revenue Sharing investors were modified and replaced by a RSA for the state of Florida for a price of $1,000,000. The revenue sharing agreement applies to net storage revenues originating from specimens from within the state of Florida. The revenue sharing agreement entitles the investors to revenues of up to a maximum of 33,000 storage spaces.

Illinois. In 1996, the Company signed agreements with a group of investors entitling them to an on-going 50% share of the Company’s 75% share of the annual storage fees (“net storage revenues”) less a deduction for 50% of billing and collection expenses generated by specimens stored in the Illinois Masonic Medical Center for a price of $1,000,000. The agreements were modified in 1998 to broaden the covered specimens to those originating in Illinois and its contiguous states and stored in Oldsmar, Florida for a maximum of up to 33,000 storage spaces.

Texas. On May 31, 2001, the Company entered into an RSA with Red Rock Partners, an Arizona general partnership, entitling them to on-going shares in a portion of the Company’s net storage revenue generated by specimens originating from within the State of Texas for a price of $750,000. The investors are entitled to a 37.5% share of net storage revenues originating in the State of Texas to a maximum of 33,000 storage spaces. During fiscal 2008, Red Rock assigned 50% of their interest in the agreement to SCC Investments, Inc., an Arizona corporation. During fiscal year 2010, SCC Investments, Inc. assigned its interest to SCF Holdings, LLC, an Arizona limited liability company.

NOTE 16 –SHARE REPURCHASE PLAN

In December 2011, the Company’s Board of Directors authorized management at its discretion to repurchase up to one million (1,000,000) shares of the Company’s outstanding common stock. On June 6, 2012, the Board of Directors of the Company increased the number of shares of the Company’s outstanding common stock that management is authorized to repurchase to up to three million (3,000,000). On April 8, 2015, the Board of Directors of the Company increased the number of shares of the Company’s outstanding common stock that management is authorized to repurchase to up to six million (6,000,000) shares. On October 6, 2016, the Board of Directors of the Company increased the number of shares of the Company’s outstanding common stock that management is authorized to repurchase to up to eight million (8,000,000) shares. The repurchases must be effectuated through open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission or in such other manner as will comply with the provisions of the Securities Exchange Act of 1934.

In March 2018, the Company received notice that shares of the Company’s common stock issued to certain executive officers pursuant to the Company’s 2012 Stock Incentive Plan had purportedly been issued in excess of the shares reserved for issuance under the Plan. The Company established an independent committee of the Board of Directors to review this issue. After completing its investigation, the independent committee determined that certain restricted stock awards and certain performance-based awards were granted in violation of the 2012 Plan (See Note 11). The Company repurchased 292,449 shares that were surrendered.

As of November 30, 2019, the Company had repurchased an aggregate of 6,093,535 shares of the Company’s common stock at an average price of $3.37 per share through open market and privately negotiated transactions. The Company purchased 292,449 and 0 shares of the Company’s common stock during the twelve months ended November 30, 2019 and November 30, 2018, respectively, at an average price of $3.39 per share and $0.00 per share, respectively.

The repurchased shares are held as treasury stock at cost and have been removed from common shares outstanding as of November 30, 2019 and November 30, 2018. As of November 30, 2019, and November 30, 2018, 6,093,535 and 5,801,086 shares, respectively, were held as treasury stock.

Subsequent to the balance sheet date, the Company has not repurchased any additional shares of the Company’s common stock.

NOTE 17 – RELATED PARTY TRANSACTIONS

David Portnoy, the Company’s Chairman and Co-Chief Executive officer, is the brother of the Company’s Co-Chief Executive Officer Mark Portnoy. The Company’s Audit Committee Chairman, Harold Berger, provides accounting services to the Company’s Co-Chief Executive Officer Mark Portnoy and to PartnerCommunity, Inc. The Company’s Chairman and Co-Chief Executive Officer, David Portnoy, serves as the Chairman of the Board of PartnerCommunity, Inc.

On August 2, 2019, the Company entered into mutual releases with each of the Co-CEOs and certain directors and officers of the Company who received incentive awards that were submitted for ratification at the 2019 Annual Meeting or forfeited in connection therewith. The Company and each counterparty to a mutual release are agreeing, among other things, not to pursue certain claims relating to such ratification and surrenders).

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A.

CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Based on their most recent review, as of the end of the period covered by this report, the Company’s principal executive officers and principal financial officer have concluded that the Company’s disclosure controls and procedures are not effective, and that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure and are effective to ensure that such information is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In March 2018, the Company received notice that shares of the Company’s common stock issued to certain executive officers pursuant to the Company’s 2012 Stock Incentive Plan had purportedly been issued in excess of the shares reserved for issuance under the Plan. The Company established an independent committee of the Board of Directors to review this issue. (See Note 11 for the independent committee’s conclusion) As part of this resolution, management is reviewing the Company’s disclosure controls and procedures.

The Company has not made an amended 8-K filing with respect to the Current Reports on Form 8-K that was filed on July 16, 2015 to announce the acquisition of PrepaCyte. Accordingly, the Company is not deemed a timely filer. Management intends to subsequently make this amended 8-K filing to include the required pre-acquisition financial statements of PrepaCyte as well as the required pro forma financial information.

Management’s Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our principal executive officers and principal financial officer, we conducted an evaluation under the criteria set forth in the 1992 Internal Control—Integrated Framework of the effectiveness of our internal control over financial reporting as of November 30, 2019. The Company’s principal executive officers and principal financial officer concluded that the Company’s disclosure controls and procedures and internal controls over financial reporting were effective.

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. We were not required to have, nor have we engaged our independent registered public accounting firm to perform, an audit on our internal control over financial reporting pursuant to the rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual Report.

Changes in Internal Control over Financial Reporting

Other than as disclosed in “Evaluation of Disclosure Controls and Procedures” above with respect to the matters reviewed in March 2018, there were no other changes in the Company’s internal controls over financial reporting during the year ended November 30, 2019 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Limitations on the Effectiveness of Controls

Our management, including our Co-CEOs and CFO, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management or board override of the control.

The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

CEO and CFO Certifications

Appearing as exhibits 31.1, 31.2 and 31.3 to this report there are Certifications of the Co-CEOs and the CFO. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certifications). This Item of this report is the information concerning the evaluation referred to in the Section 302 Certifications and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.

ITEM 9B.

OTHER INFORMATION.

Not applicable.

Part III

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE.

Below are the names, ages and background of the Board of Directors and Executive Officers of the Company, as well as the particular and specific experience, qualifications, attributes, or skills that led the Board to conclude that each director should serve on our Board of Directors in light of the Company’s business. The Board of Directors has determined that other than Messrs. Portnoy and Portnoy, who are officers of the Company, each of our directors is deemed to be independent under the Nasdaq standards which we choose to follow.

David I. Portnoy, age 57, Chairman and Co-Chief Executive Officer. Mr. Portnoy has served as Chairman of the Board and Co-Chief Executive Officer of the Company since August 2011. Since 2002, Mr. Portnoy has served as Chairman of the Board of Directors of Partner-Community, Inc., which provides software and hardware integration solutions to telecommunication companies and which was awarded the Verizon 2010 Supplier Recognition Award for Outstanding Performance. Mr. Portnoy provided the initial venture capital to Waves Audio Ltd, a leading audio technology company. Mr. Portnoy graduated Magna Cum Laude in 1984 from The Wharton School of Finance at the University of Pennsylvania where he earned a Bachelor of Science Degree in Economics with a joint major in finance and accounting. David I. Portnoy is the brother of Mark L. Portnoy, a director and Co-Chief Executive Officer of the Company. We believe that Mr. Portnoy’s knowledge of the Company having served as its Co-Chief Executive Officer assists the Board with its oversight of the strategic plan of the Company. Additionally, we believe that Mr. Portnoy’s financial and business experiences provide the Board with general business acumen.

Mark L. Portnoy, age 56, Co-Chief Executive Officer. Mr. Portnoy has served as a director and Co-Chief Executive Officer since August 2011. Additionally, since 2002 and 2007, Mr. Portnoy has served on the boards of directors of Partner-Community, Inc. and uTIPu Inc., a private Internet-based business, respectively. Mr. Portnoy has been engaged in managing his personal investments since April 1997. From January 1995 to April 1997, Mr. Portnoy was employed at Strome, Susskind Investments as its Chief Fixed Income Trader. From March 1986 until November 1991, Mr. Portnoy was employed at Donaldson, Lufkin & Jenrette Securities Corp. as a Fixed Income Arbitrage Trader, with a trading portfolio ranging in size from $1 billion to $7 billion. In addition to the finance experience, Mr. Portnoy’s experience includes negotiating contracts for National Basketball Association (NBA) players totaling approximately $30 million. Mr. Portnoy graduated Phi Beta Kappa from the University of North Carolina at Chapel Hill with a degree in Economics in December 1985. Mark L. Portnoy is the brother of David I. Portnoy, Chairman of the Board and Co-Chief Executive Officer of the Company. We believe that Mr. Portnoy’s knowledge of the Company having served as its Co-Chief Executive Officer assists the Board with its oversight of the strategic plan of the Company. Additionally, we believe that Mr. Portnoy’s financial and business experiences provide the Board with general business acumen.

Jonathan H. Wheeler M.D., age 60, has served as a director since August 2011. Dr. Wheeler is a licensed physician specializing in the fields of obstetrics and gynecology. He has practiced in these fields in Newport Beach, California since 1992. Dr. Wheeler received his B.A. in Biology from the State University of New York (SUNY) at Buffalo. He completed his medical degree at Cornell University Medical College in 1986. His Obstetrics and Gynecology training was received at UCLA Medical Center in a combined internship and residency program. There, he received honorary awards for his work in advanced laparoscopy and completed research in innovative surgical techniques. Dr. Wheeler is Board certified in Obstetrics and Gynecology. He is a member of the American College of Obstetrics and Gynecology, the American Association of Gynecologic Laparoscopists, the Orange County Obstetrics and Gynecology Society and is a Diplomat of the American Board of Obstetrics and Gynecology. In the past Dr. Wheeler has served as Chairman and Vice-Chairman of the Department of Obstetrics and Gynecology at Hoag Hospital and has served on numerous committees including education, surgery and advancement of Women’s Health Services. We believe that Dr. Wheeler’s professional experience provides the Board with critical insight into the medical fields of obstetrics and gynecology. Additionally, we believe that through his attendance at medical conferences and seminars, as well as through his daily medical practice, Dr. Wheeler provides the Company with additional business development opportunities through his extensive industry contacts.

George Gaines, age 66, has served as a director since August 2011. Since 2012 Mr. Gaines has been a Managing Director of Harpeth Fund Advisors, a division of Harpeth Capital LLC, an investment banking and private equity fund placement agent headquartered in Nashville, Tennessee. We believe that Mr. Gaines’ business experience provides the Board with general business acumen and an increased ability to effectively oversee and assess management’s execution of the Company’s business.

Harold D. Berger, age 56, has served as a director since August 2011. Mr. Berger is a certified public accountant. Prior to opening his own accounting practice in 2005, Mr. Berger was an equity partner with Habif, Arogeti & Wynne, LLP, an accounting firm based in Atlanta, Georgia. Over the past 25 years, Mr. Berger also has served on boards for a variety of charitable organizations. Mr. Berger currently serves as Treasurer and Executive Committee Member of the Holly Lane Foundation (f/k/a The Gatchell Home, Inc.), as Director and Finance committee member of the Jewish Educational Loan Fund, Inc., and as Director and financial adviser to The Atlanta Group Home Foundation, Inc. Mr. Berger graduated in December 1987 from the University of Texas at Austin with a Master’s Degree in Professional Accounting. Mr. Berger is a member of the American Institute of Certified Public Accountants (AICPA) and the Georgia Society of Certified Public Accountants (GSCPA). We believe that Mr. Berger’s years of experience as an auditor and accountant, including expertise in financial accounting, provides the Board and the Audit Committee of the Board with valuable financial and accounting experience.

Arthur Ellis, age 55, has served as a director since 2018. Mr. Ellis is a licensed attorney. Mr. Ellis received his AB and AM from The University of Chicago and his JD from Boston University. Mr. Ellis is a practicing attorney who regularly advises businesses on a broad range of legal issues from negotiating new business ventures through client disputes and litigation. Mr. Ellis currently serves as the treasurer of The Uptown People’s Law Center (UPLC), a legal aid clinic in serving residents of the Uptown neighborhood in Chicago and protecting the rights of prisoners in the Illinois Department of Corrections. Mr. Ellis served as chairman of the board of UPLC from 2008 through 2019. From 1995 through 2011, Mr. Ellis also founded and ran The Nanny Tax Company a company providing tax reporting services to domestic employers across the United States. Mr. Ellis previously served as a director for City National Bancshares, Inc. We believe that Mr. Ellis’ business and legal experience provide the Board with general business acumen, legal experience and assists in working with outside counsel.

Brian Sheehy, age 49, has served as a director since 2018. Mr. Sheehy received his B.A. in Biochemistry and Environmental Science from the University of California, Berkeley, his M.A. from University of Exeter and his M.D. from New York Medical College. Mr. Sheehy is the founder and managing partner, since 2010, of IsZo Capital. Mr. Sheehy was the cofounder in 2002 of Black Horse Capital and managing partner until 2008. He is also a Chartered Financial Analyst. We believe that Mr. Sheehy’s experience provides the Board with general business acumen and an increased ability to effectively oversee and assess management’s execution of the Company’s strategic business plan.

Biographical information regarding the Company’s executive officers who are not as directors of the Company is set forth below:

Jill Taymans, age 50, is the Company’s Vice President, Finance and Chief Financial Officer. Ms. Taymans joined the Company in April 1997 serving initially as Controller and was appointed Chief Financial Officer in May 1998. Ms. Taymans graduated from the University of Maryland in 1991 with a BS in Accounting. She has worked in the accounting industry for over 20 years in both the public and private sectors. Prior to joining the Company, she served for three years as Controller for a telecommunications company.

Oleg Mikulinsky, age 47, is the Company’s Chief Information Officer. Mr. Mikulinsky has served as Cryo-Cell’s Chief Information Officer since March 2012. Mr. Mikulinsky is a software technologist and serial entrepreneur. He has been a founding member of several software enterprises and most recently served as Chief Technology Officer of Partner-Community, Inc and Chief Technology Officer at uTIPu Inc. from 2007 to 2009. Before that, Mr. Mikulinsky served as the Director of Enterprise Architecture at WebLayers, Inc. where he defined enterprise architecture best practices for companies like AT&T, Defense Information’s Systems Agency (DISA), as well as for many major banking institutions. He contributed to the development of International systems interoperability standards at OASIS-OPEN.ORG and WS-I.ORG. Prior to starting his professional career as a software engineer in United States, Mr. Mikulinsky studied radio electronics at the Bauman Moscow State Technical University (BMSTU), Russia.

Audit Committee Financial Expert

The audit committee is comprised entirely of non-employee, independent members of the board of directors. The purpose of the audit committee is to assist the board of directors in fulfilling its oversight responsibilities by reviewing the Company’s internal control systems, audit functions, financial reporting processes, and methods of monitoring compliance with legal and regulatory matters and engaging the Company’s independent principal accountants. The board of directors has determined that each of the audit committee members is able to read and understand fundamental financial statements. In addition, the board of directors has determined that the chairman of the audit committee, Mr. Harold Berger, is an “audit committee financial expert” as that term is defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities and Exchange Act of 1934. Mr. Berger’s relevant experience includes his current position with his own accounting practice, as well as, his prior position as an equity partner with Habif, Arogeti & Wynne, LLP, an accounting firm based in Atlanta, Georgia.

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our officers, directors and persons who are the beneficial owners of more than 10% of our common stock to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock. Officers, directors and beneficial owners of more than 10% of our common stock are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. Based solely on a review of the copies of the Forms 3, 4 and 5 and amendments that we received with respect to transactions during the fiscal year ended November 30, 2018, we believe that all such forms were filed on a timely basis.

Code of Ethics

The Company has adopted a code of ethics for its chief executive officer and all senior financial officers, including the chief financial officer and principal accounting officer. The code of ethics is available to any shareholder, without charge, upon written request to the Company in care of the Corporate Secretary at 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, Florida 34677. The code of ethics is also available on the Company’s website, www.cryo-cell.com.

ITEM 11.

EXECUTIVE COMPENSATION.

Summary Compensation Table

The table below summarizes the total compensation paid or earned during the fiscal years ended November 30, 2019 and November 30, 2018 by (i) the Company’s Co-Chief Executive Officers and (ii) the two other most highly compensated individuals that served as executive officers of the Company as of November 30, 2019 whose total compensation received from the Company during such fiscal year (other than non-qualified deferred compensation earnings, if any) exceeded $100,000 (collectively, the “named executives”).


Name and Principal Position	Year		Salary ($)		Bonus ($)		Option and Restricted Common Stock Awards ($) (1)		Non-Equity Incentive Plan Compensation ($)		All Other Compensation ($) (2)		Total ($)
David Portnoy Co-Chief Executive Officer		2019 2018	$ $	602,085 547,350	$ $	50,000 304,083	$ $	34,978 130,143	$ $	0 0	$ $	0 0	$ $	687,063 981,576
Mark Portnoy Co-Chief Executive Officer		2019 2018	$ $	478,995 435,450	$ $	40,000 241,916	$ $	32,512 79,284	$ $	0 0	$ $	0 0	$ $	551,507 756,650
Jill M. Taymans Vice President Finance, Chief Financial Officer		2019 2018	$ $	190,000 187,197	$ $	11,500 11,500	$ $	— —	$ $	0 0	$ $	0 0	$ $	201,500 198,697
Oleg Mikulinsky Chief Information Officer		2019 2018	$ $	250,000 250,114	$ $	8,333 27,775	$ $	16,611 59,689	$ $	0 0	$ $	0 0	$ $	274,944 337,578

(1)

Represents the dollar amount recognized for financial reporting purposes in fiscal 2019 and 2018. The fair value was estimated using the Black-Scholes option-pricing model. The amount reported has been adjusted to eliminate service-based forfeiture assumptions used for financial reporting purposes. See Note 11, Stockholders’ Equity, to our consolidated financial statements for a discussion of our accounting for stock options and the assumptions used.

(2)	Represents perquisites and other benefits, valued on the basis of aggregate incremental cost to the Company.

Narrative Disclosure Regarding Summary Compensation Table

Compensation Philosophy

Our executive compensation policies are designed to provide competitive levels of compensation that integrate pay with our annual objectives and long-term goals, align the long-term interests of management with those of our shareholders, reward for achieving performance objectives, recognize individual initiative and achievements, and assist us in attracting and retaining highly qualified and experienced executives. The Compensation Committee of our board of directors is primarily responsible for acting on our philosophical approach to executive compensation. There are three primary elements in our executive compensation program: base salary compensation, cash bonus and stock options.

Base salary compensation is based on the potential impact the individual may have on the Company, the skills and experience required by the job, comparisons with comparable companies and the performance and potential of the incumbent in the job.

A cash bonus pool along with Company performance targets and individual performance objectives are established at the beginning of each fiscal year by the Compensation Committee. At the end of the fiscal year each performance target is measured and bonuses are paid if the set performance targets established at the beginning of the fiscal year are attained. A percentage of the pre-determined cash bonus pool is paid to the named executive officer depending on the performance targets met by the Company and the individual. In fiscal 2018 and 2019, pursuant to their Employment Agreements, the Company’s Co-CEOs were entitled to a cash bonus equal to the sum of (x) 11.11% of base salary times the number of the six performance targets achieved (based on threshold, target and stretch performance standards for each of the Company’s annual net revenue and weighted average stock price), plus (y) 11.11% times the number of three subjective performance criteria achieved (as determined in the sole discretion of the Compensation Committee of the Board of Directors after consultation with Co-CEOs, respectively). In fiscal 2018 and 2019, pursuant to his Employment Agreement, the Company’s Chief Information Officer was entitled to a cash bonus equal to a percentage of 20% of his Base Salary equal to the sum of (x) 11.11% of base salary times the number of the six performance targets achieved (based on threshold, target and stretch performance standards for each of the Company’s annual net revenue and weighted average stock price), plus (y) up to 33.33% times the number of three subjective performance criteria achieved (as subjectively determined by the Co-CEOs in their sole discretion). In fiscal 2019 and 2019, the Company’s Chief Financial Officer was entitled to a discretion cash bonus, pursuant to her Employment Agreement.

With respect to the subjective performance reviews, in addition to evaluating the Company’s overall financial performance, the Compensation Committee considers the performance of each named executive officer’s business line or area of responsibility. Several key management competencies and behaviors are assessed, including the named executive officer’s effectiveness as a leader and his or her role in building a cohesive executive team, as well as other strategic core competencies such as accountability, analytical ability and decision making, communication, cooperation and teamwork, creativity and problem-solving, and integrity. The named executive officer’s performance relating to these competencies forms the basis of a performance review discussion with the named executive officer that reinforces his or her role in achieving the Company’s business plan and short- and long-term strategies.

In fiscal 2019, the Company’s threshold, target and stretch performance standards required to earn cash bonuses were based on an increase of net revenue as of November 30, 2019, of 12%, 14% and 16%, respectively, and the Company’s weighted average stock price as of November 30, 2019 of $9.50, $10.50 and $11.50, respectively. In fiscal 2019, Cash bonuses were earned and are payable to the Co-CEO’s, Chief Information Officer and Chief Financial Officer in amounts totaling $50,000, $40,000, $8,333 and $11,500, respectively. In fiscal 2018, the Company’s threshold, target and stretch performance standards required to earn cash bonuses were based on an increase of net revenue as of November 30, 2018, of 6%, 8% and 10%, respectively, and the Company’s weighted average stock price as of November 30, 2018 of $8.75, $9.50 and $10.25, respectively. In fiscal 2018, cash bonuses were paid to the Co-CEO’s, Chief Information Officer and Chief Financial Officer totaling $304,053, $241,892, $27,775 and $11,500, respectively.

In fiscal 2019, pursuant to their Employment Agreements, David Portnoy and Mark Portnoy, the Company’s Co-CEOs, were granted 23,636 and 20,000 stock options, respectively. One-third of each grant vested upon grant, one-third will vest on December 1, 2020 and one-third will vest on November 30, 2021. In addition, the Employment Agreements for David Portnoy and Mark Portnoy provide that they are entitled to receive up to an additional 47,273 and 40,000 stock options, respectively, based on performance, with award being equal to the sum of (x) 11.11% times the number of the six performance targets achieved (based on threshold, target and stretch performance standards for each of the Company’s annual net revenue and weighted average stock price), plus (y) 11.11% times the number of three subjective performance criteria achieved (as determined in the sole discretion of the Compensation Committee of the Board of Directors after consultation with Co-CEOs, respectively). In 2019, neither of the Co-CEOs received any performance-based stock options.

In fiscal 2018, David Portnoy and Mark Portnoy, the Company’s Co-CEOs, were granted 23,636 and 20,000 stock options, respectively. One-third of each grant vested upon grant, one-third vested on December 1, 2018 and one-third vested on December 1, 2019. In addition, the Employment Agreements for David Portnoy and Mark Portnoy provide that they are entitled to receive up to an additional 47,273 and 40,000 stock options, respectively, based on performance, with award being equal to the sum of (x) 11.11% times the number of the six performance targets achieved (based on threshold, target and stretch performance standards for each of the Company’s annual net revenue and weighted average stock price), plus (y) 11.11% times the number of three subjective performance criteria achieved (as determined in the sole discretion of the Compensation Committee of the Board of Directors after consultation with Co-CEOs, respectively). In fiscal 2018, David Portnoy and Mark Portnoy were granted 26,243 and 22,222 performance-based stock options, respectively.

In fiscal 2019, pursuant to his Employment Agreement, the Company’s Chief Information Officer was granted 8,000 stock options. One-third vested upon grant, one-third will vest on December 1, 2020 and one-third will vest on November 30, 2021. In addition, pursuant to his Employment Agreement, the Company’s CIO is entitled to up to 8,000 stock options based on performance, with the award being equal to the sum of (x) the product of 11.11% and the number of the net revenue and weighted average stock price performance goals achieved at the “threshold”, “target” and “stretch” levels and (y) up to 33.33% at the discretion of the Co-CEOs based on his subjective performance. In 2019, no performance-based stock options were issued to the Chief Information Officer.

In fiscal 2018, pursuant to his Employment Agreement, the Company’s Chief Information Officer was granted 8,000 stock options. One-third vested upon grant, one-third vested on December 1, 2018 and one-third vested on December 1, 2019. In addition, pursuant to his Employment Agreement, the Company’s CIO is entitled to up to 8,000 stock options based on performance, with the award being equal to the sum of (x) the product of 11.11% and the number of the net revenue and weighted average stock price performance goals achieved at the “threshold”, “target” and “stretch” levels and (y) up to 33.33% at the discretion of the Co-CEOs based on his subjective performance. In 2018, 4,444 performance-based stock options were issued to the Chief Information Officer.

Stock options are granted to our executive officers in order to maintain competitive pay packages and to align management’s long-term interests with those of our stockholders. The compensation committee approves stock option grants to our executives and key personnel. Awards vest and options become exercisable based upon criteria established by the Compensation Committee.

Overall, the compensation committee attempts to establish levels of executive compensation that it believes to be competitive with those offered by employers of comparable size, growth and profitability in the Company’s industry and in general industry. In establishing the levels of the various compensation elements, the compensation committee has from time to time used the services of compensation consultants.

Employment Agreements and Change in Control Arrangements

David Portnoy and Mark Portnoy Employment Agreements. On March 8, 2018, the Company entered into new two-year employment agreements, effective December 1, 2017, with David Portnoy, Co-Chief Executive Officer of the Company, and Mark Portnoy, Co-Chief Executive Officer of the Company. The agreements superseded and replaced prior employment agreements with each of the executives. The employment agreements expired on November 30, 2019 and have not been renewed. The Company and the Co-CEOs are, currently negotiating new employment agreements and, as of the date hereof, the Co-CEOs are receiving a base salary consistent with the base salary stipulated in their employment agreements.

The agreements provided for an annual base salary of $547,350 for David Portnoy and $435,450 for Mark Portnoy. In addition to base salary. the agreements also provided for reimbursement for all business expenses, including reasonable commuting expenses for David Portnoy between his home in Miami, Florida to the Company’s headquarters in Tampa, Florida, including lodging and rental car expenses for when he is working in the Company’s offices in Tampa. David Portnoy’s principal place of employment shall be at the Company’s offices in Miami, Florida, provided he shall travel to the Company’s headquarters as necessary to fulfill his responsibilities under the agreement. The Company shall pay reasonable legal and financial consulting fees and costs incurred in negotiating the agreements and shall pay each executive up to $75,000 in legal fees related to any dispute or question of interpretation regarding the agreements. The executives will also participate in the employee benefit plans that the Company generally makes available to Company employees from time to time, including retirement and health plans.

Upon the occurrence of (i) an involuntary termination of employment; (ii) a voluntary termination of employment for “Good Reason” (as defined in the agreements); or (iii) an involuntary termination of employment or voluntary termination of employment for “Good Reason” at any time following a change in control (as defined in the agreement), the agreements provide for severance pay equal to two times the executive’s then-current annual base salary, paid in a lump sum no later than 30 days after the occurrence of the triggering event. The Company will also reimburse the executives, on a grossed-up basis, for any penalty taxes owed on any excess parachute amounts under Section 280G of the Internal Revenue Code of 1986, as amended. In addition, the Company shall provide, at no cost to the executives, continued life insurance coverage and nontaxable medical, dental and disability insurance coverage substantially similar to the coverage maintained by the Company for the executives prior to such termination for 36 months after the termination. If the termination of employment is due to disability (as defined in the agreement), the Company shall pay the executive two times his then-current base salary in a cash lump sum no later than 30 days after such disability, reduced by any amount paid to him from any disability insurance, Social Security, workman’s compensation or other disability program. In addition, all unvested shares and options held by the executive shall become fully vested upon his disability. If the termination of employment is due to death, the Company shall pay the executive two times his then-current base salary as a cash lump sum within 30 days after his date of death, and the Company will continue to provide medical and dental coverage for the executive’s family for two years after his death. The agreements include a one-year non-competition restriction and an 18-month restriction on solicitation of employees or customers.

Taymans Employment Agreement. On November 1, 2005, the Company entered into a one-year employment agreement with Jill M. Taymans, the Company’s Chief Financial Officer and Vice President (the “Taymans Employment Agreement”). Under the Taymans Employment Agreement, the one-year term is automatically extended for an additional one-year period unless, at least 60 days prior to the end

of the then-current term, either party notifies the other in writing of its intent not to renew the agreement. The Taymans Employment Agreement was amended in July 2008 to provide that the then-current term would expire on November 30, 2008. The ending date of the current term of the Taymans Employment Agreement is November 30, 2020.

At all times during the term of the Taymans Employment Agreement (as the same may be extended), Ms. Taymans will be eligible for discretionary merit increases and adjustments in base salary, in addition to discretionary annual bonuses awarded at the discretion of the compensation committee of the Company’s board of directors. The Taymans Employment Agreement provides that she will be eligible to receive long-term incentive awards provided to the Company’s senior executives generally, on terms finally determined by the compensation committee of the Company’s board of directors.

In the event of a termination of employment of Ms. Taymans upon or within one year of a Change in Control (as defined in the Taymans Employment Agreement), or prior to the Change in Control if the termination was related to the Change in Control, if the termination was by the Company without cause or was by Ms. Taymans due to being requested to accept without cause a demotion or relocation, Ms. Taymans will be entitled to receive the following: (i) all earned compensation through the date of termination (or, if greater, on the date immediately preceding a Change in Control); and (ii) 12 months of base salary as in effect on the termination date (or, if greater, base salary in effect immediately prior to the Change in Control).

Under the Taymans Employment Agreement, the Company will also provide Ms. Taymans with certain other benefits, including continued participation in all applicable Company benefit plans and payment of reasonable business expenses.

In the Taymans Employment Agreement, Ms. Taymans agreed not to compete with the Company or solicit its customers, clients or employees during the term of her Employment Agreement and for a 12-month period following her termination of employment under the agreement.

Mikulinsky Employment Agreement. On March 5, 2012, the Company entered into a one-year employment agreement (the “Mikulinsky Employment Agreement”) with Oleg Mikulinsky, as the Company’s Chief Information Officer. Under the Mikulinksy Employment Agreement, the one-year term was automatically extended for additional one-year periods unless, at least 30 days prior to the end of the then-current term, either party notifies the other in writing of its intent not to renew the agreement. On May 1, 2013, the Company entered into an Amendment Agreement amending certain terms of the Mikulinsky Employment Agreement dated March 5, 2012. On April 18, 2016, the Company entered into a second Amendment Agreement (the “Amendment”), effective December 1, 2015, amending certain terms of the Amendment Agreement dated May 1, 2013 and Mikulinsky Employment Agreement dated March 5, 2012. On May 18, 2018, the Company entered into an Amendment Agreement (the “Amendment”), effective December 1, 2017, amending certain terms of the Amendment Agreement dated April 20, 2016, Amendment Agreement dated May 1, 2013 and Employment Agreement dated March 5, 2012. The term of the Amendment is two years (“Initial Term”) and shall be automatically extended for successive additional one-year periods (“Additional Employment Terms”) unless, at least thirty (30) days prior to the end of the Initial Term or an Additional Employment Term, the Company or the Executive has notified the other in writing that the Agreement shall terminate at the end of the then-current term. The ending date of the current term of the Mikulinksy Employment Agreement is November 30, 2020.

Pursuant to the Amendment, the Executive’s base salary was $250,000 (the “Base Salary”).

At all times during the term of the Mikulinsky Employment Agreement (as the same may be extended), Mr. Mikulinsky will be eligible for discretionary merit increases and base salary adjustments, in addition to cash and equity annual bonuses discussed above. The Mikulinsky Employment Agreement provides he will also be eligible for long-term incentive awards provided to the Company’s senior executives generally, on terms finally determined by the compensation committee of the Company’s board of directors.

Per the Amendment, in the event of the Executive’s voluntary resignation from the Company’s employment upon a Change in Control or the Executive’s employment is terminated upon or within one (1) year after a Change in Control, as defined in the Employment Agreement, or prior to the Change in Control if the Executive’s termination, demotion or relocation was either a condition of the Change in Control or was at the request of any person related to the Change in Control, and such termination was initiated by the Company without cause or by the Executive due to being requested to accept without cause a demotion or relocation:

(i)

The Company shall pay to the Executive any earned and accrued but unpaid installment of Base Salary through the date of resignation or termination, at the rate in effect on the date of termination, or if greater, on the date immediately preceding the date that a Change in Control occurs, and all other unpaid amounts to which the Executive is entitled as of the date of termination under any compensation plan or program of the Company, including, without limitation, all accrued vacation time. Stock options, shares of restricted stock, performance awards, stock appreciation rights, and LTI awards granted to Executive by the Company through the date of termination shall be treated in accordance with the applicable plans and policies of the Company. All outstanding stock options shall vest upon termination.

(ii)

In lieu of any further Base Salary, bonus payments and benefits to the Executive for periods subsequent to the date of resignation or termination, the Company shall pay as liquidated damages to the Executive, an amount equal to twelve (12) months of the Executive’s annual Base Salary at the rate in effect as of the date of termination, or if greater, on the date immediately preceding the date that a Change in Control occurs.

In the Mikulinsky Employment Agreement, Mr. Mikulinsky agreed not to compete with the Company or solicit its customers, clients or employees during the term of his respective Employment Agreement and for a 12-month period following the termination of employment under agreements.

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth information concerning stock options held by the named executive officers at November 30, 2019:


Name	Grant Date	Number of Securities Underlying Unexercised Options (#) Exercisable		Option Exercise Price ($)		Option Expiration Date
David Portnoy	August 31, 2011 December 1, 2011 April 15, 2016 March 8, 2018 (1) August 30, 2019 (1)		100,000 200,000 70,270 23,636 26,243	$ $ $ $ $	2.90 1.72 3.14 7.92 7.53	August 31, 2021 December 1, 2021 April 15, 2026 March 8, 2023 August 30, 2029
Mark Portnoy	August 31, 2011 December 1, 2011 April 15, 2016 March 8, 2018 (1) August 30, 2019 (1)		100,000 200,000 59,459 20,000 22,222	$ $ $ $ $	2.90 1.72 3.14 7.92 7.53	August 31, 2021 December 1, 2021 April 15, 2026 March 8, 2023 August 30, 2029
Jill Taymans	June 2, 2016		7,500	$	3.10	June 3, 2026
Oleg Mikulinsky	March 5, 2012 April 18, 2016 May 21, 2018 (1) September 4, 2019 (1)		20,000 40,000 8,000 4,444	$ $ $ $	2.05 3.20 7.49 7.13	March 5, 2022 April 18, 2026 May 21, 2028 September 4, 2029

(1)	1/3 of the options vest immediately on the date of grant, 1/3 of the options vest one-year from the date of grant and 1/3 of the options vest two-years from the date of grant.

Director Compensation

Directors who are employees of the Company receive no compensation for their services as directors or as members of board committees. Effective November 25, 2019, non-employee directors are paid an annual retainer in the amount of $25,500. Each non-employee director receives an annual stock option grant in the amount of 5,300 shares on the date of the annual stockholders meeting in each year with an exercise price equal to the fair market value of the common stock on the date of grant. Prior to November 25, 2019, non-employee directors were paid an annual retainer in the amount of $15,000 and an attendance fee of $4,000 for each board meeting and $2,000 for each telephonic quarterly board meetings, a $1,000 fee per committee per year and reimbursed for their reasonable expenses incurred for attending a meeting. Prior to November 25, 2019, each non-employee director received an annual stock option grant in the amount of 7,500 shares on the date of the annual stockholders meeting in each year. All of such stock options had an exercise equal to the fair market value of the common stock on the date of grant.

The table below summarizes the compensation paid by the Company to its non-employee directors for the fiscal year ended November 30, 2019:


Name	Fees Earned or Paid in Cash ($)		Option Awards ($) (1)		Total ($)
Harold Berger	$	30,750	$	10,422	$	41,172
George Gaines	$	31,750	$	10,422	$	42,172
Jonathan Wheeler	$	31,750	$	10,422	$	42,172
Arthur Ellis	$	31,750	$	35,871	$	67,621
Brian Sheehy	$	25,750	$	35,871	$	61,621

(1)

Represents the dollar amount recognized for financial reporting purposes in fiscal 2019 with respect to stock options. The fair value was estimated using the Black-Scholes option-pricing model. The amount reported has been adjusted to eliminate service-based forfeiture assumptions used for financial reporting purposes. See Note 11, Stockholders’ Equity, to our consolidated financial statements for a discussion of our accounting for stock options and the assumptions used.

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The following table sets forth certain information regarding beneficial ownership of our common stock as of February 21, 2020 by (i) each person who is known by the Company to own beneficially more than 5% of the outstanding shares of our common stock, (ii) each director and director nominee of the Company, (iii) each executive officer of the Company, and (iv) all current directors and executive officers of the Company as a group. Except as otherwise indicated below, each of the stockholders named in the table has sole voting and investment power with respect to their shares of common stock, except to the extent authority is shared by spouses under applicable law.


Name and Address of Beneficial Owner ⁽¹⁾	Number of Shares Beneficially Owned ⁽²⁾		Percent of Class ⁽¹⁾
Five Percent Shareholders:
Mary J. Nyberg Trustee of the CDMJ Nyberg Family Trust, U/A/D June 9, 2005 ⁽³⁾		600,000		7.95	%
CU Blood, Inc. ⁽⁴⁾		465,426		6.17	%
Adam Fleishman Trustee of the Adam Fleishman Trust dated April 13, 2001 ⁽⁵⁾		509,000		6.75	%
Current directors, nominees and executive officers:
David Portnoy ⁽⁶⁾		1,455,714		18.30	%
Mark Portnoy ⁽⁷⁾		958,964		12.09	%
George Gaines ⁽⁸⁾		1,112,908		14.67	%
IsZo Capital LP⁽⁹⁾		493,074		6.53	%
Harold Berger ⁽¹⁰⁾		65,838		*
Jonathan Wheeler ⁽¹¹⁾		104,708		1.38	%
Arthur Ellis ⁽¹²⁾		125,746		1.66	%
Jill Taymans ⁽¹³⁾		52,896		*
Oleg Mikulinsky⁽¹⁴⁾		101,164		1.33	%
All current directors and executive officers as a group (9 persons) ⁽¹⁵⁾		4,471,013		52.39	%

*	Less than 1%.

(1)

Pursuant to applicable SEC rules, the percentage of voting stock for each stockholder is calculated by dividing (i) the number of shares deemed to be beneficially held by such stockholders as February 21, 2020 by (ii) the sum of (a) 7,545,613 which is the number of shares of common stock outstanding as February 21, 2020 plus (b) the number of shares issuable upon exercise of options (which are shares that are not voting until exercised) held by such stockholder which were exercisable as of February 21, 2020 or will become exercisable within 60 days of that date. Unless otherwise indicated, the address of each director and executive officer in the table is 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, Florida 34677.

(2)

In accordance with Rule 13d-3 under the Securities Exchange Act of 1934, a person is deemed to be the beneficial owner for purposes of this table, of any shares of Common Stock if he or she has shared voting or investment power with respect to such security, or has a right to acquire beneficial ownership at any time within 60 days from February 21, 2020. As used herein, “voting power” is the power to vote or direct the voting of shares, and “investment power” is the power to dispose or direct the disposition of shares. The shares set forth above for directors and executive officers include all shares held directly, as well as by spouses and minor children, in trust and other indirect ownership, over which shares the named individuals effectively exercise sole or shared voting and investment power.

(3)

Mary J. Nyberg, as trustee of CDMJ Nyberg Family Trust, U/A/D June 9, 2005 filed a Schedule 13G/A on January 17, 2018 (“the Schedule 13G”) reporting the following beneficial ownership: (i) 600,000 shares of common stock held by CDMJ Nyberg Family Trust U/A/D June 9, 2005, as to which this trust has the sole power to vote and dispose or direct the disposition. Beneficial ownership information is supplied per the Schedule 13G. The address for the CDMJ Nyberg Family Trust is 4555 E. Mayo Blvd., Phoenix, AZ 85050.

(4)

CU Blood, Inc. filed a Schedule 13G on June 21, 2018 (“the CU Schedule 13G”) reporting the following beneficial ownership: (i) 465,426 shares of common stock held by CU Blood, Inc. as to which CU Blood, Inc. has the sole power to vote and dispose or direct the disposition. Beneficial ownership information is supplied per the Schedule 13G. The address for CU Blood, Inc. is 1991 Summit Park Drive, Suite 2000, Orlando, FL 32810.

(5)

Adam Fleishman as trustee of Adam Fleishman Trust April 13, 2001 filed a 13G on January 5, 2015 (”the Schedule 13G”) reporting the following beneficial ownership: (i) 279,000 shares of common stock held by Adam Fleishman Trust dated April 13, 2001, as to which this trust has sole power to vote and dispose or direct the disposition, and (ii) 230,000 shares of common stock held by Adam Fleishman. Beneficial ownership information is supplied per the Schedule 13G. The address for Adam Fleishman is 775 Summit Drive, Deerfield, Illinois 60015.

(6)

Includes 58,011 shares of Common Stock held directly through a 401(k) plan account, 199,080 shares of Common Stock held directly through IRA accounts of David Portnoy, 424,661 shares he owns individually, 151,224 shares of Common Stock held by Partner-Community, Inc., as to which David Portnoy may be deemed the beneficial owner as Chairman of the Board and Secretary, 55,219 shares of Common Stock held by uTIPu, as to which David Portnoy may be deemed the beneficial owner as Chairman of the Board, 59,027 shares of Common Stock held by Mayim Investment Limited Partnership, as to which David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership; 78,864 shares of Common Stock held by spouse, 9,974 shares held by David Portnoy as custodian for his minor son; and 9,122 shares held by David Portnoy as custodian for his minor daughter. Includes 410,532 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 21, 2020.

(7)

Includes 18,055 shares of Common Stock held directly through a 401(k)-plan account, 482,514 shares that he owns individually and 71,529 shares of common stock held by Capital Asset Fund #1 Limited Partnership, as to which Mark Portnoy may be deemed beneficial owner as its general partner. Also, includes 386,866 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 21, 2020.

(8)	Includes 39,708 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 21, 2020.

(9)

Includes 484,199 shares of Common Stock held by IsZo Capital L.P (the “Fund”)., IsZo Capital GP LLC (“IsZo GP”), IsZo Capital Management LP (“ICM”) and Brian Sheehy. Also, includes 8,875 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 21, 2020.

(10)	Includes 39,708 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 21, 2020.

(11)	Includes 39,708 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 21, 2020.

(12)	Includes 8,875 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 21, 2020.

(13)	Includes 7,500 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 21, 2020.

(14)	Includes 46,815 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 21, 2020.

(15)	Includes 988,588 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 21, 2020.

As discussed in further detail in the Company’s Proxy Statement filed with the Securities and Exchange Commission on October 29, 2019 in connection with the Company’s 2019 Annual Meeting (the “2019 Proxy Statement”), on or about March 26, 2018, the Company received a letter from counsel for a purported stockholder. Among other things, the letter identified equity awards allegedly made in violation of the 2012 Plan. The Board formed a committee of directors (the “Demand Review Committee”) to (among other things) conduct an investigation of the allegations in that letter. After completing its investigation, the Demand Review Committee determined that certain restricted stock awards and certain performance-based awards were granted in violation of the 2012 Plan and the Delaware General Corporation Law (“DGCL”). The Demand Review Committee also determined that certain stock option awards were granted in violation of the 2012 Plan, the 2006 Plan, the 2000 Stock Incentive Plan, as amended (the “2000 Plan”) and the DGCL. Annex II attached to the 2019 Proxy Statement describes each of these awards and the applicable Plan that the awards were purportedly granted under, and Annexes I and II of the 2019 Proxy Statement describe each defective award and defective stock issuance identified by the Demand Review Committee (the “Defective Awards and Issuances”).

Based on the recommendation of the Demand Review Committee, the Board of Directors approved the proposed treatment of each award and issuance listed on Annexes I and II in the manner identified in the column entitled “Recommended Disposition” in each of those Annexes and recommended to the Company’s stockholders that such awards and issuances be ratified as proposed by the Recommended Dispositions. On November 21, 2019, the Company held its Annual Meeting of Stockholders. At the 2019 Annual Meeting, the Company’s stockholders considered various matters presented to them, including the ratification of certain equity-based awards and stock issuances made pursuant to the Company’s incentive Plans, as well as the approval of certain amendments to those incentive Plans. All such matters presented to the stockholders were duly approved by the stockholders at the 2019 Annual Meeting. Accordingly, all references contained in this Annual Report on Form 10-K to the number of options or shares of common stock granted under the Company’s incentive Plans, the value thereof, and the number of securities that remain available for future issuance under the Company’s 2012 Plan for all periods presented in this Annual Report on Form 10-K have been calculated and are being presented after taking into account the ratification and surrender of the Defective Awards and Issuances in accordance with the Recommended Disposition, as further described in the 2019 Proxy Statement.

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

David Portnoy, the Company’s Chairman and Co-Chief Executive officer, is the brother of the Company’s Co-Chief Executive Officer, Mark Portnoy. The Company’s Audit Committee Chairman, Harold Berger, provides accounting services to the Company’s Co-Chief Executive Officer Mark Portnoy and to PartnerCommunity, Inc. The Company’s Chairman and Co-Chief Executive Officer, David Portnoy, serves as the Chairman of the Board of PartnerCommunity, Inc.

Approval of Related Party Transactions

Historically, the Company followed a policy of review and approval of transactions with directors, executive officers and their affiliates by the board of directors, with interested members of the board of directors abstaining from voting on approval of the transactions. Under this policy, the board of directors would approve such transactions only if they were found to be on terms no less favorable to the Company than would be available from third parties in arms-length transactions. The Board of Directors has a policy that the Company will not enter into any transaction or commercial relationship with any director, director nominee, executive officer or greater than 5% stockholder of the Company.

ITEM 14.

PRINCIPAL ACCOUNTANT FEES AND SERVICES.

Porter Keadle Moore, LLC (“PKM”) served as the Company’s independent registered public accounting firm for the fiscal year ended November 30, 2018.

Effective October 1, 2019 PKM combined its practice (the “Practice Combination”) with WIPFLI LLP (“WIPFLI”). As a result of the Practice Combination, PKM effectively resigned as the Company’s independent registered public accounting firm and WIPFLI, as the successor to PKM following the Practice Combination, was engaged as the Company’s independent registered public accounting firm. The Company’s Audit Committee was notified of the Practice Combination and the effective resignation of PKM and ratified and approved the engagement of WIPFLI. On November 21, 2019 the appointment was ratified by the Company’s shareholders at the 2019 Annual Meeting of Shareholders.

The following table presents fees for professional audit services rendered by PKM for the audit of the Company’s financial statements for the fiscal year ended November 30, 2018, tax services rendered by PKM for fiscal year ended November 30, 2018, professional audit services rendered by PKM and WIPFLI for the fiscal year ended November 30, 2019, tax services rendered by PKM and WIPFLI for the fiscal year ended November 30, 2019 and fees billed for other services rendered by PKM and WIPFLI during these periods.


	2019		2018
Audit Fees	$	238,665	$	255,457
Audit Related Fees		7,500		49,718
Tax Fees		64,858		84,478
Other		—		—

Total	$	312,023	$	389,653

Audit Fees

Audit fees consisted of the aggregate fees billed by our principal accountants for professional services rendered for the audit of the Company’s annual financial statements set forth in the Company’s Annual Report on Form 10-K for the fiscal years ended November 30, 2018 and November 30, 2017 as well as assistance with and review of documents filed with the SEC.

Audit Related Fees

Audit related fees consisted of fees billed for professional services rendered by our principal accounts during the fiscal years ended November 30, 2019 and November 30, 2018.

Tax Fees

Tax fees consisted of the aggregate fees billed by our principal accountants for professional services rendered for tax compliance, tax advice and tax planning for the fiscal years ended November 30, 2019 and November 30, 2018.

Other Fees

The Company did not incur other fees by our principal accountants for the fiscal years ended November 30, 2019 and November 30, 2018.

The policy of the Company’s audit committee is to review and pre-approve both audit and non-audit services to be provided by the independent auditors (other than with de minimis exceptions permitted by the Sarbanes-Oxley Act of 2002). This duty may be delegated to one or more designated members of the audit committee with any such approval reported to the committee at its next regularly scheduled meeting. All of the fees described above under the captions “Audit-Related Fees”, “Tax Fees” and “Other Fees” and paid to PKM were pre-approved by the audit committee.

No services in connection with appraisal or valuation services, fairness opinions or contribution-in-kind reports were rendered by PKM or WIPFLI. Furthermore, no work of PKM and WIPFLI with respect to its services rendered to the Company was performed by anyone other than PKM and WIPFLI.

Part IV

ITEM 15.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.


Exhibit No.		Description
3.1 (1)		Amended and Restated Certificate of Incorporation
3.2 (2)		Amended and Restated By-Laws
10.6 (3)		Secondary Storage Agreement with Safti-Cell, Inc. dated October 1, 2001
10.7 (3)		Addendum Agreement dated November 2001 to Secondary Storage Agreement with Safti-Cell, Inc.
10.9 (4)		Lease Agreement dated April 15, 2004 between Brooker Creek North, LLP and the Company
10.10 (5)		Employment Agreement with Mercedes Walton, dated August 15, 2005
10.11 (6)		Employment Agreement with Jill M. Taymans dated November 1, 2005.
10.12 (6)		Forms of Stock Option Agreements under 2000 Stock Incentive Plan.
10.13 (7)		First Lease Amendment by and between the Company and Brooker Creek North I, LLP, dated June 7, 2006.
10.14 (8)		2006 Stock Incentive Plan
10.15 (9)		Employment Agreement dated April 1, 2007 between the Company and Julie Allickson
10.16 (10)		Agreement dated June 4, 2007 by and among the Company and Andrew J. Filipowski, the Andrew J. Filipowski Revocable Trust and Matthew G. Roszak
10.17 (11)		Agreement dated January 24, 2008 by and among the Company and Andrew J. Filipowski, the Andrew J. Filipowski Revocable Trust, Matthew G. Roszak and SilkRoad Equity LLC
10.18 (11)		Agreement dated January 24, 2008 by and among the Company and Ki Yong Choi and the UAD 7/21/01 FBO Choi Family Living Trust
10.20 (12)		Amendment dated July 16, 2007, amending Employment Agreement with Mercedes Walton, dated August 15, 2005
10.21 (13)		Amendment dated July 18, 2008, amending Employment Agreement with Mercedes Walton, dated August 15, 2005
10.22 (13)		Amendment dated July 18, 2008, amending Employment Agreement with Jill M. Taymans, dated November 1, 2005
10.23 (14)		2000 Stock Incentive Plan
10.24 (14)		Amendment to 2000 Stock Incentive Plan dated April 6, 2004
10.25 (14)		Amendment to 2000 Stock Incentive Plan dated August 14, 2008
10.26 (12)		Stipulation and Order of Court of Chancery of the State of Delaware dated June 18, 2008
10.27 (15)		Employment Agreement with David Portnoy dated December 1, 2011
10.28 (15)		Employment Agreement with Mark Portnoy dated December 1, 2011
10.29 (16)		Amendment dated, February 13, 2012, amending Employment Agreement with David Portnoy
10.30 (16)		Amendment dated, February 13, 2012, amending Employment Agreement with Mark Portnoy
10.31 (17) 10.32 (18) 10.33 (19) 10.34 (19) 10.35 (20) 10.36 (20) 10.37 (21) 10.38 (22) 10.39 (21) 10.40 (23) 10.41 (24) 10.42 (25) 10.43 (25)		Employment Agreement with Oleg Mikulinsky dated March 5, 2012 Amendment dated May 1, 2013, amending Employment Agreement with Oleg Mikulinsky dated March 5, 2012 Employment Agreement with David Portnoy dated December 1, 2013 Employment Agreement with Mark Portnoy dated December 1, 2013 Employment Agreement with Linda Kelley dated June 18, 2012 Amendment dated October 29, 2013, amending Employment Agreement with Linda Kelley dated June 18, 2012 Certificate of Designation of Series A Junior Participating Preferred Stock of Cryo-Cell International, Inc. Asset Purchase Agreement by and between Cytomedical Design Group LLC and Cryo-Cell International, Inc. dated June 15, 2015 Rights Agreement dated December 5, 2014 Amendment No. 1 to Asset Purchase Agreement dated June 30, 2015 Third Lease Amendment by and between the Company and EJB Brooker Creek, LLC., dated January 12, 2016. Amended and Restated Employment Agreement with David Portnoy dated December 1, 2015 Amended and Restated Employment Agreement with Mark Portnoy dated December 1, 2015
10.44 (26)		Amendment Agreement with Oleg Mikulinsky dated December 1, 2015.
10.45 (27)		Stock Purchase Agreement dated June 16, 2016.
10.46 (28)		2012 Equity Incentive Plan.
10.47 (29)		Amended and restated Employment Agreement with David Portnoy dated March 8, 2018.
10.48 (29)		Amended and restated Employment Agreement with Mark Portnoy dated March 8, 2018.
10.49 (30)		Amended Agreement with Oleg Mikulinsky effective December 1, 2017.
10.50 (31)		Second Amendment to Credit Agreement with Texas Capital Bank dated June 11, 2018.
10.51 (31)		Second Amended and Restated Promissory Note dated June 11, 2018
10.52 (32)		Retrospective Amendments to the 2000 Stock Incentive Plan
10.53 (32)		Retrospective Amendments to the 2006 Stock Incentive Plan
10.54 (32)		2012 Amended and Restated Equity Incentive Plan
24		Power of Attorney (included on signature page)
31.1		Certification of Co-CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of CoCEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.3		Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonony Extension Definition Linkbase Document
101.LAB		XBRL Taxonony Extension Label Linkbase Document
101.PRE		XBRL Taxonony Extension Presentation Linkbase Document
(1)		Incorporated by reference to the Company’s Quarterly Report on Form 10-QSB for the quarter ended May 31, 2002.
(2)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on December 11, 2018.
(3)		Incorporated by reference to the Company’s Annual Report on Form 10-KSB for the year ended November 30, 2002.
(4)		Incorporated by reference to the Company’s Quarterly Report on Form 10-QSB for the quarter ended May 31, 2004.
(5)		Incorporated by reference to the Company’s Quarterly Report on Form 10-QSB filed for the quarter ended August 31, 2005.
(6)		Incorporated by reference to the Company’s Annual Report on Form 10-KSB for the year ended November 30, 2005.
(7)		Incorporated to the Company’s Quarterly Report on Form 10-QSB for the quarter ended May 31, 2006.
(8)		Incorporated by reference to Annex B to the Definitive Proxy Statement filed June 1, 2006.
(9)		Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended May 31, 2007.
(10)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on June 8, 2007.
(11)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 25, 2008.
(12)		Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended May 31, 2008.
(13)		Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended August 31, 2008.
(14)		Incorporated by reference to the Company’s Annual Report on Form 10-KSB for the year ended November 30, 2008.
(15)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on December 7, 2011.
(16)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 17, 2012.
(17) (18) (19)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on March 9, 2012 Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended May 31, 2013. Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 27, 2014.
(20)		Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended November 30, 2013.
(21)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on December 3, 2014.
(22)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on June 19, 2015
(23)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on July 16, 2015
(24)		Incorporated by reference to the Company’s Annual Report on Form 10-K for the year ended November 30, 2015
(25)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on April 19, 2016.
(26)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on April 20, 2016.
(27)		Incorporated by reference to the Company’s Current Report on Form 8-K filed on June 24, 2016.
(28)		Incorporated by reference to Appendix B to the proxy statement for the Annual Meeting of Stockholders of the Company (Commission File No. 000-23386), filed by the Company under the Exchange Act with the Commission on June 21, 2012.
(29)		Incorporated by reference to the Company’s Current Report on Form 8-K filed March 13, 2018.
(30)		Incorporated by reference to the Company’s Current Report on Form 8-K filed May 24, 2018.
(31)		Incorporated by reference to the Company’s Current Report on Form 8-K filed June 15, 2018.
(32)		Incorporated by reference the proxy statement for the Annual Meeting of Stockholders of the Company (Commission File No. 000-23386 ), filed by the Company under the Exchange Act with the Commission on October 29, 2019.

ITEM 16.

FORM 10-K SUMMARY

Not applicable.

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized.


CRYO-CELL INTERNATIONAL, INC.

By:		/s/ David Portnoy
		David Portnoy, Co-Chief Executive Officer

Dated: February 28, 2020

POWER OF ATTORNEY

Each of the undersigned officers and directors of Cryo-Cell International, Inc., hereby constitutes and appoints David Portnoy, Mark Portnoy and Jill Taymans, each their true and lawful attorneys-in-fact and agents, for them and in their name, place and stead, in any and all capacities, to sign their names to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself or herself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons in the capacities indicated:


SIGNATURE	TITLE	DATE

/s/ David Portnoy	Chairman of the Board and
David Portnoy	Co-Chief Executive Officer
	(principal executive officer)	February 28, 2020

/s/ Mark Portnoy	Co-Chief Executive Officer	February 28, 2020
Mark Portnoy

/s/ Jill Taymans	Chief Financial Officer
Jill Taymans	(principal financial
	and accounting officer)	February 28, 2020

/s/ Harold Berger	Director	February 28, 2020
Harold Berger

/s/ Arthur Ellis	Director	February 28, 2020
Arthur Ellis

/s/ George Gaines	Director	February 28, 2020
George Gaines

/s/ Brian Sheehy	Director	February 28, 2020
Brian Sheehy

/s/ Jonathan Wheeler	Director	February 28, 2020
Jonathan Wheeler

EX-31.1 2 d807043dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

I, David Portnoy, certify that:

1.	I have reviewed this annual report on Form 10-K of Cryo-Cell International, Inc. (the “Registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting;

5.	The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Dated: February 28, 2020						/s/ David Portnoy
						David Portnoy

EX-31.2 3 d807043dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

I, Mark Portnoy, certify that:

1.	I have reviewed this annual report on Form 10-K of Cryo-Cell International, Inc. (the “Registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Dated: February 28, 2020						/s/ Mark Portnoy
						Mark Portnoy

EX-31.3 4 d807043dex313.htm EX-31.3 EX-31.3

EXHIBIT 31.3

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Jill M. Taymans, certify that:

1.	I have reviewed this annual report on Form 10-K of Cryo-Cell International, Inc. (the “Registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Dated: February 28, 2020						/s/ Jill M. Taymans
						Jill M. Taymans

EX-32.1 5 d807043dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Cryo-Cell International, Inc. (the “Company”) on Form 10-K for the year ended November 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Portnoy, Co-Chief Executive Officer of the Company, I, Mark Portnoy, Co-Chief Executive Officer of the Company and I, Jill M. Taymans, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ David Portnoy

David Portnoy

Co-Chief Executive Officer

February 28, 2020

/s/ Mark Portnoy

Mark Portnoy

Co-Chief Executive Officer

February 28, 2020

/s/ Jill M. Taymans

Jill M. Taymans

Vice President, Finance, Chief Financial Officer

February 28, 2020

EX-101.INS 6 ccel-20191130.xml XBRL INSTANCE DOCUMENT 0000862692 2018-12-01 2019-11-30 0000862692 2017-12-01 2018-11-30 0000862692 2019-11-30 0000862692 2018-11-30 0000862692 2018-12-01 2019-05-31 0000862692 2011-12-31 0000862692 2012-06-06 0000862692 2015-04-08 0000862692 2016-10-06 0000862692 2019-05-31 0000862692 2005-12-01 2005-12-31 0000862692 2012-02-01 2012-02-01 0000862692 2017-06-01 2017-06-01 0000862692 2018-12-01 0000862692 2018-12-01 2019-02-28 0000862692 2014-04-09 2014-04-30 0000862692 2018-07-10 2018-07-31 0000862692 2016-12-01 2017-11-30 0000862692 2018-01-31 2018-01-31 0000862692 2020-02-15 0000862692 2017-11-30 0000862692 us-gaap:SeriesAPreferredStockMember 2018-11-30 0000862692 ccel:AllOtherMember 2018-11-30 0000862692 ccel:PublicBankingMember 2018-11-30 0000862692 ccel:ServiceBasedVestingConditionOptionsMember us-gaap:MeasurementInputExpectedDividendRateMember 2018-11-30 0000862692 ccel:ServiceBasedVestingConditionOptionsMember us-gaap:MeasurementInputPriceVolatilityMember 2018-11-30 0000862692 ccel:ServiceBasedVestingConditionOptionsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-11-30 0000862692 us-gaap:PatentsMember 2018-11-30 0000862692 us-gaap:LicensingAgreementsMember 2018-11-30 0000862692 us-gaap:CustomerRelationshipsMember 2018-11-30 0000862692 ccel:BrandMember 2018-11-30 0000862692 ccel:CustomerRelationshipsOneMember 2018-11-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember 2018-11-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2018-11-30 0000862692 ccel:TianheStemCellBiotechnologiesIncMember 2018-11-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2018-11-30 0000862692 ccel:TwoThousandSixPlanMember us-gaap:EmployeeStockOptionMember 2018-11-30 0000862692 ccel:SaneronMember 2018-11-30 0000862692 ccel:RsaMember 2018-11-30 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceMember 2018-11-30 0000862692 ccel:PrepacytecbMember 2018-11-30 0000862692 ccel:PublicCordBloodBankingMember 2018-11-30 0000862692 us-gaap:FurnitureAndFixturesMember 2018-11-30 0000862692 us-gaap:LeaseholdImprovementsMember 2018-11-30 0000862692 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-11-30 0000862692 us-gaap:AccountingStandardsUpdate201409Member 2018-12-01 0000862692 us-gaap:AccountingStandardsUpdate201409Member 2018-12-01 2018-12-01 0000862692 ccel:BloodBankIncAndTianheStemCellBiotechnologiesIncMember 2018-06-11 2018-06-11 0000862692 us-gaap:CustomerRelationshipsMember ccel:BloodBankIncAndTianheStemCellBiotechnologiesIncMember 2018-06-11 2018-06-11 0000862692 ccel:BrandMember ccel:BloodBankIncAndTianheStemCellBiotechnologiesIncMember 2018-06-11 2018-06-11 0000862692 ccel:BloodBankIncAndTianheStemCellBiotechnologiesIncMember 2018-06-11 0000862692 ccel:BloodBankIncAndTianheStemCellBiotechnologiesIncMember ccel:BrandMember 2018-06-11 0000862692 ccel:BloodBankIncAndTianheStemCellBiotechnologiesIncMember us-gaap:CustomerRelationshipsMember 2018-06-11 0000862692 ccel:SecondAmendedSeniorCreditFacilityMember ccel:TexasCapitalBankNationalAssociationMember ccel:TermLoanMember 2018-06-11 0000862692 ccel:TexasCapitalBankNationalAssociationMember ccel:AmendedAndRestatedPromissoryNotesMember ccel:TermLoanMember 2018-06-11 0000862692 ccel:SeniorCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember ccel:TexasCapitalBankNationalAssociationMember ccel:TermLoanMember 2016-05-20 0000862692 ccel:AmendedSeniorCreditFacilityMember ccel:TexasCapitalBankNationalAssociationMember ccel:AmendedAndRestatedPromissoryNotesMember ccel:TermLoanMember 2016-08-26 0000862692 ccel:TwoThousandTwelvePlanMember us-gaap:EmployeeStockOptionMember 2012-05-01 2012-05-31 0000862692 us-gaap:CommonStockMember 2017-12-01 2018-11-30 0000862692 country:IN ccel:ProcessingAndStorageRoyaltiesMember 2017-12-01 2018-11-30 0000862692 country:IN ccel:LicenseeAndRoyaltyIncomeRecognitionMember 2017-12-01 2018-11-30 0000862692 ccel:ProcessingAndStorageRoyaltiesMember 2017-12-01 2018-11-30 0000862692 ccel:LicenseeAndRoyaltyIncomeRecognitionMember 2017-12-01 2018-11-30 0000862692 ccel:ProcessingAndStorageFeesMember 2017-12-01 2018-11-30 0000862692 ccel:PublicBankingMember 2017-12-01 2018-11-30 0000862692 us-gaap:ProductMember 2017-12-01 2018-11-30 0000862692 ccel:PublicBankingRevenueMember 2017-12-01 2018-11-30 0000862692 ccel:ProductRevenueMember 2017-12-01 2018-11-30 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceMember 2017-12-01 2018-11-30 0000862692 ccel:PrepacytecbMember 2017-12-01 2018-11-30 0000862692 ccel:PublicCordBloodBankingMember 2017-12-01 2018-11-30 0000862692 ccel:ServiceBasedVestingConditionOptionsMember 2017-12-01 2018-11-30 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceMember us-gaap:OperatingSegmentsMember 2017-12-01 2018-11-30 0000862692 ccel:PrepacytecbMember us-gaap:OperatingSegmentsMember 2017-12-01 2018-11-30 0000862692 us-gaap:OperatingSegmentsMember 2017-12-01 2018-11-30 0000862692 us-gaap:AdditionalPaidInCapitalMember 2017-12-01 2018-11-30 0000862692 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-01 2018-11-30 0000862692 us-gaap:RetainedEarningsMember 2017-12-01 2018-11-30 0000862692 ccel:TexasCapitalBankNationalAssociationMember ccel:AmendedAndRestatedPromissoryNotesMember 2017-12-01 2018-11-30 0000862692 ccel:ServiceBasedStockOptionsMember ccel:TwoThousandTwelvePlanMember 2017-12-01 2018-11-30 0000862692 ccel:ServiceBasedRestrictedSharesMember ccel:TwoThousandTwelvePlanMember 2017-12-01 2018-11-30 0000862692 ccel:PerformanceBasedStockOptionsMember ccel:TwoThousandTwelvePlanMember 2017-12-01 2018-11-30 0000862692 ccel:MarketBasedStockOptionsMember ccel:TwoThousandTwelvePlanMember 2017-12-01 2018-11-30 0000862692 us-gaap:StockOptionMember 2017-12-01 2018-11-30 0000862692 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-12-01 2018-11-30 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-12-01 2018-11-30 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-12-01 2018-11-30 0000862692 ccel:ChiefInformationOfficerMember ccel:SecondAmendmentAgreementMember 2017-12-01 2018-11-30 0000862692 ccel:MarketBasedVestingConditionOptionsMember ccel:CoCeoTwoMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-12-01 2018-11-30 0000862692 ccel:MarketBasedVestingConditionOptionsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-12-01 2018-11-30 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember ccel:CoCeoOneMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-12-01 2018-11-30 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember ccel:CoCeoTwoMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-12-01 2018-11-30 0000862692 stpr:TX 2017-12-01 2018-11-30 0000862692 ccel:CoCeoOneMember 2018-03-08 2018-03-08 0000862692 ccel:CoCeoTwoMember 2018-03-08 2018-03-08 0000862692 ccel:ChiefInformationOfficerMember ccel:SecondAmendmentAgreementMember 2018-05-21 2018-05-21 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceAndPrepacytecbMember 2018-12-01 2019-11-30 0000862692 ccel:ServiceBasedVestingConditionOptionsMember 2018-12-01 2019-11-30 0000862692 us-gaap:CommonStockMember 2018-12-01 2019-11-30 0000862692 country:IN ccel:ProcessingAndStorageRoyaltiesMember 2018-12-01 2019-11-30 0000862692 country:IN ccel:LicenseeAndRoyaltyIncomeRecognitionMember 2018-12-01 2019-11-30 0000862692 ccel:ProcessingAndStorageRoyaltiesMember 2018-12-01 2019-11-30 0000862692 ccel:LicenseeAndRoyaltyIncomeRecognitionMember 2018-12-01 2019-11-30 0000862692 ccel:ProcessingAndStorageFeesMember 2018-12-01 2019-11-30 0000862692 ccel:PublicBankingMember 2018-12-01 2019-11-30 0000862692 us-gaap:ProductMember 2018-12-01 2019-11-30 0000862692 ccel:PublicBankingRevenueMember 2018-12-01 2019-11-30 0000862692 ccel:ProductRevenueMember 2018-12-01 2019-11-30 0000862692 ccel:RangeOneMember 2018-12-01 2019-11-30 0000862692 ccel:RangeTwoMember 2018-12-01 2019-11-30 0000862692 ccel:RangeThreeMember 2018-12-01 2019-11-30 0000862692 ccel:RangeFourMember 2018-12-01 2019-11-30 0000862692 ccel:RangeFiveMember 2018-12-01 2019-11-30 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceMember 2018-12-01 2019-11-30 0000862692 ccel:PrepacytecbMember 2018-12-01 2019-11-30 0000862692 ccel:PublicCordBloodBankingMember 2018-12-01 2019-11-30 0000862692 ccel:SalesCommissionsMember 2018-12-01 2019-11-30 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceMember us-gaap:OperatingSegmentsMember 2018-12-01 2019-11-30 0000862692 ccel:PrepacytecbMember us-gaap:OperatingSegmentsMember 2018-12-01 2019-11-30 0000862692 ccel:PublicCordBloodBankingMember us-gaap:OperatingSegmentsMember 2018-12-01 2019-11-30 0000862692 us-gaap:OperatingSegmentsMember 2018-12-01 2019-11-30 0000862692 us-gaap:PatentsMember srt:MinimumMember 2018-12-01 2019-11-30 0000862692 us-gaap:PatentsMember srt:MaximumMember 2018-12-01 2019-11-30 0000862692 us-gaap:LicensingAgreementsMember 2018-12-01 2019-11-30 0000862692 us-gaap:CustomerRelationshipsMember 2018-12-01 2019-11-30 0000862692 ccel:BrandMember 2018-12-01 2019-11-30 0000862692 ccel:CustomerRelationshipsOneMember 2018-12-01 2019-11-30 0000862692 us-gaap:AccountsReceivableMember 2018-12-01 2019-11-30 0000862692 us-gaap:AdditionalPaidInCapitalMember 2018-12-01 2019-11-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember ccel:ContingentConsiderationMember 2018-12-01 2019-11-30 0000862692 us-gaap:AccumulatedOtherComprehensiveIncomeMember us-gaap:AccountingStandardsUpdate201601Member 2018-12-01 2019-11-30 0000862692 us-gaap:RetainedEarningsMember us-gaap:AccountingStandardsUpdate201601Member 2018-12-01 2019-11-30 0000862692 ccel:DeferredRevenueMember 2018-12-01 2019-11-30 0000862692 us-gaap:RetainedEarningsMember 2018-12-01 2019-11-30 0000862692 us-gaap:TreasuryStockMember 2018-12-01 2019-11-30 0000862692 ccel:SeniorCreditFacilityMember ccel:TexasCapitalBankNationalAssociationMember ccel:TermLoanMember 2018-12-01 2019-11-30 0000862692 ccel:TexasCapitalBankNationalAssociationMember ccel:AmendedAndRestatedPromissoryNotesMember 2018-12-01 2019-11-30 0000862692 ccel:OptionThreeMember 2018-12-01 2019-11-30 0000862692 ccel:ServiceBasedStockOptionsMember ccel:TwoThousandTwelvePlanMember 2018-12-01 2019-11-30 0000862692 ccel:ServiceBasedRestrictedSharesMember ccel:TwoThousandTwelvePlanMember 2018-12-01 2019-11-30 0000862692 ccel:TwoThousandTwelvePlanMember ccel:PerformanceBasedStockOptionsMember 2018-12-01 2019-11-30 0000862692 ccel:TwoThousandTwelvePlanMember ccel:MarketBasedStockOptionsMember 2018-12-01 2019-11-30 0000862692 ccel:OptioneeMember 2018-12-01 2019-11-30 0000862692 us-gaap:StockOptionMember 2018-12-01 2019-11-30 0000862692 us-gaap:StockOptionMember ccel:ServiceBasedVestingConditionOptionsMember 2018-12-01 2019-11-30 0000862692 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-12-01 2019-11-30 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-12-01 2019-11-30 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-12-01 2019-11-30 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-12-01 2019-11-30 0000862692 ccel:ChiefInformationOfficerMember ccel:SecondAmendmentAgreementMember 2018-12-01 2019-11-30 0000862692 ccel:MarketBasedVestingConditionOptionsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-12-01 2019-11-30 0000862692 ccel:MarketBasedVestingConditionOptionsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-12-01 2019-11-30 0000862692 ccel:MarketBasedVestingConditionOptionsMember ccel:CoCeoOneMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-12-01 2019-11-30 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember ccel:CoCeoTwoMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-12-01 2019-11-30 0000862692 ccel:CoCeoOneMember 2018-12-01 2019-11-30 0000862692 ccel:CoCeoTwoMember 2018-12-01 2019-11-30 0000862692 us-gaap:AccountsReceivableMember 2018-12-01 2019-11-30 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceAndPrepacytecbMember ccel:DukeUniversityMember srt:MaximumMember 2018-12-01 2019-11-30 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceAndPrepacytecbMember ccel:DukeUniversityMember 2018-12-01 2019-11-30 0000862692 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2018-12-01 2019-11-30 0000862692 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2018-12-01 2019-11-30 0000862692 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2018-12-01 2019-11-30 0000862692 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2018-12-01 2019-11-30 0000862692 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember srt:MinimumMember 2018-12-01 2019-11-30 0000862692 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember srt:MaximumMember 2018-12-01 2019-11-30 0000862692 stpr:IL 2018-12-01 2019-11-30 0000862692 us-gaap:EmployeeStockOptionMember 2018-12-01 2019-11-30 0000862692 stpr:TX 2018-12-01 2019-11-30 0000862692 srt:MinimumMember 2018-12-01 2019-11-30 0000862692 srt:MaximumMember 2018-12-01 2019-11-30 0000862692 us-gaap:DomesticCountryMember us-gaap:EarliestTaxYearMember 2018-12-01 2019-11-30 0000862692 us-gaap:DomesticCountryMember us-gaap:LatestTaxYearMember 2018-12-01 2019-11-30 0000862692 us-gaap:StateAndLocalJurisdictionMember us-gaap:EarliestTaxYearMember 2018-12-01 2019-11-30 0000862692 us-gaap:StateAndLocalJurisdictionMember us-gaap:LatestTaxYearMember 2018-12-01 2019-11-30 0000862692 us-gaap:DomesticCountryMember 2018-12-01 2019-11-30 0000862692 us-gaap:StateAndLocalJurisdictionMember 2018-12-01 2019-11-30 0000862692 ccel:TwoThousandTwelvePlanMember us-gaap:PerformanceSharesMember 2018-12-01 2019-11-30 0000862692 ccel:TwoThousandTwelvePlanMember 2018-12-01 2019-11-30 0000862692 ccel:TwoThousandSixPlanMember 2018-12-01 2019-11-30 0000862692 ccel:TwoThousandPlanMember 2018-12-01 2019-11-30 0000862692 ccel:CaseOneMember 2015-12-03 2015-12-03 0000862692 ccel:NonQualifiedStockOptionsMember ccel:PerformanceAndMarketBasedVestingConditionOptionsMember ccel:CoCeoOneMember 2019-08-01 2019-08-30 0000862692 ccel:NonQualifiedStockOptionsMember ccel:PerformanceAndMarketBasedVestingConditionOptionsMember ccel:CoCeoTwoMember 2019-08-01 2019-08-30 0000862692 ccel:SeniorCreditFacilityMember ccel:TexasCapitalBankNationalAssociationMember ccel:PromissoryNotesMember ccel:TermLoanMember 2016-07-01 0000862692 ccel:SeniorCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember ccel:TexasCapitalBankNationalAssociationMember ccel:TermLoanMember 2016-05-20 2016-05-20 0000862692 us-gaap:SeriesAPreferredStockMember 2019-11-30 0000862692 ccel:AllOtherMember 2019-11-30 0000862692 us-gaap:CommonStockMember 2019-11-30 0000862692 ccel:PublicBankingMember 2019-11-30 0000862692 ccel:ServiceBasedVestingConditionOptionsMember 2019-11-30 0000862692 ccel:RangeTwoMember 2019-11-30 0000862692 ccel:RangeThreeMember 2019-11-30 0000862692 ccel:RangeFourMember 2019-11-30 0000862692 ccel:RangeFiveMember 2019-11-30 0000862692 ccel:RangeOneMember 2019-11-30 0000862692 ccel:ServiceBasedVestingConditionOptionsMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-11-30 0000862692 ccel:ServiceBasedVestingConditionOptionsMember us-gaap:MeasurementInputPriceVolatilityMember 2019-11-30 0000862692 ccel:ServiceBasedVestingConditionOptionsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-11-30 0000862692 us-gaap:PatentsMember 2019-11-30 0000862692 us-gaap:LicensingAgreementsMember 2019-11-30 0000862692 us-gaap:CustomerRelationshipsMember 2019-11-30 0000862692 ccel:BrandMember 2019-11-30 0000862692 ccel:CustomerRelationshipsOneMember 2019-11-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember 2019-11-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-11-30 0000862692 ccel:SalesCommissionsMember 2019-11-30 0000862692 us-gaap:AccountsReceivableMember ccel:LifecellLicenseAndAgreementMember 2019-11-30 0000862692 ccel:LifecellLicenseAndAgreementMember srt:MaximumMember 2019-11-30 0000862692 ccel:LifecellLicenseAndAgreementMember 2019-11-30 0000862692 us-gaap:AccountsReceivableMember 2019-11-30 0000862692 ccel:TianheStemCellBiotechnologiesIncMember 2019-11-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2019-11-30 0000862692 ccel:OptionOneMember 2019-11-30 0000862692 ccel:OptionTwoMember 2019-11-30 0000862692 ccel:TwoThousandSixPlanMember us-gaap:EmployeeStockOptionMember 2019-11-30 0000862692 ccel:TwoThousandTwelvePlanMember 2019-11-30 0000862692 ccel:TwoThousandSixPlanMember ccel:ServiceBasedVestingConditionOptionsMember 2019-11-30 0000862692 ccel:TwoThousandTwelvePlanMember ccel:ServiceBasedVestingConditionOptionsMember 2019-11-30 0000862692 ccel:PerformanceAndMarketBasedVestingConditionOptionsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-11-30 0000862692 ccel:ChiefInformationOfficerMember 2019-11-30 0000862692 ccel:SaneronMember 2019-11-30 0000862692 stpr:IL 2019-11-30 0000862692 ccel:IllinoisAndItsContiguousStatesMember 2019-11-30 0000862692 ccel:RsaMember 2019-11-30 0000862692 ccel:UmbilicalCordBloodAndCordTissueStemCellServiceMember 2019-11-30 0000862692 ccel:PrepacytecbMember 2019-11-30 0000862692 ccel:PublicCordBloodBankingMember 2019-11-30 0000862692 us-gaap:FurnitureAndFixturesMember 2019-11-30 0000862692 us-gaap:LeaseholdImprovementsMember 2019-11-30 0000862692 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-11-30 0000862692 us-gaap:CommonStockMember 2019-11-30 2019-11-30 0000862692 ccel:TwoThousandTwelveStockIncentivePlanMember 2018-03-31 2018-03-31 0000862692 stpr:TX 2001-05-31 0000862692 stpr:TX 2007-12-01 2008-11-30 0000862692 ccel:SaneronTherapeuticsMember ccel:StemCellPreservationTechnologiesincMember 2001-10-10 0000862692 ccel:SaneronTherapeuticsMember ccel:BioTherapiesIncMember 2001-10-10 0000862692 ccel:SaneronMember ccel:BioTherapiesIncMember 2001-10-10 0000862692 ccel:SaneronTherapeuticsMember ccel:BioTherapiesIncMember 2001-10-10 2001-10-10 0000862692 ccel:SaneronTherapeuticsMember ccel:StemCellPreservationTechnologiesincMember 2001-10-10 2001-10-10 0000862692 stpr:FL 1999-02-09 0000862692 ccel:MiamiMember 2013-11-30 0000862692 ccel:MiamiMember 2013-11-01 2013-11-30 0000862692 ccel:LifecellLicenseAndAgreementMember srt:MaximumMember 2018-03-31 0000862692 ccel:LifecellLicenseAndAgreementMember srt:MaximumMember 2017-03-31 0000862692 us-gaap:PerformanceSharesMember ccel:TwoThousandTwelvePlanMember 2019-01-01 2019-12-31 0000862692 us-gaap:CommonStockMember 2017-11-30 0000862692 us-gaap:AdditionalPaidInCapitalMember 2017-11-30 0000862692 us-gaap:TreasuryStockMember 2017-11-30 0000862692 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-11-30 0000862692 us-gaap:RetainedEarningsMember 2017-11-30 0000862692 us-gaap:CommonStockMember 2018-11-30 0000862692 us-gaap:AdditionalPaidInCapitalMember 2018-11-30 0000862692 us-gaap:TreasuryStockMember 2018-11-30 0000862692 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-11-30 0000862692 us-gaap:RetainedEarningsMember 2018-11-30 0000862692 ccel:ServiceBasedVestingConditionOptionsMember 2018-11-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember ccel:ContingentConsiderationMember 2018-11-30 0000862692 us-gaap:FairValueMeasurementsRecurringMember ccel:ContingentConsiderationMember 2019-11-30 0000862692 ccel:DeferredRevenueMember 2018-11-30 0000862692 ccel:DeferredRevenueMember 2019-11-30 0000862692 us-gaap:AdditionalPaidInCapitalMember 2019-11-30 0000862692 us-gaap:TreasuryStockMember 2019-11-30 0000862692 us-gaap:RetainedEarningsMember 2019-11-30 10-K Yes false 2019-11-30 2019 FY CRYO CELL INTERNATIONAL INC 0000862692 --11-30 Yes Non-accelerated Filer CCEL false true false FL 7545613

6541037

6040033

904053

875689

500260

461815

1084533

1260557

260397

254465

15387611

14759894

1846467

1493401

308000

1249254

1341336

12646000

14775316

1941411

9079994

7656897

427423 113888

25652082

26136848

42886160

42390143

1369111

1261653

2085180

2702788

15429429

15429725

3495057

4282975

1425000

34409582

35868716

49839011

51298441

135989

135964

35918827

35515382

20563357

19571113

340984

-22444310

-25329515

-6952851

-8908298

42886160

42390143

2584091

2264848

0.01

500000

0.01

500000

0.01

20000

0.01

20000

0.01

20000000

0.01

20000000

13598909

7510884

13596409

7800833

29991972

27817872

652204

296295

172395

104323

31816571

29218490

10036175

8539662

14891462

15632696

30145

91845

206238

180264

26753865

24029187

32155

-24723

1703446

1546900

-1671291

-1571623

3391415

3617680

0.29

-0.11

7794828

7463051

0.27

-0.11

8412414

7463051

2290774

-554705

12899517

128995

31373048

-19571113

40865

-24474691

-12502896

6969

3663956

3670925

5675

2290774

401311

317326

2332763

-162307

-742918

-415280

397770

478378

767128

727483

-1517289

2378491

112642

109292

997124

1347773

38445

20796

27423

-316650

5932

48329

-15696 85000

107458

-666889

-599200

120313

3825996

4095416

6323207

5333330

662295

446163

200000

28364

136248

10500000

-690659

-11282411

4100000

3291665

5700

170925

9000000

169300

-5131544

5709960

501004

-239121

6279154

-340984

20103661

1405406

-854824

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 1 – DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Business. </div></div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cryo-Cell International, Inc. (“the Company” or “Cryo-Cell”) was incorporated in Delaware on September 11, 1989 and is headquartered in Oldsmar, Florida. The Company is organized in three reportable segments, cellular processing and cryogenic cellular storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use, the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Revenues for the cellular processing and cryogenic cellular storage represent sales of the umbilical cord blood stem cells program to customers and income from licensees selling the umbilical cord blood stem cells program to customers outside the United States. Revenues for the manufacture of PrepaCyte CB units represent sales of the PrepaCyte CB units to customers. Revenue for the cryogenic storage of umbilical cord blood stem cells for public use, stored at Duke University (see below), is generated from the sale of the cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States and around the world. The Company’s headquarters facility in Oldsmar, Florida handles all aspects of its U.S.-based business operations including the processing and storage of specimens, including specimens obtained from certain of its licensees’ customers. The specimens are stored in commercially available cryogenic storage equipment. </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On October 10, 2001, Saneron Therapeutics, Inc. merged into one of the Company’s wholly owned subsidiaries, CCEL <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Bio-Therapies,</div> Inc. (”CCBT”), which then changed its name to Saneron CCEL Therapeutics, Inc. (“SCTI” or ”Saneron”). As part of the merger, the Company contributed 260,000 shares of its common stock, whose fair value was $1,924,000 and 195,000 common shares of another of its subsidiaries, Stem Cell Preservation Technologies, Inc., whose fair value was $3,900. At the conclusion of the merger, the Company retained a 43.42% <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in the voting stock of SCTI. As of November 30, 2019 and 2018, the Company had an interest of approximately 33% in the voting stock of SCTI. The accompanying consolidated financial statements as of November 30, 2019 and 2018 reflect the investment in SCTI under the equity method of accounting.</div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements as of November 30, 2019 and November 30, 2018 and for the years then ended includes the accounts of the Company and all of its subsidiaries, which are inactive. All intercompany balances have been eliminated upon consolidation. </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Risks </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit. The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate. </div></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company depends on one supplier for the source of its collection kits, a critical component of the umbilical cord blood stem cell collection process. However, the Company believes that alternative sources of supply are available. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units. However, the Company believes that alternative sources of supply and manufacturing are available. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for transplant. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2019 and 2018, there were no concentration of risks. </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Effective December 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. The Company recognized the cumulative effect of applying the new revenue standard to all contracts with customers that were not completed as of December 1, 2018 as an adjustment to the opening balance of stockholders’ deficit at the beginning of fiscal year 2019. The reported results for 2019 reflect the application of ASC 606 guidance while the reported results for 2018 were prepared under the guidance of ASC 605, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue Recognition </div>(ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. ASC 606 also requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The adoption of ASC 606 did not have an impact on the amount of reported revenues with respect to the Company’s product or service revenues. In connection with the adoption of ASC 606, the Company is required to capitalize certain contract acquisition costs consisting primarily of commissions paid when contracts are signed and amortize these costs on a systematic basis, consistent with the pattern of transfer of the storage services provided over time for which the asset relates. As of December 1, 2018, the Company capitalized in deposits and other assets, net, $329,231 in incremental contract acquisition costs related to sales commissions on prepaid storage contracts and reversed $18,408 of its variable consideration that the Company determined to be fully constrained, with a corresponding change in the opening balance of stockholders’ deficit of $253,447, net of tax, of $94,192. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under ASC 606, revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised services are transferred to the customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring services to a customer (“transaction price”). </div></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At contract inception, if the contract is determined to be within the scope of ASC 606, the Company evaluates its contracts with customers using the five-step model: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to separate performance obligations; and (5) recognize revenue when (or as) each performance obligation is satisfied. The Company evaluates its contracts for legal enforceability at contract inception and subsequently throughout the Company’s relationship with its customers. If legal enforceability with regards to the rights and obligations exist for both the Company and the customer, then the Company has an enforceable contract and revenue recognition is permitted subject to the satisfaction of the other criteria. If, at the outset of an arrangement, the Company determines that a contract with enforceable rights and obligations does not exist, revenues are deferred until all criteria for an enforceable contract are met. The Company only applies the five-step model to contracts when it is probable that collection of the consideration that the Company is entitled to in exchange for the goods or services being transferred to the customer, will occur. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Contract modifications exist when the modification either creates new or changes in the existing enforceable rights and obligations. The Company’s contracts are occasionally modified to account for changes in contract terms and conditions, which the Company refers to as an upgrade or downgrade. An upgrade occurs when a customer wants to pay for additional years of storage. A downgrade occurs when a customer originally entered into a long-term contract (such as <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">twenty-one</div> year or life-time plan) but would like to change the term to a <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> contract. Upgrade modifications qualify for treatment as a separate contract as the additional services are distinct and the increase in contract price reflects the Company’s stand-alone selling price for the additional services and will be accounted for on a prospective basis. Downgrade modifications do not qualify for treatment as a separate contract as there is no increase in price over the original contract, thus failing the separate contract criteria. As such, the Company separately considers downgrade modifications to determine if these should be accounted for as a termination of the existing contract and creation of a new contract (prospective method) or as part of the existing contract (cumulative <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustment). ASC 606 requires that an entity account for the contract modification as if it were a termination of the existing contract, and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. As the services after the modification were previously determined to be distinct, the Company concluded that downgrade modifications qualify under this method and will be accounted for on a prospective basis. Although contract modifications do occur, they are infrequent.</div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance Obligations </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At contract inception, the Company assesses the goods and services promised in the contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good or service (or bundle of goods or services) that is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. The Company determined that the following distinct goods and services represent separate performance obligations involving the sale of its umbilical cord blood product: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:1%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;">•</td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Collection and processing services </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:1%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;">•</td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Storage services </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:1%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;">•</td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:1%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;">•</td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">License and royalties </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:1%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;">•</td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Sale of PrepaCyte CB product </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 1px; margin-top: 6px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>)</div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Processing</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Processing and storage fees include the Company providing umbilical cord blood and tissue cellular processing and cryogenic cellular storage for private use. Revenues recognized for the cellular processing and cryogenic cellular storage represent sales of the umbilical cord blood stem cells program to customers and income from licensees who are selling the umbilical cord blood stem cells program to customers outside the United States. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period as well as other income from royalties paid by licensees related to long-term storage contracts which the Company has under license agreements. Contracted storage periods are <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">annual, twenty-one</div> years and life-time. The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual, the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">twenty-one-year</div></div> and the life-time storage fees that are being recognized over the contractual storage period as well as royalties received from foreign licensees relating to long-term storage contracts for which the Company has future obligations under the license agreement. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.</div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Significant financing </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. For all plans being <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">annual, twenty-one years</div> and life-time, the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans (including a stated service fee) for customers to pay over time for a period of one to twenty-four plus months. The <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> plan includes the collection kit, processing and testing, return medical courier service and <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">twenty-one</div> years of <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> storage fees. The life-time plan includes the collection kit, processing and testing, return medical courier service and <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> storage fees for the life of the customer. The Company concluded that a significant financing component is not present within either the prepaid or overtime payment plans. The Company has determined that the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">twenty-one</div> year and life-time prepayment options do not include a significant financing component as the payment terms were structured primarily for reasons other than the provision of financing and to maximize profitability.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that the majority of plans that are paid over time are paid in less than a year. When considered over a twenty-four-month payment plan, the difference between the cash selling price and the consideration paid is nominal. As such, the Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when considered in the context of all contracts entered into nor significant at the individual contract level. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company elected to apply the practical expedient where the Company does not need to assess whether a significant financing component exists if the period between when it performs its obligations under the contract and when the customer pays is one year or less. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of November 30, 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>, the total aggregate transaction price allocated to the unsatisfied performance obligations was recorded as deferred revenue amounting to $32,508,511, which will be recognized ratably on a straight-line basis over the contractual period of which $8,875,138 will be recognized over the next twelve months. </div></div><div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Variable consideration </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. In the processing and storage agreements, the Company provides limited rights which are offered to customers automatically upon contract execution. The Company has determined that the payment warranty represents variable consideration payable to the customer. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Based on the Company’s historical experience to date, the Company has determined the payment warranty to be fully constrained under the most likely amount method. Consequently, the transaction price does not currently reflect any expectation of service level credits.    At the end of each reporting period, the Company will update the estimated transaction price related to the payment warranty including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period. </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Allocation of transaction price </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As the Company’s processing and storage agreements contain multiple performance obligations, ASC 606 requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the stand-alone selling prices of the processing services and storage services and concluded that the published list price is the price that a customer in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Costs to Obtain a Contract </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Prior to the adoption of ASC 606, the Company expensed in the period, all commissions paid to its internal and external sales representatives the Company employs and to its customers for generating new contracts. <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>With the adoption of ASC 606 as of December 1, 2018, the Company capitalizes commissions that are incremental in obtaining customer contracts and the costs incurred to fulfill a customer contract if those costs are not within the scope of another topic within the accounting literature and meet the specified criteria. These costs are deferred in other current or long-term assets and are expensed to selling, general and administrative expenses as the Company satisfies the performance obligations by transferring the service to the customer. These assets will be periodically assessed for impairment. As a practical expedient, the Company elected to recognize the incremental costs of obtaining its annual contracts as an expense when incurred, as the amortization period of the asset recognized would have been one year. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has determined that payments under the Company’s <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">refer-a-friend</div></div> program (“RAF program”) are incremental costs of obtaining a contract as they provide an incentive for existing customers to refer new customers to the Company and is referred to as commission. The amount paid under the RAF program (either through issuance of credits to customers or check payments) which exceeds the typical commission payment to a sales representative is recorded as a reduction to revenue under ASC 606. During the twelve months ended November 30, 2019, the Company recorded $35,300, in commission payments to customers under the RAF program as a reduction to revenue. As of December 1, 2018, the Company capitalized $329,231 in incremental contract acquisition costs related to contracts that were not completed, net of the cumulative amortization expense of $66,533 through the adoption date. The Company did not record any impairment losses in relation to costs capitalized. For the twelve months ended November 30, 2019, the Company capitalized additional contract acquisition costs of $87,518, net of amortization expense.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 6pt;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div>)</div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Public banking revenue </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company sells and provides units not likely to be of therapeutic use for research to qualified organizations and companies operating under Institutional Review Board approval. Control is transferred at the point in time when the shipment has occurred, at which time, the Company records revenue. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 6pt;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>)</div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Licensee and royalty income </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Licensee and royalty income consist of royalty income earned on the processing and storage of cord blood stem cell specimens by an affiliate where the Company has a License and Royalty Agreement. The Company records revenue from processing and storage of specimens and pursuant to agreements with licensees. The Company records the royalty revenue in same period that the related processing and storage is being completed by the affiliate. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 6pt;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div>)</div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product Revenue </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company records revenue from the sale of the PrepaCyte CB product line upon shipment of the product to the Company’s customers. </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; margin: 6pt auto 0in 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; vertical-align: top;;text-align:left;;width:4%;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div>)</div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif; vertical-align: top;;text-align:left;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shipping and handling </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company elected to apply the practical expedient to account for shipping and handling activities performed after the control of a good has been transferred to the customer as a fulfillment cost. Shipping and handling costs that the Company incurs are therefore expensed and included in cost of sales. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The adoption of ASC 606 did not have an impact on the timing of revenue recognition for any of the Company’s revenue streams. </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Disaggregation of Revenue </div></div></div> <div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about disaggregated revenue by products and services: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:64%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Twelve months ended</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">November 30, 2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">November 30, 2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Processing and storage fees</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29,991,972</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">27,817,872</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public banking revenue</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">652,204</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">296,295</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Licensee and royalty income</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Product revenue</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">172,395</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">104,323</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">31,816,571</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29,218,490</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about assets and liabilities from contracts with customers: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:68%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">November 30, 2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">At Adoption</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract assets (sales commissions)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">398,535</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">329,231</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6,097,331</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">5,867,335</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Short-term contract liabilities (deferred revenue)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,875,138</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,365,284</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Long-term contract liabilities (deferred revenue)</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">23,633,373</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">20,317,231</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company, in general, requires the customer to pay for processing and storage services at the time of processing. Contract assets include deferred contract acquisition costs, which will be amortized along with the associated revenue. Contract liabilities include payments received in advance of performance under the contract and are realized with the associated revenue recognized under the contract. Accounts receivable consists of amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs related to renewals of annual plans and amounts due from license affiliates, and sublicensee territories. The Company did not have asset impairment charges related to contract assets in the twelve <div style="letter-spacing: 0px; top: 0px;;display:inline;">months </div>ended November 30, 2019. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents changes in the Company’s contract assets and liabilities during the twelve months ended November 30, 2019:</div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 52%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 8%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 8.5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 0.5%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Balance at<br/>December 1, 2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Additions</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Deductions</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Balance at<br/>November 30,<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 52%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract assets (sales commissions)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">329,231</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">88,569</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">19,265</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8.5%;;text-align:right;;vertical-align:bottom;">398,535</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 52%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 8%;;text-align:right;;vertical-align:bottom;">5,867,335</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 7%;;text-align:right;;vertical-align:bottom;">36,579,504</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; width: 7%;;text-align:right;;vertical-align:bottom;">36,349,508</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 8.5%;;text-align:right;;vertical-align:bottom;">6,097,331</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 0.5%;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 52%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract liabilities (deferred revenue)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">28,682,515</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">18,759,963</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">14,933,967</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8.5%;;text-align:right;;vertical-align:bottom;">32,508,511</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Sharing Agreements </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company entered into Revenue Sharing Agreements (“RSAs”) prior to 2002 with various third and related parties. The Company’s RSAs provide that in exchange for a <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment, the Company would share for the duration of the contract a percentage of its future storage revenue collected from the annual storage fees charged related to a certain number of specimens that originated from specific geographical areas. The RSAs have no definitive term or termination provisions. The sharing applies to the storage fees collected for all specified specimens in the area up to the number covered in the contract. When the number of specimens is filled, any additional specimens stored in that area are not subject to revenue sharing. As there are empty spaces resulting from attrition, the Company agrees to fill them as soon as possible. The Company has reflected these <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments as long-term liabilities on the accompanying consolidated balance sheets. The Company does not intend to enter into additional RSAs.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the future, the Company could reverse the liability relating to the RSAs over an appropriate period of time, based on the Company’s expectations of the total amount of payments it expects to pay to the other party under the particular RSA. However, the RSAs do not establish a finite term or time frame over which to estimate the total payments and the Company had not previously estimated and has concluded that it is not currently practicable to estimate the projected cash flows under the RSAs. At present, the Company intends to defer the reversal of the liability, until such time as these amounts can</div><div style="text-indent: 0in; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;">be determined. During the periods when the Company defers the reversal of the liability, the quarterly payments made during these periods will be treated as interest expense, which will be recognized as the payments become due. In future periods, if a portion of the liability can be <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">de-recognized</div> based on the effective interest method, the payments will be allocated between interest and amortization of the liability. As cash is paid out to the other party during any period, the liability would be <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">de-recognized</div> based on the portion of the total anticipated payouts made during the period, using the effective interest method. That is, a portion of the payment would be recorded as interest expense, and the remainder would be treated as repayment of principal, which would reduce the liability.</div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">License and Royalty Agreements </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has entered into licensing agreements with certain investors in various international markets in an attempt to capitalize on the Company’s technology. The investors typically pay a licensing fee to receive Company marketing programs, technology and <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> in a selected area. The investor may be given a right to sell <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">sub-license</div> agreements as well. As part of the accounting for the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> license fee paid, or payable, to the Company, revenue from the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> license fee is recognized based on such factors as when the payment is due, collectability and when all material services or conditions relating to the sale have been substantially performed by the Company based on the terms of the agreement. The Company has twelve active licensing agreements. The following areas each have one license agreement: El Salvador, Guatemala, Panama, Honduras, China and Pakistan. The following areas each have two license agreements: India, Nicaragua and Costa Rica.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to the license fee, the Company earns processing and storage fees on subsequent processing and storage revenues received by the licensee in the licensed territory and a fee on any <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">sub-license</div> agreements that are sold by the licensee where applicable. These fees are included in processing and storage fees revenue on the consolidated statements of comprehensive income (loss). As part of the accounting for royalty revenue from India, the Company uses estimates and judgments based on historical processing and storage volume in determining the timing and amount of royalty revenue to recognize. The Company periodically reviews license and royalty receivables for collectability and, if necessary, will record an expense for an allowance for uncollectible accounts.</div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash and Cash Equivalents </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents consist of highly liquid investments with a maturity date of three months or less at the time of purchase. </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Receivable </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Accounts receivable consist of uncollateralized amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs and amounts due from license affiliates, and sublicensee territories. Accounts receivable are due within 30 days and are stated at amounts net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering the length of time accounts receivable are past due, the Company’s previous loss history, and the client’s current ability to pay its obligations. Therefore, if the financial condition of the Company’s clients were to deteriorate beyond the estimates, the Company may have to increase the allowance for doubtful accounts which could have a negative impact on earnings. The Company <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">writes-off</div> accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.</div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inventory </div></div> </div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;;display:inline;">As part of the Asset Purchase Agreement, (see Note 2), the Company has an agreement with Duke University (“Duke”) expiring on January 31, 2025 for Duke to receive, process, and store cord blood units for the Public Cord Blood Bank (“Duke Services”). As of November 30, 2019, the Company had approximately 6,000 cord blood units in inventory. These units are valued at the lower of cost or net realizable value. Costs include the cost of collecting, transporting, processing and storing the unit. Costs charged by Duke for their Duke Services are based on a monthly fixed fee for processing and storing 12 blood units per month. The Company computes the cost per unit for these Duke Services and capitalizes the unit cost on all blood units shipped and stored in a year at Duke. If the Company ships and stores less than 144 blood units with Duke in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> period, a portion of these fixed costs are expensed and included in facility operating costs. Certain costs of collection incurred, such as the cost of collection staff and transportation costs incurred to ship Public Bank units from hospitals to the stem cell laboratory are allocated to banked units based on an average cost method. The change in the number of expected units to be sold could have a significant impact on the estimated net realizable value of banked units which could have a material effect on the value of the inventory. Costs incurred related to cord blood units that cannot be sold are expensed in the period incurred and are included in facility operating costs in the accompanying statements of operations. The Company records a reserve against inventory for units which have been processed and frozen but may not ultimately become distributable (see Note 3). Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of</div><div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;;display:inline;"> $</div>2,332,763<div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;;display:inline;"> was recognized during the second quarter of fiscal </div>2019<div style="font-size: 10pt; text-indent: 9%; letter-spacing: 0px; top: 0px;;display:inline;"> to reduce inventory from cost to net realizable value and is included in the accompanying consolidated statements of comprehensive income (loss).</div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Property and Equipment </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost. Depreciation is provided primarily by the straight-line method over the estimated useful lives of the related assets. Estimated useful lives of property and equipment are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; width: 100%;;margin : 0px auto;;text-align:left;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:51%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;width:48%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">Furniture and equipment</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3-10</div> years</td></tr><tr><td style="font-family: "times new roman", times, serif; line-height: 5pt; font-size: 5pt;;vertical-align:bottom;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 5pt; font-size: 5pt;;vertical-align:bottom;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 5pt; font-size: 5pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">Leasehold improvements</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">Lesser of <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8-10</div> years or the lives of the leases</td></tr><tr><td style="font-family: "times new roman", times, serif; line-height: 6pt; font-size: 6pt;;vertical-align:bottom;"><div style="font-size: 6pt; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 6pt; font-size: 6pt;;vertical-align:bottom;"><div style="font-size: 6pt; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 6pt; font-size: 6pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 6pt; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">Computer software – internal use</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1-5</div> years</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements are amortized over the shorter of the respective life of the lease or the estimated useful lives of the improvements. Upon the sale or retirement of depreciable assets, the cost and related accumulated depreciation is removed from the accounts and the resulting profit or loss is reflected in earnings. Expenditures for maintenance, repairs and minor betterments are expensed as incurred. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company capitalizes external direct costs of materials and services consumed in developing or obtaining <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">internal-use</div> computer software. Capitalized <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">internal-use</div> software costs, which are included in property and equipment, are depreciated over the estimated useful lives of the software.</div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Long-Lived Assets </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates the realizability of its long-lived assets, which requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment, such as reductions in demand or when significant economic slowdowns are present. Reviews are performed to determine whether the carrying value of an asset is impaired, based on comparisons to undiscounted expected future cash flows. If this comparison indicates that there is impairment and carrying value is in excess of fair value, the impaired asset is written down to fair value, which is typically calculated using: (i) quoted market prices or (ii) discounted expected future cash flows utilizing a discount rate. The Company did not </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">note any indicators of impairment as of November 30, 2019 and November 30, 2018, respectively.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Goodwill </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Goodwill represents the excess of the purchase price of the assets acquired from Cord:Use (Note 2) over the estimated fair value of the net tangible, intangible and identifiable assets acquired. The annual assessment of the reporting unit is performed as of September 1st, and an assessment is performed at other times if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below its carrying value. The Company first performs a qualitative assessment to test goodwill for impairment and concludes if it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment concludes that it is not more likely than not that the fair value is less than the carrying value, the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">two-step</div> goodwill impairment test is not required. If the qualitative assessment concludes that it is more likely than not that the fair value of the reporting unit is less than the carrying value, then the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">two-step</div> goodwill impairment test is required. Step one of the impairment assessment compares the fair value of the reporting unit to its carrying value and if the fair value exceeds its carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, the implied fair value of goodwill is compared to the carrying value of goodwill. If the implied fair value exceeds the carrying value then goodwill is not impaired; otherwise, an impairment loss would be recorded by the amount the carrying value exceeds the implied fair value. </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div></div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The Company records a valuation allowance when it is “more likely than not” that all of the future income tax benefits will not be realized. When the Company changes its determination as to the amount of deferred income tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to income tax expense in the period in which such determination is made. The ultimate realization of the Company’s deferred income tax assets depends upon generating sufficient taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, the Company projects future levels of taxable income. This assessment requires significant judgment. The Company examines the evidence related to the recent history of losses, the economic conditions in which the Company operates and forecasts and projections to make that determination. </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management’s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. For fiscal 2019 and 2018 the Company had no uncertain tax provisions and therefore no material provisions for interest or penalties related to uncertain tax positions. </div></div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research, Development and Related Engineering Costs </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research, development and related engineering costs are expensed as incurred. </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost of Sales </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales represents the associated expenses resulting from the processing, testing, storage and delivery of the umbilical cord blood. Cost of sales related to PrepaCyte CB represents the associated expenses resulting from the manufacturing of the PrepaCyte CB units. Cost of sales related to the Public Cord Blood Bank represents the associated expenses resulting from the collection, shipping, processing and storage of the cord blood stem cell units. </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Advertising </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). Total advertising expense for the fiscal years ended November 30, 2019 and 2018 was approximately $981,448 and $986,664, respectively. </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rent Expense </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Rent is expensed on a straight-line basis over the term of the lease and is included in cost of sales and selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). All leases include provisions for escalations and related costs. </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal Expense </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Legal fees are expensed as incurred and are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management uses a fair value hierarchy, which gives the highest priority to quoted prices in active markets. The fair value of financial instruments is estimated based on market trading information, where available. Absent published market values for an instrument or other assets, management uses observable market data to arrive at its estimates of fair value. Management believes that the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments. The Company believes that the fair value of its Revenue Sharing Agreements (”RSA”) liability recorded on the balance sheet is between the recorded book value and up to the Company’s previous settlement experience, due to the various terms and conditions associated with each RSA. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company uses an accounting standard that defines fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The three levels of inputs used to measure fair value are as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:96%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:6%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;width:93%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level 1</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities.</div></td></tr><tr style="font-size: 1pt;"><td style="font-family: "times new roman", times, serif;;height:8;"> </td><td colspan="2" style="font-family: "times new roman", times, serif;;height:8;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level 2</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</div></td></tr><tr style="font-size: 1pt;"><td style="font-family: "times new roman", times, serif;;height:8;"> </td><td colspan="2" style="font-family: "times new roman", times, serif;;height:8;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level 3</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of November 30, 2019 and November 30, 2018, respectively, segregated among the appropriate levels within the fair value hierarchy: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:64%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;margin-left :auto;margin-right :auto;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair Value at</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">at November 30, 2019 Using</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-size: 8pt; white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">November 30,<br/>2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 1</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 2</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 3</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Assets:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contingent consideration</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contingent Consideration:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Beginning Balance as of November 30, 2018</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Subtractions – Cord:Use earnout payment</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(45,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustment as of November 30, 2019</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(742,918</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Ending balance as of November 30, 2019</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-size: 1pt;"><td style="font-family: "times new roman", times, serif; padding: 0px;;height:16;"></td><td colspan="4" style="font-family: "times new roman", times, serif; padding: 0px;;height:16;"></td><td colspan="12" style="font-family: "times new roman", times, serif; padding: 0px;;height:16;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;margin-left :auto;margin-right :auto;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair Value at</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Fair Value Measurements<br/>at November 30, 2018 Using</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-size: 8pt; white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">November 30,<br/>2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 1</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 2</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 3</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Assets:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trading securities</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">68,816</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">68,816</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap;;display:inline;">Available-for-sale</div></div> securities</div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">806,873</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">806,873</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">875,689</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">875,689</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Liabilities:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following is a description of the valuation techniques used for these items, as well as the general classification of such items pursuant to the fair value hierarchy: </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trading securities – </div>Fair values for these investments are based on quoted prices of identical securities in active markets and are therefore classified within Level 1 of the fair value hierarchy. For trading securities, there was approximately ($28,000) in unrealized holding losses, respectively, recorded in other income and expense on the accompanying consolidated statements of comprehensive income (loss) for the twelve months ended November 30, 2018. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">Available-for-sale</div></div> securities –</div> These investments are classified as available for sale and consist of marketable equity securities that we intend to hold for an indefinite period of time. Investments are stated at fair value and unrealized holding gains and losses are reported as a component of accumulated other comprehensive income until realized. Realized gains or losses on disposition of investments are computed using the first in, first out (FIFO) method and reported as income or loss in the period of disposition in the accompanying consolidated statements of comprehensive income (loss). For <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">available-for-sale</div></div> securities, there was approximately $300,000 in unrealized holding gains (loss), net of tax, respectively, reported as comprehensive income on the accompanying statements of comprehensive income (loss) for the year ended November 30, 2018.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Marketable securities</div> - Effective December 1, 2018, the Company adopted ASU <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2016-01,</div> which requires equity securities with readily determinable fair values to be measured at fair value with the changes in fair value recognized through net income. Such securities are no longer reflected as trading or <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">available-for-sale</div></div> but are noted as marketable securities. As a result of this accounting change, in the first quarter of 2019, the Company recognized a cumulative-effect adjustment from accumulated other comprehensive income to retained earnings of approximately $341,000 in the consolidated statements of stockholders’ deficit as of the date of adoption. Prior periods have not been restated for the impact of this accounting change. There was $28,000 in unrealized holding gain recorded in other income and expense on the accompanying consolidated statements of comprehensive income (loss) for the twelve months ended November 30, 2019.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Contingent consideration -</div> The contingent consideration is the earnout that Cord:Use is entitled to from the Company’s sale of the public cord blood inventory from and after closing. See Note 2. The estimated fair value of the contingent earnout was determined using a monte carlo analysis examining the frequency and mean value of the resulting earnout payments. The resulting value captures the risk associated with the form of the payout structure. The risk-neutral method is applied, resulting in a value that captures the risk associated with the form of the payout structure and the projection risk. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different from the estimated value of the liability. </div></div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product Warranty and Cryo-Cell Cares<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">TM</div> Program </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. Upon the adoption of ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits at November 30, 2019. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period. </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income (Loss) per Common Share </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic income (loss) per common share was computed by dividing net income by the weighted average number of common shares outstanding for the fiscal year ended or as of the date indicated. Diluted income per common share includes the effect of all dilutive stock options. The composition of basic and diluted net (loss) income per share is as follows:</div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 77%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 6%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 5.5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 6.5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">November 30, 2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">November 30, 2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Numerator:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6.5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 6%;;text-align:right;;vertical-align:bottom;">2,290,774</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; width: 6.5%;;text-align:right;;vertical-align:bottom;">854,824</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Denominator:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6.5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding-basic</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 6%;;text-align:right;;vertical-align:bottom;">7,794,828</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 6.5%;;text-align:right;;vertical-align:bottom;">7,463,051</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Dilutive common shares issuable upon exercise of stock options</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 6%;;text-align:right;;vertical-align:bottom;">617,586</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 5.5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 6.5%;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 77%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6.5%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares-diluted</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 6%;;text-align:right;;vertical-align:bottom;">8,412,414</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 6.5%;;text-align:right;;vertical-align:bottom;">7,463,051</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 77%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6.5%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Income(Loss) per share:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6.5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 6%;;text-align:right;;vertical-align:bottom;">0.29</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; width: 6.5%;;text-align:right;;vertical-align:bottom;">0.11</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 77%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6.5%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Diluted</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 6%;;text-align:right;;vertical-align:bottom;">0.27</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 6.5%;;text-align:right;;vertical-align:bottom;">0.11</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 77%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6.5%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For the year ended November 30, 2019, the Company excluded the effect of 70,136 outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For the year ended November 30, 2018, the Company excluded the effect of all outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive. </div></div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock Compensation </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of November 30, 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>, the Company has two stock-based employee compensation plans, which are described in Note 11 to the consolidated financial statements. The Company’s stock-based employee compensation plan became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting. The Company recognized approximately $398,000 and $478,000 for the fiscal years ended November 30, 2019 and November 30, 2018, respectively, of stock compensation expense. The Company reversed $444,000 of stock compensation expense during the twelve months ended November 30, 2018 as the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Co-CEOs</div> each opted to receive a lump sum cash payment in lieu of 30,000 shares of earned common stock pursuant to the terms of their Employment Agreements. The reversal had no impact on the accompanying consolidated statements of comprehensive income (loss) as other compensation expense was recognized to offset the reversal.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes stock-based compensation based on the fair value of the related awards. Under the fair value recognition guidance of stock-based compensation accounting rules, stock-based compensation expense is estimated at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the award. The fair value of service-based vesting condition and performance-based vesting condition stock option awards is determined using the Black-Scholes valuation model. For stock option awards with only service-based vesting conditions and graded vesting features, the Company recognizes stock compensation expense based on the graded-vesting method. To value awards with market-based vesting conditions the Company uses a binomial valuation model. The Company recognizes compensation cost for awards with market-based vesting conditions on a graded-vesting basis over the derived service period calculated by the binomial valuation model. The use of these valuation models involves assumptions that are judgmental and highly sensitive in the determination of compensation expense and include the expected life of the option, stock price volatility, risk-free interest rate, dividend yield, exercise price, and forfeiture rate. Forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The estimation of stock awards that will ultimately vest requires judgment and to the extent that actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period they become known. The Company considered many factors when estimating forfeitures, including the recipient groups and historical experience. Actual results and future changes in estimates may differ substantially from current estimates. </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company issues performance-based equity awards which vest upon the achievement of certain financial performance goals, including revenue and income targets. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the required performance targets and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance goals are not met, the award does not vest, so no compensation cost is recognized and any previously stock-recognized stock-based compensation expense is reversed. </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company issues equity awards with market-based vesting conditions which vest upon the achievement of certain stock price targets. If the awards are forfeited prior to the completion of the derived service period, any recognized compensation is reversed. If the awards are forfeited after the completion of the derived service period, the compensation cost is not reversed, even if the awards never vest.</div></div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications </div></div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no <div style="display:inline;">material </div>effect on the reported results of operations. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recently Issued Accounting Pronouncements </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2018, the FASB issued Accounting Standards Update <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No. 2018-15,</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Intangibles – Goodwill and Other <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Internal-Use</div> Software (Topic <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">350-40):</div> Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.</div> This update addresses how a customer should account for the costs of implementing a cloud computing service arrangement (also referred to as a “hosting arrangement”). Entities should account for costs associated with implementing a cloud computing arrangement that is considered a service contract in the same way as accounting for implementation costs incurred to develop or obtain software for internal use using the guidance in Topic <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">350-40.</div> The amendments address when costs should be capitalized rather than expensed, the term to use when amortizing capitalized costs, and how to evaluate the unamortized portion of these capitalized implementation costs for impairment. The ASU also includes guidance on how to present implementation costs in the financial statements and creates additional disclosure requirements. The guidance is effective for annual periods beginning after December 15, 2019, and interim periods within that reporting period. The Company is currently evaluating the effect that the updated standard will have on our financial statements.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2018, the FASB issued Accounting Standards Update <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No. 2018-07,</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. </div>This update simplifies the accounting for nonemployee share-based payment transactions by expanding the scope of Topic 718, Compensation-Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within that reporting period. The Company is currently evaluating the effect that the updated standard will have on our financial statements.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2017, the FASB issued Accounting Standards Update <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No. 2017-04,</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</div>. The update removes Step 2 from the goodwill impairment test. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, although early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on our financial statements.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2016, the FASB issued Accounting Standards Update <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-02,</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases (Topic 842).</div> This update requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. It also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated balance sheets and related disclosures.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Effective December 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. The Company recognized the cumulative effect of applying the new revenue standard to all contracts with customers that were not completed as of December 1, 2018 as an adjustment to the opening balance of stockholders’ deficit at the beginning of fiscal year 2019. The reported results for 2019 reflect the application of ASC 606 guidance while the reported results for 2018 were prepared under the guidance of ASC 605, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue Recognition </div>(ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. ASC 606 also requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The adoption of ASC 606 did not have an impact on the amount of reported revenues with respect to the Company’s product or service revenues. In connection with the adoption of ASC 606, the Company is required to capitalize certain contract acquisition costs consisting primarily of commissions paid when contracts are signed and amortize these costs on a systematic basis, consistent with the pattern of transfer of the storage services provided over time for which the asset relates. As of December 1, 2018, the Company capitalized in deposits and other assets, net, $329,231 in incremental contract acquisition costs related to sales commissions on prepaid storage contracts and reversed $18,408 of its variable consideration that the Company determined to be fully constrained, with a corresponding change in the opening balance of stockholders’ deficit of $253,447, net of tax, of $94,192. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under ASC 606, revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised services are transferred to the customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring services to a customer (“transaction price”). </div></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At contract inception, if the contract is determined to be within the scope of ASC 606, the Company evaluates its contracts with customers using the five-step model: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to separate performance obligations; and (5) recognize revenue when (or as) each performance obligation is satisfied. The Company evaluates its contracts for legal enforceability at contract inception and subsequently throughout the Company’s relationship with its customers. If legal enforceability with regards to the rights and obligations exist for both the Company and the customer, then the Company has an enforceable contract and revenue recognition is permitted subject to the satisfaction of the other criteria. If, at the outset of an arrangement, the Company determines that a contract with enforceable rights and obligations does not exist, revenues are deferred until all criteria for an enforceable contract are met. The Company only applies the five-step model to contracts when it is probable that collection of the consideration that the Company is entitled to in exchange for the goods or services being transferred to the customer, will occur. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Contract modifications exist when the modification either creates new or changes in the existing enforceable rights and obligations. The Company’s contracts are occasionally modified to account for changes in contract terms and conditions, which the Company refers to as an upgrade or downgrade. An upgrade occurs when a customer wants to pay for additional years of storage. A downgrade occurs when a customer originally entered into a long-term contract (such as <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">twenty-one</div> year or life-time plan) but would like to change the term to a <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> contract. Upgrade modifications qualify for treatment as a separate contract as the additional services are distinct and the increase in contract price reflects the Company’s stand-alone selling price for the additional services and will be accounted for on a prospective basis. Downgrade modifications do not qualify for treatment as a separate contract as there is no increase in price over the original contract, thus failing the separate contract criteria. As such, the Company separately considers downgrade modifications to determine if these should be accounted for as a termination of the existing contract and creation of a new contract (prospective method) or as part of the existing contract (cumulative <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustment). ASC 606 requires that an entity account for the contract modification as if it were a termination of the existing contract, and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. As the services after the modification were previously determined to be distinct, the Company concluded that downgrade modifications qualify under this method and will be accounted for on a prospective basis. Although contract modifications do occur, they are infrequent.</div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Performance Obligations </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At contract inception, the Company assesses the goods and services promised in the contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good or service (or bundle of goods or services) that is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. The Company determined that the following distinct goods and services represent separate performance obligations involving the sale of its umbilical cord blood product: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:1%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;">•</td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Collection and processing services </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:1%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;">•</td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Storage services </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:1%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;">•</td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:1%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;">•</td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">License and royalties </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:1%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;">•</td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"> </td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Sale of PrepaCyte CB product </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 1px; margin-top: 6px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>)</div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Processing</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Processing and storage fees include the Company providing umbilical cord blood and tissue cellular processing and cryogenic cellular storage for private use. Revenues recognized for the cellular processing and cryogenic cellular storage represent sales of the umbilical cord blood stem cells program to customers and income from licensees who are selling the umbilical cord blood stem cells program to customers outside the United States. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period as well as other income from royalties paid by licensees related to long-term storage contracts which the Company has under license agreements. Contracted storage periods are <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">annual, twenty-one</div> years and life-time. The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual, the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">twenty-one-year</div></div> and the life-time storage fees that are being recognized over the contractual storage period as well as royalties received from foreign licensees relating to long-term storage contracts for which the Company has future obligations under the license agreement. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.</div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Significant financing </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. For all plans being <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">annual, twenty-one years</div> and life-time, the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans (including a stated service fee) for customers to pay over time for a period of one to twenty-four plus months. The <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> plan includes the collection kit, processing and testing, return medical courier service and <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">twenty-one</div> years of <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> storage fees. The life-time plan includes the collection kit, processing and testing, return medical courier service and <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> storage fees for the life of the customer. The Company concluded that a significant financing component is not present within either the prepaid or overtime payment plans. The Company has determined that the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">twenty-one</div> year and life-time prepayment options do not include a significant financing component as the payment terms were structured primarily for reasons other than the provision of financing and to maximize profitability.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that the majority of plans that are paid over time are paid in less than a year. When considered over a twenty-four-month payment plan, the difference between the cash selling price and the consideration paid is nominal. As such, the Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when considered in the context of all contracts entered into nor significant at the individual contract level. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company elected to apply the practical expedient where the Company does not need to assess whether a significant financing component exists if the period between when it performs its obligations under the contract and when the customer pays is one year or less. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of November 30, 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>, the total aggregate transaction price allocated to the unsatisfied performance obligations was recorded as deferred revenue amounting to $32,508,511, which will be recognized ratably on a straight-line basis over the contractual period of which $8,875,138 will be recognized over the next twelve months. </div></div><div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Variable consideration </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. In the processing and storage agreements, the Company provides limited rights which are offered to customers automatically upon contract execution. The Company has determined that the payment warranty represents variable consideration payable to the customer. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Based on the Company’s historical experience to date, the Company has determined the payment warranty to be fully constrained under the most likely amount method. Consequently, the transaction price does not currently reflect any expectation of service level credits.    At the end of each reporting period, the Company will update the estimated transaction price related to the payment warranty including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period. </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Allocation of transaction price </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As the Company’s processing and storage agreements contain multiple performance obligations, ASC 606 requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the stand-alone selling prices of the processing services and storage services and concluded that the published list price is the price that a customer in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Costs to Obtain a Contract </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Prior to the adoption of ASC 606, the Company expensed in the period, all commissions paid to its internal and external sales representatives the Company employs and to its customers for generating new contracts. <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>With the adoption of ASC 606 as of December 1, 2018, the Company capitalizes commissions that are incremental in obtaining customer contracts and the costs incurred to fulfill a customer contract if those costs are not within the scope of another topic within the accounting literature and meet the specified criteria. These costs are deferred in other current or long-term assets and are expensed to selling, general and administrative expenses as the Company satisfies the performance obligations by transferring the service to the customer. These assets will be periodically assessed for impairment. As a practical expedient, the Company elected to recognize the incremental costs of obtaining its annual contracts as an expense when incurred, as the amortization period of the asset recognized would have been one year. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has determined that payments under the Company’s <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">refer-a-friend</div></div> program (“RAF program”) are incremental costs of obtaining a contract as they provide an incentive for existing customers to refer new customers to the Company and is referred to as commission. The amount paid under the RAF program (either through issuance of credits to customers or check payments) which exceeds the typical commission payment to a sales representative is recorded as a reduction to revenue under ASC 606. During the twelve months ended November 30, 2019, the Company recorded $35,300, in commission payments to customers under the RAF program as a reduction to revenue. As of December 1, 2018, the Company capitalized $329,231 in incremental contract acquisition costs related to contracts that were not completed, net of the cumulative amortization expense of $66,533 through the adoption date. The Company did not record any impairment losses in relation to costs capitalized. For the twelve months ended November 30, 2019, the Company capitalized additional contract acquisition costs of $87,518, net of amortization expense.</div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 6pt;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div>)</div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Public banking revenue </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company sells and provides units not likely to be of therapeutic use for research to qualified organizations and companies operating under Institutional Review Board approval. Control is transferred at the point in time when the shipment has occurred, at which time, the Company records revenue. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 6pt;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>)</div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Licensee and royalty income </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Licensee and royalty income consist of royalty income earned on the processing and storage of cord blood stem cell specimens by an affiliate where the Company has a License and Royalty Agreement. The Company records revenue from processing and storage of specimens and pursuant to agreements with licensees. The Company records the royalty revenue in same period that the related processing and storage is being completed by the affiliate. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 6pt;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div>)</div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product Revenue </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company records revenue from the sale of the PrepaCyte CB product line upon shipment of the product to the Company’s customers. </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; margin: 6pt auto 0in 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; vertical-align: top;;text-align:left;;width:4%;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div>)</div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif; vertical-align: top;;text-align:left;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shipping and handling </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company elected to apply the practical expedient to account for shipping and handling activities performed after the control of a good has been transferred to the customer as a fulfillment cost. Shipping and handling costs that the Company incurs are therefore expensed and included in cost of sales. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The adoption of ASC 606 did not have an impact on the timing of revenue recognition for any of the Company’s revenue streams. </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Disaggregation of Revenue </div></div></div> <div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about disaggregated revenue by products and services: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:64%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Twelve months ended</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">November 30, 2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">November 30, 2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Processing and storage fees</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29,991,972</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">27,817,872</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public banking revenue</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">652,204</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">296,295</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Licensee and royalty income</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Product revenue</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">172,395</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">104,323</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">31,816,571</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29,218,490</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about assets and liabilities from contracts with customers: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:68%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">November 30, 2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">At Adoption</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract assets (sales commissions)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">398,535</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">329,231</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6,097,331</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">5,867,335</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Short-term contract liabilities (deferred revenue)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,875,138</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,365,284</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Long-term contract liabilities (deferred revenue)</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">23,633,373</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">20,317,231</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company, in general, requires the customer to pay for processing and storage services at the time of processing. Contract assets include deferred contract acquisition costs, which will be amortized along with the associated revenue. Contract liabilities include payments received in advance of performance under the contract and are realized with the associated revenue recognized under the contract. Accounts receivable consists of amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs related to renewals of annual plans and amounts due from license affiliates, and sublicensee territories. The Company did not have asset impairment charges related to contract assets in the twelve <div style="letter-spacing: 0px; top: 0px;;display:inline;">months </div>ended November 30, 2019. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents changes in the Company’s contract assets and liabilities during the twelve months ended November 30, 2019:</div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 52%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 8%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 8.5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 0.5%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Balance at<br/>December 1, 2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Additions</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Deductions</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Balance at<br/>November 30,<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 52%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract assets (sales commissions)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">329,231</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">88,569</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">19,265</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8.5%;;text-align:right;;vertical-align:bottom;">398,535</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 52%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 8%;;text-align:right;;vertical-align:bottom;">5,867,335</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 7%;;text-align:right;;vertical-align:bottom;">36,579,504</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; width: 7%;;text-align:right;;vertical-align:bottom;">36,349,508</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 8.5%;;text-align:right;;vertical-align:bottom;">6,097,331</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 0.5%;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 52%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract liabilities (deferred revenue)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">28,682,515</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">18,759,963</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">14,933,967</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8.5%;;text-align:right;;vertical-align:bottom;">32,508,511</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management uses a fair value hierarchy, which gives the highest priority to quoted prices in active markets. The fair value of financial instruments is estimated based on market trading information, where available. Absent published market values for an instrument or other assets, management uses observable market data to arrive at its estimates of fair value. Management believes that the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments. The Company believes that the fair value of its Revenue Sharing Agreements (”RSA”) liability recorded on the balance sheet is between the recorded book value and up to the Company’s previous settlement experience, due to the various terms and conditions associated with each RSA. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company uses an accounting standard that defines fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The three levels of inputs used to measure fair value are as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:96%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:6%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;width:93%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level 1</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities.</div></td></tr><tr style="font-size: 1pt;"><td style="font-family: "times new roman", times, serif;;height:8;"> </td><td colspan="2" style="font-family: "times new roman", times, serif;;height:8;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level 2</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</div></td></tr><tr style="font-size: 1pt;"><td style="font-family: "times new roman", times, serif;;height:8;"> </td><td colspan="2" style="font-family: "times new roman", times, serif;;height:8;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level 3</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of November 30, 2019 and November 30, 2018, respectively, segregated among the appropriate levels within the fair value hierarchy: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:64%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;margin-left :auto;margin-right :auto;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair Value at</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">at November 30, 2019 Using</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-size: 8pt; white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">November 30,<br/>2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 1</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 2</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 3</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Assets:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contingent consideration</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contingent Consideration:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Beginning Balance as of November 30, 2018</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Subtractions – Cord:Use earnout payment</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(45,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustment as of November 30, 2019</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(742,918</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Ending balance as of November 30, 2019</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-size: 1pt;"><td style="font-family: "times new roman", times, serif; padding: 0px;;height:16;"></td><td colspan="4" style="font-family: "times new roman", times, serif; padding: 0px;;height:16;"></td><td colspan="12" style="font-family: "times new roman", times, serif; padding: 0px;;height:16;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;margin-left :auto;margin-right :auto;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair Value at</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Fair Value Measurements<br/>at November 30, 2018 Using</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-size: 8pt; white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">November 30,<br/>2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 1</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 2</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 3</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Assets:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trading securities</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">68,816</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">68,816</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap;;display:inline;">Available-for-sale</div></div> securities</div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">806,873</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">806,873</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">875,689</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">875,689</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Liabilities:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following is a description of the valuation techniques used for these items, as well as the general classification of such items pursuant to the fair value hierarchy: </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trading securities – </div>Fair values for these investments are based on quoted prices of identical securities in active markets and are therefore classified within Level 1 of the fair value hierarchy. For trading securities, there was approximately ($28,000) in unrealized holding losses, respectively, recorded in other income and expense on the accompanying consolidated statements of comprehensive income (loss) for the twelve months ended November 30, 2018. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">Available-for-sale</div></div> securities –</div> These investments are classified as available for sale and consist of marketable equity securities that we intend to hold for an indefinite period of time. Investments are stated at fair value and unrealized holding gains and losses are reported as a component of accumulated other comprehensive income until realized. Realized gains or losses on disposition of investments are computed using the first in, first out (FIFO) method and reported as income or loss in the period of disposition in the accompanying consolidated statements of comprehensive income (loss). For <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">available-for-sale</div></div> securities, there was approximately $300,000 in unrealized holding gains (loss), net of tax, respectively, reported as comprehensive income on the accompanying statements of comprehensive income (loss) for the year ended November 30, 2018.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Marketable securities</div> - Effective December 1, 2018, the Company adopted ASU <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2016-01,</div> which requires equity securities with readily determinable fair values to be measured at fair value with the changes in fair value recognized through net income. Such securities are no longer reflected as trading or <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">available-for-sale</div></div> but are noted as marketable securities. As a result of this accounting change, in the first quarter of 2019, the Company recognized a cumulative-effect adjustment from accumulated other comprehensive income to retained earnings of approximately $341,000 in the consolidated statements of stockholders’ deficit as of the date of adoption. Prior periods have not been restated for the impact of this accounting change. There was $28,000 in unrealized holding gain recorded in other income and expense on the accompanying consolidated statements of comprehensive income (loss) for the twelve months ended November 30, 2019.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Contingent consideration -</div> The contingent consideration is the earnout that Cord:Use is entitled to from the Company’s sale of the public cord blood inventory from and after closing. See Note 2. The estimated fair value of the contingent earnout was determined using a monte carlo analysis examining the frequency and mean value of the resulting earnout payments. The resulting value captures the risk associated with the form of the payout structure. The risk-neutral method is applied, resulting in a value that captures the risk associated with the form of the payout structure and the projection risk. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different from the estimated value of the liability. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about disaggregated revenue by products and services: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:64%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Twelve months ended</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">November 30, 2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">November 30, 2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Processing and storage fees</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29,991,972</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">27,817,872</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public banking revenue</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">652,204</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">296,295</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Licensee and royalty income</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Product revenue</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">172,395</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">104,323</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">31,816,571</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29,218,490</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about assets and liabilities from contracts with customers: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:68%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">November 30, 2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">At Adoption</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract assets (sales commissions)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">398,535</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">329,231</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6,097,331</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">5,867,335</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Short-term contract liabilities (deferred revenue)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,875,138</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,365,284</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Long-term contract liabilities (deferred revenue)</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">23,633,373</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">20,317,231</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company, in general, requires the customer to pay for processing and storage services at the time of processing. Contract assets include deferred contract acquisition costs, which will be amortized along with the associated revenue. Contract liabilities include payments received in advance of performance under the contract and are realized with the associated revenue recognized under the contract. Accounts receivable consists of amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs related to renewals of annual plans and amounts due from license affiliates, and sublicensee territories. The Company did not have asset impairment charges related to contract assets in the twelve <div style="letter-spacing: 0px; top: 0px;;display:inline;">months </div>ended November 30, 2019. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents changes in the Company’s contract assets and liabilities during the twelve months ended November 30, 2019:</div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 52%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 8%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 8.5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 0.5%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Balance at<br/>December 1, 2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Additions</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Deductions</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">Balance at<br/>November 30,<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 52%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract assets (sales commissions)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">329,231</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">88,569</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">19,265</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8.5%;;text-align:right;;vertical-align:bottom;">398,535</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 52%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 8%;;text-align:right;;vertical-align:bottom;">5,867,335</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 7%;;text-align:right;;vertical-align:bottom;">36,579,504</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; width: 7%;;text-align:right;;vertical-align:bottom;">36,349,508</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 8.5%;;text-align:right;;vertical-align:bottom;">6,097,331</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 0.5%;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 52%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract liabilities (deferred revenue)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8%;;text-align:right;;vertical-align:bottom;">28,682,515</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">18,759,963</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 7%;;text-align:right;;vertical-align:bottom;">14,933,967</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 8.5%;;text-align:right;;vertical-align:bottom;">32,508,511</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 0.5%;;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of November 30, 2019 and November 30, 2018, respectively, segregated among the appropriate levels within the fair value hierarchy: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:64%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;margin-left :auto;margin-right :auto;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair Value at</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">at November 30, 2019 Using</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-size: 8pt; white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">November 30,<br/>2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 1</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 2</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 3</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Assets:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">904,053</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contingent consideration</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contingent Consideration:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Beginning Balance as of November 30, 2018</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Subtractions – Cord:Use earnout payment</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(45,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair value adjustment as of November 30, 2019</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(742,918</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Ending balance as of November 30, 2019</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,495,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-size: 1pt;"><td style="font-family: "times new roman", times, serif; padding: 0px;;height:16;"></td><td colspan="4" style="font-family: "times new roman", times, serif; padding: 0px;;height:16;"></td><td colspan="12" style="font-family: "times new roman", times, serif; padding: 0px;;height:16;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;margin-left :auto;margin-right :auto;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair Value at</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Fair Value Measurements<br/>at November 30, 2018 Using</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-size: 8pt; white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">November 30,<br/>2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 1</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 2</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Level 3</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Assets:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trading securities</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">68,816</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">68,816</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="white-space: nowrap;;display:inline;">Available-for-sale</div></div> securities</div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">806,873</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">806,873</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">875,689</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">875,689</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Liabilities:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,282,975</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

904053

3495057

4282975

-742918

3495057

68816

806873

875689

4282975

398535

329231

6097331

5867335

8875138

8365284

23633373

20317231

329231 88569 19265 398535 5867335 36579504 36349508 6097331

28682515

18759963 14933967

32508511

696892

478378

300119

-854824

13596409

135964

35515382

-19571113

340984

-25329515

2500

5700

397770

253447

2290774

13598909

135989

35918827

-20563357

-22444310

652204

296295

172395

104323

329231 18408

253447

94192

The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue

life-time

P21Y

32508511

8875138 50000 75000 100000 10000

35300

329231

66533

87518 P30D

28000

300000

28000

50000

75000

100000

10000 444000 2

P1Y

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 12—LICENSE AGREEMENTS </div></div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company enters into two types of licensing agreements and in both types, the Company earns revenue on the initial license fees. Under the technology agreements, the Company earns processing and storage royalties from the affiliates that process in their own facility. Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Company’s facility in Oldsmar, Florida. </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Technology Agreements </div></div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has entered into a definitive License and Royalty Agreement with LifeCell International Private Limited, formerly Asia Cryo-Cell Private Limited, (“LifeCell”) to establish and market its umbilical cord blood and menstrual stem cell programs in India. </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Per the License and Royalty Agreement with Lifecell, there is a $1,000,000 cap on the amount of royalties due to the Company per year and a $10,000,000 cap on the amount of royalties due to the Company for the term of the License and Royalty Agreement. The cap(s) are calculated based on Lifecell’s fiscal year end, March 31<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">st</div>. As of the end of the Company’s fiscal years ended November 30, 2019 and November 30, 2018, Lifecell had reached the $1,000,000. Since inception of the License and Royalty Agreement, the Company has recorded $9,300,000 in royalty income due under the terms of the License and Royalty Agreement, of which, Lifecell has paid the Company $8,400,000 as of November 30, 2019. The balance of $900,000 is reflected as Accounts Receivable on the accompanying consolidated balance sheets. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table details the processing and storage royalties earned for the technology agreements for fiscal years 2019 and 2018. The initial license fees and processing and storage royalties are reflected in licensee income in the accompanying consolidated statements of comprehensive income (loss). </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:54%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="22" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">For the years ended November 30,</td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">2019</td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">2018</td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">License<br/>Fee</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Processing<br/>and Storage<br/>Royalties</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Total</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">License<br/>Fee</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Processing<br/>and Storage<br/>Royalties</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Total</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">India</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 2%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 2%; padding: 0pt 5pt 0pt 0pt;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 2%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Marketing Agreements </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has definitive license agreements to market the Company’s umbilical cord blood stem cell programs in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and<div style="display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pakistan.    ` </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table details the processing and storage royalties earned for the technology agreements for fiscal years 2019 and 2018. The initial license fees and processing and storage royalties are reflected in licensee income in the accompanying consolidated statements of comprehensive income (loss). </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:54%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="22" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">For the years ended November 30,</td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">2019</td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">2018</td><td style="padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">License<br/>Fee</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Processing<br/>and Storage<br/>Royalties</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Total</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">License<br/>Fee</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Processing<br/>and Storage<br/>Royalties</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Total</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">India</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 2%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 2%; padding: 0pt 5pt 0pt 0pt;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 2%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,000,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Significant option groups outstanding and exercisable at November 30, 2019 and related price and contractual life information are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:58%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Outstanding</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Exercisable</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Weighted<br/>Average</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Remaining</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Weighted</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Weighted</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-size: 8pt; white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Range of Exercise Prices</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Outstanding</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Contractual<br/>Life (Years)</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Average<br/>Exercise Price</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Outstanding</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Average<br/>Exercise Price</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$1.01 to $2.00</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">422,500</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.10</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.73</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">422,500</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.73</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$2.01 to $3.00</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">265,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.11</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.72</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">265,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.72</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$3.01 to $4.00</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">204,729</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6.23</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.14</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">204,729</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.14</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$6.01 to $7.00</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2,500</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4.65</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6.50</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,667</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6.50</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$7.01 to $8.00</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">195,045</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.84</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.63</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">70,644</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.67</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:top;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,089,774</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3.91</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3.30</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">964,540</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.75</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summary of the status of the Company’s <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> options as of November 30, 2019, and changes during the fiscal year then ended, is presented below:</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:73%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Weighted Average</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Grant-Date</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Options</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Fair Value</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-vested</div> at November 30, 2018</div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">40,254</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.06</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">143,409</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">5.02</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Vested</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(58,429</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.36</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">0</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">0</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-vested</div> at November 30, 2019</div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">125,234</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.70</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-weight:bold;display:inline;">Note 6</div>– <div style="font-weight:bold;display:inline;">Segment Reporting</div> </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During the third quarter of fiscal 2018, the Company purchased the assets and assumed contracts that Cord:Use used in the operation of its cord blood business (See Note 2). The Company evaluated and determined that this acquisition qualifies as a separate segment. </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is organized in three reportable segments: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:4%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:5%;">1.</td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. Revenue is generated from the initial processing and testing fees and the annual storage fees charged each year for storage (the “Umbilical cord blood and cord tissue stem cell service”). </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:4%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:5%;">2.</td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells. Revenue is generated from the sales of the PrepaCyte CB units (the “PrepaCyte CB”). </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:4%;"> </td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:5%;">3.</td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Revenue is generated from the sale of the cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States, and around the world. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax (expense) benefit, other comprehensive loss, and assets for the years ended November 30, 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div> and 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 4%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 4%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="6" style="font-family: "times new roman", times, serif; padding-bottom: 0in; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;;width:;">For the years ended November 30,</td><td style="font-family: "times new roman", times, serif; padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="font-family: "times new roman", times, serif; padding-bottom: 0in; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;;width:;">2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="font-family: "times new roman", times, serif; padding-bottom: 0in; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;;width:;">2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net revenue:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">30,991,972</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">28,817,872</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">172,395</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">104,323</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">652,204</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">296,295</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total net revenue</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">31,816,571</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29,218,490</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales:</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,490,824</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,744,208</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">249,487</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">169,397</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,295,864</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">626,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total cost of sales</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,036,175</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,539,662</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Operating profit:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,152,475</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,620,394</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(113,346</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(101,329</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,976,423</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(329,762</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total operating profit</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">5,062,706</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">5,189,303</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization:</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">365,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">281,072</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">36,254</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">36,254</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 9%; height: 16px; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total depreciation and amortization</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">401,311</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">317,326</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Interest expense:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,703,446</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,546,900</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 9%; height: 16px; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 9%; height: 16px; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total interest expense</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,703,446</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,546,900</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Income tax (expense) benefit:</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr><td style="font-size: 1pt; font-family: "times new roman", times, serif; width: 70%; line-height: 1pt; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(1,100,641</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(4,472,504</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">) </td></tr><tr><td style="font-size: 1pt; font-family: "times new roman", times, serif; width: 70%; line-height: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 9%; padding: 0pt 5pt 0in 0pt; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0in; border-bottom: 0.75pt solid black;;text-align:right;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 9%; height: 16px; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 9%; height: 16px; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total income tax (expense) benefit</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,100,641</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4,472,504</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss):</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 9%; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">300,119</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 9%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 9%; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr><td style="font-size: 1pt; font-family: "times new roman", times, serif; width: 70%; line-height: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 9%; padding: 0pt 5pt 0in 0pt; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in; border-bottom: 0.75pt solid black;;text-align:right;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total other comprehensive income (loss)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 9%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">300,119</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the assets by segment as of November 30, 2019 and November 30, 2018: </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:70%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr><td style="font-size: 8pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgba(255, 255, 255, 0); line-height: 8pt; padding-bottom: 0.375pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; margin-top: 0px; margin-bottom: 0px; margin-left: 3em; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0); line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); text-align: center; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: "times new roman", times, serif; line-height: 8pt; font-size: 8pt;;display:inline;">2019</div></div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0); line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); padding: 0px; text-align: center; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr><tr><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">  </div></div></td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">  </div></div></td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">28,975,002</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">26,239,260</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">289,804</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">319,802</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">13,621,354</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">15,831,081</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">42,886,160</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">42,390,143</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax (expense) benefit, other comprehensive loss, and assets for the years ended November 30, 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div> and 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 4%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 4%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="6" style="font-family: "times new roman", times, serif; padding-bottom: 0in; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;;width:;">For the years ended November 30,</td><td style="font-family: "times new roman", times, serif; padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="font-family: "times new roman", times, serif; padding-bottom: 0in; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;;width:;">2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="font-family: "times new roman", times, serif; padding-bottom: 0in; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;;width:;">2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net revenue:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">30,991,972</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">28,817,872</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">172,395</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">104,323</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">652,204</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">296,295</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total net revenue</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">31,816,571</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29,218,490</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales:</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,490,824</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,744,208</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">249,487</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">169,397</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,295,864</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">626,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total cost of sales</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,036,175</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,539,662</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Operating profit:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,152,475</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,620,394</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(113,346</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(101,329</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,976,423</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(329,762</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total operating profit</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">5,062,706</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">5,189,303</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization:</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">365,057</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">281,072</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">36,254</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">36,254</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 9%; height: 16px; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total depreciation and amortization</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">401,311</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">317,326</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Interest expense:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,703,446</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,546,900</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 9%; height: 16px; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 9%; height: 16px; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total interest expense</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,703,446</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">1,546,900</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Income tax (expense) benefit:</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr><td style="font-size: 1pt; font-family: "times new roman", times, serif; width: 70%; line-height: 1pt; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(1,100,641</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">(4,472,504</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">) </td></tr><tr><td style="font-size: 1pt; font-family: "times new roman", times, serif; width: 70%; line-height: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 9%; padding: 0pt 5pt 0in 0pt; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0in; border-bottom: 0.75pt solid black;;text-align:right;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 9%; height: 16px; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 9%; height: 16px; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total income tax (expense) benefit</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,100,641</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(4,472,504</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss):</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 9%; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">300,119</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 9%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 9%; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr><td style="font-size: 1pt; font-family: "times new roman", times, serif; width: 70%; line-height: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 9%; padding: 0pt 5pt 0in 0pt; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0in; border-bottom: 0.75pt solid black;;text-align:right;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; line-height: 1pt; font-size: 1pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total other comprehensive income (loss)</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 9%; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">300,119</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the assets by segment as of November 30, 2019 and November 30, 2018: </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:70%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr><td style="font-size: 8pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgba(255, 255, 255, 0); line-height: 8pt; padding-bottom: 0.375pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; margin-top: 0px; margin-bottom: 0px; margin-left: 3em; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0); line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); text-align: center; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; font-family: "times new roman", times, serif; line-height: 8pt; font-size: 8pt;;display:inline;">2019</div></div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0); line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); padding: 0px; text-align: center; line-height: 8pt; font-size: 8pt; border-bottom: 0.75pt solid black;;vertical-align:bottom;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2018</div></div></div></td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); line-height: 8pt; font-size: 8pt; padding-bottom: 0.375pt;;vertical-align:bottom;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; line-height: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr><tr><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:top;"><div style="margin-top:0in; margin-right:0in; margin-bottom:.0001pt; margin-left:12.0pt; text-indent:-12.0pt; line-height:normal; font-family:calibri,sans-serif"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">  </div></div></td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"><div style="margin-bottom:.0001pt; line-height:normal; font-family:calibri,sans-serif"><div style="font-size: 10pt; font-family: "times new roman", serif; letter-spacing: 0px; top: 0px;;display:inline;">  </div></div></td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td><td style="background:#cceeff; padding:0in 0in 0in 0in;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Umbilical cord blood and cord tissue stem cell service</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">28,975,002</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">26,239,260</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">PrepaCyte CB</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">289,804</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">319,802</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Public cord blood banking</div></div></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">13,621,354</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">15,831,081</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 70%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">42,886,160</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">42,390,143</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 70%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td><td style="font-family: "times new roman", times, serif; width: 4%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

30991972

28817872

172395

104323

652204

296295

8490824

7744208

249487

169397

1295864

626057

10500000

3500000

4698255

18698255

188019

16037957

68867

568407

308000

31000

960000

18162250

-1405406

1941411

18698255

31388278

2658679

0.36

14000000 465426

0.01

7.52

0.75

580000

0.19 0.03 0.01

330508

1074898

P30Y

P1Y

200000 5000000 500000

341000 <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Business. </div></div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cryo-Cell International, Inc. (“the Company” or “Cryo-Cell”) was incorporated in Delaware on September 11, 1989 and is headquartered in Oldsmar, Florida. The Company is organized in three reportable segments, cellular processing and cryogenic cellular storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use, the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Revenues for the cellular processing and cryogenic cellular storage represent sales of the umbilical cord blood stem cells program to customers and income from licensees selling the umbilical cord blood stem cells program to customers outside the United States. Revenues for the manufacture of PrepaCyte CB units represent sales of the PrepaCyte CB units to customers. Revenue for the cryogenic storage of umbilical cord blood stem cells for public use, stored at Duke University (see below), is generated from the sale of the cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States and around the world. The Company’s headquarters facility in Oldsmar, Florida handles all aspects of its U.S.-based business operations including the processing and storage of specimens, including specimens obtained from certain of its licensees’ customers. The specimens are stored in commercially available cryogenic storage equipment. </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On October 10, 2001, Saneron Therapeutics, Inc. merged into one of the Company’s wholly owned subsidiaries, CCEL <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Bio-Therapies,</div> Inc. (”CCBT”), which then changed its name to Saneron CCEL Therapeutics, Inc. (“SCTI” or ”Saneron”). As part of the merger, the Company contributed 260,000 shares of its common stock, whose fair value was $1,924,000 and 195,000 common shares of another of its subsidiaries, Stem Cell Preservation Technologies, Inc., whose fair value was $3,900. At the conclusion of the merger, the Company retained a 43.42% <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in the voting stock of SCTI. As of November 30, 2019 and 2018, the Company had an interest of approximately 33% in the voting stock of SCTI. The accompanying consolidated financial statements as of November 30, 2019 and 2018 reflect the investment in SCTI under the equity method of accounting.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

30374581 No No Estimated useful lives of property and equipment are as follows:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; width: 100%;;margin : 0px auto;;text-align:left;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:51%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;width:48%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">Furniture and equipment</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3-10</div> years</td></tr><tr><td style="font-family: "times new roman", times, serif; line-height: 5pt; font-size: 5pt;;vertical-align:bottom;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 5pt; font-size: 5pt;;vertical-align:bottom;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 5pt; font-size: 5pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">Leasehold improvements</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">Lesser of <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8-10</div> years or the lives of the leases</td></tr><tr><td style="font-family: "times new roman", times, serif; line-height: 6pt; font-size: 6pt;;vertical-align:bottom;"><div style="font-size: 6pt; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 6pt; font-size: 6pt;;vertical-align:bottom;"><div style="font-size: 6pt; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; line-height: 6pt; font-size: 6pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 6pt; line-height: 6pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">Computer software – internal use</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1-5</div> years</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

The composition of basic and diluted net (loss) income per share is as follows:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 77%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 6%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 5.5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 6.5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 1%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">November 30, 2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;;width:;">November 30, 2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Numerator:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6.5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 6%;;text-align:right;;vertical-align:bottom;">2,290,774</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; width: 6.5%;;text-align:right;;vertical-align:bottom;">854,824</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Denominator:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6.5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding-basic</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 6%;;text-align:right;;vertical-align:bottom;">7,794,828</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 6.5%;;text-align:right;;vertical-align:bottom;">7,463,051</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Dilutive common shares issuable upon exercise of stock options</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 6%;;text-align:right;;vertical-align:bottom;">617,586</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 5.5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 6.5%;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 77%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6.5%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares-diluted</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 6%;;text-align:right;;vertical-align:bottom;">8,412,414</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 6.5%;;text-align:right;;vertical-align:bottom;">7,463,051</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 77%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6.5%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Income(Loss) per share:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 6.5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; width: 6%;;text-align:right;;vertical-align:bottom;">0.29</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; width: 6.5%;;text-align:right;;vertical-align:bottom;">0.11</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 77%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6.5%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Diluted</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 6%;;text-align:right;;vertical-align:bottom;">0.27</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">($</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 6.5%;;text-align:right;;vertical-align:bottom;">0.11</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); width: 1%;;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 77%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td><td style="font-family: "times new roman", times, serif; width: 5.5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; width: 1%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 6.5%;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; width: 1%;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

-854824

617586

-0.11

6093535

5801086

6093535

3.37

292449

1000000

3000000

6000000

8000000

3.39

0.00

992244

P3Y

P10Y

P8Y

P10Y

P1Y

P5Y

66565

992244

8000000

Subject to the terms of the Agreement, on May 20, 2016, TCB advanced the Company $100.00. On July 1, 2016, TCB advanced the remaining principal amount of $7,999,900 per a promissory note dated May 20, 2016 between the Company and TCB, at a rate of 3.75% per annum plus LIBOR, payable monthly with a maturity date of July 2021.

100.00

7999900

2021-07-31

2133433

9000000

15500000

646744

589583

548085

9108433

13208433

152281

264923

8956152

12943510

3100000

5856152

9843510

monthly

3.75% per annum plus LIBOR

0.0375

646744

589583

112642 109293

759386

698876

292449

The Company depends on one supplier for the source of its collection kits

0.33

981448

986664

832587 671245

45000

70136

398000

478000

909765

798292

944060

848024

33000 750000 0.375

0.50

0.75 33000

260000

1924000

195000

3900

0.4342

0.50 0.50 1000000 33000 1000000

0.15

205000 158000 P12M

149972

188085

52451

5262

13491375

15831081

44453 19163

7718

13730533 16035873

2332763

234570

35526

23663

470000

185000 185000

155194

123528

41000

26267 26267

6329

5276

31000

15500

960000

48000

16000

1249254

1341336

P10Y

P20Y

P10Y

P15Y

P1Y

P30Y

67667

910919

<div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected amortization related to these intangible assets for each of the next five fiscal years and for periods thereafter is as follows: </div></div></div><div style="text-indent: -2%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fiscal years ending November 30: </div></div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 85%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; width: 5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 85%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></td><td style="font-family: "times new roman", times, serif; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">67,667</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">67,667</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 85%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td><td style="font-family: "times new roman", times, serif; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">67,667</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">67,667</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 85%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td><td style="font-family: "times new roman", times, serif; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">67,667</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0); width: 5%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:right;;vertical-align:bottom;">910,919</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 85%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; width: 85%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: "times new roman", times, serif; width: 5%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,249,254</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px; width: 85%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; width: 5%; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

92000

76000

228148

224928

18744

17600 17600 800

38000

322984

312307

15000

1000000

1000000 1000000 1000000 9300000 8400000 900000

64.02

50.85

1.55

2.67

P8Y4M24D

P5Y

1001365

2.77

P3Y11M19D

4580967

143409

7.55

4851

2500

2.28

14175

52500

4.82

143450

1089774

3.30

P3Y10M27D

4648111

964540

2.75

P3D

4644277

40254

3.06

143409

5.02

58429

4.36

125234

4.70

1.01

2.00

2.01

3.00

3.01

4.00

6.01

7.00

7.01

8.00

8152475

5620394

-113346

-101329

-2976423

-329762

5062706

5189303

365057

281072

36254

401311

317326

1703446

1546900

1703446

1546900

1100641

4472504

1100641

4472504

28975002

26239260

289804

319802

13621354

15831081

300119

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;">NOTE <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7—</div>ALLOWANCE FOR DOUBTFUL ACCOUNTS </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The activity in the allowance for doubtful accounts is as follows for the years ended November 30, 2019 and 2018: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:85%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">December 1, 2017</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,098,991</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Bad Debt Expense</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">727,483</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Write-offs</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(907,263</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Recoveries</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">345,637</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">November 30, 2018</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,264,848</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Bad Debt Expense</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">767,128</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Write-offs</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(756,688</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Recoveries</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">308,803</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">November 30, 2019</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,584,091</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The activity in the allowance for doubtful accounts is as follows for the years ended November 30, 2019 and 2018: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:85%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">December 1, 2017</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,098,991</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Bad Debt Expense</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">727,483</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Write-offs</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(907,263</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Recoveries</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">345,637</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">November 30, 2018</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,264,848</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Bad Debt Expense</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">767,128</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Write-offs</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(756,688</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Recoveries</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">308,803</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">November 30, 2019</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,584,091</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

2098991

907263

345637

756688

308803

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 8—PROPERTY AND EQUIPMENT </div></div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The major classes of property and equipment are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:73%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Furniture and equipment</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6,568,205</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,905,910</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,200,934</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,200,934</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Computer software – internal use</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,194,039</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,194,039</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:top;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">8,963,178</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">8,300,883</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less: Accumulated Depreciation</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(7,116,711</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(6,807,482</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total Property and Equipment</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,846,467</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,493,401</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense was approximately $309,000 in fiscal 2019 and approximately $241,000 in fiscal 2018 of which approximately $195,000 and $137,000 is included in cost of sales, respectively, in the accompanying consolidated statements of comprehensive income (loss). </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The major classes of property and equipment are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:73%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Furniture and equipment</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6,568,205</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,905,910</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,200,934</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,200,934</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Computer software – internal use</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,194,039</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,194,039</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:top;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">8,963,178</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">8,300,883</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less: Accumulated Depreciation</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(7,116,711</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(6,807,482</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total Property and Equipment</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,846,467</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,493,401</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

6568205

5905910

1200934

1194039

8963178

8300883

7116711

6807482

309000

241000

195000

137000

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded the following income tax provision for the years ended November 30, 2019 and 2018. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:73%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Current:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,637,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,467,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">State</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">769,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">622,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">108,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">108,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Subtotal</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,514,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,197,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred:</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Federal</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,106,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,716,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(307,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(441,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Foreign</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-right: 5pt;;text-align:right;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-right: 5pt;;text-align:right;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Subtotal</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(1,413,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2,275,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Income Tax Expense</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; border-bottom: 0.75pt solid black;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; border-bottom: 0.75pt solid black;;text-align:right;;vertical-align:bottom;">1,101,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;vertical-align:bottom;">4,472,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

The table below summarizes the open tax years and ongoing tax examinations in major jurisdictions as of November 30, 2019:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman"; padding: 0px;;width:72%;"></td><td style="font-family: "times new roman"; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman"; padding: 0px;"></td><td style="font-family: "times new roman"; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman"; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-size: 8pt; white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Jurisdiction</div></div></td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Open Tax<br/>Years</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Examinations<br/>in Process</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">United States – Federal Income Tax</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">2015 – 2018</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">N/A</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">United States – Various States</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:center;;vertical-align:bottom;">2013 – 2018</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:center;;vertical-align:bottom;">N/A</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 9—ACCRUED EXPENSES </div></div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:74%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="6" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">November 30,</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Professional fees</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">115,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,867</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Payroll and payroll taxes (1)</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">513,108</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,021,004</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Interest expense</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">950,300</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">864,676</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General expenses</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">330,726</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">478,449</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Federal and state taxes</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">176,046</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">323,792</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:top;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2,085,180</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2,702,788</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:4%;">(1)</td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">– Payroll and payroll taxes includes accrued vacation and wages due as of November 30, 2019 and November 30, 2018. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:74%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="6" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">November 30,</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Professional fees</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">115,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,867</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Payroll and payroll taxes (1)</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">513,108</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,021,004</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Interest expense</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">950,300</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">864,676</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General expenses</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">330,726</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">478,449</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Federal and state taxes</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">176,046</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">323,792</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:top;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2,085,180</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2,702,788</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:4%;">(1)</td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">– Payroll and payroll taxes includes accrued vacation and wages due as of November 30, 2019 and November 30, 2018. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1637000

1467000

769000

622000

108000

2514000

2197000

-1106000

2716000

-307000

-441000

-1413000

2275000

6256000

5157000

1224000 1214000

82000

257000

1589000

868000

411000

330000

450000 428000

18000

1095000 1210000

11125000

9482000

117000

112000

-282000 -79000

399000

191000

1646000

1634000

9080000

7657000

115000

14867

513108

1021004

950300

864676

422500

1.73

422500

1.73

265000

2.72

265000

2.72

204729

3.14

204729

3.14

2500

6.50

1667

6.50

195045

7.63

70644

7.67

1089774

3.30

964540

2.75

P2Y1M6D

P2Y1M9D

P6Y2M23D

P4Y7M24D

P7Y10M2D

P3Y10M27D

2500

5700

63750

170925

1000000

325000 380000

1500000

2500000

763274

129729

530851

116218

621365

129729

823415

116240

667479

3.23

519000

P1Y1M27D

255000

47273

40000

15756

13332

18200

144300

8000

2666

19200

13500

P10Y P1Y P1Y P2Y 2

23636

20000

77000

62000

8000

18000

10000

26243

22222

86000

172000

4444

8000

15000

-340984 340984

330726

478449

176046

323792

12000

711000

0.34

0.21

3100000

0.50 0.50

733198

0.2100

799507

0.2210

220527

0.0632

216608

0.0599

0.0000 0.0000

26330

0.0075

260845

0.0721

76775 0.0220 149141 0.0412

0.0000

3078094

0.8508

24533 -0.0070 -28337 0.0078

19278

-0.0010

-3354

-0.0009

108150

0.0310

108314

0.0299

108150 0.0310 108314 0.0299

1100641

0.3087

4472504

1.2363

2015

2018

2013

2018

N/A N/A

3100000

2908433

Common Stock

open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission

2801000

2204000

1500

NONE 6000 12 1129247 144 70270 75000 77500

34349

The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 14pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 10—INCOME TAXES </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded the following income tax provision for the years ended November 30, 2019 and 2018. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:73%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Current:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,637,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,467,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">State</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">769,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">622,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">108,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">108,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Subtotal</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,514,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,197,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred:</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Federal</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,106,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,716,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(307,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(441,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Foreign</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-right: 5pt;;text-align:right;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-right: 5pt;;text-align:right;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Subtotal</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(1,413,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2,275,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Income Tax Expense</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; border-bottom: 0.75pt solid black;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt; border-bottom: 0.75pt solid black;;text-align:right;;vertical-align:bottom;">1,101,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;;vertical-align:bottom;">4,472,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of November 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div> and 2018, the tax effects of temporary differences that give rise to the deferred tax assets are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:71%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax Assets:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred income (Net of Discounts)</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6,256,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">5,157,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax over book basis in unconsolidated affiliate</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,224,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,214,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">82,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">257,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Reserves and other accruals</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,589,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">868,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock compensation</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">411,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">330,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Depreciation and Amortization</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">450,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">428,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">18,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">18,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">RSA <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Buy-out</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,095,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,210,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total Assets:</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">11,125,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">9,482,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax Liabilities:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gains on <div style="letter-spacing: 0px; top: 0px;;display:inline;">marketable</div> securities</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(117,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(112,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">NOL’s credits, and other carryforward items</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(282,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(79,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities:</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(399,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(191,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less: Valuation Allowance</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,646,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,634,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net Deferred Tax Asset</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">9,080,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">7,657,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-size: 1px; margin-top: 6px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A valuation allowance covering the deferred tax assets of the Company for November 30, 2019 and November 30, 2018, has been provided as the Company does not believe it is more likely than not that all of the future income tax benefits will be realized. The valuation allowance changed by approximately ($12,000)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>and ($711,000) during the years ended November 30, 2019 and 2018, respectively. The change for year ended November 30, 2019 was primarily due to changes in statutory rates. The change for year ended November 30, 2018 was a result of the revaluation impact of the Tax Cuts and Jobs Act of 2017 which reduced the federal tax rate from 34% to 21%. </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates the recoverability of our deferred tax assets as of the end of each quarter, weighing all positive and negative evidence, and are required to establish and maintain a valuation allowance for these assets if we determine that it is more likely than not that some or all of the deferred tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed. </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The positive evidence that weighed in favor of releasing the allowance as of November 30, 2017 and ultimately outweighed the negative evidence against releasing the allowance was the following: </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Identifiable sources of future income relating to the Company’s deferred revenue accounts; </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certainty as to the amount available of deferred tax assets and nature in which the deferred tax assets reverse; </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Profitability for years ended November 30, 2015 and 2016 and our expectations regarding the sustainability of these profits; </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s three-year cumulative position as of November 30, 2017; and </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;width:10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;;width:2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td><td style="font-family: "times new roman", times, serif;;vertical-align:top;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="font-size: 10pt; font-family: "times new roman", times, serif;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s taxable income projection for fiscal years ending November 30, 2018, 2019 and 2020. </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Tax Cuts and Jobs Act (the “Tax Act”) was signed into law on December 22, 2017. The Tax Act makes significant changes to provision of the Internal Revenue Code, including changing the corporate tax rate to a flat 21% rate as of January 1, 2018. This requires the Company’s net deferred tax assets and liabilities to be revalued at the newly enacted U.S. corporate rate. The impact will be recognized in tax expense in the year of enactment. Based on evaluation, the Company’s discrete expense for the rate impact will be approximately $3.1 million. Based on the Company’s evaluation, the Tax Act is not expected to impact the recoverability of its deferred tax asset. </div></div><div style="font-size: 1px; margin-top: 6px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the income tax provision with the amount of tax computed by applying the federal statutory rate to pretax income follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:64%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="14" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">For the Years Ended November 30</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">%</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">%</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax at Federal Statutory Rate</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">733,198</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">21.00</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">799,507</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">22.10</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">State Income Tax Effect</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">220,527</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6.32</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">216,608</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">5.99</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Valuation Allowance Release</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-right: 5pt;;text-align:right;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-right: 5pt;;text-align:right;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Tax Compensation Differences</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">26,330</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">0.75</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">260,845</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">7.21</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Permanent Disallowances</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">76,775</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.20</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">149,141</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.12</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Impact of Tax Reform</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; vertical-align: bottom; padding-right: 5pt;;text-align:right;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3,078,094</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">85.08</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Deferred Repricing</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">24,533</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.70</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(28,337</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(0.78</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">19,278</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(0.10</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(3,354</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(0.09</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Foreign tax credits</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(108,150</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(3.10</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(108,314</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2.99</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Foreign tax withholding</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">108,150</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3.10</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">108,314</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.99</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total income taxes</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,100,641</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">30.87</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,472,504</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">123.63</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company adopted the accounting standard for uncertain tax positions, ASC <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> on December 1, 2007. As required by the standard, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management’s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions. There were no uncertain tax positions as of November 30, 2019 and 2018.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">There was approximately $2,801,000 and $2,204,000 of U.S. income taxes paid for the fiscal years ended November 30, 2019 and November 30, 2018, respectively. </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. For the years ended November 30, 2019 and 2018, the Company had no material provisions for interest or penalties related to uncertain tax positions. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. The table below summarizes the open tax years and ongoing tax examinations in major jurisdictions as of November 30, 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman"; padding: 0px;;width:72%;"></td><td style="font-family: "times new roman"; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman"; padding: 0px;"></td><td style="font-family: "times new roman"; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman"; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-size: 8pt; white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Jurisdiction</div></div></td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Open Tax<br/>Years</td><td style="padding-bottom: 0.5pt; font-family: "times new roman";;vertical-align:bottom;">  </td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Examinations<br/>in Process</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">United States – Federal Income Tax</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">2015 – 2018</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">N/A</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">United States – Various States</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:center;;vertical-align:bottom;">2013 – 2018</td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgba(255, 255, 255, 0);;text-align:center;;vertical-align:bottom;">N/A</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

157472 134977 534917 457327

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the income tax provision with the amount of tax computed by applying the federal statutory rate to pretax income follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:64%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="14" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">For the Years Ended November 30</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">%</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">%</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax at Federal Statutory Rate</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">733,198</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">21.00</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">799,507</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">22.10</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">State Income Tax Effect</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">220,527</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6.32</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">216,608</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">5.99</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Valuation Allowance Release</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-right: 5pt;;text-align:right;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom; padding-right: 5pt;;text-align:right;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Tax Compensation Differences</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">26,330</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">0.75</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">260,845</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">7.21</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Permanent Disallowances</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">76,775</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.20</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">149,141</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.12</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Impact of Tax Reform</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; vertical-align: bottom; padding-right: 5pt;;text-align:right;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3,078,094</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">85.08</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Deferred Repricing</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">24,533</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.70</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(28,337</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(0.78</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">19,278</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(0.10</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(3,354</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(0.09</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Foreign tax credits</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(108,150</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(3.10</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(108,314</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2.99</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Foreign tax withholding</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">108,150</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3.10</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">108,314</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.99</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total income taxes</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,100,641</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">30.87</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,472,504</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">123.63</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of November 201<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div> and 2018, the tax effects of temporary differences that give rise to the deferred tax assets are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:71%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax Assets:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Deferred income (Net of Discounts)</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6,256,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">5,157,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax over book basis in unconsolidated affiliate</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,224,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,214,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">82,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">257,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Reserves and other accruals</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,589,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">868,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock compensation</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">411,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">330,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Depreciation and Amortization</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">450,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">428,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">18,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">18,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">RSA <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Buy-out</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,095,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,210,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total Assets:</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">11,125,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">9,482,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tax Liabilities:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gains on <div style="letter-spacing: 0px; top: 0px;;display:inline;">marketable</div> securities</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(117,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(112,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">NOL’s credits, and other carryforward items</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(282,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(79,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities:</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(399,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">(191,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;">) </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less: Valuation Allowance</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,646,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(1,634,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Net Deferred Tax Asset</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">9,080,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">7,657,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

45000

94192

<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 14pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 11—STOCKHOLDERS’ EQUITY. </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock Issuances </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During the year ended November 30, 2019, the Company issued 2,500 common shares to option holders who exercised options for $5,700. During the year ended November 30, 2018, the Company issued 63,750 common shares to option holders who exercised options for $170,925. </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee Stock Incentive Plan </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains the 2006 Stock Incentive Plan (the “2006 Plan”) under which it has reserved 1,000,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, stock-appreciation rights (commonly referred to as “SARs”) and stock awards (i.e. performance options to purchase shares and performance units). As of November 30, 2019, and November 30, 2018, there were 325,000 and 380,000 options issued, but not yet exercised, under the 2006 Plan, respectively. As of November 30, 2019, there were 0 shares available for future issuance under the 2006 Plan. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains the 2012 Equity Incentive Plan (the “2012 Plan”) which became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting on July 10, 2012. The 2012 Plan originally reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, SARs, and other stock awards (i.e. performance shares and performance units). In May 2012, the Board of Directors approved an amendment to the 2012 Plan to increase the number of shares of the Company’s common stock reserved for issuance to 2,500,000 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">shares. In October 2019, the Board of Directors approved amendments to the plan, subject to ratification by the stockholders, which occurred at the Company’s 2019 Annual Meeting of Stockholders on November 21, 2019. See the Company’s Proxy Statement filed with the Securities and Exchange Commission on October 29, 2019 in connection with the Company’s 2019 Annual Meeting (the “2019 Proxy Statement”). As of November 30, 2019, there </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">were 763,274 service-based options issued, 129,729 service-based restricted common shares granted, 530,851 performance-based and 116,218 market-based restricted common shares granted under the 2012 Plan. As of November 30, 2018, there were 621,365 service-based options issued, 129,729 service-based restricted common shares granted, 823,415 performance-based and 116,240 market-based restricted common shares granted under the 2012 Plan. As of November 30, 2019, there were 667,479 shares available for future issuance under the 2012 Plan.</div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company granted 1,500 options to an optionee during the second fiscal quarter of 2019 as approved by the Board of Directors. These options <div style="letter-spacing: 0px; top: 0px;;display:inline;">were</div> not issued <div style="letter-spacing: 0px; top: 0px;;display:inline;">under either </div>the 2006 or 2012 Plan. </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As discussed in further detail in the 2019 Proxy Statement, on or about March 26, 2018, the Company received a letter from counsel for a purported stockholder. Among other things, the letter identified equity awards allegedly made in violation of the 2012 Plan. The Board formed a committee of directors (the “Demand Review Committee”) to (among other things) conduct an investigation of the allegations in that letter. After completing its investigation, the Demand Review Committee determined that 1,129,247 restricted stock performance based awards were granted in violation of the 2012 Plan and the Delaware General Corporation Law (“DGCL”). The Demand Review Committee also determined that 70,270, 75,000 and 77,500 stock option awards were granted in violation of the 2012 Plan, the 2006 Plan, the 2000 Stock Incentive Plan, respectively, as amended (the “2000 Plan”) and the DGCL. Annex II attached to the 2019 Proxy Statement describes each of these awards and the applicable Plan that the awards were purportedly granted under, and Annexes I and II of the 2019 Proxy Statement describe each defective award and defective stock issuance identified by the Demand Review Committee (the “Defective Awards and Issuances”). </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Based on the recommendation of the Demand Review Committee, the Board of Directors approved that 776,798 restricted stock performance based awards be ratified that were in violation of the 2012 Plan and that 352,449 restricted stock performance based awards be surrendered for cash in the amount of $1,436,244 that were in violation of the 2012 Plan. The Board of Directors also approved the recommendation that 45,000 stock option awards not be ratified and 177,770 stock options be ratified under the 2012 Plan, the 2006 Plan and the 2000 Stock Incentive Plan. The proposed treatment of each award and issuance is listed on Annexes I and II in the manner identified in the column entitled “Recommended Disposition” in each of those Annexes and recommended to the Company’s stockholders that such awards and issuances be ratified as proposed by the Recommended Dispositions. On November 21, 2019, the Company held its Annual Meeting of Stockholders. At the 2019 Annual Meeting, the Company’s stockholders considered various matters presented to them, including the ratification of certain equity-based awards and stock issuances made pursuant to the Company’s incentive Plans, as well as the approval of certain amendments to those incentive Plans. All such matters presented to the stockholders were duly approved by the stockholders at the 2019 Annual Meeting. Accordingly, all references contained herein to the number of options or shares of common stock granted under the Company’s incentive Plans, the value thereof, and the number of securities that remain available for future issuance under the Company’s 2012 Plan for all periods presented in this Annual Report on Form <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> have been calculated and are being presented after taking into account the ratification and surrender of the Defective Awards and Issuances in accordance with the Recommended Disposition, as further described in the 2019 Proxy Statement. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under the DGCL, any claim that the defective corporate acts, or the shares of stock or awards, listed as having been purportedly issued or granted on Annexes I and II, are void or voidable due to the failures of authorization listed on Annex III, or that the Delaware Court of Chancery should declare in its discretion that the ratification not be effective or be effective only on certain conditions, must be brought within 120 days from the date of the 2019 Annual Meeting, which was on November 21, 2019. </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Service-based vesting condition options </div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value of each option award is estimated on the date of the grant using the Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatility is based on the historical volatility of the Company’s stock over the most recent period commensurate with the expected life of the Company’s stock options. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected term of options granted to employees is based upon historical exercise data. Expected dividends are based on the historical trend of the Company not issuing dividends. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Variables used to determine the fair value of the options granted for the years ended November 30, 2019 and November 30, 2018 are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:79%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:2%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">2019</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">2018</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average values:</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected dividends</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">0%</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">0%</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">64.02%</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">50.85%</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk free interest rate</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">1.55%</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">2.67%</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected life</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">8.4 years</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">5.0 years</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock option activity for options with only service-based vesting conditions for the year ended November 30, 2019, was as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:63%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Options</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Weighted<br/>Average<br/>Exercise<br/>Price</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Aggregate<br/>Intrinsic<br/>Value</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at November 30, 2018</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,001,365</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.77</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.97</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,580,967</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">143,409</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">7.55</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,851</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,500</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.28</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14,175</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expired/forfeited</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;text-align:right;;vertical-align:bottom;">(52,500</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;text-align:right;;vertical-align:bottom;">4.82</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;text-align:right;;vertical-align:bottom;"> </td><td style="white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">143,450</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.375pt;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at November 30, 2019</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,089,774</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.30</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.91</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,648,111</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at November 30, 2019</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">964,540</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.75</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3.33</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4,644,277</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The weighted average grant date fair value of options granted during the years ended November 30, 2019 and November 30, 2018 was $5.02 and $3.23, respectively. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The aggregate intrinsic value represents the total value of the difference between the Company’s closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap;;display:inline;">in-the-money</div></div> stock options that would have been received by the option holders had all option holders exercised their options on either November 30, 2019 or November 30, 2018, as applicable. The intrinsic value of the Company’s stock options changes based on the closing price of the Company’s stock.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Significant option groups outstanding and exercisable at November 30, 2019 and related price and contractual life information are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:58%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Outstanding</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Exercisable</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Weighted<br/>Average</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Remaining</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Weighted</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Weighted</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-size: 8pt; white-space: nowrap; font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 8pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Range of Exercise Prices</div></div></td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Outstanding</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Contractual<br/>Life (Years)</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Average<br/>Exercise Price</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Outstanding</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Average<br/>Exercise Price</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$1.01 to $2.00</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">422,500</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.10</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.73</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">422,500</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.73</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$2.01 to $3.00</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">265,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.11</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.72</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">265,000</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.72</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$3.01 to $4.00</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">204,729</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6.23</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.14</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">204,729</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.14</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$6.01 to $7.00</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2,500</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">4.65</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6.50</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,667</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">6.50</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$7.01 to $8.00</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">195,045</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.84</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.63</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">70,644</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.67</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:top;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">1,089,774</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3.91</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">3.30</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">964,540</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">2.75</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A summary of the status of the Company’s <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> options as of November 30, 2019, and changes during the fiscal year then ended, is presented below:</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; font-family: "times new roman", times, serif;"><div style="font-size: 12pt; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;width:73%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Weighted Average</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td colspan="2" style="font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Grant-Date</td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Options</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); font-family: "times new roman", times, serif;;text-align:center;;vertical-align:bottom;">Fair Value</td><td style="font-family: "times new roman", times, serif; padding-bottom: 0.5pt;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-vested</div> at November 30, 2018</div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">40,254</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.06</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">143,409</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;text-align:right;;vertical-align:bottom;">5.02</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Vested</div></div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(58,429</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.36</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; font-family: "times new roman", times, serif;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 4%; height: 15px; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; width: 5%; height: 15px; padding: 0pt 5pt 0pt 0pt;;text-align:right;;vertical-align:bottom;">—</td><td style="white-space: nowrap; font-family: "times new roman", times, serif;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-vested</div> at November 30, 2019</div></td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">125,234</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.70</td><td style="white-space: nowrap; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-family: "times new roman", times, serif; line-height: normal;"><div style="font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="font-family: "times new roman", times, serif;"> </td><td style="font-family: "times new roman", times, serif;;vertical-align:bottom;">  </td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td><td style="font-family: "times new roman", times, serif; padding: 0px;;vertical-align:bottom;"></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-size: 1px; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">As of November 30, 2019, there was approximately $519,000 of total unrecognized compensation cost related to <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> share-based compensation arrangements granted under the 2006 Plan and the 2012 Plan. The cost is expected to be recognized over a weighted-average period of 1.16 years as of November 30, 2019. The total fair value of options vested during the fiscal year ended November 30, 2019 was approximately $255,000.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the second fiscal quarter of 2018, the Company entered into Amended and Restated Employment Agreements (“2018 Employment Agreements”) with each of the Company’s <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Co-CEOs.</div> Per the Employment Agreements, each of the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Co-CEOs</div> is to receive base grant equity awards in the form of qualified stock options of the Company’s common stock. As of March 8, 2018, David Portnoy and Mark Portnoy were granted 23,636 and 20,000 stock options of the Company’s common stock, respectively. The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019. The fair value of the options that vested through the twelve months ended November 30, 2019 and November 30, 2018 was approximately $77,000 and $62,000, respectively, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss).</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During the second fiscal quarter of 2018, the Company entered into an Amendment Agreement (“CIO Agreement”) with the Company’s CIO. Per the CIO Agreement, the CIO is to receive a base grant equity award in the form of qualified stock options of the Company’s common stock. As of May 21, 2018, Oleg Mikulinsky was granted 8,000 stock options of the Company’s common stock. The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019. The fair value of the options that vested through the twelve months ended November 30, 2019 and November 30, 2018 was approximately $18,000 and $10,000, respectively, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss). </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Performance and market-based vesting condition options</div> </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Per the 2018 Employment Agreements, based upon certain performance criteria, the Company shall grant David Portnoy and Mark Portnoy a percentage of up to 47,273 and 40,000, respectively, of qualified stock options of the Company’s common stock. For market-based vesting condition options, accounting principles do not require that the market condition be met in order for the compensation cost to be recognized. Fair value of these options has been determined using a Monte Carlo valuation approach and is being recognized over the requisite service period, regardless if the market condition will be met. During fiscal 2019 and 2018, 15,756 and 13,332, respectively, of qualified stock options were forfeited as certain market conditions were not met by the end of the requisite service period. The fair value of these options as of November 30, 2019 and November 30, 2018 was approximately $182,00 and $144,300, respectively, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss). For performance-based vesting condition options, the Company estimates the fair value of qualified stock options that met certain performance targets by the end of the fiscal 2018 requisite service period using a Black-Scholes valuation model. As of August 30, 2019, the Company granted David Portnoy and Mark Portnoy 26,243 and 22,222 of <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options of the Company’s common stock based upon certain performance criteria met by the end of the fiscal 2018 service period and per the 2018 Employment Agreements. These options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon date of grant, 1/3 on December 1, 2019 and 1/3 on November 30, 2020. The fair value of these options as of November 30, 2019 was approximately $86,000 and is reflected as selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). As of November 30, 2019, there was approximately $172,000 of total unrecognized compensation cost related to the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> options of common stock.</div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Per the Amendment Agreement, based upon certain performance criteria, the Company shall grant Oleg Mikulinsky a percentage of up to 8,000 of qualified stock options of the Company’s common stock. For market-based vesting condition options, accounting principles do not require that the market condition be met in order for the compensation cost to be recognized. Fair value of these options has been determined using a Monte Carlo valuation approach and is being recognized over the requisite service period, regardless if the market condition will be met. During fiscal 2019 and 2018, 2,666, respectively, of qualified stock options were forfeited as certain market conditions were not met by the end of the requisite service period. The fair value of these options as of November 30, 2019 and November 30, 2018 was approximately $19,200 and $13,500, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss). For performance-based vesting condition options, the Company estimated the fair value of the qualified stock options that met certain performance targets by the end of the fiscal 2018 requisite service period using a Black-Scholes valuation model. As of September 4, 2019, the Company granted Oleg Mikulinsky 4,444 of qualified stock options of the Company’s common stock based upon certain performance criteria met by the end of the fiscal 2018 service period and the per the Amendment Agreement. These options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon date of grant, 1/3 on December 1, 2019 and 1/3 on November 30, 2020. The fair value of these options as of November 30, 2019 was approximately $8,000 and is reflected as selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). As of November 30, 2019, there was approximately $15,000 of total unrecognized compensation cost related to the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> options of common stock.</div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Restricted common shares </div></div></div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Based upon performance measures being obtained during prior fiscal years, David Portnoy and Mark Portnoy earned 304,946 and 265,172 shares of common stock, respectively. Pursuant to the terms of the Employment Agreements, the <div style="white-space: nowrap; font-family: "times new roman", times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Co-CEOs</div> each opted to receive a lump sum cash payment in lieu of 30,000 shares of earned common stock which amounted to approximately $444,000 each <div style="display:inline;">paid in<div style="display:inline;"> fiscal 2018<div style="display:inline;">. Per </div></div></div>the recommendation of the DCCL, as described above, David Portnoy and Mark Portnoy surrendered 157,472 and 134,977 commons shares, respectively, for cash which amounted to $534,917 and $457,327, respectively<div style="display:inline;"> in 2019</div>. </div></div><div style="text-indent: 4%; font-family: "times new roman", times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Based upon performance measures being obtained during prior fiscal years, Oleg Mikulinsky was granted 34,349 shares of common stock.</div></div></div>

iso4217:USD xbrli:shares xbrli:pure utr:sqft iso4217:USD xbrli:shares ccel:Segments ccel:Agreement ccel:CompensationPlan ccel:Unit ccel:Store

EX-101.SCH 7 ccel-20191130.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Consolidated Statements of Stockholders' Deficit link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Consolidated Statements of Stockholders' Deficit (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Description of Business, Basis of Presentation and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Acquisition link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Inventory link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Note Payable link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Allowance for Doubtful Accounts link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Accured Expenses link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - License Agreements link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Retirement Plan link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Revenue Sharing Agreements ("RSAs") link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Share Repurchase Plan link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Description of Business, Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Description of Business, Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Acquisition (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Inventory (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Note Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Allowance for Doubtful Accounts (Tables) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Accured Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - License Agreements (Tables) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Disaggregation of Revenue (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Assets and Liabilities From Contracts With Customers (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Calculation of Basic and Diluted Net (loss) Income per Common Share (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Acquisition - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Acquisition - Summary of Fair Value of Consideration (Detail) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Acquisition - Summary of Preliminary Allocation of Total Purchase Price (Detail) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Acquisition - Schedule of Unaudited Pro Forma Results (Detail) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Inventory - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Inventory - Components of Inventory (Detail) link:presentationLink link:definitionLink link:calculationLink 1051 - Disclosure - Intangible Assets - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1052 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail) link:presentationLink link:definitionLink link:calculationLink 1053 - Disclosure - Intangible Assets - Schedule of Expected Amortization Expenses (Detail) link:presentationLink link:definitionLink link:calculationLink 1054 - Disclosure - Note Payable - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1055 - Disclosure - Note Payable - Schedule of Note Payable Obligation (Detail) link:presentationLink link:definitionLink link:calculationLink 1056 - Disclosure - Notes Payable - Summary of Future Principal Payments under Note Payable Obligation (Detail) link:presentationLink link:definitionLink link:calculationLink 1057 - Disclosure - Note Payable - Summary of Interest Expense on Note Payable (Detail) link:presentationLink link:definitionLink link:calculationLink 1058 - Disclosure - Segment Reporting - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1059 - Disclosure - Segment Reporting - Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, Interest Expense, Income Tax (Expense) Benefit and Assets by Segment (Detail) link:presentationLink link:definitionLink link:calculationLink 1060 - Disclosure - Allowance for Doubtful Accounts - Allowance for Doubtful Accounts (Detail) link:presentationLink link:definitionLink link:calculationLink 1061 - Disclosure - Property and Equipment - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1062 - Disclosure - Property and Equipment - Summary of Major Classes of Propery and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 1063 - Disclosure - Accrued Expenses - Summary of Accured Expnses (Detail) link:presentationLink link:definitionLink link:calculationLink 1064 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1065 - Disclosure - Income Taxes - Summary of Income Tax Provision (Benefit) (Detail) link:presentationLink link:definitionLink link:calculationLink 1066 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1067 - Disclosure - Income Taxes - Summary of Federal Statutory Rate to Pretax Income (Detail) link:presentationLink link:definitionLink link:calculationLink 1068 - Disclosure - Income Taxes - Summary of Open Tax Years and Ongoing Tax Examinations in Major Jurisdictions (Detail) link:presentationLink link:definitionLink link:calculationLink 1069 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1070 - Disclosure - Stockholders' Equity - Fair Value of Options Granted (Detail) link:presentationLink link:definitionLink link:calculationLink 1071 - Disclosure - Stockholders' Equity - Stock Option Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1072 - Disclosure - Stockholders' Equity - Significant Option Groups Outstanding and Exercisable Option and its Price and Contractual Life (Detail) link:presentationLink link:definitionLink link:calculationLink 1073 - Disclosure - Stockholders' Equity - Summary of Non-Vested Options (Detail) link:presentationLink link:definitionLink link:calculationLink 1074 - Disclosure - License Agreements - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1075 - Disclosure - License Agreements - Summary of License Fees Earned (Detail) link:presentationLink link:definitionLink link:calculationLink 1076 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1077 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Rental Payments Under Operating Leases (Detail) link:presentationLink link:definitionLink link:calculationLink 1078 - Disclosure - Retirement Plan - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1079 - Disclosure - Revenue Sharing Agreements ("RSAs") - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1080 - Disclosure - Share Repurchase Plan - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 ccel-20191130_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ccel-20191130_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ccel-20191130_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Entity Interactive Data Current Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Trading Symbol Entity Central Index Key Current Fiscal Year End Date Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Security Exchange Name Entity Address, State or Province Title of 12(b) Security Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Public Float Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Tianhe Stem Cell Biotechnologies Inc [Member] Tianhe Stem Cell Biotechnologies Inc [Member] Tianhe Stem Cell Biotechnologies Inc. Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series A Preferred Stock [Member] Series A Junior Participating Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current Assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Marketable Securities, Current Marketable securities Total Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable (net of allowance for doubtful accounts of $2,584,091 and $2,264,848, respectively) Accounts receivables Prepaid Expense, Current Prepaid expenses Inventory, Net Inventory, current portion Other Assets, Current Other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and Equipment-net Total Property and Equipment Long-term Investments and Receivables, Net [Abstract] Other Assets Investments Investment Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Inventory, Noncurrent Inventory, net of current portion Goodwill Goodwill Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred tax assets Deposits And Other Assets Deposits and other assets, net Deposits and other assets. Other Assets, Noncurrent Total other assets Assets Total assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities, Current [Abstract] Current Liabilities Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Notes Payable, Current Current portion of note payable Contract with Customer, Liability, Current Deferred revenue Short-term contract liabilities (deferred revenue) Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Other Liabilities Contract with Customer, Liability, Noncurrent Deferred revenue, net of current portion Long-term contract liabilities (deferred revenue) Business Combination, Contingent Consideration, Liability Contingent Consideration Contingent consideration Cord blood inventory earnout Notes Payable, Noncurrent Note payable, net of current portion and debt issuance costs Long-term note payable, net of debt issuance costs Other Long-term Debt, Noncurrent Long-term liability - revenue sharing agreements Other Liabilities, Noncurrent Total other liabilities Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Note 13) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Deficit Preferred Stock, Value, Issued Preferred stock Common Stock, Value, Issued Common stock ($.01 par value, 20,000,000 authorized; 13,598,909 issued and 7,510,884 outstanding as of November 30, 2019 and 13,596,409 issued and 7,800,833 outstanding as of November 30, 2018) Additional Paid in Capital, Common Stock Additional paid-in capital Treasury Stock, Value Treasury stock, at cost Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' deficit Beginning balance Ending balance Liabilities and Equity Total liabilities and stockholders' deficit Accounts Receivable, Allowance for Credit Loss, Current Accounts receivable, allowance for doubtful accounts Beginning Balance Ending Balance Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common stock par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Income Statement [Abstract] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Processing and Storage Fees [Member] Processing and Storage Fees [Member] Processing and storage fees. Public Banking [Member] Public Banking [Member] Public Banking [Member] Public banking. Licensee And Royalty Income Recognition [Member] Licensee and royalty income [Member] License and royalty income [Member] Licensee And Royalty Income Recognition Product [Member] Product [Member] Revenue from Contract with Customer, Including Assessed Tax Revenue Revenues Total net revenue Costs and Expenses [Abstract] Costs and Expenses: Cost of Goods and Services Sold Cost of sales Total cost of sales Selling, General and Administrative Expense Selling, general and administrative expenses Other Asset Impairment Charges Impairment of public inventory Impairment charges Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Change in fair value of contingent consideration Change in fair value of contingent consideration Research and Development Expense Research, development and related engineering Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Total depreciation and amortization Costs and Expenses Total costs and expenses Operating Income (Loss) Operating Income Total operating profit Nonoperating Income (Expense) [Abstract] Other Expense: Other Nonoperating Income (Expense) Other income (expense) Interest Expense Interest expense Interest expense Total interest expense Nonoperating Income (Expense) Total other expense Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income before income tax expense Income Tax Expense (Benefit) Income tax expense Total income tax (expense) benefit Income Tax Expense Net Income (Loss) Attributable to Parent Net Income (Loss) Net income (loss) Net Income (Loss) Earnings Per Share, Basic Net income (loss) per common share—basic Basic Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding—basic Weighted-average shares outstanding-basic Earnings Per Share, Diluted Net income (loss) per common share—diluted Diluted Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding—diluted Weighted-average shares-diluted Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other Comprehensive Income Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized gain on marketable securities (net of tax) Unrealized gain on marketable securities, net of tax Unrealized loss on available for sale securities Total other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Income (Loss) Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income (loss) Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation, Depletion and Amortization Depreciation and amortization expense Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of property and equipment Share-based Payment Arrangement, Noncash Expense, Total Compensatory element of stock options Accounts Receivable, Credit Loss Expense (Reversal) Provision for doubtful accounts Bad Debt Expense Deferred Income Taxes and Tax Credits Deferred income tax expense Amortization of Debt Issuance Costs Amortization of debt issuance costs Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Inventories Inventory Increase (Decrease) in Other Current Assets Other current assets Increase Decrease In Deposits And Other Assets Deposits and other assets, net Increase (decrease) in deposits and other assets. Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Contract with Customer, Liability Deferred revenue Increase Decrease In Goodwill Goodwill Increase decrease in goodwill. Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows used in investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Intangible Assets Purchase of intangible asset Payments for (Proceeds from) Investments Purchases of marketable securities and other investments, net Payments to Acquire Businesses, Gross Purchase of Cord Use Payment under asset purchase agreement Cash Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Repayments of Notes Payable Repayments of note payable Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Proceeds from Notes Payable Proceeds from note payable Payments of Debt Issuance Costs Issuance costs associated with the proceeds from the note payable Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Payments for Repurchase of Common Stock Treasury stock purchases Payment of Earnout Payment of Cord Use earnout Payment of earnout. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Increase (decrease) in cash and cash equivalents Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental non-cash investing activities: Cumulative Effect of New Accounting Principle in Period of Adoption Cumulative-effect adjustment due to the adoption of ASU 2016-01 Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract] Assets acquired and liabilities assumed in acquisitions: Noncash or Part Noncash Acquisition, Value of Assets Acquired Assets acquired in acquisition Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Liabilities assumed in acquisition Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Treasury Stock [Member] Treasury Stock [Member] AOCI Attributable to Parent [Member] Other Comprehensive Income [Member] Retained Earnings [Member] Accumulated Deficit [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-01 [Member] Accounting Standards Update 2016-01 [Member] Shares, Issued Beginning balance, shares Ending balance, shares Stock Issued During Period, Value, New Issues Common stock issued Stock Issued During Period, Shares, New Issues Common stock issued, shares APIC, Share-based Payment Arrangement, Recognition and Exercise Compensatory element of stock options Cumulative Effect on Retained Earnings, Net of Tax ASC 606 adoption adjustment, net of tax Treasury Stock, Value, Acquired, Cost Method Treasury Stock Cumulative Effect Adjustment From Accumulated Other Comprehensive Income To Retained Earnings Cumulative-effect adjustment due to the adoption of ASU 2016-01 Cumulative-effect adjustment from accumulated other comprehensive income to retained earnings Cumulative effect adjustment from accumulated other comprehensive income to retained earnings. Cumulative Effect on Retained Earnings, Tax Cumulative effect on retained earnings, tax Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] Description of Business, Basis of Presentation and Significant Accounting Policies Business Combinations [Abstract] Business Combination Disclosure [Text Block] Acquisition Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventory Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] Intangible Assets Debt Disclosure [Abstract] Debt Disclosure [Text Block] Note Payable Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] Segment Reporting Receivables [Abstract] Allowance for Credit Losses [Text Block] Allowance for Doubtful Accounts Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property and Equipment EX-101.PRE 11 ccel-20191130_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 g807043g0228054232370.jpg GRAPHIC begin 644 g807043g0228054232370.jpg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g807043g0228054232542.jpg GRAPHIC begin 644 g807043g0228054232542.jpg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htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Significant Accounting Policies (Policies)

12 Months Ended

Nov. 30, 2019

Accounting Policies [Abstract]

Description of Business

Description of Business.

On October 10, 2001, Saneron Therapeutics, Inc. merged into one of the Company’s wholly owned subsidiaries, CCEL

Bio-Therapies,

Inc. (”CCBT”), which then changed its name to Saneron CCEL Therapeutics, Inc. (“SCTI” or ”Saneron”). As part of the merger, the Company contributed 260,000 shares of its common stock, whose fair value was $1,924,000 and 195,000 common shares of another of its subsidiaries, Stem Cell Preservation Technologies, Inc., whose fair value was $3,900. At the conclusion of the merger, the Company retained a 43.42%

non-controlling

interest in the voting stock of SCTI. As of November 30, 2019 and 2018, the Company had an interest of approximately 33% in the voting stock of SCTI. The accompanying consolidated financial statements as of November 30, 2019 and 2018 reflect the investment in SCTI under the equity method of accounting.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.

Concentration of Risks

The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units. However, the Company believes that alternative sources of supply and manufacturing are available.

The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for transplant.

During fiscal 2019 and 2018, there were no concentration of risks.

Use of Estimates

Revenue Recognition

(ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. ASC 606 also requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

twenty-one

year or life-time plan) but would like to change the term to a

one-year

contract. Upgrade modifications qualify for treatment as a separate contract as the additional services are distinct and the increase in contract price reflects the Company’s stand-alone selling price for the additional services and will be accounted for on a prospective basis. Downgrade modifications do not qualify for treatment as a separate contract as there is no increase in price over the original contract, thus failing the separate contract criteria. As such, the Company separately considers downgrade modifications to determine if these should be accounted for as a termination of the existing contract and creation of a new contract (prospective method) or as part of the existing contract (cumulative

catch-up

adjustment). ASC 606 requires that an entity account for the contract modification as if it were a termination of the existing contract, and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. As the services after the modification were previously determined to be distinct, the Company concluded that downgrade modifications qualify under this method and will be accounted for on a prospective basis. Although contract modifications do occur, they are infrequent.

Performance Obligations

•

Collection and processing services

•

Storage services

•

Public cord blood banking

•

License and royalties

•

Sale of PrepaCyte CB product

a )	Processing

annual, twenty-one

years and life-time. The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual, the

twenty-one-year

and the life-time storage fees that are being recognized over the contractual storage period as well as royalties received from foreign licensees relating to long-term storage contracts for which the Company has future obligations under the license agreement. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.

Significant financing

annual, twenty-one years

and life-time, the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans (including a stated service fee) for customers to pay over time for a period of one to twenty-four plus months. The

one-time

plan includes the collection kit, processing and testing, return medical courier service and

twenty-one

years of

pre-paid

storage fees. The life-time plan includes the collection kit, processing and testing, return medical courier service and

pre-paid

storage fees for the life of the customer. The Company concluded that a significant financing component is not present within either the prepaid or overtime payment plans. The Company has determined that the

twenty-one

year and life-time prepayment options do not include a significant financing component as the payment terms were structured primarily for reasons other than the provision of financing and to maximize profitability.

As of November 30, 201

, the total aggregate transaction price allocated to the unsatisfied performance obligations was recorded as deferred revenue amounting to $32,508,511, which will be recognized ratably on a straight-line basis over the contractual period of which $8,875,138 will be recognized over the next twelve months.

Variable consideration

Allocation of transaction price

Costs to Obtain a Contract

With the adoption of ASC 606 as of December 1, 2018, the Company capitalizes commissions that are incremental in obtaining customer contracts and the costs incurred to fulfill a customer contract if those costs are not within the scope of another topic within the accounting literature and meet the specified criteria. These costs are deferred in other current or long-term assets and are expensed to selling, general and administrative expenses as the Company satisfies the performance obligations by transferring the service to the customer. These assets will be periodically assessed for impairment. As a practical expedient, the Company elected to recognize the incremental costs of obtaining its annual contracts as an expense when incurred, as the amortization period of the asset recognized would have been one year.

The Company has determined that payments under the Company’s

refer-a-friend

program (“RAF program”) are incremental costs of obtaining a contract as they provide an incentive for existing customers to refer new customers to the Company and is referred to as commission. The amount paid under the RAF program (either through issuance of credits to customers or check payments) which exceeds the typical commission payment to a sales representative is recorded as a reduction to revenue under ASC 606. During the twelve months ended November 30, 2019, the Company recorded $35,300, in commission payments to customers under the RAF program as a reduction to revenue. As of December 1, 2018, the Company capitalized $329,231 in incremental contract acquisition costs related to contracts that were not completed, net of the cumulative amortization expense of $66,533 through the adoption date. The Company did not record any impairment losses in relation to costs capitalized. For the twelve months ended November 30, 2019, the Company capitalized additional contract acquisition costs of $87,518, net of amortization expense.

b )	Public banking revenue

c )	Licensee and royalty income

d )	Product Revenue

The Company records revenue from the sale of the PrepaCyte CB product line upon shipment of the product to the Company’s customers.

e )	Shipping and handling

The adoption of ASC 606 did not have an impact on the timing of revenue recognition for any of the Company’s revenue streams.

Disaggregation of Revenue

The following table provides information about disaggregated revenue by products and services:


	Twelve months ended
	November 30, 2019		November 30, 2018
Processing and storage fees	$	29,991,972	$	27,817,872
Public banking revenue		652,204		296,295
Licensee and royalty income		1,000,000		1,000,000
Product revenue		172,395		104,323

	$	31,816,571	$	29,218,490

The following table provides information about assets and liabilities from contracts with customers:


	November 30, 2019		At Adoption
Contract assets (sales commissions)	$	398,535	$	329,231
Accounts receivables	$	6,097,331	$	5,867,335
Short-term contract liabilities (deferred revenue)	$	8,875,138	$	8,365,284
Long-term contract liabilities (deferred revenue)	$	23,633,373	$	20,317,231

months

ended November 30, 2019.

The following table presents changes in the Company’s contract assets and liabilities during the twelve months ended November 30, 2019:


	Balance at December 1, 2018		Additions		Deductions			Balance at November 30, 2019
Contract assets (sales commissions)	$	329,231	$	88,569	($	19,265	)	$	398,535
Accounts receivables	$	5,867,335	$	36,579,504	($	36,349,508	)	$	6,097,331
Contract liabilities (deferred revenue)	$	28,682,515	$	18,759,963	($	14,933,967	)	$	32,508,511

Revenue Sharing Agreements

The Company entered into Revenue Sharing Agreements (“RSAs”) prior to 2002 with various third and related parties. The Company’s RSAs provide that in exchange for a

non-refundable

up-front

payment, the Company would share for the duration of the contract a percentage of its future storage revenue collected from the annual storage fees charged related to a certain number of specimens that originated from specific geographical areas. The RSAs have no definitive term or termination provisions. The sharing applies to the storage fees collected for all specified specimens in the area up to the number covered in the contract. When the number of specimens is filled, any additional specimens stored in that area are not subject to revenue sharing. As there are empty spaces resulting from attrition, the Company agrees to fill them as soon as possible. The Company has reflected these

up-front

payments as long-term liabilities on the accompanying consolidated balance sheets. The Company does not intend to enter into additional RSAs.

de-recognized

based on the effective interest method, the payments will be allocated between interest and amortization of the liability. As cash is paid out to the other party during any period, the liability would be

de-recognized

based on the portion of the total anticipated payouts made during the period, using the effective interest method. That is, a portion of the payment would be recorded as interest expense, and the remainder would be treated as repayment of principal, which would reduce the liability.

License and Royalty Agreements

know-how

in a selected area. The investor may be given a right to sell

sub-license

agreements as well. As part of the accounting for the

up-front

license fee paid, or payable, to the Company, revenue from the

up-front

license fee is recognized based on such factors as when the payment is due, collectability and when all material services or conditions relating to the sale have been substantially performed by the Company based on the terms of the agreement. The Company has twelve active licensing agreements. The following areas each have one license agreement: El Salvador, Guatemala, Panama, Honduras, China and Pakistan. The following areas each have two license agreements: India, Nicaragua and Costa Rica.

In addition to the license fee, the Company earns processing and storage fees on subsequent processing and storage revenues received by the licensee in the licensed territory and a fee on any

sub-license

agreements that are sold by the licensee where applicable. These fees are included in processing and storage fees revenue on the consolidated statements of comprehensive income (loss). As part of the accounting for royalty revenue from India, the Company uses estimates and judgments based on historical processing and storage volume in determining the timing and amount of royalty revenue to recognize. The Company periodically reviews license and royalty receivables for collectability and, if necessary, will record an expense for an allowance for uncollectible accounts.

Cash and Cash Equivalents

Cash and cash equivalents consist of highly liquid investments with a maturity date of three months or less at the time of purchase.

Accounts Receivable

writes-off

accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.

Inventory

one-year

period, a portion of these fixed costs are expensed and included in facility operating costs. Certain costs of collection incurred, such as the cost of collection staff and transportation costs incurred to ship Public Bank units from hospitals to the stem cell laboratory are allocated to banked units based on an average cost method. The change in the number of expected units to be sold could have a significant impact on the estimated net realizable value of banked units which could have a material effect on the value of the inventory. Costs incurred related to cord blood units that cannot be sold are expensed in the period incurred and are included in facility operating costs in the accompanying statements of operations. The Company records a reserve against inventory for units which have been processed and frozen but may not ultimately become distributable (see Note 3). Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of

2,332,763

was recognized during the second quarter of fiscal

2019

to reduce inventory from cost to net realizable value and is included in the accompanying consolidated statements of comprehensive income (loss).

Property and Equipment


Furniture and equipment		3-10 years

Leasehold improvements		Lesser of 8-10 years or the lives of the leases

Computer software – internal use		1-5 years

The Company capitalizes external direct costs of materials and services consumed in developing or obtaining

internal-use

computer software. Capitalized

internal-use

software costs, which are included in property and equipment, are depreciated over the estimated useful lives of the software.

Long-Lived Assets

note any indicators of impairment as of November 30, 2019 and November 30, 2018, respectively.

Goodwill

two-step

goodwill impairment test is not required. If the qualitative assessment concludes that it is more likely than not that the fair value of the reporting unit is less than the carrying value, then the

two-step

goodwill impairment test is required. Step one of the impairment assessment compares the fair value of the reporting unit to its carrying value and if the fair value exceeds its carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, the implied fair value of goodwill is compared to the carrying value of goodwill. If the implied fair value exceeds the carrying value then goodwill is not impaired; otherwise, an impairment loss would be recorded by the amount the carrying value exceeds the implied fair value.

Income Taxes

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The Company records a valuation allowance when it is “more likely than not” that all of the future income tax benefits will not be realized. When the Company changes its determination as to the amount of deferred income tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to income tax expense in the period in which such determination is made. The ultimate realization of the Company’s deferred income tax assets depends upon generating sufficient taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, the Company projects future levels of taxable income. This assessment requires significant judgment. The Company examines the evidence related to the recent history of losses, the economic conditions in which the Company operates and forecasts and projections to make that determination.

more-likely-than-not

threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management’s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions.

Research, Development and Related Engineering Costs

Research, development and related engineering costs are expensed as incurred.

Legal fees are expensed as incurred and are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss).

Fair Value of Financial Instruments


Level 1		Quoted prices in active markets for identical assets or liabilities.

Level 2		Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3		Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.


	Fair Value at			at November 30, 2019 Using
Description	November 30, 2019			Level 1		Level 2		Level 3
Assets:
Marketable securities	$	904,053		$	904,053		—		—

Total	$	904,053		$	904,053		—		—

Liabilities:
Contingent consideration	$	3,495,057		$	—		—	$	3,495,057

Total	$	3,495,057		$	—		—	$	3,495,057

Contingent Consideration:
Beginning Balance as of November 30, 2018	$	4,282,975
Subtractions – Cord:Use earnout payment		(45,000	)
Fair value adjustment as of November 30, 2019		(742,918	)

Ending balance as of November 30, 2019	$	3,495,057


	Fair Value at			Fair Value Measurements at November 30, 2018 Using
Description	November 30, 2018			Level 1		Level 2		Level 3
Assets:
Trading securities	$	68,816		$	68,816		—		—
Available-for-sale securities		806,873			806,873		—		—

Total	$	875,689		$	875,689		—		—

Liabilities:
Contingent consideration	$	4,282,975		$	—		—	$	4,282,975

Total	$	4,282,975		$	—		—	$	4,282,975

The following is a description of the valuation techniques used for these items, as well as the general classification of such items pursuant to the fair value hierarchy:

Trading securities –

Fair values for these investments are based on quoted prices of identical securities in active markets and are therefore classified within Level 1 of the fair value hierarchy. For trading securities, there was approximately ($28,000) in unrealized holding losses, respectively, recorded in other income and expense on the accompanying consolidated statements of comprehensive income (loss) for the twelve months ended November 30, 2018.

Available-for-sale

securities –

These investments are classified as available for sale and consist of marketable equity securities that we intend to hold for an indefinite period of time. Investments are stated at fair value and unrealized holding gains and losses are reported as a component of accumulated other comprehensive income until realized. Realized gains or losses on disposition of investments are computed using the first in, first out (FIFO) method and reported as income or loss in the period of disposition in the accompanying consolidated statements of comprehensive income (loss). For

available-for-sale

securities, there was approximately $300,000 in unrealized holding gains (loss), net of tax, respectively, reported as comprehensive income on the accompanying statements of comprehensive income (loss) for the year ended November 30, 2018.

Marketable securities

- Effective December 1, 2018, the Company adopted ASU

2016-01,

which requires equity securities with readily determinable fair values to be measured at fair value with the changes in fair value recognized through net income. Such securities are no longer reflected as trading or

available-for-sale

but are noted as marketable securities. As a result of this accounting change, in the first quarter of 2019, the Company recognized a cumulative-effect adjustment from accumulated other comprehensive income to retained earnings of approximately $341,000 in the consolidated statements of stockholders’ deficit as of the date of adoption. Prior periods have not been restated for the impact of this accounting change. There was $28,000 in unrealized holding gain recorded in other income and expense on the accompanying consolidated statements of comprehensive income (loss) for the twelve months ended November 30, 2019.

Contingent consideration -

Product Warranty and Cryo-Cell CaresTM Program

Product Warranty and Cryo-Cell Cares

Program

In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.

Income (Loss) per Common Share


	November 30, 2019		November 30, 2018
Numerator:
Net income (loss)	$	2,290,774	($	854,824	)
Denominator:
Weighted-average shares outstanding-basic		7,794,828		7,463,051
Dilutive common shares issuable upon exercise of stock options		617,586		—

Weighted-average shares-diluted		8,412,414		7,463,051

Income(Loss) per share:
Basic	$	0.29	($	0.11	)

Diluted	$	0.27	($	0.11	)

Stock Compensation

As of November 30, 201

, the Company has two stock-based employee compensation plans, which are described in Note 11 to the consolidated financial statements. The Company’s stock-based employee compensation plan became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting. The Company recognized approximately $398,000 and $478,000 for the fiscal years ended November 30, 2019 and November 30, 2018, respectively, of stock compensation expense. The Company reversed $444,000 of stock compensation expense during the twelve months ended November 30, 2018 as the

Co-CEOs

each opted to receive a lump sum cash payment in lieu of 30,000 shares of earned common stock pursuant to the terms of their Employment Agreements. The reversal had no impact on the accompanying consolidated statements of comprehensive income (loss) as other compensation expense was recognized to offset the reversal.

Reclassifications

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no

material

effect on the reported results of operations.

Recently Issued Accounting Pronouncements

In August 2018, the FASB issued Accounting Standards Update

No. 2018-15,

Intangibles – Goodwill and Other

Internal-Use

Software (Topic

350-40):

Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.

This update addresses how a customer should account for the costs of implementing a cloud computing service arrangement (also referred to as a “hosting arrangement”). Entities should account for costs associated with implementing a cloud computing arrangement that is considered a service contract in the same way as accounting for implementation costs incurred to develop or obtain software for internal use using the guidance in Topic

350-40.

The amendments address when costs should be capitalized rather than expensed, the term to use when amortizing capitalized costs, and how to evaluate the unamortized portion of these capitalized implementation costs for impairment. The ASU also includes guidance on how to present implementation costs in the financial statements and creates additional disclosure requirements. The guidance is effective for annual periods beginning after December 15, 2019, and interim periods within that reporting period. The Company is currently evaluating the effect that the updated standard will have on our financial statements.

In June 2018, the FASB issued Accounting Standards Update

No. 2018-07,

Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.

This update simplifies the accounting for nonemployee share-based payment transactions by expanding the scope of Topic 718, Compensation-Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within that reporting period. The Company is currently evaluating the effect that the updated standard will have on our financial statements.

In January 2017, the FASB issued Accounting Standards Update

No. 2017-04,

Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment

. The update removes Step 2 from the goodwill impairment test. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, although early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on our financial statements.

In February 2016, the FASB issued Accounting Standards Update

No. 2016-02,

Leases (Topic 842).

This update requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. It also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated balance sheets and related disclosures.

XML 15 R21.htm IDEA: XBRL DOCUMENT

Retirement Plan

12 Months Ended

Nov. 30, 2019

Retirement Benefits [Abstract]

Retirement Plan

NOTE 14 - RETIREMENT PLAN

XML 16 R29.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

12 Months Ended

Nov. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets were as follows as of November 30, 2019 and 2018:


	Useful lives	November 30, 2019			November 30, 2018
Patents	10-20 years	$	234,570		$	234,570
Less: Accumulated amortization			(35,526	)		(23,663	)
License agreement	10 years		470,000			470,000
Less: Intangible asset impairment			(185,000	)		(185,000	)
Less: Accumulated amortization			(155,194	)		(123,528	)
Customer relationships – Prepacyte ® CB	15 years		41,000			41,000
Less: Intangible asset impairment			(26,267	)		(26,267	)
Less: Accumulated amortization			(6,329	)		(5,276	)
Brand	1 year		31,000			31,000
Less: Accumulated amortization			(31,000	)		(15,500	)
Customer relationships – Cord:Use	30 years		960,000			960,000
Less: Accumulated amortization			(48,000	)		(16,000	)

Net Intangible Assets		$	1,249,254		$	1,341,336

Schedule of Expected Amortization Expenses

Expected amortization related to these intangible assets for each of the next five fiscal years and for periods thereafter is as follows:

Fiscal years ending November 30:


2020	$	67,667
2021	$	67,667
2022	$	67,667
2023	$	67,667
2024	$	67,667
Thereafter	$	910,919

Total	$	1,249,254

XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 263 539 1 false 106 0 false 10 false false R1.htm 1001 - Document - Cover Page Sheet http://cryo-cell.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Consolidated Balance Sheets Sheet http://cryo-cell.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://cryo-cell.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://cryo-cell.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 4 false false R5.htm 1005 - Statement - Consolidated Statements of Cash Flows Sheet http://cryo-cell.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 1006 - Statement - Consolidated Statements of Stockholders' Deficit Sheet http://cryo-cell.com/role/ConsolidatedStatementsOfStockholdersDeficit Consolidated Statements of Stockholders' Deficit Statements 6 false false R7.htm 1007 - Statement - Consolidated Statements of Stockholders' Deficit (Parenthetical) Sheet http://cryo-cell.com/role/ConsolidatedStatementsOfStockholdersDeficitParenthetical Consolidated Statements of Stockholders' Deficit (Parenthetical) Statements 7 false false R8.htm 1008 - Disclosure - Description of Business, Basis of Presentation and Significant Accounting Policies Sheet http://cryo-cell.com/role/DescriptionOfBusinessBasisOfPresentationAndSignificantAccountingPolicies Description of Business, Basis of Presentation and Significant Accounting Policies Notes 8 false false R9.htm 1009 - Disclosure - Acquisition Sheet http://cryo-cell.com/role/Acquisition Acquisition Notes 9 false false R10.htm 1010 - Disclosure - Inventory Sheet http://cryo-cell.com/role/Inventory Inventory Notes 10 false false R11.htm 1011 - Disclosure - Intangible Assets Sheet http://cryo-cell.com/role/IntangibleAssets Intangible Assets Notes 11 false false R12.htm 1012 - Disclosure - Note Payable Sheet http://cryo-cell.com/role/NotePayable Note Payable Notes 12 false false R13.htm 1013 - Disclosure - Segment Reporting Sheet http://cryo-cell.com/role/SegmentReporting Segment Reporting Notes 13 false false R14.htm 1014 - Disclosure - Allowance for Doubtful Accounts Sheet http://cryo-cell.com/role/AllowanceForDoubtfulAccounts Allowance for Doubtful Accounts Notes 14 false false R15.htm 1015 - Disclosure - Property and Equipment Sheet http://cryo-cell.com/role/PropertyAndEquipment Property and Equipment Notes 15 false false R16.htm 1016 - Disclosure - Accured Expenses Sheet http://cryo-cell.com/role/AccuredExpenses Accured Expenses Notes 16 false false R17.htm 1017 - Disclosure - Income Taxes Sheet http://cryo-cell.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 1018 - Disclosure - Stockholders' Equity Sheet http://cryo-cell.com/role/StockholdersEquity Stockholders' Equity Notes 18 false false R19.htm 1019 - Disclosure - License Agreements Sheet http://cryo-cell.com/role/LicenseAgreements License Agreements Notes 19 false false R20.htm 1020 - Disclosure - Commitments and Contingencies Sheet http://cryo-cell.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 1021 - Disclosure - Retirement Plan Sheet http://cryo-cell.com/role/RetirementPlan Retirement Plan Notes 21 false false R22.htm 1022 - Disclosure - Revenue Sharing Agreements ("RSAs") Sheet http://cryo-cell.com/role/RevenueSharingAgreementsRsas Revenue Sharing Agreements ("RSAs") Notes 22 false false R23.htm 1023 - Disclosure - Share Repurchase Plan Sheet http://cryo-cell.com/role/ShareRepurchasePlan Share Repurchase Plan Notes 23 false false R24.htm 1024 - Disclosure - Related Party Transactions Sheet http://cryo-cell.com/role/RelatedPartyTransactions Related Party Transactions Notes 24 false false R25.htm 1025 - Disclosure - Description of Business, Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://cryo-cell.com/role/DescriptionOfBusinessBasisOfPresentationAndSignificantAccountingPoliciesPolicies Description of Business, Basis of Presentation and Significant Accounting Policies (Policies) Policies http://cryo-cell.com/role/DescriptionOfBusinessBasisOfPresentationAndSignificantAccountingPolicies 25 false false R26.htm 1026 - Disclosure - Description of Business, Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://cryo-cell.com/role/DescriptionOfBusinessBasisOfPresentationAndSignificantAccountingPoliciesTables Description of Business, Basis of Presentation and Significant Accounting Policies (Tables) Tables http://cryo-cell.com/role/DescriptionOfBusinessBasisOfPresentationAndSignificantAccountingPolicies 26 false false R27.htm 1027 - Disclosure - Acquisition (Tables) Sheet http://cryo-cell.com/role/AcquisitionTables Acquisition (Tables) Tables http://cryo-cell.com/role/Acquisition 27 false false R28.htm 1028 - Disclosure - Inventory (Tables) Sheet http://cryo-cell.com/role/InventoryTables Inventory (Tables) Tables http://cryo-cell.com/role/Inventory 28 false false R29.htm 1029 - Disclosure - Intangible Assets (Tables) Sheet http://cryo-cell.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://cryo-cell.com/role/IntangibleAssets 29 false false R30.htm 1030 - Disclosure - Note Payable (Tables) Sheet http://cryo-cell.com/role/NotePayableTables Note Payable (Tables) Tables http://cryo-cell.com/role/NotePayable 30 false false R31.htm 1031 - Disclosure - Segment Reporting (Tables) Sheet http://cryo-cell.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://cryo-cell.com/role/SegmentReporting 31 false false R32.htm 1032 - Disclosure - Allowance for Doubtful Accounts (Tables) Sheet http://cryo-cell.com/role/AllowanceForDoubtfulAccountsTables Allowance for Doubtful Accounts (Tables) Tables http://cryo-cell.com/role/AllowanceForDoubtfulAccounts 32 false false R33.htm 1033 - Disclosure - Property and Equipment (Tables) Sheet http://cryo-cell.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://cryo-cell.com/role/PropertyAndEquipment 33 false false R34.htm 1034 - Disclosure - Accured Expenses (Tables) Sheet http://cryo-cell.com/role/AccuredExpensesTables Accured Expenses (Tables) Tables http://cryo-cell.com/role/AccuredExpenses 34 false false R35.htm 1035 - Disclosure - Income Taxes (Tables) Sheet http://cryo-cell.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://cryo-cell.com/role/IncomeTaxes 35 false false R36.htm 1036 - Disclosure - Stockholders' Equity (Tables) Sheet http://cryo-cell.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://cryo-cell.com/role/StockholdersEquity 36 false false R37.htm 1037 - Disclosure - License Agreements (Tables) Sheet http://cryo-cell.com/role/LicenseAgreementsTables License Agreements (Tables) Tables http://cryo-cell.com/role/LicenseAgreements 37 false false R38.htm 1038 - Disclosure - Commitments and Contingencies (Tables) Sheet http://cryo-cell.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://cryo-cell.com/role/CommitmentsAndContingencies 38 false false R39.htm 1039 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://cryo-cell.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) Details 39 false false R40.htm 1040 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Disaggregation of Revenue (Detail) Sheet http://cryo-cell.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetail Description of Business and Summary of Significant Accounting Policies - Disaggregation of Revenue (Detail) Details 40 false false R41.htm 1041 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Assets and Liabilities From Contracts With Customers (Detail) Sheet http://cryo-cell.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesFromContractsWithCustomersDetail Description of Business and Summary of Significant Accounting Policies - Schedule of Assets and Liabilities From Contracts With Customers (Detail) Details 41 false false R42.htm 1042 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://cryo-cell.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Description of Business and Summary of Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 42 false false R43.htm 1043 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Calculation of Basic and Diluted Net (loss) Income per Common Share (Detail) Sheet http://cryo-cell.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetLossIncomePerCommonShareDetail Description of Business and Summary of Significant Accounting Policies - Calculation of Basic and Diluted Net (loss) Income per Common Share (Detail) Details 43 false false R44.htm 1044 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail) Sheet http://cryo-cell.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyAndEquipmentDetail Description of Business and Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail) Details 44 false false R45.htm 1045 - Disclosure - Acquisition - Additional Information (Detail) Sheet http://cryo-cell.com/role/AcquisitionAdditionalInformationDetail Acquisition - Additional Information (Detail) Details 45 false false R46.htm 1046 - Disclosure - Acquisition - Summary of Fair Value of Consideration (Detail) Sheet http://cryo-cell.com/role/AcquisitionSummaryOfFairValueOfConsiderationDetail Acquisition - Summary of Fair Value of Consideration (Detail) Details 46 false false R47.htm 1047 - Disclosure - Acquisition - Summary of Preliminary Allocation of Total Purchase Price (Detail) Sheet http://cryo-cell.com/role/AcquisitionSummaryOfPreliminaryAllocationOfTotalPurchasePriceDetail Acquisition - Summary of Preliminary Allocation of Total Purchase Price (Detail) Details 47 false false R48.htm 1048 - Disclosure - Acquisition - Schedule of Unaudited Pro Forma Results (Detail) Sheet http://cryo-cell.com/role/AcquisitionScheduleOfUnauditedProFormaResultsDetail Acquisition - Schedule of Unaudited Pro Forma Results (Detail) Details 48 false false R49.htm 1049 - Disclosure - Inventory - Additional Information (Detail) Sheet http://cryo-cell.com/role/InventoryAdditionalInformationDetail Inventory - Additional Information (Detail) Details 49 false false R50.htm 1050 - Disclosure - Inventory - Components of Inventory (Detail) Sheet http://cryo-cell.com/role/InventoryComponentsOfInventoryDetail Inventory - Components of Inventory (Detail) Details 50 false false R51.htm 1051 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://cryo-cell.com/role/IntangibleAssetsAdditionalInformationDetail Intangible Assets - Additional Information (Detail) Details 51 false false R52.htm 1052 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail) Sheet http://cryo-cell.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetail Intangible Assets - Schedule of Intangible Assets (Detail) Details 52 false false R53.htm 1053 - Disclosure - Intangible Assets - Schedule of Expected Amortization Expenses (Detail) Sheet http://cryo-cell.com/role/IntangibleAssetsScheduleOfExpectedAmortizationExpensesDetail Intangible Assets - Schedule of Expected Amortization Expenses (Detail) Details 53 false false R54.htm 1054 - Disclosure - Note Payable - Additional Information (Detail) Sheet http://cryo-cell.com/role/NotePayableAdditionalInformationDetail Note Payable - Additional Information (Detail) Details 54 false false R55.htm 1055 - Disclosure - Note Payable - Schedule of Note Payable Obligation (Detail) Sheet http://cryo-cell.com/role/NotePayableScheduleOfNotePayableObligationDetail Note Payable - Schedule of Note Payable Obligation (Detail) Details 55 false false R56.htm 1056 - Disclosure - Notes Payable - Summary of Future Principal Payments under Note Payable Obligation (Detail) Notes http://cryo-cell.com/role/NotesPayableSummaryOfFuturePrincipalPaymentsUnderNotePayableObligationDetail Notes Payable - Summary of Future Principal Payments under Note Payable Obligation (Detail) Details 56 false false R57.htm 1057 - Disclosure - Note Payable - Summary of Interest Expense on Note Payable (Detail) Sheet http://cryo-cell.com/role/NotePayableSummaryOfInterestExpenseOnNotePayableDetail Note Payable - Summary of Interest Expense on Note Payable (Detail) Details 57 false false R58.htm 1058 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://cryo-cell.com/role/SegmentReportingAdditionalInformationDetail Segment Reporting - Additional Information (Detail) Details 58 false false R59.htm 1059 - Disclosure - Segment Reporting - Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, Interest Expense, Income Tax (Expense) Benefit and Assets by Segment (Detail) Sheet http://cryo-cell.com/role/SegmentReportingSummaryOfNetRevenueCostOfSalesDepreciationAndAmortizationOperatingProfitInterestExpenseIncomeTaxExpenseBenefitAndAssetsBySegmentDetail Segment Reporting - Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, Interest Expense, Income Tax (Expense) Benefit and Assets by Segment (Detail) Details 59 false false R60.htm 1060 - Disclosure - Allowance for Doubtful Accounts - Allowance for Doubtful Accounts (Detail) Sheet http://cryo-cell.com/role/AllowanceForDoubtfulAccountsAllowanceForDoubtfulAccountsDetail Allowance for Doubtful Accounts - Allowance for Doubtful Accounts (Detail) Details 60 false false R61.htm 1061 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://cryo-cell.com/role/PropertyAndEquipmentAdditionalInformationDetail Property and Equipment - Additional Information (Detail) Details 61 false false R62.htm 1062 - Disclosure - Property and Equipment - Summary of Major Classes of Propery and Equipment (Detail) Sheet http://cryo-cell.com/role/PropertyAndEquipmentSummaryOfMajorClassesOfProperyAndEquipmentDetail Property and Equipment - Summary of Major Classes of Propery and Equipment (Detail) Details 62 false false R63.htm 1063 - Disclosure - Accrued Expenses - Summary of Accured Expnses (Detail) Sheet http://cryo-cell.com/role/AccruedExpensesSummaryOfAccuredExpnsesDetail Accrued Expenses - Summary of Accured Expnses (Detail) Details 63 false false R64.htm 1064 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Detail) Sheet http://cryo-cell.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetail Income Taxes - Summary of Deferred Tax Assets and Liabilities (Detail) Details 64 false false R65.htm 1065 - Disclosure - Income Taxes - Summary of Income Tax Provision (Benefit) (Detail) Sheet http://cryo-cell.com/role/IncomeTaxesSummaryOfIncomeTaxProvisionBenefitDetail Income Taxes - Summary of Income Tax Provision (Benefit) (Detail) Details 65 false false R66.htm 1066 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://cryo-cell.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 66 false false R67.htm 1067 - Disclosure - Income Taxes - Summary of Federal Statutory Rate to Pretax Income (Detail) Sheet http://cryo-cell.com/role/IncomeTaxesSummaryOfFederalStatutoryRateToPretaxIncomeDetail Income Taxes - Summary of Federal Statutory Rate to Pretax Income (Detail) Details 67 false false R68.htm 1068 - Disclosure - Income Taxes - Summary of Open Tax Years and Ongoing Tax Examinations in Major Jurisdictions (Detail) Sheet http://cryo-cell.com/role/IncomeTaxesSummaryOfOpenTaxYearsAndOngoingTaxExaminationsInMajorJurisdictionsDetail Income Taxes - Summary of Open Tax Years and Ongoing Tax Examinations in Major Jurisdictions (Detail) Details 68 false false R69.htm 1069 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://cryo-cell.com/role/StockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 69 false false R70.htm 1070 - Disclosure - Stockholders' Equity - Fair Value of Options Granted (Detail) Sheet http://cryo-cell.com/role/StockholdersEquityFairValueOfOptionsGrantedDetail Stockholders' Equity - Fair Value of Options Granted (Detail) Details 70 false false R71.htm 1071 - Disclosure - Stockholders' Equity - Stock Option Activity (Detail) Sheet http://cryo-cell.com/role/StockholdersEquityStockOptionActivityDetail Stockholders' Equity - Stock Option Activity (Detail) Details 71 false false R72.htm 1072 - Disclosure - Stockholders' Equity - Significant Option Groups Outstanding and Exercisable Option and its Price and Contractual Life (Detail) Sheet http://cryo-cell.com/role/StockholdersEquitySignificantOptionGroupsOutstandingAndExercisableOptionAndItsPriceAndContractualLifeDetail Stockholders' Equity - Significant Option Groups Outstanding and Exercisable Option and its Price and Contractual Life (Detail) Details 72 false false R73.htm 1073 - Disclosure - Stockholders' Equity - Summary of Non-Vested Options (Detail) Sheet http://cryo-cell.com/role/StockholdersEquitySummaryOfNonVestedOptionsDetail Stockholders' Equity - Summary of Non-Vested Options (Detail) Details 73 false false R74.htm 1074 - Disclosure - License Agreements - Additional Information (Detail) Sheet http://cryo-cell.com/role/LicenseAgreementsAdditionalInformationDetail License Agreements - Additional Information (Detail) Details 74 false false R75.htm 1075 - Disclosure - License Agreements - Summary of License Fees Earned (Detail) Sheet http://cryo-cell.com/role/LicenseAgreementsSummaryOfLicenseFeesEarnedDetail License Agreements - Summary of License Fees Earned (Detail) Details 75 false false R76.htm 1076 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://cryo-cell.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 76 false false R77.htm 1077 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Rental Payments Under Operating Leases (Detail) Sheet http://cryo-cell.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumRentalPaymentsUnderOperatingLeasesDetail Commitments and Contingencies - Summary of Future Minimum Rental Payments Under Operating Leases (Detail) Details 77 false false R78.htm 1078 - Disclosure - Retirement Plan - Additional Information (Detail) Sheet http://cryo-cell.com/role/RetirementPlanAdditionalInformationDetail Retirement Plan - Additional Information (Detail) Details 78 false false R79.htm 1079 - Disclosure - Revenue Sharing Agreements ("RSAs") - Additional Information (Detail) Sheet http://cryo-cell.com/role/RevenueSharingAgreementsRsasAdditionalInformationDetail Revenue Sharing Agreements ("RSAs") - Additional Information (Detail) Details http://cryo-cell.com/role/RevenueSharingAgreementsRsas 79 false false R80.htm 1080 - Disclosure - Share Repurchase Plan - Additional Information (Detail) Sheet http://cryo-cell.com/role/ShareRepurchasePlanAdditionalInformationDetail Share Repurchase Plan - Additional Information (Detail) Details 80 false false All Reports Book All Reports ccel-20191130.xml ccel-20191130.xsd ccel-20191130_cal.xml ccel-20191130_def.xml ccel-20191130_lab.xml ccel-20191130_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 18 R67.htm IDEA: XBRL DOCUMENT

Income Taxes - Summary of Federal Statutory Rate to Pretax Income (Detail) - USD ($)		12 Months Ended
	Jan. 31, 2018	Nov. 30, 2019	Nov. 30, 2018	Nov. 30, 2017
Income Tax Disclosure [Abstract]
Tax at Federal Statutory Rate, Amount		$ 733,198	$ 799,507
State Income Tax Effect, Amount		220,527	216,608
Tax Compensation Differences, Amount		26,330	260,845
Permanent Disallowances, Amount		76,775	149,141
Impact of Tax Reform, Amount			3,078,094
Deferred Repricing, Amount		24,533	(28,337)
Other, Amount		19,278	(3,354)
Foreign tax credits, Amount		(108,150)	(108,314)
Foreign tax withholding, Amount		108,150	108,314
Income Tax Expense		$ 1,100,641	$ 4,472,504
Tax at Federal Statutory Rate	21.00%	21.00%	22.10%	34.00%
State Income Tax Effect, Rate		6.32%	5.99%
Valuation Allowance Release, Rate		0.00%	0.00%
Tax Compensation Differences, Rate		0.75%	7.21%
Permanent Disallowances, Rate		2.20%	4.12%
Impact of Tax Reform, Rate		0.00%	85.08%
Deferred Repricing, Rate		(0.70%)	0.78%
Other, Rate		(0.10%)	(0.09%)
Foreign tax credits, Rate		(3.10%)	(2.99%)
Foreign tax withholding, Rate		3.10%	2.99%
Total income taxes, Rate		30.87%	123.63%

XML 19 R63.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Summary of Accured Expnses (Detail) - USD ($)	Nov. 30, 2019	Nov. 30, 2018
Payables and Accruals [Abstract]
Professional fees	$ 115,000	$ 14,867
Payroll and payroll taxes	513,108	1,021,004
Interest expense	950,300	864,676
General expenses	330,726	478,449
Federal and state taxes	176,046	323,792
Total	$ 2,085,180	$ 2,702,788

XML 20 R48.htm IDEA: XBRL DOCUMENT

Acquisition - Schedule of Unaudited Pro Forma Results (Detail)	12 Months Ended
	Nov. 30, 2018 USD ($) $ / shares
Business Combinations [Abstract]
Revenue \| $	$ 31,388,278
Net income (loss) \| $	$ 2,658,679
Earnings (loss) per share:
Basic \| $ / shares	$ 0.36
Diluted \| $ / shares	$ 0.36

XML 21 R40.htm IDEA: XBRL DOCUMENT

Description of Business and Summary of Significant Accounting Policies - Disaggregation of Revenue (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Revenues	$ 31,816,571	$ 29,218,490
Processing and Storage Fees [Member]
Revenues	29,991,972	27,817,872
Public Banking Revenue [Member]
Revenues	652,204	296,295
Licensee and royalty income [Member]
Revenues	1,000,000	1,000,000
Product Revenue [Member]
Revenues	$ 172,395	$ 104,323

XML 22 R44.htm IDEA: XBRL DOCUMENT

Description of Business and Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)	12 Months Ended
	Nov. 30, 2019
Furniture and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Furniture and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Leasehold Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Leasehold Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Computer Software - Internal Use [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Computer Software - Internal Use [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	1 year

XML 23 R72.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Significant Option Groups Outstanding and Exercisable Option and its Price and Contractual Life (Detail)	12 Months Ended
	Nov. 30, 2019 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Outstanding \| shares	1,089,774
Outstanding, Weighted Average Remaining Contractual Life (Years)	3 years 10 months 27 days
Outstanding, Weighted Average Exercise Price	$ 3.30
Exercisable, Outstanding \| shares	964,540
Exercisable, Weighted Average Exercise Price	$ 2.75
Range 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Minimum	1.01
Range of Exercise Prices Maximum	$ 2.00
Outstanding, Outstanding \| shares	422,500
Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 1 month 6 days
Outstanding, Weighted Average Exercise Price	$ 1.73
Exercisable, Outstanding \| shares	422,500
Exercisable, Weighted Average Exercise Price	$ 1.73
Range 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Minimum	2.01
Range of Exercise Prices Maximum	$ 3.00
Outstanding, Outstanding \| shares	265,000
Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 1 month 9 days
Outstanding, Weighted Average Exercise Price	$ 2.72
Exercisable, Outstanding \| shares	265,000
Exercisable, Weighted Average Exercise Price	$ 2.72
Range 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Minimum	3.01
Range of Exercise Prices Maximum	$ 4.00
Outstanding, Outstanding \| shares	204,729
Outstanding, Weighted Average Remaining Contractual Life (Years)	6 years 2 months 23 days
Outstanding, Weighted Average Exercise Price	$ 3.14
Exercisable, Outstanding \| shares	204,729
Exercisable, Weighted Average Exercise Price	$ 3.14
Range 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Minimum	6.01
Range of Exercise Prices Maximum	$ 7.00
Outstanding, Outstanding \| shares	2,500
Outstanding, Weighted Average Remaining Contractual Life (Years)	4 years 7 months 24 days
Outstanding, Weighted Average Exercise Price	$ 6.50
Exercisable, Outstanding \| shares	1,667
Exercisable, Weighted Average Exercise Price	$ 6.50
Range 5 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Minimum	7.01
Range of Exercise Prices Maximum	$ 8.00
Outstanding, Outstanding \| shares	195,045
Outstanding, Weighted Average Remaining Contractual Life (Years)	7 years 10 months 2 days
Outstanding, Weighted Average Exercise Price	$ 7.63
Exercisable, Outstanding \| shares	70,644
Exercisable, Weighted Average Exercise Price	$ 7.67

XML 24 R76.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)		1 Months Ended			12 Months Ended
	Dec. 03, 2015 USD ($)	Jul. 31, 2018 ft²	Apr. 30, 2014 ft²	Nov. 30, 2013 USD ($) ft²	Nov. 30, 2019 USD ($)	Nov. 30, 2018 USD ($)
Commitment And Contingencies [Line Items]
Operating lease area \| ft²			17,600
Operating lease period			10 years
Extensions on main lease \| ft²		17,600
Rent charged to operation \| $					$ 322,984	$ 312,307
Miami [Member]
Commitment And Contingencies [Line Items]
Operating lease period				1 year
Rent charged to operation \| $				$ 38,000
Area covered under lease after amendment \| ft²				800
Minimum [Member]
Commitment And Contingencies [Line Items]
Employee agreements period					1 year
Maximum [Member]
Commitment And Contingencies [Line Items]
Employee agreements period					2 years
Case No.15-007461-CI [Member]
Commitment And Contingencies [Line Items]
Minimum jurisdictional amount \| $	$ 15,000

XML 25 R55.htm IDEA: XBRL DOCUMENT

Note Payable - Schedule of Note Payable Obligation (Detail) - USD ($)	Nov. 30, 2019	Nov. 30, 2018
Debt Disclosure [Abstract]
Note payable	$ 9,108,433	$ 13,208,433
Unamortized debt issuance costs	(152,281)	(264,923)
Net note payable	8,956,152	12,943,510
Current portion of note payable	3,100,000	3,100,000
Long-term note payable, net of debt issuance costs	5,856,152	9,843,510
Total	$ 8,956,152	$ 12,943,510

XML 26 R51.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Finite-Lived Intangible Assets, Net [Abstract]
Amortization expense	$ 92,000	$ 76,000

XML 27 R59.htm IDEA: XBRL DOCUMENT

Segment Reporting - Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, Interest Expense, Income Tax (Expense) Benefit and Assets by Segment (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Segment Reporting Information [Line Items]
Total net revenue	$ 31,816,571	$ 29,218,490
Total cost of sales	10,036,175	8,539,662
Total operating profit	5,062,706	5,189,303
Total depreciation and amortization	206,238	180,264
Total interest expense	1,703,446	1,546,900
Total income tax (expense) benefit	(1,100,641)	(4,472,504)
Total other comprehensive income (loss)	0	300,119
Total assets	42,886,160	42,390,143
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]
Segment Reporting Information [Line Items]
Total net revenue	30,991,972	28,817,872
Total cost of sales	8,490,824	7,744,208
Total operating profit	8,152,475	5,620,394
Total interest expense	1,703,446	1,546,900
Total income tax (expense) benefit	(1,100,641)	(4,472,504)
Total other comprehensive income (loss)	0	300,119
PrepaCyte CB [Member]
Segment Reporting Information [Line Items]
Total net revenue	172,395	104,323
Total cost of sales	249,487	169,397
Total operating profit	(113,346)	(101,329)
Total interest expense	0
Total income tax (expense) benefit	0
Total other comprehensive income (loss)	0
Public Cord Blood Banking [Member]
Segment Reporting Information [Line Items]
Total net revenue	652,204	296,295
Total cost of sales	1,295,864	626,057
Total operating profit	(2,976,423)	(329,762)
Total interest expense	0
Total income tax (expense) benefit	0
Total other comprehensive income (loss)	0
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total depreciation and amortization	401,311	317,326
Operating Segments [Member] \| Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]
Segment Reporting Information [Line Items]
Total depreciation and amortization	365,057	281,072
Operating Segments [Member] \| PrepaCyte CB [Member]
Segment Reporting Information [Line Items]
Total depreciation and amortization	36,254	36,254
Operating Segments [Member] \| Public Cord Blood Banking [Member]
Segment Reporting Information [Line Items]
Total depreciation and amortization	0
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]
Segment Reporting Information [Line Items]
Total assets	28,975,002	26,239,260
PrepaCyte CB [Member]
Segment Reporting Information [Line Items]
Total assets	289,804	319,802
Public Cord Blood Banking [Member]
Segment Reporting Information [Line Items]
Total assets	$ 13,621,354	$ 15,831,081

XML 28 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

12 Months Ended

Nov. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Summary of Future Minimum Rental Payments Under Operating Leases

The future minimum rental payments under the operating lease are as follows:


Fiscal Year Ending November 30,	Rent
2020	$	228,148
2021	$	224,928
2022	$	18,744

XML 29 R30.htm IDEA: XBRL DOCUMENT

Note Payable (Tables)

12 Months Ended

Nov. 30, 2019

Debt Disclosure [Abstract]

Schedule of Note Payable Obligation

As of November 30, 2019, and November 30, 2018, the note payable obligation was as follows:


	November 30, 2019			November 30, 2018
Note payable	$	9,108,433		$	13,208,433
Unamortized debt issuance costs		(152,281	)		(264,923	)

Net note payable	$	8,956,152		$	12,943,510

Current portion of note payable	$	3,100,000		$	3,100,000
Long-term note payable, net of debt issuance costs		5,856,152			9,843,510

Total	$	8,956,152		$	12,943,510

Summary of Future Principal Payments under the Note Payable Obligation

Future principal payments under the note payable obligation are as follows:


Years ending November 30:	Amount
2020		3,100,000
2021		3,100,000
2022		2,908,433

Total	$	9,108,433

Summary of Interest Expense on Note Payable

Interest expense on the note payable for the years ended November 30, 2019 and November 30, 2018 was as follows:


	November 30, 2019		November 30, 2018
Interest expense on notes payable	$	646,744	$	589,583
Debt issuance costs		112,642		109,293

Total interest expense	$	759,386	$	698,876

XML 30 R34.htm IDEA: XBRL DOCUMENT

Accured Expenses (Tables)

12 Months Ended

Nov. 30, 2019

Payables and Accruals [Abstract]

Summary of Accured Expenses

Accrued expenses are as follows:


	November 30,
	2019		2018
Professional fees	$	115,000	$	14,867
Payroll and payroll taxes (1)		513,108		1,021,004
Interest expense		950,300		864,676
General expenses		330,726		478,449
Federal and state taxes		176,046		323,792

	$	2,085,180	$	2,702,788

(1)	– Payroll and payroll taxes includes accrued vacation and wages due as of November 30, 2019 and November 30, 2018.

XML 31 R9.htm IDEA: XBRL DOCUMENT

Acquisition

12 Months Ended

Nov. 30, 2019

Business Combinations [Abstract]

Acquisition

Note 2 – Acquisition

Additionally, Cord:Use is entitled to an earnout from Cryo-Cell’s sale of the public cord blood inventory from and after closing. Each calendar year after the closing, Cryo-Cell will pay to Cord:Use 75% of all gross revenues, net of any returns, received from the sale of public cord blood inventory in excess of $500,000. Such payments will be made quarterly, within 30 days of the end of the last month of each calendar quarter, until the public cord blood inventory is exhausted. In addition, each calendar year after closing, until the public cord blood inventory is exhausted, for every $500,000 of retained gross revenues, net of any returns, received and retained by Cryo-Cell in excess of the initial $500,000 retained by Cryo-Cell during such year, Cryo-Cell will deliver $200,000 worth of Cryo-Cell Common stock to Cord:Use, up to an aggregate value of $5,000,000. Cord:Use is also entitled to a portion of the gross profits generated, or deemed to have been generated, by Cryo-Cell from its ownership of the Tianhe Capital Stock.

The Company incurred $580,000 in costs associated with the acquisition of Cord:Use.

The following summarizes the fair value of the consideration of the Acquisition as of the purchase date:


Consideration
Cash	$	10,500,000
Cryo-Cell common stock		3,500,000
Cord blood inventory earnout		4,698,255

Consideration	$	18,698,255

The following summarizes the allocation of the total purchase price for the Acquisition:


Accounts receivable	$	188,019
Inventory		16,037,957
Prepaid expenses		68,867
Property and equipment		568,407
Other asset—Tianhe capital stock		308,000
Brand		31,000
Customer relationships		960,000

Total identifiable net assets acquired		18,162,250

Less: Deferred revenue		(1,405,406	)

Goodwill		1,941,411

Total	$	18,698,255

The property and equipment are stated at an estimate of fair value.

The fair values of the license agreement and customer relationships reflect the anticipated cash flows over their expected lives.

The fair value of deferred revenue is valued based on the cost method. Deferred revenues are

pre-payment

fees for future storage of umbilical cord blood and/or cord tissue specimens. The short- and long-term deferred revenue is $330,508 and $1,074,898, respectively.

Unaudited Pro forma Results


	Twelve months ended November 30, 2018
Revenue	$	31,388,278
Net income (loss)	($	2,658,679	)
Earnings (loss) per share:
Basic	($	0.36	)
Diluted	($	0.36	)

XML 32 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended

Nov. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 10—INCOME TAXES

The Company recorded the following income tax provision for the years ended November 30, 2019 and 2018.


	2019			2018
Current:
Federal	$	1,637,000		$	1,467,000
State		769,000			622,000
Foreign		108,000			108,000

Subtotal		2,514,000			2,197,000
Deferred:
Federal		(1,106,000	)		2,716,000
State		(307,000	)		(441,000	)
Foreign		—			—

Subtotal		(1,413,000	)		2,275,000

Income Tax Expense	$	1,101,000		$	4,472,000

As of November 201

and 2018, the tax effects of temporary differences that give rise to the deferred tax assets are as follows:


	2019			2018
Tax Assets:
Deferred income (Net of Discounts)	$	6,256,000		$	5,157,000
Tax over book basis in unconsolidated affiliate		1,224,000			1,214,000
Accrued payroll		82,000			257,000
Reserves and other accruals		1,589,000			868,000
Stock compensation		411,000			330,000
Depreciation and Amortization		450,000			428,000
Transaction costs		18,000			18,000
RSA Buy-out		1,095,000			1,210,000

Total Assets:		11,125,000			9,482,000
Tax Liabilities:
Unrealized gains on marketable securities		(117,000	)		(112,000	)
NOL’s credits, and other carryforward items		(282,000	)		(79,000	)

Total Liabilities:		(399,000	)		(191,000	)
Less: Valuation Allowance		(1,646,000	)		(1,634,000	)

Net Deferred Tax Asset	$	9,080,000		$	7,657,000

and ($711,000) during the years ended November 30, 2019 and 2018, respectively. The change for year ended November 30, 2019 was primarily due to changes in statutory rates. The change for year ended November 30, 2018 was a result of the revaluation impact of the Tax Cuts and Jobs Act of 2017 which reduced the federal tax rate from 34% to 21%.

The positive evidence that weighed in favor of releasing the allowance as of November 30, 2017 and ultimately outweighed the negative evidence against releasing the allowance was the following:

•

Identifiable sources of future income relating to the Company’s deferred revenue accounts;

•

Certainty as to the amount available of deferred tax assets and nature in which the deferred tax assets reverse;

•

Profitability for years ended November 30, 2015 and 2016 and our expectations regarding the sustainability of these profits;

•

The Company’s three-year cumulative position as of November 30, 2017; and

•

The Company’s taxable income projection for fiscal years ending November 30, 2018, 2019 and 2020.

The

Tax Cuts and Jobs Act (the “Tax Act”) was signed into law on December 22, 2017. The Tax Act makes significant changes to provision of the Internal Revenue Code, including changing the corporate tax rate to a flat 21% rate as of January 1, 2018. This requires the Company’s net deferred tax assets and liabilities to be revalued at the newly enacted U.S. corporate rate. The impact will be recognized in tax expense in the year of enactment. Based on evaluation, the Company’s discrete expense for the rate impact will be approximately $3.1 million. Based on the Company’s evaluation, the Tax Act is not expected to impact the recoverability of its deferred tax asset.

A reconciliation of the income tax provision with the amount of tax computed by applying the federal statutory rate to pretax income follows:


	For the Years Ended November 30
	2019			%			2018			%
Tax at Federal Statutory Rate		733,198			21.00			799,507			22.10
State Income Tax Effect		220,527			6.32			216,608			5.99
Valuation Allowance Release		—			0.00			—			0.00
Tax Compensation Differences		26,330			0.75			260,845			7.21
Permanent Disallowances		76,775			2.20			149,141			4.12
Impact of Tax Reform		—			0.00			3,078,094			85.08
Deferred Repricing		24,533			0.70			(28,337	)		(0.78	)
Other		19,278			(0.10	)		(3,354	)		(0.09	)
Foreign tax credits		(108,150	)		(3.10	)		(108,314	)		(2.99	)
Foreign tax withholding		108,150			3.10			108,314			2.99

Total income taxes	$	1,100,641			30.87		$	4,472,504			123.63

The Company adopted the accounting standard for uncertain tax positions, ASC

740-10,

on December 1, 2007. As required by the standard, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management’s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions. There were no uncertain tax positions as of November 30, 2019 and 2018.

There was approximately $2,801,000 and $2,204,000 of U.S. income taxes paid for the fiscal years ended November 30, 2019 and November 30, 2018, respectively.


Jurisdiction	Open Tax Years	Examinations in Process
United States – Federal Income Tax	2015 – 2018	N/A
United States – Various States	2013 – 2018	N/A

XML 33 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Nov. 30, 2019	Nov. 30, 2018
Cash flows from operating activities:
Net income (loss)	$ 2,290,774	$ (854,824)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization expense	401,311	317,326
Impairment of public inventory	2,332,763
Loss on disposal of property and equipment		162,307
Change in fair value of contingent consideration	(742,918)	(415,280)
Compensatory element of stock options	397,770	478,378
Provision for doubtful accounts	767,128	727,483
Deferred income tax expense	(1,517,289)	2,378,491
Amortization of debt issuance costs	112,642	109,292
Changes in assets and liabilities:
Accounts receivable	(997,124)	(1,347,773)
Prepaid expenses	(38,445)	(20,796)
Inventory	(27,423)	316,650
Other current assets	(5,932)	(48,329)
Goodwill		66,565
Deposits and other assets, net	15,696	(85,000)
Accounts payable	107,458	(666,889)
Accrued expenses	(599,200)	120,313
Deferred revenue	3,825,996	4,095,416
Net cash provided by operating activities	6,323,207	5,333,330
Cash flows used in investing activities:
Purchases of property and equipment	(662,295)	(446,163)
Purchase of intangible asset		(200,000)
Purchases of marketable securities and other investments, net	(28,364)	(136,248)
Purchase of Cord Use		(10,500,000)
Net cash used in investing activities	(690,659)	(11,282,411)
Cash flows from financing activities:
Treasury stock purchases	(992,244)
Repayments of note payable	(4,100,000)	(3,291,665)
Proceeds from the exercise of stock options	5,700	170,925
Proceeds from note payable		9,000,000
Issuance costs associated with the proceeds from the note payable		(169,300)
Payment of Cord Use earnout	(45,000)
Net cash (used in) provided by financing activities	(5,131,544)	5,709,960
Increase (decrease) in cash and cash equivalents	501,004	(239,121)
Cash and cash equivalents - beginning of period	6,040,033	6,279,154
Cash and cash equivalents - end of period	6,541,037	6,040,033
Supplemental non-cash investing activities:
Unrealized gain on marketable securities, net of tax	0	300,119
Cumulative-effect adjustment due to the adoption of ASU 2016-01	$ (340,984)
Assets acquired and liabilities assumed in acquisitions:
Assets acquired in acquisition		20,103,661
Liabilities assumed in acquisition		$ 1,405,406

XML 34 R1.htm IDEA: XBRL DOCUMENT

Cover Page - USD ($)	12 Months Ended
Cover Page - USD ($)	Nov. 30, 2019	Feb. 15, 2020	May 31, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Nov. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--11-30
Entity Interactive Data Current	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Trading Symbol	CCEL
Entity Central Index Key	0000862692
Entity Registrant Name	CRYO CELL INTERNATIONAL INC
Entity Public Float			$ 30,374,581
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Address, State or Province	FL
Title of 12(b) Security	Common Stock
Entity Common Stock, Shares Outstanding		7,545,613
Security Exchange Name	NONE

XML 35 R13.htm IDEA: XBRL DOCUMENT

Segment Reporting

12 Months Ended

Nov. 30, 2019

Segment Reporting [Abstract]

Segment Reporting

Note 6

–

Segment Reporting

The Company is organized in three reportable segments:

and 201


	For the years ended November 30,
	2019			2018
Net revenue:
Umbilical cord blood and cord tissue stem cell service	$	30,991,972		$	28,817,872
PrepaCyte CB		172,395			104,323
Public cord blood banking		652,204			296,295

Total net revenue	$	31,816,571		$	29,218,490

Cost of sales:
Umbilical cord blood and cord tissue stem cell service	$	8,490,824		$	7,744,208
PrepaCyte CB		249,487			169,397
Public cord blood banking		1,295,864			626,057

Total cost of sales	$	10,036,175		$	8,539,662

Operating profit:
Umbilical cord blood and cord tissue stem cell service	$	8,152,475		$	5,620,394
PrepaCyte CB		(113,346	)		(101,329	)
Public cord blood banking		(2,976,423	)		(329,762	)

Total operating profit	$	5,062,706		$	5,189,303

Depreciation and amortization:
Umbilical cord blood and cord tissue stem cell service	$	365,057		$	281,072
PrepaCyte CB		36,254			36,254
Public cord blood banking		—			—

Total depreciation and amortization	$	401,311		$	317,326

Interest expense:
Umbilical cord blood and cord tissue stem cell service	$	1,703,446		$	1,546,900
PrepaCyte CB		—			—
Public cord blood banking		—			—

Total interest expense	$	1,703,446		$	1,546,900

Income tax (expense) benefit:

Umbilical cord blood and cord tissue stem cell service	$	(1,100,641	)	$	(4,472,504	)

PrepaCyte CB		—			—
Public cord blood banking		—			—

Total income tax (expense) benefit	$	(1,100,641	)	$	(4,472,504	)

Other comprehensive income (loss):
Umbilical cord blood and cord tissue stem cell service	$	—		$	300,119
PrepaCyte CB		—			—
Public cord blood banking		—			—

Total other comprehensive income (loss)	$	—		$	300,119

The following table shows the assets by segment as of November 30, 2019 and November 30, 2018:

	2019		2018
Assets:
Umbilical cord blood and cord tissue stem cell service	$	28,975,002	$	26,239,260
PrepaCyte CB		289,804		319,802
Public cord blood banking		13,621,354		15,831,081

Total assets	$	42,886,160	$	42,390,143

XML 36 R73.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Non-Vested Options (Detail) - $ / shares	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Share-based Payment Arrangement [Abstract]
Non-vested at November 30, 2018 Shares	40,254
Granted, Shares	143,409
Vested, Shares	(58,429)
Non-vested at November 30, 2019 Shares	125,234	40,254
Non-vested at November 30, 2018, Weighted Average Grant-Date Fair Value	$ 3.06
Granted, Weighted Average Grant-Date Fair Value	5.02	$ 3.23
Vested, Weighted Average Grant-Date Fair Value	4.36
Non-vested at November 30, 2019, Weighted Average Grant-Date Fair Value	$ 4.70	$ 3.06

XML 37 R77.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Summary of Future Minimum Rental Payments Under Operating Leases (Detail)	Nov. 30, 2019 USD ($)
Leases [Abstract]
2020	$ 228,148
2021	224,928
2022	$ 18,744

XML 38 R58.htm IDEA: XBRL DOCUMENT

Segment Reporting - Additional Information (Detail)	12 Months Ended
Segment Reporting - Additional Information (Detail)	Nov. 30, 2019 Segments
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member]
Segment Reporting Information [Line Items]
Number of reportable segments	3

XML 39 R54.htm IDEA: XBRL DOCUMENT

Note Payable - Additional Information (Detail) - USD ($)		12 Months Ended
	May 20, 2016	Nov. 30, 2019	Nov. 30, 2018	Jun. 11, 2018	Aug. 26, 2016	Jul. 01, 2016
Debt Instrument [Line Items]
Interest expense		$ 1,703,446	$ 1,546,900
Debt issuance costs		548,085
Amortization of debt issuance costs		112,642	109,293
Texas Capital Bank National Association [Member] \| Amended And Restated Promissory Notes [Member]
Debt Instrument [Line Items]
Interest expense		$ 646,744	$ 589,583
Texas Capital Bank National Association [Member] \| Amended And Restated Promissory Notes [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Second amended and restated promissory note principal amount				$ 15,500,000
Senior Credit Facilities [Member] \| Texas Capital Bank National Association [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Line of credit facility, description		Subject to the terms of the Agreement, on May 20, 2016, TCB advanced the Company $100.00. On July 1, 2016, TCB advanced the remaining principal amount of $7,999,900 per a promissory note dated May 20, 2016 between the Company and TCB, at a rate of 3.75% per annum plus LIBOR, payable monthly with a maturity date of July 2021.
Line of credit facility, frequency of payment		monthly
Line of credit facility, interest rate description		3.75% per annum plus LIBOR
Senior Credit Facilities [Member] \| Texas Capital Bank National Association [Member] \| Promissory Notes [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Line of credit facility, amount advanced						$ 7,999,900
Senior Credit Facilities [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Texas Capital Bank National Association [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Term loan, maximum borrowing capacity	$ 8,000,000
Line of credit facility, amount advanced	$ 100.00
Line of credit facility, interest rate	3.75%
Line of credit facility, expiration date	Jul. 31, 2021
Amended Senior Credit Facility [Member] \| Texas Capital Bank National Association [Member] \| Amended And Restated Promissory Notes [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Line of credit facility, amount advanced					$ 2,133,433
Second Amended Senior Credit Facility [Member] \| Texas Capital Bank National Association [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Line of credit facility, amount advanced				$ 9,000,000

XML 40 R50.htm IDEA: XBRL DOCUMENT

Inventory - Components of Inventory (Detail) - USD ($)	Nov. 30, 2019	Nov. 30, 2018
Inventory [Line Items]
Collection kits	$ 44,453	$ 19,163
Inventory reserve	(7,718)	(7,718)
Total inventory	13,730,533	16,035,873
All Other [Member]
Inventory [Line Items]
Work-in-process	149,972	188,085
Finished goods	52,451	5,262
Public Banking [Member]
Inventory [Line Items]
Finished goods	$ 13,491,375	$ 15,831,081

XML 41 R31.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables)

12 Months Ended

Nov. 30, 2019

Segment Reporting [Abstract]

Summary of Net Revenue, Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment

and 201


	For the years ended November 30,
	2019			2018
Net revenue:
Umbilical cord blood and cord tissue stem cell service	$	30,991,972		$	28,817,872
PrepaCyte CB		172,395			104,323
Public cord blood banking		652,204			296,295

Total net revenue	$	31,816,571		$	29,218,490

Cost of sales:
Umbilical cord blood and cord tissue stem cell service	$	8,490,824		$	7,744,208
PrepaCyte CB		249,487			169,397
Public cord blood banking		1,295,864			626,057

Total cost of sales	$	10,036,175		$	8,539,662

Operating profit:
Umbilical cord blood and cord tissue stem cell service	$	8,152,475		$	5,620,394
PrepaCyte CB		(113,346	)		(101,329	)
Public cord blood banking		(2,976,423	)		(329,762	)

Total operating profit	$	5,062,706		$	5,189,303

Depreciation and amortization:
Umbilical cord blood and cord tissue stem cell service	$	365,057		$	281,072
PrepaCyte CB		36,254			36,254
Public cord blood banking		—			—

Total depreciation and amortization	$	401,311		$	317,326

Interest expense:
Umbilical cord blood and cord tissue stem cell service	$	1,703,446		$	1,546,900
PrepaCyte CB		—			—
Public cord blood banking		—			—

Total interest expense	$	1,703,446		$	1,546,900

Income tax (expense) benefit:

Umbilical cord blood and cord tissue stem cell service	$	(1,100,641	)	$	(4,472,504	)

PrepaCyte CB		—			—
Public cord blood banking		—			—

Total income tax (expense) benefit	$	(1,100,641	)	$	(4,472,504	)

Other comprehensive income (loss):
Umbilical cord blood and cord tissue stem cell service	$	—		$	300,119
PrepaCyte CB		—			—
Public cord blood banking		—			—

Total other comprehensive income (loss)	$	—		$	300,119

The following table shows the assets by segment as of November 30, 2019 and November 30, 2018:

	2019		2018
Assets:
Umbilical cord blood and cord tissue stem cell service	$	28,975,002	$	26,239,260
PrepaCyte CB		289,804		319,802
Public cord blood banking		13,621,354		15,831,081

Total assets	$	42,886,160	$	42,390,143

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

XML 43 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes (Tables)
12 Months Ended

Nov. 30, 2019

Income Tax Disclosure [Abstract]

Summary of Income Tax Provision (Benefit)
The Company recorded the following income tax provision for the years ended November 30, 2019 and 2018.


2019

2018

Current:

Federal
   $ 1,637,000    $ 1,467,000
State
   769,000    622,000
Foreign
   108,000    108,000




Subtotal
   2,514,000    2,197,000
Deferred:

Federal
   (1,106,000 )    2,716,000
State
   (307,000 )    (441,000 )
Foreign
   —    —




Subtotal
   (1,413,000 )    2,275,000




Income Tax Expense
   $ 1,101,000    $ 4,472,000


Summary of Deferred Tax Assets and Liabilities
As of November 201
9
and 2018, the tax effects of temporary differences that give rise to the deferred tax assets are as follows:


2019

2018

Tax Assets:

Deferred income (Net of Discounts)
   $ 6,256,000    $ 5,157,000
Tax over book basis in unconsolidated affiliate
   1,224,000    1,214,000
Accrued payroll
   82,000    257,000
Reserves and other accruals
   1,589,000    868,000
Stock compensation
   411,000    330,000
Depreciation and Amortization
   450,000    428,000
Transaction costs
   18,000    18,000
RSA
Buy-out
   1,095,000    1,210,000




Total Assets:
   11,125,000    9,482,000
Tax Liabilities:

Unrealized gains on
marketable
securities
   (117,000 )    (112,000 )
NOL’s credits, and other carryforward items
   (282,000 )    (79,000 )




Total Liabilities:
   (399,000 )    (191,000 )
Less: Valuation Allowance
   (1,646,000 )    (1,634,000 )




Net Deferred Tax Asset
   $ 9,080,000    $ 7,657,000




Summary of Federal Statutory Rate to Pretax Income
A reconciliation of the income tax provision with the amount of tax computed by applying the federal statutory rate to pretax income follows:


For the Years Ended November 30


2019

%

2018

%

Tax at Federal Statutory Rate
   733,198    21.00    799,507    22.10
State Income Tax Effect
   220,527    6.32    216,608    5.99
Valuation Allowance Release
   —    0.00    —    0.00
Tax Compensation Differences
   26,330    0.75    260,845    7.21
Permanent Disallowances
   76,775    2.20    149,141    4.12
Impact of Tax Reform
   —    0.00    3,078,094    85.08
Deferred Repricing
   24,533    0.70    (28,337 )    (0.78 )
Other
   19,278    (0.10 )    (3,354 )    (0.09 )
Foreign tax credits
   (108,150 )    (3.10 )    (108,314 )    (2.99 )
Foreign tax withholding
   108,150    3.10    108,314    2.99








Total income taxes
   $ 1,100,641    30.87    $ 4,472,504    123.63








Summary of Open Tax Years and Ongoing Tax Examinations in Major Jurisdictions The table below summarizes the open tax years and ongoing tax examinations in major jurisdictions as of November 30, 2019:

Jurisdiction
   Open Tax
Years    Examinations
in Process
United States – Federal Income Tax
2015 – 2018 N/A
United States – Various States
2013 – 2018 N/A

X

- Definition
Tabular disclosure of the federal tax basis of investment holdings. This item captures the aggregate cost of securities, aggregate gross unrealized appreciation for all securities in which there is an excess of value over tax cost, aggregate gross unrealized depreciation for all securities in which there is an excess of tax cost over value, net unrealized appreciation (depreciation), and an explanation of the differences between tax and book.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-12C)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010
+ Details

Name: us-gaap_FederalIncomeTaxNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319
+ Details

Name: us-gaap_SummaryOfIncomeTaxContingenciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended

Dec. 01, 2018

USD ($)

Jun. 01, 2017

USD ($)

Feb. 01, 2012

USD ($)

Oct. 10, 2001

USD ($)

shares

Dec. 31, 2005

USD ($)

Feb. 28, 2019

USD ($)

May 31, 2019

USD ($)

Nov. 30, 2019

USD ($)

CompensationPlan

Unit

shares

Nov. 30, 2018

USD ($)

Debt Securities, Available-for-sale [Line Items]

ASC 606 adoption adjustment, net of tax $ 253,447

Cumulative effect on retained earnings, tax 94,192

Deferred revenue 32,508,511

Deferred revenue current 8,875,138

Warranty payment $ 100,000 $ 75,000 $ 50,000

Offset personal expenses 10,000

Commission paid 35,300

Capitalized contract acquisition costs, net of amortization expense $ 329,231

Cumulative amortization expense 66,533

Additional capitalized contract acquisition costs, net of amortization expense 87,518

Provisions for interest or penalties related to uncertain tax positions 0 $ 0

Uncertain tax provisions 0 0

Impairment on long lived assets $ 0 0

Number of employee stock based compensation plan | CompensationPlan 2

Unrealized holding gains, trading securities 28,000

Cumulative-effect adjustment from accumulated other comprehensive income to retained earnings $ 341,000

Unrealized holding gain (losses), marketable securities $ 28,000 300,000

Payment warranty $ 50,000

Increased payment warranty $ 100,000 75,000

Additional payment warranty $ 10,000

Stock compensation expense reversed $ 444,000

Stock compensation, number of shares opted to lump sum cash payment | shares 30,000

Impairment charges $ 2,332,763 $ 2,332,763

Concentration risk related to supplier The Company depends on one supplier for the source of its collection kits

Advertising cost included in selling, general and administrative expenses $ 981,448 986,664

Stock-based option compensation expense $ 398,000 $ 478,000

Deferred revenue recognition period 12 months

Employee Stock Incentive Plan [Member]

Debt Securities, Available-for-sale [Line Items]

Number of outstanding options excluded from computation of diluted earnings per share | shares 70,136

Saneron [Member]

Debt Securities, Available-for-sale [Line Items]

Ownership interest 33.00% 33.00%

Saneron [Member] | CCEL Bio-Therapies, Inc. [Member]

Debt Securities, Available-for-sale [Line Items]

Non-Controlling interest after merger 43.42%

Saneron Therapeutics, Inc. [Member] | CCEL Bio-Therapies, Inc. [Member]

Debt Securities, Available-for-sale [Line Items]

Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares 260,000

Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary $ 1,924,000

Saneron Therapeutics, Inc. [Member] | Stem Cell Preservation Technologies, Inc. [Member]

Debt Securities, Available-for-sale [Line Items]

Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares 195,000

Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary $ 3,900

Accounting Standards Update 2014-09 [Member]

Debt Securities, Available-for-sale [Line Items]

Incremental contract acquisition cost 329,231

Reversed incremental acquisition cost 18,408

ASC 606 adoption adjustment, net of tax 253,447

Cumulative effect on retained earnings, tax $ 94,192

Option One [Member]

Debt Securities, Available-for-sale [Line Items]

Contracted storage amortization period 21 years

Option Two [Member]

Debt Securities, Available-for-sale [Line Items]

Contracted storage amortization period 1 year

Option Three [Member]

Debt Securities, Available-for-sale [Line Items]

Contracted storage amortization period life-time

Contracted storage amortization description The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue

Accounts Receivables [Member]

Debt Securities, Available-for-sale [Line Items]

Period of doubtful for accounts receivable due from client 30 days

Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member]

Debt Securities, Available-for-sale [Line Items]

Inventory, in units | Unit 6,000

Number of units, per month | Unit 12

Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member] | Maximum [Member]

Debt Securities, Available-for-sale [Line Items]

Inventory, in units | Unit 144

X

- Definition
Additional payment warranty.
+ References
No definition available.
+ Details

Name: ccel_AdditionalPaymentWarranty

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Allocated share based compensation expenses reversed.
+ References
No definition available.
+ Details

Name: ccel_AllocatedShareBasedCompensationExpensesReversed

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Capitalized contract cost net incremental assets related to acquisition costs.
+ References
No definition available.
+ Details

Name: ccel_CapitalizedContractCostNetIncrementalAssetsRelatedToAcquisitionCosts

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cumulative effect adjustment from accumulated other comprehensive income to retained earnings.
+ References
No definition available.
+ Details

Name: ccel_CumulativeEffectAdjustmentFromAccumulatedOtherComprehensiveIncomeToRetainedEarnings

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Deferred Revenue Recognition Period.
+ References
No definition available.
+ Details

Name: ccel_DeferredRevenueRecognitionPeriod

Namespace Prefix: ccel_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Increase Decrease In Capitalized Contract Cost
+ References
No definition available.
+ Details

Name: ccel_IncreaseDecreaseInCapitalizedContractCost

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Increased payment warranty.
+ References
No definition available.
+ Details

Name: ccel_IncreasedPaymentWarranty

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of employee stock based compensation plan.
+ References
No definition available.
+ Details

Name: ccel_NumberOfEmployeeStockBasedCompensationPlan

Namespace Prefix: ccel_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Number Of Inventory Units
+ References
No definition available.
+ Details

Name: ccel_NumberOfInventoryUnits

Namespace Prefix: ccel_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of inventory units per month.
+ References
No definition available.
+ Details

Name: ccel_NumberOfInventoryUnitsPerMonth

Namespace Prefix: ccel_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Other current contract assets amortization periods.
+ References
No definition available.
+ Details

Name: ccel_OtherCurrentContractAssetsAmortizationPeriods

Namespace Prefix: ccel_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Payment warranty.
+ References
No definition available.
+ Details

Name: ccel_PaymentWarranty

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period for doubtful of accounts receivable due from client.
+ References
No definition available.
+ Details

Name: ccel_PeriodForDoubtfulOfAccountsReceivableDueFromClient

Namespace Prefix: ccel_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Reimbursement Of Personal Expenses
+ References
No definition available.
+ Details

Name: ccel_ReimbursementOfPersonalExpenses

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue Remaining Performance Obligation Next Twelve Months
+ References
No definition available.
+ Details

Name: ccel_RevenueRemainingPerformanceObligationNextTwelveMonths

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reversed incremental acquisition cost.
+ References
No definition available.
+ Details

Name: ccel_ReversedIncrementalAcquisitionCost

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Shares Settled For Cash In Period
+ References
No definition available.
+ Details

Name: ccel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesSettledForCashInPeriod

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848
+ Details

Name: us-gaap_AdvertisingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054
+ Details

Name: us-gaap_CapitalizedContractCostAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of method used for amortizing cost capitalized in obtaining or fulfilling contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 40
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131251-203054
+ Details

Name: us-gaap_CapitalizedContractCostAmortizationMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 40
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131251-203054
+ Details

Name: us-gaap_CapitalizedContractCostAmortizationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054
+ Details

Name: us-gaap_CapitalizedContractCostNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Description of risks that arise due to the volume of business transacted with a particular supplier or reliance placed on that supplier. At a minimum, the description informs financial statement users of the general nature of the risk.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99380358&loc=d3e7102-108593

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592
+ Details

Name: us-gaap_ConcentrationRiskSupplier

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cumulative effect on retained earnings net of related income tax effect.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794
+ Details

Name: us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the related income tax effect of a cumulative effect on retained earnings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794
+ Details

Name: us-gaap_CumulativeEffectOnRetainedEarningsTax1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 220
-Section 45
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount recognized for uncertainty in income taxes classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilityForUncertainTaxPositionsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).
+ References
No definition available.
+ Details

Name: us-gaap_MarketableSecuritiesGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph ((c)(2))
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249
+ Details

Name: us-gaap_ProductWarrantyAccrualPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SalesCommissionsAndFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28511-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28446-109314
+ Details

Name: us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrealized holding gain (loss) recognized in the income statement for investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.
+ References
No definition available.
+ Details

Name: us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_OwnershipAxis=ccel_SaneronMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ccel_BioTherapiesIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=ccel_SaneronTherapeuticsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=ccel_StemCellPreservationTechnologiesincMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedContractCostAxis=ccel_OptionOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedContractCostAxis=ccel_OptionTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedContractCostAxis=ccel_OptionThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=ccel_UmbilicalCordBloodAndCordTissueStemCellServiceAndPrepacytecbMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=ccel_DukeUniversityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Accured Expenses
12 Months Ended

Nov. 30, 2019

Payables and Accruals [Abstract]

Accured Expenses
NOTE 9—ACCRUED EXPENSES
Accrued expenses are as follows:


November 30,


2019

2018

Professional fees
   $ 115,000    $ 14,867
Payroll and payroll taxes (1)
   513,108    1,021,004
Interest expense
   950,300    864,676
General expenses
   330,726    478,449
Federal and state taxes
   176,046    323,792




   $ 2,085,180    $ 2,702,788




(1)
– Payroll and payroll taxes includes accrued vacation and wages due as of November 30, 2019 and November 30, 2018.

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Statements of Comprehensive Income (Loss) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Revenue $ 31,816,571 $ 29,218,490

Costs and Expenses:

Cost of sales 10,036,175 8,539,662

Selling, general and administrative expenses 14,891,462 15,632,696

Impairment of public inventory 2,332,763

Change in fair value of contingent consideration (742,918) (415,280)

Research, development and related engineering 30,145 91,845

Depreciation and amortization 206,238 180,264

Total costs and expenses 26,753,865 24,029,187

Operating Income 5,062,706 5,189,303

Other Expense:

Other income (expense) 32,155 (24,723)

Interest expense (1,703,446) (1,546,900)

Total other expense (1,671,291) (1,571,623)

Income before income tax expense 3,391,415 3,617,680

Income tax expense (1,100,641) (4,472,504)

Net Income (Loss) $ 2,290,774 $ (854,824)

Net income (loss) per common share—basic $ 0.29 $ (0.11)

Weighted average common shares outstanding—basic 7,794,828 7,463,051

Net income (loss) per common share—diluted $ 0.27 $ (0.11)

Weighted average common shares outstanding—diluted 8,412,414 7,463,051

Other Comprehensive Income

Unrealized gain on marketable securities (net of tax) $ 0 $ 300,119

Comprehensive Income (Loss) 2,290,774 (554,705)

Processing and Storage Fees [Member]

Revenue 29,991,972 27,817,872

Public Banking [Member]

Revenue 652,204 296,295

Licensee and royalty income [Member]

Revenue 1,000,000 1,000,000

Product [Member]

Revenue $ 172,395 $ 104,323

X

- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=ccel_ProcessingAndStorageFeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=ccel_PublicBankingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=ccel_LicenseeAndRoyaltyIncomeRecognitionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note Payable
12 Months Ended

Nov. 30, 2019

Debt Disclosure [Abstract]

Note Payable
Note 5– Note Payable
On May 20, 2016, the Company entered into a Credit Agreement (“Agreement”) with Texas Capital Bank, National Association (“TCB”) for a term loan of $8.0 million in senior credit facilities. The proceeds of the term loan were used by the Company to fund repurchases of the Company’s common stock. Subject to the terms of the Agreement, on May 20, 2016, TCB advanced the Company $100.00. On July 1, 2016, TCB advanced the remaining principal amount of $7,999,900 per a promissory note dated May 20, 2016 between the Company and TCB, at a rate of 3.75% per annum plus LIBOR, payable monthly with a maturity date of July 2021. On August 26, 2016, the Company entered into a First Amendment to Credit Agreement with TCB. Pursuant to terms of the First Amendment to Credit Agreement, on August 26, 2016, TCB made an additional advance to the Company in principal amount of $2,133,433 per an Amended and Restated Promissory Note dated August 26, 2016 between the Company and TCB. The additional proceeds of the term loan were used by the Company to fund the extinguishment of revenue sharing agreements. On June 11, 2018, the Company entered into a Second Amendment to Credit Agreement with TCB. Pursuant to the terms of the Second Amendment to Credit Agreement, TCB increased the current outstanding principal amount of the loan from TCB by $9,000,000 to finance a portion of the purchase price of the Cord:Use Purchase. In connection therewith, Cryo-Cell executed and delivered to TCB a Second Amended and Restated Promissory Note, in the principal amount of $15,500,000. As of November 30, 2019, and November 30, 2018, the Company paid interest of $646,744 and $589,583, respectively, which is reflected in interest expense on the accompanying consolidated statements of comprehensive income (loss).
Collateral of the term and subordinated loans includes all money, securities and property of the Company.
The Company incurred debt issuance costs related to the term and subordinated loans in the amount of $548,085 which is recorded as a direct reduction of the carrying amount of the note payable and amortized over the life of the loan. As of November 30, 2019, and November 30, 2018, $112,642 and $109,293, respectively, of the debt issuance costs were amortized and are reflected in interest expense on the accompanying consolidated statements of comprehensive income (loss).
As of November 30, 2019, and November 30, 2018, the note payable obligation was as follows:

   November 30,
2019    November 30,
2018
Note payable
   $ 9,108,433    $ 13,208,433
Unamortized debt issuance costs
   (152,281 )    (264,923 )




Net note payable
   $ 8,956,152    $ 12,943,510




Current portion of note payable
   $ 3,100,000    $ 3,100,000
Long-term note payable, net of debt issuance costs
   5,856,152    9,843,510




Total
   $ 8,956,152    $ 12,943,510




Future principal payments under the note payable obligation are as follows:

Years ending November 30:
   Amount
2020
   3,100,000
2021
   3,100,000
2022
   2,908,433


Total
   $ 9,108,433


Interest expense on the note payable for the years ended November 30, 2019 and November 30, 2018 was as follows:

   November 30,
2019    November 30,
2018
Interest expense on notes payable
   $ 646,744    $ 589,583
Debt issuance costs
   112,642    109,293




Total interest expense
   $ 759,386    $ 698,876




X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Description of Business, Basis of Presentation and Significant Accounting Policies
12 Months Ended

Nov. 30, 2019

Accounting Policies [Abstract]

Description of Business, Basis of Presentation and Significant Accounting Policies
NOTE 1 – DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business.
Cryo-Cell International, Inc. (“the Company” or “Cryo-Cell”) was incorporated in Delaware on September 11, 1989 and is headquartered in Oldsmar, Florida. The Company is organized in three reportable segments, cellular processing and cryogenic cellular storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use, the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Revenues for the cellular processing and cryogenic cellular storage represent sales of the umbilical cord blood stem cells program to customers and income from licensees selling the umbilical cord blood stem cells program to customers outside the United States. Revenues for the manufacture of PrepaCyte CB units represent sales of the PrepaCyte CB units to customers. Revenue for the cryogenic storage of umbilical cord blood stem cells for public use, stored at Duke University (see below), is generated from the sale of the cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States and around the world. The Company’s headquarters facility in Oldsmar, Florida handles all aspects of its U.S.-based business operations including the processing and storage of specimens, including specimens obtained from certain of its licensees’ customers. The specimens are stored in commercially available cryogenic storage equipment.
On October 10, 2001, Saneron Therapeutics, Inc. merged into one of the Company’s wholly owned subsidiaries, CCEL
Bio-Therapies,
Inc. (”CCBT”), which then changed its name to Saneron CCEL Therapeutics, Inc. (“SCTI” or ”Saneron”). As part of the merger, the Company contributed 260,000 shares of its common stock, whose fair value was $1,924,000 and 195,000 common shares of another of its subsidiaries, Stem Cell Preservation Technologies, Inc., whose fair value was $3,900. At the conclusion of the merger, the Company retained a 43.42%
non-controlling
interest in the voting stock of SCTI. As of November 30, 2019 and 2018, the Company had an interest of approximately 33% in the voting stock of SCTI. The accompanying consolidated financial statements as of November 30, 2019 and 2018 reflect the investment in SCTI under the equity method of accounting.

Basis of Presentation
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.
The accompanying consolidated financial statements as of November 30, 2019 and November 30, 2018 and for the years then ended includes the accounts of the Company and all of its subsidiaries, which are inactive. All intercompany balances have been eliminated upon consolidation.

Concentration of Risks
Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit. The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.

The Company depends on one supplier for the source of its collection kits, a critical component of the umbilical cord blood stem cell collection process. However, the Company believes that alternative sources of supply are available.
The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units. However, the Company believes that alternative sources of supply and manufacturing are available.
The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for transplant.
During fiscal 2019 and 2018, there were no concentration of risks.

Use of Estimates
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition
Effective December 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. The Company recognized the cumulative effect of applying the new revenue standard to all contracts with customers that were not completed as of December 1, 2018 as an adjustment to the opening balance of stockholders’ deficit at the beginning of fiscal year 2019. The reported results for 2019 reflect the application of ASC 606 guidance while the reported results for 2018 were prepared under the guidance of ASC 605,
Revenue Recognition
(ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. ASC 606 also requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.
The adoption of ASC 606 did not have an impact on the amount of reported revenues with respect to the Company’s product or service revenues. In connection with the adoption of ASC 606, the Company is required to capitalize certain contract acquisition costs consisting primarily of commissions paid when contracts are signed and amortize these costs on a systematic basis, consistent with the pattern of transfer of the storage services provided over time for which the asset relates. As of December 1, 2018, the Company capitalized in deposits and other assets, net, $329,231 in incremental contract acquisition costs related to sales commissions on prepaid storage contracts and reversed $18,408 of its variable consideration that the Company determined to be fully constrained, with a corresponding change in the opening balance of stockholders’ deficit of $253,447, net of tax, of $94,192.
Under ASC 606, revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised services are transferred to the customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring services to a customer (“transaction price”).

At contract inception, if the contract is determined to be within the scope of ASC 606, the Company evaluates its contracts with customers using the five-step model: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to separate performance obligations; and (5) recognize revenue when (or as) each performance obligation is satisfied. The Company evaluates its contracts for legal enforceability at contract inception and subsequently throughout the Company’s relationship with its customers. If legal enforceability with regards to the rights and obligations exist for both the Company and the customer, then the Company has an enforceable contract and revenue recognition is permitted subject to the satisfaction of the other criteria. If, at the outset of an arrangement, the Company determines that a contract with enforceable rights and obligations does not exist, revenues are deferred until all criteria for an enforceable contract are met. The Company only applies the five-step model to contracts when it is probable that collection of the consideration that the Company is entitled to in exchange for the goods or services being transferred to the customer, will occur.
Contract modifications exist when the modification either creates new or changes in the existing enforceable rights and obligations. The Company’s contracts are occasionally modified to account for changes in contract terms and conditions, which the Company refers to as an upgrade or downgrade. An upgrade occurs when a customer wants to pay for additional years of storage. A downgrade occurs when a customer originally entered into a long-term contract (such as
twenty-one
year or life-time plan) but would like to change the term to a
one-year
contract. Upgrade modifications qualify for treatment as a separate contract as the additional services are distinct and the increase in contract price reflects the Company’s stand-alone selling price for the additional services and will be accounted for on a prospective basis. Downgrade modifications do not qualify for treatment as a separate contract as there is no increase in price over the original contract, thus failing the separate contract criteria. As such, the Company separately considers downgrade modifications to determine if these should be accounted for as a termination of the existing contract and creation of a new contract (prospective method) or as part of the existing contract (cumulative
catch-up
adjustment). ASC 606 requires that an entity account for the contract modification as if it were a termination of the existing contract, and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. As the services after the modification were previously determined to be distinct, the Company concluded that downgrade modifications qualify under this method and will be accounted for on a prospective basis. Although contract modifications do occur, they are infrequent.
Performance Obligations
At contract inception, the Company assesses the goods and services promised in the contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good or service (or bundle of goods or services) that is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. The Company determined that the following distinct goods and services represent separate performance obligations involving the sale of its umbilical cord blood product:

•
Collection and processing services

•
Storage services

•
Public cord blood banking

•
License and royalties

•
Sale of PrepaCyte CB product

a
)
Processing
Processing and storage fees include the Company providing umbilical cord blood and tissue cellular processing and cryogenic cellular storage for private use. Revenues recognized for the cellular processing and cryogenic cellular storage represent sales of the umbilical cord blood stem cells program to customers and income from licensees who are selling the umbilical cord blood stem cells program to customers outside the United States.
The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period as well as other income from royalties paid by licensees related to long-term storage contracts which the Company has under license agreements. Contracted storage periods are
annual, twenty-one
years and life-time. The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual, the
twenty-one-year
and the life-time storage fees that are being recognized over the contractual storage period as well as royalties received from foreign licensees relating to long-term storage contracts for which the Company has future obligations under the license agreement. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.
Significant financing
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. For all plans being
annual, twenty-one years
and life-time, the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans (including a stated service fee) for customers to pay over time for a period of one to twenty-four plus months. The
one-time
plan includes the collection kit, processing and testing, return medical courier service and
twenty-one
years of
pre-paid
storage fees. The life-time plan includes the collection kit, processing and testing, return medical courier service and
pre-paid
storage fees for the life of the customer. The Company concluded that a significant financing component is not present within either the prepaid or overtime payment plans. The Company has determined that the
twenty-one
year and life-time prepayment options do not include a significant financing component as the payment terms were structured primarily for reasons other than the provision of financing and to maximize profitability.
The Company has determined that the majority of plans that are paid over time are paid in less than a year. When considered over a twenty-four-month payment plan, the difference between the cash selling price and the consideration paid is nominal. As such, the Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when considered in the context of all contracts entered into nor significant at the individual contract level.
The Company elected to apply the practical expedient where the Company does not need to assess whether a significant financing component exists if the period between when it performs its obligations under the contract and when the customer pays is one year or less.
As of November 30, 201
9
, the total aggregate transaction price allocated to the unsatisfied performance obligations was recorded as deferred revenue amounting to $32,508,511, which will be recognized ratably on a straight-line basis over the contractual period of which $8,875,138 will be recognized over the next twelve months.

Variable consideration
In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. In the processing and storage agreements, the Company provides limited rights which are offered to customers automatically upon contract execution. The Company has determined that the payment warranty represents variable consideration payable to the customer.
Based on the Company’s historical experience to date, the Company has determined the payment warranty to be fully constrained under the most likely amount method. Consequently, the transaction price does not currently reflect any expectation of service level credits.    At the end of each reporting period, the Company will update the estimated transaction price related to the payment warranty including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.
Allocation of transaction price
As the Company’s processing and storage agreements contain multiple performance obligations, ASC 606 requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the stand-alone selling prices of the processing services and storage services and concluded that the published list price is the price that a customer in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage.

Costs to Obtain a Contract
Prior to the adoption of ASC 606, the Company expensed in the period, all commissions paid to its internal and external sales representatives the Company employs and to its customers for generating new contracts.

With the adoption of ASC 606 as of December 1, 2018, the Company capitalizes commissions that are incremental in obtaining customer contracts and the costs incurred to fulfill a customer contract if those costs are not within the scope of another topic within the accounting literature and meet the specified criteria. These costs are deferred in other current or long-term assets and are expensed to selling, general and administrative expenses as the Company satisfies the performance obligations by transferring the service to the customer. These assets will be periodically assessed for impairment. As a practical expedient, the Company elected to recognize the incremental costs of obtaining its annual contracts as an expense when incurred, as the amortization period of the asset recognized would have been one year.
The Company has determined that payments under the Company’s
refer-a-friend
program (“RAF program”) are incremental costs of obtaining a contract as they provide an incentive for existing customers to refer new customers to the Company and is referred to as commission. The amount paid under the RAF program (either through issuance of credits to customers or check payments) which exceeds the typical commission payment to a sales representative is recorded as a reduction to revenue under ASC 606. During the twelve months ended November 30, 2019, the Company recorded $35,300, in commission payments to customers under the RAF program as a reduction to revenue. As of December 1, 2018, the Company capitalized $329,231 in incremental contract acquisition costs related to contracts that were not completed, net of the cumulative amortization expense of $66,533 through the adoption date. The Company did not record any impairment losses in relation to costs capitalized. For the twelve months ended November 30, 2019, the Company capitalized additional contract acquisition costs of $87,518, net of amortization expense.

b
)
Public banking revenue
The Company sells and provides units not likely to be of therapeutic use for research to qualified organizations and companies operating under Institutional Review Board approval. Control is transferred at the point in time when the shipment has occurred, at which time, the Company records revenue.

c
)
Licensee and royalty income
Licensee and royalty income consist of royalty income earned on the processing and storage of cord blood stem cell specimens by an affiliate where the Company has a License and Royalty Agreement. The Company records revenue from processing and storage of specimens and pursuant to agreements with licensees. The Company records the royalty revenue in same period that the related processing and storage is being completed by the affiliate.

d
)
Product Revenue
The Company records revenue from the sale of the PrepaCyte CB product line upon shipment of the product to the Company’s customers.
e
)
Shipping and handling
The Company elected to apply the practical expedient to account for shipping and handling activities performed after the control of a good has been transferred to the customer as a fulfillment cost. Shipping and handling costs that the Company incurs are therefore expensed and included in cost of sales.
The adoption of ASC 606 did not have an impact on the timing of revenue recognition for any of the Company’s revenue streams.
Disaggregation of Revenue

The following table provides information about disaggregated revenue by products and services:

   Twelve months ended
   November 30, 2019    November 30, 2018
Processing and storage fees
   $ 29,991,972    $ 27,817,872
Public banking revenue
   652,204    296,295
Licensee and royalty income
   1,000,000    1,000,000
Product revenue
   172,395    104,323




   $ 31,816,571    $ 29,218,490




The following table provides information about assets and liabilities from contracts with customers:

   November 30, 2019    At Adoption
Contract assets (sales commissions)
   $ 398,535    $ 329,231
Accounts receivables
   $ 6,097,331    $ 5,867,335
Short-term contract liabilities (deferred revenue)
   $ 8,875,138    $ 8,365,284
Long-term contract liabilities (deferred revenue)
   $ 23,633,373    $ 20,317,231
The Company, in general, requires the customer to pay for processing and storage services at the time of processing. Contract assets include deferred contract acquisition costs, which will be amortized along with the associated revenue. Contract liabilities include payments received in advance of performance under the contract and are realized with the associated revenue recognized under the contract. Accounts receivable consists of amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs related to renewals of annual plans and amounts due from license affiliates, and sublicensee territories. The Company did not have asset impairment charges related to contract assets in the twelve
months
ended November 30, 2019.
The following table presents changes in the Company’s contract assets and liabilities during the twelve months ended November 30, 2019:

   Balance at
December 1, 2018    Additions    Deductions    Balance at
November 30,

2019
Contract assets (sales commissions)
   $ 329,231    $ 88,569    ($ 19,265 )    $ 398,535
Accounts receivables
   $ 5,867,335    $ 36,579,504    ($ 36,349,508 )    $ 6,097,331
Contract liabilities (deferred revenue)
   $ 28,682,515    $ 18,759,963    ($ 14,933,967 )    $ 32,508,511

Revenue Sharing Agreements
The Company entered into Revenue Sharing Agreements (“RSAs”) prior to 2002 with various third and related parties. The Company’s RSAs provide that in exchange for a
non-refundable

up-front
payment, the Company would share for the duration of the contract a percentage of its future storage revenue collected from the annual storage fees charged related to a certain number of specimens that originated from specific geographical areas. The RSAs have no definitive term or termination provisions. The sharing applies to the storage fees collected for all specified specimens in the area up to the number covered in the contract. When the number of specimens is filled, any additional specimens stored in that area are not subject to revenue sharing. As there are empty spaces resulting from attrition, the Company agrees to fill them as soon as possible. The Company has reflected these
up-front
payments as long-term liabilities on the accompanying consolidated balance sheets. The Company does not intend to enter into additional RSAs.
In the future, the Company could reverse the liability relating to the RSAs over an appropriate period of time, based on the Company’s expectations of the total amount of payments it expects to pay to the other party under the particular RSA. However, the RSAs do not establish a finite term or time frame over which to estimate the total payments and the Company had not previously estimated and has concluded that it is not currently practicable to estimate the projected cash flows under the RSAs. At present, the Company intends to defer the reversal of the liability, until such time as these amounts can
be determined. During the periods when the Company defers the reversal of the liability, the quarterly payments made during these periods will be treated as interest expense, which will be recognized as the payments become due. In future periods, if a portion of the liability can be
de-recognized
based on the effective interest method, the payments will be allocated between interest and amortization of the liability. As cash is paid out to the other party during any period, the liability would be
de-recognized
based on the portion of the total anticipated payouts made during the period, using the effective interest method. That is, a portion of the payment would be recorded as interest expense, and the remainder would be treated as repayment of principal, which would reduce the liability.

License and Royalty Agreements
The Company has entered into licensing agreements with certain investors in various international markets in an attempt to capitalize on the Company’s technology. The investors typically pay a licensing fee to receive Company marketing programs, technology and
know-how
in a selected area. The investor may be given a right to sell
sub-license
agreements as well. As part of the accounting for the
up-front
license fee paid, or payable, to the Company, revenue from the
up-front
license fee is recognized based on such factors as when the payment is due, collectability and when all material services or conditions relating to the sale have been substantially performed by the Company based on the terms of the agreement. The Company has twelve active licensing agreements. The following areas each have one license agreement: El Salvador, Guatemala, Panama, Honduras, China and Pakistan. The following areas each have two license agreements: India, Nicaragua and Costa Rica.
In addition to the license fee, the Company earns processing and storage fees on subsequent processing and storage revenues received by the licensee in the licensed territory and a fee on any
sub-license
agreements that are sold by the licensee where applicable. These fees are included in processing and storage fees revenue on the consolidated statements of comprehensive income (loss). As part of the accounting for royalty revenue from India, the Company uses estimates and judgments based on historical processing and storage volume in determining the timing and amount of royalty revenue to recognize. The Company periodically reviews license and royalty receivables for collectability and, if necessary, will record an expense for an allowance for uncollectible accounts.

Cash and Cash Equivalents
Cash and cash equivalents consist of highly liquid investments with a maturity date of three months or less at the time of purchase.

Accounts Receivable
Accounts receivable consist of uncollateralized amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs and amounts due from license affiliates, and sublicensee territories. Accounts receivable are due within 30 days and are stated at amounts net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering the length of time accounts receivable are past due, the Company’s previous loss history, and the client’s current ability to pay its obligations. Therefore, if the financial condition of the Company’s clients were to deteriorate beyond the estimates, the Company may have to increase the allowance for doubtful accounts which could have a negative impact on earnings. The Company
writes-off
accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.

Inventory

As part of the Asset Purchase Agreement, (see Note 2), the Company has an agreement with Duke University (“Duke”) expiring on January 31, 2025 for Duke to receive, process, and store cord blood units for the Public Cord Blood Bank (“Duke Services”). As of November 30, 2019, the Company had approximately 6,000 cord blood units in inventory. These units are valued at the lower of cost or net realizable value. Costs include the cost of collecting, transporting, processing and storing the unit. Costs charged by Duke for their Duke Services are based on a monthly fixed fee for processing and storing 12 blood units per month. The Company computes the cost per unit for these Duke Services and capitalizes the unit cost on all blood units shipped and stored in a year at Duke. If the Company ships and stores less than 144 blood units with Duke in a
one-year
period, a portion of these fixed costs are expensed and included in facility operating costs. Certain costs of collection incurred, such as the cost of collection staff and transportation costs incurred to ship Public Bank units from hospitals to the stem cell laboratory are allocated to banked units based on an average cost method. The change in the number of expected units to be sold could have a significant impact on the estimated net realizable value of banked units which could have a material effect on the value of the inventory. Costs incurred related to cord blood units that cannot be sold are expensed in the period incurred and are included in facility operating costs in the accompanying statements of operations. The Company records a reserve against inventory for units which have been processed and frozen but may not ultimately become distributable (see Note 3). Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of
$
2,332,763
was recognized during the second quarter of fiscal
2019
to reduce inventory from cost to net realizable value and is included in the accompanying consolidated statements of comprehensive income (loss).

Property and Equipment
Property and equipment are stated at cost. Depreciation is provided primarily by the straight-line method over the estimated useful lives of the related assets. Estimated useful lives of property and equipment are as follows:

Furniture and equipment
3-10
years

Leasehold improvements    Lesser of
8-10
years or the lives of the leases

Computer software – internal use
1-5
years

Leasehold improvements are amortized over the shorter of the respective life of the lease or the estimated useful lives of the improvements. Upon the sale or retirement of depreciable assets, the cost and related accumulated depreciation is removed from the accounts and the resulting profit or loss is reflected in earnings. Expenditures for maintenance, repairs and minor betterments are expensed as incurred.
The Company capitalizes external direct costs of materials and services consumed in developing or obtaining
internal-use
computer software. Capitalized
internal-use
software costs, which are included in property and equipment, are depreciated over the estimated useful lives of the software.

Long-Lived Assets
The Company evaluates the realizability of its long-lived assets, which requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment, such as reductions in demand or when significant economic slowdowns are present. Reviews are performed to determine whether the carrying value of an asset is impaired, based on comparisons to undiscounted expected future cash flows. If this comparison indicates that there is impairment and carrying value is in excess of fair value, the impaired asset is written down to fair value, which is typically calculated using: (i) quoted market prices or (ii) discounted expected future cash flows utilizing a discount rate. The Company did not
note any indicators of impairment as of November 30, 2019 and November 30, 2018, respectively.

Goodwill
Goodwill represents the excess of the purchase price of the assets acquired from Cord:Use (Note 2) over the estimated fair value of the net tangible, intangible and identifiable assets acquired. The annual assessment of the reporting unit is performed as of September 1st, and an assessment is performed at other times if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below its carrying value. The Company first performs a qualitative assessment to test goodwill for impairment and concludes if it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment concludes that it is not more likely than not that the fair value is less than the carrying value, the
two-step
goodwill impairment test is not required. If the qualitative assessment concludes that it is more likely than not that the fair value of the reporting unit is less than the carrying value, then the
two-step
goodwill impairment test is required. Step one of the impairment assessment compares the fair value of the reporting unit to its carrying value and if the fair value exceeds its carrying value, goodwill is not impaired. If the carrying value exceeds the fair value, the implied fair value of goodwill is compared to the carrying value of goodwill. If the implied fair value exceeds the carrying value then goodwill is not impaired; otherwise, an impairment loss would be recorded by the amount the carrying value exceeds the implied fair value.

Income Taxes

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be recovered or settled. The Company records a valuation allowance when it is “more likely than not” that all of the future income tax benefits will not be realized. When the Company changes its determination as to the amount of deferred income tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to income tax expense in the period in which such determination is made. The ultimate realization of the Company’s deferred income tax assets depends upon generating sufficient taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, the Company projects future levels of taxable income. This assessment requires significant judgment. The Company examines the evidence related to the recent history of losses, the economic conditions in which the Company operates and forecasts and projections to make that determination.
The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the
more-likely-than-not
threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from management’s belief that a position can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions.
The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. For fiscal 2019 and 2018 the Company had no uncertain tax provisions and therefore no material provisions for interest or penalties related to uncertain tax positions.

Research, Development and Related Engineering Costs
Research, development and related engineering costs are expensed as incurred.

Cost of Sales
Cost of sales represents the associated expenses resulting from the processing, testing, storage and delivery of the umbilical cord blood. Cost of sales related to PrepaCyte CB represents the associated expenses resulting from the manufacturing of the PrepaCyte CB units. Cost of sales related to the Public Cord Blood Bank represents the associated expenses resulting from the collection, shipping, processing and storage of the cord blood stem cell units.

Advertising
Advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). Total advertising expense for the fiscal years ended November 30, 2019 and 2018 was approximately $981,448 and $986,664, respectively.

Rent Expense
Rent is expensed on a straight-line basis over the term of the lease and is included in cost of sales and selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). All leases include provisions for escalations and related costs.

Legal Expense
Legal fees are expensed as incurred and are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss).

Fair Value of Financial Instruments
Management uses a fair value hierarchy, which gives the highest priority to quoted prices in active markets. The fair value of financial instruments is estimated based on market trading information, where available. Absent published market values for an instrument or other assets, management uses observable market data to arrive at its estimates of fair value. Management believes that the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments. The Company believes that the fair value of its Revenue Sharing Agreements (”RSA”) liability recorded on the balance sheet is between the recorded book value and up to the Company’s previous settlement experience, due to the various terms and conditions associated with each RSA.
The Company uses an accounting standard that defines fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The three levels of inputs used to measure fair value are as follows:

Level 1

Quoted prices in active markets for identical assets or liabilities.

Level 2

Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of November 30, 2019 and November 30, 2018, respectively, segregated among the appropriate levels within the fair value hierarchy:


Fair Value at
   at November 30, 2019 Using
Description
   November 30,
2019    Level 1    Level 2    Level 3
Assets:

Marketable securities
   $ 904,053    $ 904,053    —    —








Total
   $ 904,053    $ 904,053    —    —








Liabilities:

Contingent consideration
   $ 3,495,057    $ —    —    $ 3,495,057








Total
   $ 3,495,057    $ —    —    $ 3,495,057








Contingent Consideration:

Beginning Balance as of November 30, 2018
   $ 4,282,975
Subtractions – Cord:Use earnout payment
   (45,000 )
Fair value adjustment as of November 30, 2019
   (742,918 )



Ending balance as of November 30, 2019
   $ 3,495,057




Fair Value at
   Fair Value Measurements
at November 30, 2018 Using
Description
   November 30,
2018    Level 1    Level 2    Level 3
Assets:

Trading securities
   $ 68,816    $ 68,816    —      —
Available-for-sale
securities
   806,873    806,873    —      —








Total
   $ 875,689    $ 875,689    —      —








Liabilities:

Contingent consideration
   $ 4,282,975    $ —      —      $ 4,282,975








Total
   $ 4,282,975    $ —      —      $ 4,282,975








The following is a description of the valuation techniques used for these items, as well as the general classification of such items pursuant to the fair value hierarchy:
Trading securities –
Fair values for these investments are based on quoted prices of identical securities in active markets and are therefore classified within Level 1 of the fair value hierarchy. For trading securities, there was approximately ($28,000) in unrealized holding losses, respectively, recorded in other income and expense on the accompanying consolidated statements of comprehensive income (loss) for the twelve months ended November 30, 2018.
Available-for-sale
securities –
These investments are classified as available for sale and consist of marketable equity securities that we intend to hold for an indefinite period of time. Investments are stated at fair value and unrealized holding gains and losses are reported as a component of accumulated other comprehensive income until realized. Realized gains or losses on disposition of investments are computed using the first in, first out (FIFO) method and reported as income or loss in the period of disposition in the accompanying consolidated statements of comprehensive income (loss). For
available-for-sale
securities, there was approximately $300,000 in unrealized holding gains (loss), net of tax, respectively, reported as comprehensive income on the accompanying statements of comprehensive income (loss) for the year ended November 30, 2018.
Marketable securities
- Effective December 1, 2018, the Company adopted ASU
2016-01,
which requires equity securities with readily determinable fair values to be measured at fair value with the changes in fair value recognized through net income. Such securities are no longer reflected as trading or
available-for-sale
but are noted as marketable securities. As a result of this accounting change, in the first quarter of 2019, the Company recognized a cumulative-effect adjustment from accumulated other comprehensive income to retained earnings of approximately $341,000 in the consolidated statements of stockholders’ deficit as of the date of adoption. Prior periods have not been restated for the impact of this accounting change. There was $28,000 in unrealized holding gain recorded in other income and expense on the accompanying consolidated statements of comprehensive income (loss) for the twelve months ended November 30, 2019.
Contingent consideration -
The contingent consideration is the earnout that Cord:Use is entitled to from the Company’s sale of the public cord blood inventory from and after closing. See Note 2. The estimated fair value of the contingent earnout was determined using a monte carlo analysis examining the frequency and mean value of the resulting earnout payments. The resulting value captures the risk associated with the form of the payout structure. The risk-neutral method is applied, resulting in a value that captures the risk associated with the form of the payout structure and the projection risk. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different from the estimated value of the liability.

Product Warranty and Cryo-Cell Cares
TM
Program
In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.
As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. Upon the adoption of ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits at November 30, 2019. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.

Income (Loss) per Common Share
Basic income (loss) per common share was computed by dividing net income by the weighted average number of common shares outstanding for the fiscal year ended or as of the date indicated. Diluted income per common share includes the effect of all dilutive stock options. The composition of basic and diluted net (loss) income per share is as follows:

   November 30, 2019    November 30, 2018
Numerator:

Net income (loss)
   $ 2,290,774    ($ 854,824 )
Denominator:

Weighted-average shares outstanding-basic
   7,794,828    7,463,051
Dilutive common shares issuable upon exercise of stock options
   617,586    —




Weighted-average shares-diluted
   8,412,414    7,463,051




Income(Loss) per share:

Basic
   $ 0.29    ($ 0.11 )




Diluted
   $ 0.27    ($ 0.11 )




For the year ended November 30, 2019, the Company excluded the effect of 70,136 outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.
For the year ended November 30, 2018, the Company excluded the effect of all outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.

Stock Compensation
As of November 30, 201
9
, the Company has two stock-based employee compensation plans, which are described in Note 11 to the consolidated financial statements. The Company’s stock-based employee compensation plan became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting. The Company recognized approximately $398,000 and $478,000 for the fiscal years ended November 30, 2019 and November 30, 2018, respectively, of stock compensation expense. The Company reversed $444,000 of stock compensation expense during the twelve months ended November 30, 2018 as the
Co-CEOs
each opted to receive a lump sum cash payment in lieu of 30,000 shares of earned common stock pursuant to the terms of their Employment Agreements. The reversal had no impact on the accompanying consolidated statements of comprehensive income (loss) as other compensation expense was recognized to offset the reversal.
The Company recognizes stock-based compensation based on the fair value of the related awards. Under the fair value recognition guidance of stock-based compensation accounting rules, stock-based compensation expense is estimated at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the award. The fair value of service-based vesting condition and performance-based vesting condition stock option awards is determined using the Black-Scholes valuation model. For stock option awards with only service-based vesting conditions and graded vesting features, the Company recognizes stock compensation expense based on the graded-vesting method. To value awards with market-based vesting conditions the Company uses a binomial valuation model. The Company recognizes compensation cost for awards with market-based vesting conditions on a graded-vesting basis over the derived service period calculated by the binomial valuation model. The use of these valuation models involves assumptions that are judgmental and highly sensitive in the determination of compensation expense and include the expected life of the option, stock price volatility, risk-free interest rate, dividend yield, exercise price, and forfeiture rate. Forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period.
The estimation of stock awards that will ultimately vest requires judgment and to the extent that actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period they become known. The Company considered many factors when estimating forfeitures, including the recipient groups and historical experience. Actual results and future changes in estimates may differ substantially from current estimates.
The Company issues performance-based equity awards which vest upon the achievement of certain financial performance goals, including revenue and income targets. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the required performance targets and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance goals are not met, the award does not vest, so no compensation cost is recognized and any previously stock-recognized stock-based compensation expense is reversed.
The Company issues equity awards with market-based vesting conditions which vest upon the achievement of certain stock price targets. If the awards are forfeited prior to the completion of the derived service period, any recognized compensation is reversed. If the awards are forfeited after the completion of the derived service period, the compensation cost is not reversed, even if the awards never vest.

Reclassifications
Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no
material
effect on the reported results of operations.

Recently Issued Accounting Pronouncements
In August 2018, the FASB issued Accounting Standards Update
No. 2018-15,

Intangibles – Goodwill and Other
Internal-Use
Software (Topic
350-40):
Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.
This update addresses how a customer should account for the costs of implementing a cloud computing service arrangement (also referred to as a “hosting arrangement”). Entities should account for costs associated with implementing a cloud computing arrangement that is considered a service contract in the same way as accounting for implementation costs incurred to develop or obtain software for internal use using the guidance in Topic
350-40.
The amendments address when costs should be capitalized rather than expensed, the term to use when amortizing capitalized costs, and how to evaluate the unamortized portion of these capitalized implementation costs for impairment. The ASU also includes guidance on how to present implementation costs in the financial statements and creates additional disclosure requirements. The guidance is effective for annual periods beginning after December 15, 2019, and interim periods within that reporting period. The Company is currently evaluating the effect that the updated standard will have on our financial statements.
In June 2018, the FASB issued Accounting Standards Update
No. 2018-07,

Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.
This update simplifies the accounting for nonemployee share-based payment transactions by expanding the scope of Topic 718, Compensation-Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within that reporting period. The Company is currently evaluating the effect that the updated standard will have on our financial statements.
In January 2017, the FASB issued Accounting Standards Update
No. 2017-04,

Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment
. The update removes Step 2 from the goodwill impairment test. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, although early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on our financial statements.
In February 2016, the FASB issued Accounting Standards Update
No. 2016-02,

Leases (Topic 842).
This update requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. It also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on its consolidated balance sheets and related disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Inventory (Tables)
12 Months Ended

Nov. 30, 2019

Inventory Disclosure [Abstract]

Components of Inventory
The components of inventory at November 30, 2019 and November 30, 2018 are as follows:

   As of
November 30,
2019    As of
November 30,
2018
Raw materials
   $ —    $ —
Work-in-process
   149,972    188,085
Work-in-process
– Public Bank
   —    —
Finished goods
   52,451    5,262
Finished goods – Public Bank
   13,491,375    15,831,081
Collection kits
   44,453    19,163
Inventory reserve
   (7,718 )    (7,718 )




Total inventory
   $ 13,730,533    $ 16,035,873




X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Related Party Transactions
12 Months Ended

Nov. 30, 2019

Related Party Transactions [Abstract]

Related Party Transactions
NOTE 17 – RELATED PARTY TRANSACTIONS
David Portnoy, the Company’s Chairman and
Co-Chief
Executive officer, is the brother of the Company’s
Co-Chief
Executive Officer Mark Portnoy. The Company’s Audit Committee Chairman, Harold Berger, provides accounting services to the Company’s
Co-Chief
Executive Officer Mark Portnoy and to PartnerCommunity, Inc. The Company’s Chairman and
Co-Chief
Executive Officer, David Portnoy, serves as the Chairman of the Board of PartnerCommunity, Inc.
On August 2, 2019, the Company entered into mutual releases with each of the
Co-CEOs
and certain directors and officers of the Company who received incentive awards that were submitted for ratification at the 2019 Annual Meeting or forfeited in connection therewith. The Company and each counterparty to a mutual release are agreeing, among other things, not to pursue certain claims relating to such ratification and surrenders).

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Commitments and Contingencies
12 Months Ended

Nov. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
NOTE 13 – COMMITMENTS AND CONTINGENCIES
Employment Agreements
The Company has employment agreements in place for certain members of management. These employment agreements which include severance arrangements, are for periods ranging from one to two years and contain certain provisions for severance payments in the event of termination or change of control.
Leases
The Company entered into a
ten-year
lease in April 2004 for its
17,600-square
foot cGMP/cGTP compliant corporate headquarters in Oldsmar, Florida. This facility contains the Company’s executive offices, its conference and training center, its laboratory processing and cryogenic storage facility and its scientific offices. In July 2018, the Company extended the main lease through December 31, 2021 for the 17,600 square foot space.
The Company entered into a
one-year
lease in November 2013 for an additional 800 square feet of office space in Miami, Florida for annual rent of approximately $38,000. The lease commenced during December 2013. In December 2016, the Company extended the lease through December 31, 2019.
Rent charged to operations was $322,984 and $312,307 for the fiscal years ended November 30, 2019 and 2018, respectively, and is included in cost of sales and selling, general and administrative expenses in the consolidated statements of comprehensive income (loss).
The future minimum rental payments under the operating lease are as follows:

Fiscal Year Ending November 30,
   Rent
2020
   $ 228,148
2021
   $ 224,928
2022
   $ 18,744

Legal Proceedings
On December 3, 2015, a complaint styled
Gary T. Brotherson, M.D., et al. v. Cryo-Cell International, Inc.,
Case No.
15-007461-CI,
Circuit Court, Sixth Judicial Circuit, Pinellas County, Florida, was served on the Company, naming it as defendant and alleging, among other things, that the Company breached certain agreements with plaintiffs and seeking damages in excess of $15,000, the jurisdictional amount of the court in which the action is pending. On January 12, 2016, the Company served its answer, affirmative defenses, and counterclaim against the plaintiffs. The Company believes the plaintiffs’ claims are without merit and it intends to contest the action vigorously. At this time, it is not possible for the Company to estimate the loss or the range of possible loss in the event of an unfavorable outcome, as the ultimate resolution of the complaint is uncertain at this time. No amounts have been accrued as of November 30, 2019.
In addition, from time to time the Company is subject to proceedings, lawsuits, contract disputes and other claims in the normal course of its business. The Company believes that the ultimate resolution of current matters should not have a material adverse effect on the Company’s business, consolidated financial position or results of operations. It is possible, however, that there could be an unfavorable ultimate outcome for or resolution which could be material to the Company’s results of operations for a particular quarterly reporting period. Litigation is inherently uncertain and there can be no assurance that the Company will prevail. The Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes - Additional Information (Detail) - USD ($)
12 Months Ended

Jan. 31, 2018

Nov. 30, 2019

Nov. 30, 2018

Nov. 30, 2017

Income Tax Disclosure [Abstract]

Valuation allowance, changes in amount $ 12,000 $ 711,000

Effective income tax rate reconciliation at federal statutory income tax rate 21.00% 21.00% 22.10% 34.00%

Income tax expense $ 3,100,000

Minimum percentage probability of realized tax benefit on settlement 50.00% 50.00%

Uncertain tax provisions $ 0 $ 0

Material provisions for interest or penalties related to uncertain tax positions 0 0

US income taxes paid $ 2,801,000 $ 2,204,000

X

- Definition
Minimum percentage probability of realized tax benefit on settlement.
+ References
No definition available.
+ Details

Name: ccel_MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement

Namespace Prefix: ccel_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319
+ Details

Name: us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount recognized for uncertainty in income taxes classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilityForUncertainTaxPositionsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28511-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28446-109314
+ Details

Name: us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income tax expense (benefit) for remeasurement of deferred tax from change in tax rate pursuant to Tax Cuts and Jobs Act.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 53 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Property and Equipment - Summary of Major Classes of Propery and Equipment (Detail) - USD ($)

Nov. 30, 2019

Nov. 30, 2018

Property, Plant and Equipment [Line Items]

Property and Equipment $ 8,963,178 $ 8,300,883

Less: Accumulated Depreciation (7,116,711) (6,807,482)

Total Property and Equipment 1,846,467 1,493,401

Furniture and Equipment [Member]

Property, Plant and Equipment [Line Items]

Property and Equipment 6,568,205 5,905,910

Leasehold Improvements [Member]

Property, Plant and Equipment [Line Items]

Property and Equipment 1,200,934 1,200,934

Computer Software - internal use [Member]

Property, Plant and Equipment [Line Items]

Property and Equipment $ 1,194,039 $ 1,194,039

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Description of Business and Summary of Significant Accounting Policies - Schedule of Assets and Liabilities From Contracts With Customers (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Contract assets (sales commissions) $ 398,535 $ 329,231

Accounts receivables 6,097,331 5,867,335

Short-term contract liabilities (deferred revenue) 8,875,138 8,365,284

Long-term contract liabilities (deferred revenue) 23,633,373 $ 20,317,231

Deferred Revenue [Member]

Contract with customer liability, Beginning Balance 28,682,515

Contract with customer liability, Additions 18,759,963

Contract with customer liability, Deductions 14,933,967

Contract with customer liability, Ending Balance 32,508,511

Accounts Receivables [Member]

Account Receivables, Beginning Balance 5,867,335

Account Receivables ,Additions 36,579,504

Account Receivables, Deductions 36,349,508

Account Receivables , Ending Balance 6,097,331

Sales commissions [Member]

Contract With customer asset, Beginning Balance 329,231

Contract With customer asset, Additions 88,569

Contract With customer asset, Deductions 19,265

Contract With customer asset,Ending Balance $ 398,535

X

- Definition
Accounts receivable net current additions.
+ References
No definition available.
+ Details

Name: ccel_AccountsReceivableNetCurrentAdditions

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Accounts Receivable, Net, Current, Beginning Balance.
+ References
No definition available.
+ Details

Name: ccel_AccountsReceivableNetCurrentBeginningBalance

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Accounts receivable net current deductions.
+ References
No definition available.
+ Details

Name: ccel_AccountsReceivableNetCurrentDeductions

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Accounts Receivable, Net, Current Ending Balance
+ References
No definition available.
+ Details

Name: ccel_AccountsReceivableNetCurrentEndingBalance

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Contract with customer asset net current additions.
+ References
No definition available.
+ Details

Name: ccel_ContractWithCustomerAssetNetCurrentAdditions

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Contract with customer asset net current beginning balance.
+ References
No definition available.
+ Details

Name: ccel_ContractWithCustomerAssetNetCurrentBeginningBalance

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Contract with customer asset net current deductions.
+ References
No definition available.
+ Details

Name: ccel_ContractWithCustomerAssetNetCurrentDeductions

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Contract with customer asset net current ending balance.
+ References
No definition available.
+ Details

Name: ccel_ContractWithCustomerAssetNetCurrentEndingBalance

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Contract with customer, liability, additions.
+ References
No definition available.
+ Details

Name: ccel_ContractWithCustomerLiabilityAdditions

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Contract with customer liability deductions.
+ References
No definition available.
+ Details

Name: ccel_ContractWithCustomerLiabilityDeductions

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=ccel_DeferredRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=ccel_SalesCommissionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Acquisition - Additional Information (Detail) - USD ($)
12 Months Ended

Jun. 11, 2018

Nov. 30, 2019

Nov. 30, 2018

Business Acquisition [Line Items]

Payment under asset purchase agreement $ 10,500,000

Common stock par value $ 0.01 $ 0.01

Brand [Member]

Business Acquisition [Line Items]

Useful lives 1 year

Customer Relationships [Member]

Business Acquisition [Line Items]

Useful lives 15 years

Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member]

Business Acquisition [Line Items]

Aggregate consideration payable at closing under the Purchase Agreement $ 14,000,000

Payment under asset purchase agreement $ 10,500,000

Shares issued under asset purchase agreement 465,426

Common stock par value $ 0.01

Sale of stock price per share $ 7.52

Percentage of earn out to be paid from gross revenues 75.00%

Common stock deliver $ 200,000

Common stock value 5,000,000

Costs associated with the acquisition $ 580,000

Discount rate 19.00%

Long-term sustainable growth rate 3.00%

Market royalty rate 1.00%

Fair value of inventory $ 16,037,957

Fair value of accounts receivable 188,019

Fair value of prepaid expenses 68,867

Short term deferred revenue 330,508

Long term deferred revenue 1,074,898

Amount of earn out to be paid from sale of public cord blood inventory $ 500,000

Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | Brand [Member]

Business Acquisition [Line Items]

Useful lives 1 year

Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | Customer Relationships [Member]

Business Acquisition [Line Items]

Useful lives 30 years

X

- Definition
Business Acquisition amount of Earn Out to Be Paid from Sale of Public Cord Blood Inventory
+ References
No definition available.
+ Details

Name: ccel_BusinessAcquisitionAmountOfEarnOutToBePaidFromSaleOfPublicCordBloodInventory

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Business acquisition common shares value.
+ References
No definition available.
+ Details

Name: ccel_BusinessAcquisitionCommonSharesValue

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Business combination consideration shares transferred.
+ References
No definition available.
+ Details

Name: ccel_BusinessCombinationConsiderationSharesTransferred

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Business Combination Consideration Transferred At Closing
+ References
No definition available.
+ Details

Name: ccel_BusinessCombinationConsiderationTransferredAtClosing

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Business combination fair value inputs discount rate.
+ References
No definition available.
+ Details

Name: ccel_BusinessCombinationFairValueInputsDiscountRate

Namespace Prefix: ccel_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Business combination, recognized identifiable assets acquired and liabilities assumed, current assets, prepaid expenses.
+ References
No definition available.
+ Details

Name: ccel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenses

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Noncurrent Liabilities Deferred Revenue
+ References
No definition available.
+ Details

Name: ccel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesDeferredRevenue

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Common stock transferred for cash value.
+ References
No definition available.
+ Details

Name: ccel_CommonStockTransferredForCashValue

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair Value Inputs Market Royalty Rate
+ References
No definition available.
+ Details

Name: ccel_FairValueInputsMarketRoyaltyRate

Namespace Prefix: ccel_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of Earn Out to Be Paid from Gross Revenues
+ References
No definition available.
+ Details

Name: ccel_PercentageOfEarnOutToBePaidFromGrossRevenues

Namespace Prefix: ccel_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Sustainable growth rate.
+ References
No definition available.
+ Details

Name: ccel_SustainableGrowthRate

Namespace Prefix: ccel_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460
+ Details

Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of inventory recognized as of the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ccel_BrandMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=ccel_BloodBankIncAndTianheStemCellBiotechnologiesIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 56 0001193125-20-056695-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-056695-xbrl.zip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end XML 57 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Inventory - Additional Information (Detail) - USD ($)
6 Months Ended 12 Months Ended

May 31, 2019

Nov. 30, 2019

Other Asset Impairment Charges $ 2,332,763 $ 2,332,763

X

- Definition
The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 58 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Notes Payable - Summary of Future Principal Payments under Note Payable Obligation (Detail) - USD ($)

Nov. 30, 2019

Nov. 30, 2018

Debt Disclosure [Abstract]

2020 $ 3,100,000

2021 3,100,000

2022 2,908,433

Total $ 9,108,433 $ 13,208,433

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04.(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 59 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Finite-Lived Intangible Assets [Line Items]

Net Intangible Assets $ 1,249,254 $ 1,341,336

Patents [Member]

Finite-Lived Intangible Assets [Line Items]

Finite lived intangible assets, gross 234,570 234,570

Less: Accumulated amortization $ (35,526) (23,663)

Patents [Member] | Minimum [Member]

Finite-Lived Intangible Assets [Line Items]

Useful lives 10 years

Patents [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Useful lives 20 years

License Agreement [Member]

Finite-Lived Intangible Assets [Line Items]

Useful lives 10 years

Finite lived intangible assets, gross $ 470,000 470,000

Less: Intangible asset impairment (185,000) (185,000)

Less: Accumulated amortization $ (155,194) (123,528)

Customer Relationships [Member]

Finite-Lived Intangible Assets [Line Items]

Useful lives 15 years

Finite lived intangible assets, gross $ 41,000 41,000

Less: Intangible asset impairment (26,267) (26,267)

Less: Accumulated amortization $ (6,329) (5,276)

Brand [Member]

Finite-Lived Intangible Assets [Line Items]

Useful lives 1 year

Finite lived intangible assets, gross $ 31,000 31,000

Less: Accumulated amortization $ (31,000) (15,500)

Customer Relationships One [Member]

Finite-Lived Intangible Assets [Line Items]

Useful lives 30 years

Finite lived intangible assets, gross $ 960,000 960,000

Less: Accumulated amortization $ (48,000) $ (16,000)

X

- Definition
Intangible asset impaired accumulated impairment loss.
+ References
No definition available.
+ Details

Name: ccel_IntangibleAssetImpairedAccumulatedImpairmentLoss

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ccel_BrandMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ccel_CustomerRelationshipsOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Revenue Sharing Agreements ("RSAs") - Additional Information (Detail)
12 Months Ended

Nov. 30, 2019

USD ($)

Store

Nov. 30, 2018

USD ($)

Nov. 30, 2008

May 31, 2001

USD ($)

Store

Feb. 09, 1999

USD ($)

Store

Revenue Sharing Agreement [Line Items]

Total payments to RSA holders $ 832,587 $ 671,245

Interest expense 950,300 864,676

Interest expense 1,703,446 1,546,900

Revenue Sharing Agreement ("RSA") [Member]

Revenue Sharing Agreement [Line Items]

Interest expense 909,765 798,292

Illinois [Member]

Revenue Sharing Agreement [Line Items]

Revenue sharing agreement price $ 1,000,000

Number of storage spaces | Store 33,000

Investors share in net storage revenues 50.00%

Billing and collection expense percentage 50.00%

Illinois and Its Contiguous States [Member]

Revenue Sharing Agreement [Line Items]

Percentage of 50% net storage revenue generated from specimens paid 75.00%

Texas [Member]

Revenue Sharing Agreement [Line Items]

Revenue sharing agreement price $ 750,000

Number of storage spaces | Store 33,000

Investors share in net storage revenues 37.50%

Variable interest entity, qualitative or quantitative information, ownership percentage 50.00%

Interest expense $ 944,060 $ 848,024

Florida [Member]

Revenue Sharing Agreement [Line Items]

Revenue sharing agreement price $ 1,000,000

Number of storage spaces | Store 33,000

X

- Definition
Billing and collection expense percentage.
+ References
No definition available.
+ Details

Name: ccel_BillingAndCollectionExpensePercentage

Namespace Prefix: ccel_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum number of storage area covered to determine revenue to share with investors.
+ References
No definition available.
+ Details

Name: ccel_MaximumNumberOfStorageAreaCoveredToDetermineRevenueToShareWithInvestors

Namespace Prefix: ccel_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Payment to participants of profit sharing agreement.
+ References
No definition available.
+ Details

Name: ccel_PaymentToParticipantsOfProfitSharingAgreement

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Percentage of share in profit of investor as percentage of under profit sharing agreement.
+ References
No definition available.
+ Details

Name: ccel_PercentageOfShareInProfitOfInvestorAsPercentageOfUnderProfitSharingAgreement

Namespace Prefix: ccel_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage of share in profit of investors under profit sharing agreement.
+ References
No definition available.
+ Details

Name: ccel_PercentageOfShareInProfitOfInvestorsUnderProfitSharingAgreement

Namespace Prefix: ccel_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Revenue sharing agreement
+ References
No definition available.
+ Details

Name: ccel_RevenueSharingAgreementLineItems

Namespace Prefix: ccel_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue sharing agreement percentage of payment of shareable revenue covered under agreement.
+ References
No definition available.
+ Details

Name: ccel_RevenueSharingAgreementPercentageOfPaymentOfShareableRevenueCoveredUnderAgreement

Namespace Prefix: ccel_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Revenue sharing agreement value covered under agreement.
+ References
No definition available.
+ Details

Name: ccel_RevenueSharingAgreementValueCoveredUnderAgreement

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 5A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685
+ Details

Name: us-gaap_VariableInterestEntityOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ccel_RsaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_IL

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=ccel_IllinoisAndItsContiguousStatesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_TX

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_FL

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity - Stock Option Activity (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted 143,409

Service-Based Vesting Condition Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Outstanding at November 30, 2018 1,001,365

Granted 143,409

Exercised (2,500)

Expired/forfeited (52,500)

Outstanding at November 31, 2019 1,089,774 1,001,365

Exercisable at November 30, 2019 964,540

Outstanding at November 30, 2018, Weighted Average Exercise Price $ 2.77

Granted, Weighted Average Exercise Price 7.55

Exercised, Weighted Average Exercise Price 2.28

Expired/forfeited, Weighted Average Exercise Price 4.82

Outstanding at November 30, 2019, Weighted Average Exercise Price 3.30 $ 2.77

Exercisable at November 30, 2019, Weighted Average Exercise Price $ 2.75

Outstanding, Weighted Average Remaining Contractual Term (Years) 3 years 10 months 27 days 3 years 11 months 19 days

Exercisable at November 30, 2019, Weighted Average Remaining Contractual Term (Years) 3 days

Outstanding at November 30, 2018 $ 4,580,967

Granted 4,851

Exercised 14,175

Expired/forfeited 143,450

Outstanding at November 30, 2019 4,648,111 $ 4,580,967

Exercisable at November 30, 2019 $ 4,644,277

X

- Definition
Share based compensation arrangement by share based payment award options exercisable weighted average number.
+ References
No definition available.
+ Details

Name: ccel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageNumber

Namespace Prefix: ccel_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award options forfeitures and expirations in period intrinsic value.
+ References
No definition available.
+ Details

Name: ccel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award options grants in period intrinsic value.
+ References
No definition available.
+ Details

Name: ccel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=ccel_ServiceBasedVestingConditionOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

License Agreements - Summary of License Fees Earned (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

License Agreements [Line Items]

Revenue $ 31,816,571 $ 29,218,490

Processing and Storage Royalties [Member]

License Agreements [Line Items]

Revenue 1,000,000 1,000,000

License and royalty income [Member]

License Agreements [Line Items]

Revenue 1,000,000 1,000,000

India [Member] | Processing and Storage Royalties [Member]

License Agreements [Line Items]

Revenue 1,000,000 1,000,000

India [Member] | License and royalty income [Member]

License Agreements [Line Items]

Revenue $ 1,000,000 $ 1,000,000

X

- Definition
License Agreements [Line Items]
+ References
No definition available.
+ Details

Name: ccel_LicenseAgreementsLineItems

Namespace Prefix: ccel_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=ccel_ProcessingAndStorageRoyaltiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=ccel_LicenseeAndRoyaltyIncomeRecognitionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_IN

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Allowance for Doubtful Accounts
12 Months Ended

Nov. 30, 2019

Receivables [Abstract]

Allowance for Doubtful Accounts
NOTE
7—
ALLOWANCE FOR DOUBTFUL ACCOUNTS
The activity in the allowance for doubtful accounts is as follows for the years ended November 30, 2019 and 2018:

December 1, 2017
   $ 2,098,991
Bad Debt Expense
   727,483
Write-offs
   (907,263 )
Recoveries
   345,637


November 30, 2018
   2,264,848
Bad Debt Expense
   767,128
Write-offs
   (756,688 )
Recoveries
   308,803


November 30, 2019
   $ 2,584,091

X

- Definition
The entire disclosure for allowance for credit losses.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-URI http://asc.fasb.org/topic&trid=2196771
+ Details

Name: us-gaap_AllowanceForCreditLossesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Statements of Stockholders' Deficit - USD ($)

Total

Common Stock [Member]

Additional Paid-In Capital [Member]

Treasury Stock [Member]

Other Comprehensive Income [Member]

Accumulated Deficit [Member]

Beginning balance at Nov. 30, 2017 $ (12,502,896) $ 128,995 $ 31,373,048 $ (19,571,113) $ 40,865 $ (24,474,691)

Beginning balance, shares at Nov. 30, 2017 12,899,517

Common stock issued 3,670,925 $ 6,969 3,663,956

Common stock issued, shares 696,892

Compensatory element of stock options 478,378 478,378

Unrealized loss on available for sale securities 300,119 300,119

Net income (loss) (854,824) (854,824)

Ending balance at Nov. 30, 2018 (8,908,298) $ 135,964 35,515,382 (19,571,113) 340,984 (25,329,515)

Ending balance, shares at Nov. 30, 2018 13,596,409

Common stock issued 5,700 $ 25 5,675

Common stock issued, shares 2,500

Compensatory element of stock options 397,770 397,770

Cumulative-effect adjustment due to the adoption of ASU 2016-01 | Accounting Standards Update 2016-01 [Member] $ (340,984) 340,984

Unrealized loss on available for sale securities 0

ASC 606 adoption adjustment, net of tax 253,447 253,447

Treasury Stock (992,244) (992,244)

Net income (loss) 2,290,774 2,290,774

Ending balance at Nov. 30, 2019 $ (6,952,851) $ 135,989 $ 35,918,827 $ (20,563,357) $ (22,444,310)

Ending balance, shares at Nov. 30, 2019 13,598,909

X

- Definition
Cumulative effect adjustment from accumulated other comprehensive income to retained earnings.
+ References
No definition available.
+ Details

Name: ccel_CumulativeEffectAdjustmentFromAccumulatedOtherComprehensiveIncomeToRetainedEarnings

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cumulative effect on retained earnings net of related income tax effect.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794
+ Details

Name: us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Balance Sheets - USD ($)

Nov. 30, 2019

Nov. 30, 2018

Current Assets

Cash and cash equivalents $ 6,541,037 $ 6,040,033

Marketable securities 904,053 875,689

Accounts receivable (net of allowance for doubtful accounts of $2,584,091 and $2,264,848, respectively) 6,097,331 5,867,335

Prepaid expenses 500,260 461,815

Inventory, current portion 1,084,533 1,260,557

Other current assets 260,397 254,465

Total current assets 15,387,611 14,759,894

Property and Equipment-net 1,846,467 1,493,401

Other Assets

Intangible assets, net 1,249,254 1,341,336

Inventory, net of current portion 12,646,000 14,775,316

Goodwill 1,941,411 1,941,411

Deferred tax assets 9,079,994 7,656,897

Deposits and other assets, net 427,423 113,888

Total other assets 25,652,082 26,136,848

Total assets 42,886,160 42,390,143

Current Liabilities

Accounts payable 1,369,111 1,261,653

Accrued expenses 2,085,180 2,702,788

Current portion of note payable 3,100,000 3,100,000

Deferred revenue 8,875,138 8,365,284

Total current liabilities 15,429,429 15,429,725

Other Liabilities

Deferred revenue, net of current portion 23,633,373 20,317,231

Contingent Consideration 3,495,057 4,282,975

Note payable, net of current portion and debt issuance costs 5,856,152 9,843,510

Long-term liability - revenue sharing agreements 1,425,000 1,425,000

Total other liabilities 34,409,582 35,868,716

Total liabilities 49,839,011 51,298,441

Commitments and contingencies (Note 13)

Stockholders' Deficit

Preferred stock

Common stock ($.01 par value, 20,000,000 authorized; 13,598,909 issued and 7,510,884 outstanding as of November 30, 2019 and 13,596,409 issued and 7,800,833 outstanding as of November 30, 2018) 135,989 135,964

Additional paid-in capital 35,918,827 35,515,382

Treasury stock, at cost (20,563,357) (19,571,113)

Accumulated other comprehensive income 340,984

Accumulated deficit (22,444,310) (25,329,515)

Total stockholders' deficit (6,952,851) (8,908,298)

Total liabilities and stockholders' deficit 42,886,160 42,390,143

Series A Junior Participating Preferred Stock [Member]

Stockholders' Deficit

Preferred stock

Tianhe Stem Cell Biotechnologies Inc [Member]

Other Assets

Investment $ 308,000 $ 308,000

X

- Definition
Deposits and other assets.
+ References
No definition available.
+ Details

Name: ccel_DepositsAndOtherAssets

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e31928-109318

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(d))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.1(h))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Investments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LongTermInvestmentsAndReceivablesNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investment in marketable security, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=ccel_TianheStemCellBiotechnologiesIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 66 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Inventory
12 Months Ended

Nov. 30, 2019

Inventory Disclosure [Abstract]

Inventory
Note 3 – Inventory
Inventory is comprised of public cord blood banking specimens, collection kits, finished goods,
work-in-process
and raw materials. Collection kits are used in the collection and processing of umbilical cord blood and cord tissue stem cells, finished goods include products purchased or assumed for resale and for the use in the Company’s processing and storage service. Inventory in the Public Cord Blood Bank includes finished goods that are specimens that are available for resale. The Company considers inventory in the Public Cord Blood Bank that has not completed all testing to determine viability to be work in process. Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of $2,332,763 was recognized during the second quarter of fiscal 2019 to reduce inventory from cost to net realizable value and is included in the accompanying consolidated statements of comprehensive income (loss).

The components of inventory at November 30, 2019 and November 30, 2018 are as follows:

   As of
November 30,
2019    As of
November 30,
2018
Raw materials
   $ —    $ —
Work-in-process
   149,972    188,085
Work-in-process
– Public Bank
   —    —
Finished goods
   52,451    5,262
Finished goods – Public Bank
   13,491,375    15,831,081
Collection kits
   44,453    19,163
Inventory reserve
   (7,718 )    (7,718 )




Total inventory
   $ 13,730,533    $ 16,035,873




X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 67 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity
12 Months Ended

Nov. 30, 2019

Equity [Abstract]

Stockholders' Equity
NOTE 11—STOCKHOLDERS’ EQUITY.
Common Stock Issuances
During the year ended November 30, 2019, the Company issued 2,500 common shares to option holders who exercised options for $5,700. During the year ended November 30, 2018, the Company issued 63,750 common shares to option holders who exercised options for $170,925.
Employee Stock Incentive Plan
The Company maintains the 2006 Stock Incentive Plan (the “2006 Plan”) under which it has reserved 1,000,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, stock-appreciation rights (commonly referred to as “SARs”) and stock awards (i.e. performance options to purchase shares and performance units). As of November 30, 2019, and November 30, 2018, there were 325,000 and 380,000 options issued, but not yet exercised, under the 2006 Plan, respectively. As of November 30, 2019, there were 0 shares available for future issuance under the 2006 Plan.
The Company maintains the 2012 Equity Incentive Plan (the “2012 Plan”) which became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting on July 10, 2012. The 2012 Plan originally reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, SARs, and other stock awards (i.e. performance shares and performance units). In May 2012, the Board of Directors approved an amendment to the 2012 Plan to increase the number of shares of the Company’s common stock reserved for issuance to 2,500,000
shares. In October 2019, the Board of Directors approved amendments to the plan, subject to ratification by the stockholders, which occurred at the Company’s 2019 Annual Meeting of Stockholders on November 21, 2019. See the Company’s Proxy Statement filed with the Securities and Exchange Commission on October 29, 2019 in connection with the Company’s 2019 Annual Meeting (the “2019 Proxy Statement”). As of November 30, 2019, there
were 763,274 service-based options issued, 129,729 service-based restricted common shares granted, 530,851 performance-based and 116,218 market-based restricted common shares granted under the 2012 Plan. As of November 30, 2018, there were 621,365 service-based options issued, 129,729 service-based restricted common shares granted, 823,415 performance-based and 116,240 market-based restricted common shares granted under the 2012 Plan. As of November 30, 2019, there were 667,479 shares available for future issuance under the 2012 Plan.
The Company granted 1,500 options to an optionee during the second fiscal quarter of 2019 as approved by the Board of Directors. These options
were
not issued
under either
the 2006 or 2012 Plan.
As discussed in further detail in the 2019 Proxy Statement, on or about March 26, 2018, the Company received a letter from counsel for a purported stockholder. Among other things, the letter identified equity awards allegedly made in violation of the 2012 Plan. The Board formed a committee of directors (the “Demand Review Committee”) to (among other things) conduct an investigation of the allegations in that letter. After completing its investigation, the Demand Review Committee determined that 1,129,247 restricted stock performance based awards were granted in violation of the 2012 Plan and the Delaware General Corporation Law (“DGCL”). The Demand Review Committee also determined that 70,270, 75,000 and 77,500 stock option awards were granted in violation of the 2012 Plan, the 2006 Plan, the 2000 Stock Incentive Plan, respectively, as amended (the “2000 Plan”) and the DGCL. Annex II attached to the 2019 Proxy Statement describes each of these awards and the applicable Plan that the awards were purportedly granted under, and Annexes I and II of the 2019 Proxy Statement describe each defective award and defective stock issuance identified by the Demand Review Committee (the “Defective Awards and Issuances”).
Based on the recommendation of the Demand Review Committee, the Board of Directors approved that 776,798 restricted stock performance based awards be ratified that were in violation of the 2012 Plan and that 352,449 restricted stock performance based awards be surrendered for cash in the amount of $1,436,244 that were in violation of the 2012 Plan. The Board of Directors also approved the recommendation that 45,000 stock option awards not be ratified and 177,770 stock options be ratified under the 2012 Plan, the 2006 Plan and the 2000 Stock Incentive Plan. The proposed treatment of each award and issuance is listed on Annexes I and II in the manner identified in the column entitled “Recommended Disposition” in each of those Annexes and recommended to the Company’s stockholders that such awards and issuances be ratified as proposed by the Recommended Dispositions. On November 21, 2019, the Company held its Annual Meeting of Stockholders. At the 2019 Annual Meeting, the Company’s stockholders considered various matters presented to them, including the ratification of certain equity-based awards and stock issuances made pursuant to the Company’s incentive Plans, as well as the approval of certain amendments to those incentive Plans. All such matters presented to the stockholders were duly approved by the stockholders at the 2019 Annual Meeting. Accordingly, all references contained herein to the number of options or shares of common stock granted under the Company’s incentive Plans, the value thereof, and the number of securities that remain available for future issuance under the Company’s 2012 Plan for all periods presented in this Annual Report on Form
10-K
have been calculated and are being presented after taking into account the ratification and surrender of the Defective Awards and Issuances in accordance with the Recommended Disposition, as further described in the 2019 Proxy Statement.
Under the DGCL, any claim that the defective corporate acts, or the shares of stock or awards, listed as having been purportedly issued or granted on Annexes I and II, are void or voidable due to the failures of authorization listed on Annex III, or that the Delaware Court of Chancery should declare in its discretion that the ratification not be effective or be effective only on certain conditions, must be brought within 120 days from the date of the 2019 Annual Meeting, which was on November 21, 2019.
Service-based vesting condition options
The fair value of each option award is estimated on the date of the grant using the Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatility is based on the historical volatility of the Company’s stock over the most recent period commensurate with the expected life of the Company’s stock options. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected term of options granted to employees is based upon historical exercise data. Expected dividends are based on the historical trend of the Company not issuing dividends.
Variables used to determine the fair value of the options granted for the years ended November 30, 2019 and November 30, 2018 are as follows:

   2019 2018
Weighted average values:

Expected dividends
   0% 0%
Expected volatility
   64.02% 50.85%
Risk free interest rate
   1.55% 2.67%
Expected life
   8.4 years 5.0 years

Stock option activity for options with only service-based vesting conditions for the year ended November 30, 2019, was as follows:

   Options    Weighted
Average
Exercise
Price    Weighted
Average
Remaining
Contractual
Term (Years)    Aggregate
Intrinsic
Value
Outstanding at November 30, 2018
   1,001,365    $ 2.77    3.97    $ 4,580,967
Granted
   143,409    7.55       4,851
Exercised
   (2,500 )    2.28       14,175
Expired/forfeited
   (52,500 )    4.82       143,450



Outstanding at November 30, 2019
   1,089,774    3.30    3.91    $ 4,648,111




Exercisable at November 30, 2019
   964,540    2.75    3.33    $ 4,644,277




The weighted average grant date fair value of options granted during the years ended November 30, 2019 and November 30, 2018 was $5.02 and $3.23, respectively.
The aggregate intrinsic value represents the total value of the difference between the Company’s closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of
in-the-money
stock options that would have been received by the option holders had all option holders exercised their options on either November 30, 2019 or November 30, 2018, as applicable. The intrinsic value of the Company’s stock options changes based on the closing price of the Company’s stock.
Significant option groups outstanding and exercisable at November 30, 2019 and related price and contractual life information are as follows:

   Outstanding    Exercisable
      Weighted
Average
      Remaining    Weighted       Weighted
Range of Exercise Prices
   Outstanding    Contractual
Life (Years)    Average
Exercise Price    Outstanding    Average
Exercise Price
$1.01 to $2.00
   422,500    2.10    $ 1.73    422,500    $ 1.73
$2.01 to $3.00
   265,000    2.11    $ 2.72    265,000    $ 2.72
$3.01 to $4.00
   204,729    6.23    $ 3.14    204,729    $ 3.14
$6.01 to $7.00
   2,500    4.65    $ 6.50    1,667    $ 6.50
$7.01 to $8.00
   195,045    7.84    $ 7.63    70,644    $ 7.67







   1,089,774    3.91    $ 3.30    964,540    $ 2.75







A summary of the status of the Company’s
non-vested
options as of November 30, 2019, and changes during the fiscal year then ended, is presented below:

      Weighted Average
      Grant-Date
   Options    Fair Value
Non-vested
at November 30, 2018
   40,254    $ 3.06
Granted
   143,409    5.02
Vested
   (58,429 )    4.36
Forfeited
   —    —



Non-vested
at November 30, 2019
   125,234    $ 4.70




As of November 30, 2019, there was approximately $519,000 of total unrecognized compensation cost related to
non-vested
share-based compensation arrangements granted under the 2006 Plan and the 2012 Plan. The cost is expected to be recognized over a weighted-average period of 1.16 years as of November 30, 2019. The total fair value of options vested during the fiscal year ended November 30, 2019 was approximately $255,000.
During the second fiscal quarter of 2018, the Company entered into Amended and Restated Employment Agreements (“2018 Employment Agreements”) with each of the Company’s
Co-CEOs.
Per the Employment Agreements, each of the
Co-CEOs
is to receive base grant equity awards in the form of qualified stock options of the Company’s common stock. As of March 8, 2018, David Portnoy and Mark Portnoy were granted 23,636 and 20,000 stock options of the Company’s common stock, respectively. The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019. The fair value of the options that vested through the twelve months ended November 30, 2019 and November 30, 2018 was approximately $77,000 and $62,000, respectively, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss).
During the second fiscal quarter of 2018, the Company entered into an Amendment Agreement (“CIO Agreement”) with the Company’s CIO. Per the CIO Agreement, the CIO is to receive a base grant equity award in the form of qualified stock options of the Company’s common stock. As of May 21, 2018, Oleg Mikulinsky was granted 8,000 stock options of the Company’s common stock. The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019. The fair value of the options that vested through the twelve months ended November 30, 2019 and November 30, 2018 was approximately $18,000 and $10,000, respectively, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss).
Performance and market-based vesting condition options

Per the 2018 Employment Agreements, based upon certain performance criteria, the Company shall grant David Portnoy and Mark Portnoy a percentage of up to 47,273 and 40,000, respectively, of qualified stock options of the Company’s common stock. For market-based vesting condition options, accounting principles do not require that the market condition be met in order for the compensation cost to be recognized. Fair value of these options has been determined using a Monte Carlo valuation approach and is being recognized over the requisite service period, regardless if the market condition will be met. During fiscal 2019 and 2018, 15,756 and 13,332, respectively, of qualified stock options were forfeited as certain market conditions were not met by the end of the requisite service period. The fair value of these options as of November 30, 2019 and November 30, 2018 was approximately $182,00 and $144,300, respectively, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss). For performance-based vesting condition options, the Company estimates the fair value of qualified stock options that met certain performance targets by the end of the fiscal 2018 requisite service period using a Black-Scholes valuation model. As of August 30, 2019, the Company granted David Portnoy and Mark Portnoy 26,243 and 22,222 of
non-qualified
stock options of the Company’s common stock based upon certain performance criteria met by the end of the fiscal 2018 service period and per the 2018 Employment Agreements. These options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon date of grant, 1/3 on December 1, 2019 and 1/3 on November 30, 2020. The fair value of these options as of November 30, 2019 was approximately $86,000 and is reflected as selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). As of November 30, 2019, there was approximately $172,000 of total unrecognized compensation cost related to the
non-vested
options of common stock.
Per the Amendment Agreement, based upon certain performance criteria, the Company shall grant Oleg Mikulinsky a percentage of up to 8,000 of qualified stock options of the Company’s common stock. For market-based vesting condition options, accounting principles do not require that the market condition be met in order for the compensation cost to be recognized. Fair value of these options has been determined using a Monte Carlo valuation approach and is being recognized over the requisite service period, regardless if the market condition will be met. During fiscal 2019 and 2018, 2,666, respectively, of qualified stock options were forfeited as certain market conditions were not met by the end of the requisite service period. The fair value of these options as of November 30, 2019 and November 30, 2018 was approximately $19,200 and $13,500, and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss). For performance-based vesting condition options, the Company estimated the fair value of the qualified stock options that met certain performance targets by the end of the fiscal 2018 requisite service period using a Black-Scholes valuation model. As of September 4, 2019, the Company granted Oleg Mikulinsky 4,444 of qualified stock options of the Company’s common stock based upon certain performance criteria met by the end of the fiscal 2018 service period and the per the Amendment Agreement. These options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon date of grant, 1/3 on December 1, 2019 and 1/3 on November 30, 2020. The fair value of these options as of November 30, 2019 was approximately $8,000 and is reflected as selling, general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). As of November 30, 2019, there was approximately $15,000 of total unrecognized compensation cost related to the
non-vested
options of common stock.
Restricted common shares
Based upon performance measures being obtained during prior fiscal years, David Portnoy and Mark Portnoy earned 304,946 and 265,172 shares of common stock, respectively. Pursuant to the terms of the Employment Agreements, the
Co-CEOs
each opted to receive a lump sum cash payment in lieu of 30,000 shares of earned common stock which amounted to approximately $444,000 each
paid in
fiscal 2018
. Per
the recommendation of the DCCL, as described above, David Portnoy and Mark Portnoy surrendered 157,472 and 134,977 commons shares, respectively, for cash which amounted to $534,917 and $457,327, respectively
in 2019
.
Based upon performance measures being obtained during prior fiscal years, Oleg Mikulinsky was granted 34,349 shares of common stock.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 68 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Property and Equipment (Tables)
12 Months Ended

Nov. 30, 2019

Property, Plant and Equipment [Abstract]

Summary of Major Classes of Property and Equipment
The major classes of property and equipment are as follows:


2019

2018

Furniture and equipment
   $ 6,568,205    $ 5,905,910
Leasehold improvements
   1,200,934    1,200,934
Computer software – internal use
   1,194,039    1,194,039




   8,963,178    8,300,883
Less: Accumulated Depreciation
   (7,116,711 )    (6,807,482 )




Total Property and Equipment
   $ 1,846,467    $ 1,493,401




X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 69 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

License Agreements (Tables)
12 Months Ended

Nov. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of License Fees Earned
The following table details the processing and storage royalties earned for the technology agreements for fiscal years 2019 and 2018. The initial license fees and processing and storage royalties are reflected in licensee income in the accompanying consolidated statements of comprehensive income (loss).

   For the years ended November 30,
   2019    2018
   License
Fee    Processing
and Storage
Royalties    Total    License
Fee    Processing
and Storage
Royalties    Total
India
   —    1,000,000    1,000,000    —      1,000,000    1,000,000












Total
   $ —    $ 1,000,000    $ 1,000,000    $ —      $ 1,000,000    $ 1,000,000












X

- Definition
Summary of license fees earned.
+ References
No definition available.
+ Details

Name: ccel_SummaryOfLicenseFeesEarnedTableTextBlock

Namespace Prefix: ccel_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 70 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Description of Business, Basis of Presentation and Significant Accounting Policies (Tables)
12 Months Ended

Nov. 30, 2019

Accounting Policies [Abstract]

Disaggregation of Revenue
The following table provides information about disaggregated revenue by products and services:

   Twelve months ended
   November 30, 2019    November 30, 2018
Processing and storage fees
   $ 29,991,972    $ 27,817,872
Public banking revenue
   652,204    296,295
Licensee and royalty income
   1,000,000    1,000,000
Product revenue
   172,395    104,323




   $ 31,816,571    $ 29,218,490




Schedule of Assets and Liabilities From Contracts With Customers
The following table provides information about assets and liabilities from contracts with customers:

   November 30, 2019    At Adoption
Contract assets (sales commissions)
   $ 398,535    $ 329,231
Accounts receivables
   $ 6,097,331    $ 5,867,335
Short-term contract liabilities (deferred revenue)
   $ 8,875,138    $ 8,365,284
Long-term contract liabilities (deferred revenue)
   $ 23,633,373    $ 20,317,231
The Company, in general, requires the customer to pay for processing and storage services at the time of processing. Contract assets include deferred contract acquisition costs, which will be amortized along with the associated revenue. Contract liabilities include payments received in advance of performance under the contract and are realized with the associated revenue recognized under the contract. Accounts receivable consists of amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs related to renewals of annual plans and amounts due from license affiliates, and sublicensee territories. The Company did not have asset impairment charges related to contract assets in the twelve
months
ended November 30, 2019.
The following table presents changes in the Company’s contract assets and liabilities during the twelve months ended November 30, 2019:

   Balance at
December 1, 2018    Additions    Deductions    Balance at
November 30,

2019
Contract assets (sales commissions)
   $ 329,231    $ 88,569    ($ 19,265 )    $ 398,535
Accounts receivables
   $ 5,867,335    $ 36,579,504    ($ 36,349,508 )    $ 6,097,331
Contract liabilities (deferred revenue)
   $ 28,682,515    $ 18,759,963    ($ 14,933,967 )    $ 32,508,511

Estimated Useful Lives of Property and Equipment Estimated useful lives of property and equipment are as follows:
Furniture and equipment
3-10
years

Leasehold improvements    Lesser of
8-10
years or the lives of the leases

Computer software – internal use
1-5
years

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of November 30, 2019 and November 30, 2018, respectively, segregated among the appropriate levels within the fair value hierarchy:


Fair Value at
   at November 30, 2019 Using
Description
   November 30,
2019    Level 1    Level 2    Level 3
Assets:

Marketable securities
   $ 904,053    $ 904,053    —    —








Total
   $ 904,053    $ 904,053    —    —








Liabilities:

Contingent consideration
   $ 3,495,057    $ —    —    $ 3,495,057








Total
   $ 3,495,057    $ —    —    $ 3,495,057








Contingent Consideration:

Beginning Balance as of November 30, 2018
   $ 4,282,975
Subtractions – Cord:Use earnout payment
   (45,000 )
Fair value adjustment as of November 30, 2019
   (742,918 )



Ending balance as of November 30, 2019
   $ 3,495,057




Fair Value at
   Fair Value Measurements
at November 30, 2018 Using
Description
   November 30,
2018    Level 1    Level 2    Level 3
Assets:

Trading securities
   $ 68,816    $ 68,816    —      —
Available-for-sale
securities
   806,873    806,873    —      —








Total
   $ 875,689    $ 875,689    —      —








Liabilities:

Contingent consideration
   $ 4,282,975    $ —      —      $ 4,282,975








Total
   $ 4,282,975    $ —      —      $ 4,282,975








Calculation of Basic and Diluted Net (loss) Income per Common Share The composition of basic and diluted net (loss) income per share is as follows:
   November 30, 2019    November 30, 2018
Numerator:

Net income (loss)
   $ 2,290,774    ($ 854,824 )
Denominator:

Weighted-average shares outstanding-basic
   7,794,828    7,463,051
Dilutive common shares issuable upon exercise of stock options
   617,586    —




Weighted-average shares-diluted
   8,412,414    7,463,051




Income(Loss) per share:

Basic
   $ 0.29    ($ 0.11 )




Diluted
   $ 0.27    ($ 0.11 )




X

- Definition
Property Plant And Equipment Estimated Useful Lives.
+ References
No definition available.
+ Details

Name: ccel_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock

Namespace Prefix: ccel_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of contract balances and changes in contract balances.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 72 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Revenue Sharing Agreements ("RSAs")
12 Months Ended

Nov. 30, 2019

Text Block [Abstract]

Revenue Sharing Agreements ("RSAs")
NOTE 15—REVENUE SHARING AGREEMENTS (“RSAs”)
Florida
. On February 9, 1999, the previous agreements with the Company’s Arizona Revenue Sharing investors were modified and replaced by a RSA for the state of Florida for a price of $1,000,000. The revenue sharing agreement applies to net storage revenues originating from specimens from within the state of Florida. The revenue sharing agreement entitles the investors to revenues of up to a maximum of 33,000 storage spaces.
Illinois
. In 1996, the Company signed agreements with a group of investors entitling them to an
on-going
50% share of the Company’s 75% share of the annual storage fees (“net storage revenues”) less a deduction for 50% of billing and collection expenses generated by specimens stored in the Illinois Masonic Medical Center for a price of $1,000,000. The agreements were modified in 1998 to broaden the covered specimens to those originating in Illinois and its contiguous states and stored in Oldsmar, Florida for a maximum of up to 33,000 storage spaces.
Texas
. On May 31, 2001, the Company entered into an RSA with Red Rock Partners, an Arizona general partnership, entitling them to
on-going
shares in a portion of the Company’s net storage revenue generated by specimens originating from within the State of Texas for a price of $750,000. The investors are entitled to a 37.5% share of net storage revenues originating in the State of Texas to a maximum of 33,000 storage spaces. During fiscal 2008, Red Rock assigned 50% of their interest in the agreement to SCC Investments, Inc., an Arizona corporation. During fiscal year 2010, SCC Investments, Inc. assigned its interest to SCF Holdings, LLC, an Arizona limited liability company.
The Company made total payments to all RSA holders of $832,587 and $671,245 for the fiscal years ended November 30, 2019 and 2018, respectively. The Company recorded an RSA accrual of $909,765

and $798,292 as of November 30, 2019 and 2018,
respectively, related to interest owed to the RSA holders, which is included in accrued expenses. The Company also recorded interest expense
of $944,060 and $848,024
for the fiscal years ended November 30, 2019 and 2018, respectively, which is reflected in interest expense on the accompanying consolidated statements of comprehensive income (loss).

X

- Definition
Revenue sharing agreements ("RSAs").
+ References
No definition available.
+ Details

Name: ccel_RevenueSharingAgreementsRsasTextBlock

Namespace Prefix: ccel_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 73 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Description of Business and Summary of Significant Accounting Policies - Calculation of Basic and Diluted Net (loss) Income per Common Share (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Denominator:

Weighted-average shares outstanding-basic 7,794,828 7,463,051

Dilutive common shares issuable upon exercise of stock options 617,586

Weighted-average shares-diluted 8,412,414 7,463,051

Income(Loss) per share:

Basic $ 0.29 $ (0.11)

Diluted $ 0.27 $ (0.11)

Net Income (Loss) $ 2,290,774 $ (854,824)

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 28A
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 74 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Acquisition - Summary of Preliminary Allocation of Total Purchase Price (Detail) - USD ($)

Nov. 30, 2019

Nov. 30, 2018

Jun. 11, 2018

Business Acquisition [Line Items]

Goodwill $ 1,941,411 $ 1,941,411

Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member]

Business Acquisition [Line Items]

Accounts receivable $ 188,019

Inventory 16,037,957

Prepaid expenses 68,867

Property and equipment 568,407

Other asset - Tianhe capital stock 308,000

Total identifiable net assets acquired 18,162,250

Less: Deferred revenue (1,405,406)

Goodwill 1,941,411

Total 18,698,255

Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | Brand [Member]

Business Acquisition [Line Items]

Intangible assets 31,000

Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | Customer Relationships [Member]

Business Acquisition [Line Items]

Intangible assets $ 960,000

X

- Definition
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current And Noncurrent Liabilities Deferred Revenue
+ References
No definition available.
+ Details

Name: ccel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAndNoncurrentLiabilitiesDeferredRevenue

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Business combination, recognized identifiable assets acquired and liabilities assumed, current assets, prepaid expenses.
+ References
No definition available.
+ Details

Name: ccel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenses

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of assets acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of intangible assets, excluding goodwill, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of inventory recognized as of the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=ccel_BloodBankIncAndTianheStemCellBiotechnologiesIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ccel_BrandMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 75 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes - Summary of Deferred Tax Assets and Liabilities (Detail) - USD ($)

Nov. 30, 2019

Nov. 30, 2018

Tax Assets:

Deferred income (Net of Discounts) $ 6,256,000 $ 5,157,000

Tax over book basis in unconsolidated affiliate 1,224,000 1,214,000

Accrued payroll 82,000 257,000

Reserves and other accruals 1,589,000 868,000

Stock compensation 411,000 330,000

Depreciation and Amortization 450,000 428,000

Transaction costs 18,000 18,000

RSA Buy-out 1,095,000 1,210,000

Total Assets: 11,125,000 9,482,000

Tax liabilities:

Unrealized gains on marketable securities (117,000) (112,000)

NOL's credits, and other carryforward items (282,000) (79,000)

Total Liabilities: (399,000) (191,000)

Deferred Tax Assets, Valuation Allowance (1,646,000) (1,634,000)

Net Deferred Tax Asset $ 9,080,000 $ 7,657,000

X

- Definition
Deferred tax asset from unconsolidated affiliate.
+ References
No definition available.
+ Details

Name: ccel_DeferredTaxAssetFromUnconsolidatedAffiliate

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Deferred Tax Assets Liabilities Tax Credit Carryforwards And Net Operating Losses
+ References
No definition available.
+ Details

Name: ccel_DeferredTaxAssetsLiabilitiesTaxCreditCarryforwardsAndNetOperatingLosses

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Deferred tax assets tax deferred expense depreciation and amortization.
+ References
No definition available.
+ Details

Name: ccel_DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Deferred tax assets tax revenue sharing agreements buy out.
+ References
No definition available.
+ Details

Name: ccel_DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Tax Assets [Abstract]
+ References
No definition available.
+ Details

Name: ccel_TaxAssetsAbstract

Namespace Prefix: ccel_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tax liabilities.
+ References
No definition available.
+ Details

Name: ccel_TaxLiabilitiesAbstract

Namespace Prefix: ccel_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(15)(b)(2))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(2))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredIncomeTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsDeferredIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxLiabilitiesInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 76 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Allowance for Doubtful Accounts - Allowance for Doubtful Accounts (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Beginning Balance $ 2,264,848 $ 2,098,991

Bad Debt Expense 767,128 727,483

Write-offs (756,688) (907,263)

Recoveries 308,803 345,637

Ending Balance $ 2,584,091 $ 2,264,848

X

- Definition
Amount of allowance for credit loss on accounts receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase in allowance for credit loss on accounts receivable, from recovery.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of direct write-downs of accounts receivable charged against the allowance.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (reversal of expense) for expected credit loss on accounts receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(5))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 77 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes - Summary of Open Tax Years and Ongoing Tax Examinations in Major Jurisdictions (Detail)
12 Months Ended

Nov. 30, 2019

United States - Federal Income Tax [Member]

Income Tax Contingency [Line Items]

Examinations in Process N/A

United States - Federal Income Tax [Member] | Earliest Tax Year [Member]

Income Tax Contingency [Line Items]

Open Tax Years 2015

United States - Federal Income Tax [Member] | Latest Tax Year [Member]

Income Tax Contingency [Line Items]

Open Tax Years 2018

United States - Various States [Member]

Income Tax Contingency [Line Items]

Examinations in Process N/A

United States - Various States [Member] | Earliest Tax Year [Member]

Income Tax Contingency [Line Items]

Open Tax Years 2013

United States - Various States [Member] | Latest Tax Year [Member]

Income Tax Contingency [Line Items]

Open Tax Years 2018

X

- Definition
Examination in process.
+ References
No definition available.
+ Details

Name: ccel_ExaminationInProcess

Namespace Prefix: ccel_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeTaxContingencyLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tax year that remains open to examination under enacted tax laws, in CCYY format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_OpenTaxYear

Namespace Prefix: us-gaap_

Data Type: us-types:gYearListItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 78 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Acquisition (Tables)
12 Months Ended

Nov. 30, 2019

Business Combinations [Abstract]

Summary of Fair Value of Consideration
The following summarizes the fair value of the consideration of the Acquisition as of the purchase date:

Consideration

Cash
   $ 10,500,000
Cryo-Cell common stock
   3,500,000
Cord blood inventory earnout
   4,698,255


Consideration
   $ 18,698,255


Summary of Preliminary Allocation of Total Purchase Price
The following summarizes the allocation of the total purchase price for the Acquisition:

Accounts receivable
   $ 188,019
Inventory
   16,037,957
Prepaid expenses
   68,867
Property and equipment
   568,407
Other asset—Tianhe capital stock
   308,000
Brand
   31,000
Customer relationships
   960,000


Total identifiable net assets acquired
   18,162,250


Less: Deferred revenue
   (1,405,406 )


Goodwill
   1,941,411


Total
   $ 18,698,255


Schedule of Unaudited Pro Forma Results
The following table provides the Company’s consolidated unaudited pro forma revenues, net income per basic and diluted common share had the results of the acquired businesses’ operations been included in its operations commencing on December 1, 2016, based on available information related to the respective operations. This proforma information presented is not necessarily indicative either of the combined results of operations that actually would have been realized by the Company had the acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results, and does not account for any operation improvements to be made by the Company post-acquisition.

   Twelve months ended
November 30, 2018
Revenue
   $ 31,388,278
Net income (loss)
   ($ 2,658,679 )
Earnings (loss) per share:

Basic
   ($ 0.36 )
Diluted
   ($ 0.36 )

X

- Definition
Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472
+ Details

Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 79 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Share Repurchase Plan
12 Months Ended

Nov. 30, 2019

Equity [Abstract]

Share Repurchase Plan
NOTE 16 –SHARE REPURCHASE PLAN
In December 2011, the Company’s Board of Directors authorized management at its discretion to repurchase up to one million (1,000,000) shares of the Company’s outstanding common stock. On June 6, 2012, the Board of Directors of the Company increased the number of shares of the Company’s outstanding common stock that management is authorized to repurchase to up to three million (3,000,000). On April 8, 2015, the Board of Directors of the Company increased the number of shares of the Company’s outstanding common stock that management is authorized to repurchase to up to six million (6,000,000) shares. On October 6, 2016, the Board of Directors of the Company increased the number of shares of the Company’s outstanding common stock that management is authorized to repurchase to up to eight million (8,000,000) shares. The repurchases must be effectuated through open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule
10b5-1
of the Securities and Exchange Commission or in such other manner as will comply with the provisions of the Securities Exchange Act of 1934.
In March 2018, the Company received notice that shares of the Company’s common stock issued to certain executive officers pursuant to the Company’s 2012 Stock Incentive Plan had purportedly been issued in excess of the shares reserved for issuance under the Plan. The Company established an independent committee of the Board of Directors to review this issue. After completing its investigation, the independent committee determined that certain restricted stock awards and certain performance-based awards were granted in violation of the 2012 Plan (See Note 11). The Company repurchased 292,449 shares that were surrendered.
As of November 30, 2019, the Company had repurchased an aggregate of 6,093,535 shares of the Company’s common stock at an average price of $3.37 per share through open market and privately negotiated transactions. The Company purchased 292,449 and 0 shares of the Company’s common stock during the twelve months ended November 30, 2019 and November 30, 2018, respectively, at an average price of $3.39 per share and $0.00 per share, respectively.
The repurchased shares are held as treasury stock at cost and have been removed from common shares outstanding as of November 30, 2019 and November 30, 2018. As of November 30, 2019, and November 30, 2018, 6,093,535 and 5,801,086 shares, respectively, were held as treasury stock.
Subsequent to the balance sheet date, the Company has not repurchased any additional shares of the Company’s common stock.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-URI http://asc.fasb.org/subtopic&trid=2208821
+ Details

Name: us-gaap_TreasuryStockTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 80 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 82 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Description of Business and Summary of Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total $ 904,053 $ 875,689

Contingent consideration 3,495,057 4,282,975

Fair Value, Measurements, Recurring [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable Securities 904,053

Trading Securities 68,816

Available-for-sale 806,873

Total 904,053 875,689

Contingent consideration 3,495,057 4,282,975

Total 3,495,057 4,282,975

Fair Value, Measurements, Recurring [Member] | Contingent Consideration [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Beginning Balance 4,282,975

Subtractions – Cord:Use earnout (45,000)

Fair value adjustment (742,918)

Ending balance 3,495,057

Level 1 [Member] | Fair Value, Measurements, Recurring [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable Securities 904,053

Trading Securities 68,816

Available-for-sale 806,873

Total 904,053 875,689

Level 3 [Member] | Fair Value, Measurements, Recurring [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Contingent consideration 3,495,057 4,282,975

Total $ 3,495,057 $ 4,282,975

X

- Definition
Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value of financial and nonfinancial obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investment in marketable security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.4)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_MarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in marketable security, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.4)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_TradingSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=ccel_ContingentConsiderationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 83 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Acquisition - Summary of Fair Value of Consideration (Detail) - USD ($)
12 Months Ended

Jun. 11, 2018

Nov. 30, 2018

Nov. 30, 2019

Consideration

Cash $ 10,500,000

Cord blood inventory earnout $ 4,282,975 $ 3,495,057

Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member]

Consideration

Cash $ 10,500,000

Cryo-Cell common stock 3,500,000

Cord blood inventory earnout 4,698,255

Consideration $ 18,698,255

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=ccel_BloodBankIncAndTianheStemCellBiotechnologiesIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 84 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity - Additional Information (Detail) - USD ($)
1 Months Ended 12 Months Ended

May 21, 2018

Mar. 08, 2018

Aug. 30, 2019

May 31, 2012

Dec. 31, 2019

Nov. 30, 2019

Nov. 30, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, Shares 143,409

Weighted average grant date fair value $ 5.02 $ 3.23

Plan modification description and terms The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019

Shares earned paid in cash $ 444,000

Stock compensation, number of shares opted to lump sum cash payment 30,000

David Portnoy [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, Shares 23,636

Shares earned during period 304,946

Number of shares surrendered 157,472

Payments Of Cash In Surrender Of Shares In Share Based Compensation Activities $ 534,917

Mark Portnoy [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, Shares 20,000

Shares earned during period 265,172

Number of shares surrendered 134,977

Payments Of Cash In Surrender Of Shares In Share Based Compensation Activities $ 457,327

Oleg Mikulinksy [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost related to non-vested options 15,000

Oleg Mikulinksy [Member] | Second Amendment Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, Shares 8,000

Share based compensation options fair value $ 18,000 $ 10,000

Shares granted during period 34,349

Optionee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, Shares 1,500

2006 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options granted in violation 75,000

Number of options not ratified 45,000

Number of options ratified 177,770

2006 Plan [Member] | Employee Stock Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock for issuance pursuant to stock options or restricted stock 1,000,000

Option issued 325,000 380,000

Shares issued under stock incentive plan 0

2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock for issuance pursuant to stock options or restricted stock 1,500,000

Shares issued under stock incentive plan 667,479

Options granted in violation 70,270

Number of options not ratified 45,000

Number of options ratified 177,770

2012 Plan [Member] | Employee Stock Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Increase in common stock reserved for issuance 2,500,000

2000 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options granted in violation 77,500

Number of options not ratified 45,000

Number of options ratified 177,770

Selling, General and Administrative Expenses [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation options fair value $ 77,000 $ 62,000

Selling, General and Administrative Expenses [Member] | Performance And Market Based Vesting Condition Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost related to non-vested share-based compensation arrangements granted 172,000

Share based compensation options fair value $ 86,000

Service Based Stock Options [Member] | 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, Shares 763,274 621,365

Service Based Restricted Shares [Member] | 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, Shares 129,729 129,729

Performance Based Options [Member] | 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, Shares 530,851 823,415

Market Based Options [Member] | 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, Shares 116,218 116,240

Service-Based Vesting Condition Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted, Shares 143,409

Service-Based Vesting Condition Options [Member] | 2006 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost related to non-vested share-based compensation arrangements granted $ 519,000

Service-Based Vesting Condition Options [Member] | 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Unrecognized compensation cost related to non-vested share-based compensation arrangements granted $ 519,000

Performance And Market Based Vesting Condition Options [Member] | David Portnoy [Member] | Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares granted during period 47,273

Performance And Market Based Vesting Condition Options [Member] | Mark Portnoy [Member] | Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares granted during period 40,000

Performance And Market Based Vesting Condition Options [Member] | Mark Portnoy [Member] | Share-based Compensation Award, Tranche Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares granted during period 8,000

Performance And Market Based Vesting Condition Options [Member] | Selling, General and Administrative Expenses [Member] | Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation options fair value $ 18,200 $ 144,300

Performance And Market Based Vesting Condition Options [Member] | Selling, General and Administrative Expenses [Member] | Share-based Compensation Award, Tranche Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation options fair value $ 19,200 $ 13,500

Market-Based Vesting Condition Options [Member] | Share-based Compensation Award, Tranche Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares forfeited during period 4,444 2,666

Market-Based Vesting Condition Options [Member] | David Portnoy [Member] | Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares forfeited during period 15,756

Market-Based Vesting Condition Options [Member] | Mark Portnoy [Member] | Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares forfeited during period 13,332

Market-Based Vesting Condition Options [Member] | Selling, General and Administrative Expenses [Member] | Share-based Compensation Award, Tranche Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation options fair value $ 8,000

Performance Shares [Member] | 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Other than options granted in violation 1,129,247

Other than options ratified 776,798

Other than options surrendered 352,449

Payments for surrender of shares $ 1,436,244

Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of share issued to option holder 2,500 63,750

Options exercised $ 5,700 $ 170,925

Stock Option [Member] | Service-Based Vesting Condition Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted-average period 1 year 1 month 27 days

Total fair value of shares vested $ 255,000

Non Qualified Stock Options [Member] | Performance And Market Based Vesting Condition Options [Member] | David Portnoy [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares granted during period 26,243

Non Qualified Stock Options [Member] | Performance And Market Based Vesting Condition Options [Member] | Mark Portnoy [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares granted during period 22,222

X

- Definition
Payments of cash in surrender of shares in share based compensation activity.
+ References
No definition available.
+ Details

Name: ccel_PaymentsOfCashInSurrenderOfSharesInShareBasedCompensationActivities

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Payments of cash in surrender of shares in share based compensation activity.
+ References
No definition available.
+ Details

Name: ccel_PaymentsOfCashInSurrenderOfSharesInShareBasedCompensationActivity

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cash Payments
+ References
No definition available.
+ Details

Name: ccel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCashPayments

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Earned In Period
+ References
No definition available.
+ Details

Name: ccel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Shares Settled For Cash In Period
+ References
No definition available.
+ Details

Name: ccel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesSettledForCashInPeriod

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award number of shares issued but not yet exercised.
+ References
No definition available.
+ Details

Name: ccel_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedButNotYetExercised

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award shares exercised value.
+ References
No definition available.
+ Details

Name: ccel_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExercisedValue

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Share-based compensation arrangement by share-based payment award number of equity instruments other than options granted in violation of plan.
+ References
No definition available.
+ Details

Name: ccel_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfEquityInstrumentsOtherThanOptionsGrantedInViolationOfPlan

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share-based payment award number of equity instruments other than options ratified purview of violation.
+ References
No definition available.
+ Details

Name: ccel_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfEquityInstrumentsOtherThanOptionsRatifiedPurviewOfViolation

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share-based payment award number of equity instruments other than options surrendered purview of violation.
+ References
No definition available.
+ Details

Name: ccel_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfEquityInstrumentsOtherThanOptionsSurrenderedPurviewOfViolation

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share-based payment award number of options granted in violation of plan.
+ References
No definition available.
+ Details

Name: ccel_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfOptionsGrantedInViolationOfPlan

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share-based payment award number of options not ratified purview of violation.
+ References
No definition available.
+ Details

Name: ccel_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfOptionsNotRatifiedPurviewOfViolation

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share-based payment award number of options ratified purview of violation.
+ References
No definition available.
+ Details

Name: ccel_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfOptionsRatifiedPurviewOfViolation

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based compensation arrangement by share-based payment award number of shares surrendered purview of violation.
+ References
No definition available.
+ Details

Name: ccel_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesSurrenderedPurviewOfViolation

Namespace Prefix: ccel_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of additional shares authorized for issuance under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_TitleOfIndividualAxis=ccel_CoCeoOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=ccel_CoCeoTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=ccel_ChiefInformationOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementScenarioAxis=ccel_SecondAmendmentAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=ccel_OptioneeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ccel_TwoThousandSixPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ccel_TwoThousandTwelvePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ccel_TwoThousandPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=ccel_PerformanceAndMarketBasedVestingConditionOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ccel_ServiceBasedStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ccel_ServiceBasedRestrictedSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ccel_PerformanceBasedStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ccel_MarketBasedStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ccel_ServiceBasedVestingConditionOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ccel_PerformanceAndMarketBasedVestingConditionOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ccel_MarketBasedVestingConditionOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=ccel_NonQualifiedStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 85 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Income Taxes - Summary of Income Tax Provision (Benefit) (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Current:

Federal $ 1,637,000 $ 1,467,000

State 769,000 622,000

Foreign 108,000 108,000

Subtotal 2,514,000 2,197,000

Deferred:

Federal (1,106,000) 2,716,000

State (307,000) (441,000)

Subtotal (1,413,000) 2,275,000

Income Tax Expense $ 1,100,641 $ 4,472,504

X

- Definition
Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_CurrentForeignTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 86 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Property and Equipment - Additional Information (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Property, Plant and Equipment [Abstract]

Depreciation expense $ 309,000 $ 241,000

Depreciation amount included in cost of sales $ 195,000 $ 137,000

X

- Definition
Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(2))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSoldDepreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 87 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Note Payable - Summary of Interest Expense on Note Payable (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Interest Expense, Debt [Abstract]

Interest expense on notes payable $ 646,744 $ 589,583

Debt issuance costs 112,642 109,293

Total interest expense $ 759,386 $ 698,876

X

- Definition
Amortization of debt issuance costs.
+ References
No definition available.
+ Details

Name: ccel_AmortizationOfDebtIssuanceCosts

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InterestExpenseDebtAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate amount of interest paid or due on all long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.8)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpenseLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 88 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Intangible Assets - Schedule of Expected Amortization Expenses (Detail) - USD ($)

Nov. 30, 2019

Nov. 30, 2018

Finite-Lived Intangible Assets, Net [Abstract]

2020 $ 67,667

2021 67,667

2022 67,667

2023 67,667

2024 67,667

Thereafter 910,919

Net Intangible Assets $ 1,249,254 $ 1,341,336

X

- Definition
Finite Lived Intangible Assets Amortization Expense Thereafter.
+ References
No definition available.
+ Details

Name: ccel_FiniteLivedIntangibleAssetsAmortizationExpenseThereafter

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 89 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Share Repurchase Plan - Additional Information (Detail) - $ / shares
12 Months Ended

Nov. 30, 2019

Mar. 31, 2018

Nov. 30, 2019

Nov. 30, 2018

Oct. 06, 2016

Apr. 08, 2015

Jun. 06, 2012

Dec. 31, 2011

Equity, Class of Treasury Stock [Line Items]

Number of shares authorized to repurchase 8,000,000 6,000,000 3,000,000 1,000,000

Share repurchase plan open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission

Treasury stock, shares 6,093,535 6,093,535 5,801,086

2012 Stock Incentive Plan [Member]

Equity, Class of Treasury Stock [Line Items]

Number of shares repurchased 292,449

Common Stock [Member]

Equity, Class of Treasury Stock [Line Items]

Treasury stock, shares 6,093,535 6,093,535

Repurchase agreement, purchase price per share $ 3.37 $ 3.39 $ 0.00

Number of shares repurchased 292,449 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EquityClassOfTreasuryStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total cost of shares repurchased divided by the total number of shares repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockAcquiredAverageCostPerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of share repurchase program, including accounting treatment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656
+ Details

Name: us-gaap_TreasuryStockAcquiredRepurchaseAuthorization

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=ccel_TwoThousandTwelveStockIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 90 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity - Fair Value of Options Granted (Detail) - Service-Based Vesting Condition Options [Member]
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Weighted average values:

Expected life 8 years 4 months 24 days 5 years

Measurement Input, Expected Dividend Rate [Member]

Weighted average values:

Expected dividends 0 0

Measurement Input, Price Volatility [Member]

Weighted average values:

Expected dividends 64.02 50.85

Measurement Input, Risk Free Interest Rate [Member]

Weighted average values:

Expected dividends 1.55 2.67

X

- Definition
Fair Value Of Options Weighted Average Values.
+ References
No definition available.
+ Details

Name: ccel_FairValueOfOptionsWeightedAverageValuesAbstract

Namespace Prefix: ccel_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of input used to measure alternative investment.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_AlternativeInvestmentMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=ccel_ServiceBasedVestingConditionOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 91 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

License Agreements - Additional Information (Detail)
12 Months Ended

Nov. 30, 2019

USD ($)

Agreement

Mar. 31, 2018

USD ($)

Mar. 31, 2017

USD ($)

License Agreements [Line Items]

Types of agreements | Agreement 2

LifeCell License and Agreement [Member]

License Agreements [Line Items]

Royalty income since inception of license and royalty agreement $ 9,300,000

Royalty collected since inception of license and royalty agreement 8,400,000

LifeCell License and Agreement [Member] | Accounts Receivable [Member]

License Agreements [Line Items]

Royalties receivable 900,000

LifeCell License and Agreement [Member] | Maximum [Member]

License Agreements [Line Items]

Royalties receivable $ 1,000,000 $ 1,000,000 $ 1,000,000

X

- Definition
License Agreements [Line Items]
+ References
No definition available.
+ Details

Name: ccel_LicenseAgreementsLineItems

Namespace Prefix: ccel_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Royalties Receivables
+ References
No definition available.
+ Details

Name: ccel_RoyaltiesReceivables

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Royalty Collected since Inception of License and Royalty Agreement
+ References
No definition available.
+ Details

Name: ccel_RoyaltyCollectedSinceInceptionOfLicenseAndRoyaltyAgreement

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Royalty Income since Inception of License and Royalty Agreement
+ References
No definition available.
+ Details

Name: ccel_RoyaltyIncomeSinceInceptionOfLicenseAndRoyaltyAgreement

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Types of license agreements.
+ References
No definition available.
+ Details

Name: ccel_TypesOfLicenseAgreements

Namespace Prefix: ccel_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TransactionTypeAxis=ccel_LifecellLicenseAndAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 92 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Retirement Plan - Additional Information (Detail) - USD ($)
12 Months Ended

Nov. 30, 2019

Nov. 30, 2018

Defined Benefit Plan [Abstract]

Amount allows under 401(k) retirement plan 15.00%

Contribution to 401(k) retirement plan $ 205,000 $ 158,000

X

- Definition
Defined contribution plan employer matching contribution amount.
+ References
No definition available.
+ Details

Name: ccel_DefinedContributionPlanEmployerMatchingContributionAmount

Namespace Prefix: ccel_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 93 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

License Agreements
12 Months Ended

Nov. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

License Agreements
NOTE 12—LICENSE AGREEMENTS
The Company enters into two types of licensing agreements and in both types, the Company earns revenue on the initial license fees. Under the technology agreements, the Company earns processing and storage royalties from the affiliates that process in their own facility. Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Company’s facility in Oldsmar, Florida.
Technology Agreements
The Company has entered into a definitive License and Royalty Agreement with LifeCell International Private Limited, formerly Asia Cryo-Cell Private Limited, (“LifeCell”) to establish and market its umbilical cord blood and menstrual stem cell programs in India.
Per the License and Royalty Agreement with Lifecell, there is a $1,000,000 cap on the amount of royalties due to the Company per year and a $10,000,000 cap on the amount of royalties due to the Company for the term of the License and Royalty Agreement. The cap(s) are calculated based on Lifecell’s fiscal year end, March 31
st
. As of the end of the Company’s fiscal years ended November 30, 2019 and November 30, 2018, Lifecell had reached the $1,000,000. Since inception of the License and Royalty Agreement, the Company has recorded $9,300,000 in royalty income due under the terms of the License and Royalty Agreement, of which, Lifecell has paid the Company $8,400,000 as of November 30, 2019. The balance of $900,000 is reflected as Accounts Receivable on the accompanying consolidated balance sheets.
The following table details the processing and storage royalties earned for the technology agreements for fiscal years 2019 and 2018. The initial license fees and processing and storage royalties are reflected in licensee income in the accompanying consolidated statements of comprehensive income (loss).

   For the years ended November 30,
   2019    2018
   License
Fee    Processing
and Storage
Royalties    Total    License
Fee    Processing
and Storage
Royalties    Total
India
   —    1,000,000    1,000,000    —      1,000,000    1,000,000












Total
   $ —    $ 1,000,000    $ 1,000,000    $ —      $ 1,000,000    $ 1,000,000












Marketing Agreements
The Company has definitive license agreements to market the Company’s umbilical cord blood stem cell programs in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and

Pakistan.    `

X

- Definition
The entire disclosure for license agreements.
+ References
No definition available.
+ Details

Name: ccel_LicenseAgreementsTextBlock

Namespace Prefix: ccel_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 94 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Property and Equipment
12 Months Ended

Nov. 30, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment
NOTE 8—PROPERTY AND EQUIPMENT
The major classes of property and equipment are as follows:


2019

2018

Furniture and equipment
   $ 6,568,205    $ 5,905,910
Leasehold improvements
   1,200,934    1,200,934
Computer software – internal use
   1,194,039    1,194,039




   8,963,178    8,300,883
Less: Accumulated Depreciation
   (7,116,711 )    (6,807,482 )




Total Property and Equipment
   $ 1,846,467    $ 1,493,401




Depreciation expense was approximately $309,000 in fiscal 2019 and approximately $241,000 in fiscal 2018 of which approximately $195,000 and $137,000 is included in cost of sales, respectively, in the accompanying consolidated statements of comprehensive income (loss).

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 95 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Statements of Stockholders' Deficit (Parenthetical)
12 Months Ended

Nov. 30, 2019

USD ($)

Statement of Stockholders' Equity [Abstract]

Cumulative Effect on Retained Earnings, Tax $ 94,192

X

- Definition
Amount of the related income tax effect of a cumulative effect on retained earnings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794
+ Details

Name: us-gaap_CumulativeEffectOnRetainedEarningsTax1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 96 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Consolidated Balance Sheets (Parenthetical) - USD ($)

Nov. 30, 2019

Nov. 30, 2018

Accounts receivable, allowance for doubtful accounts $ 2,584,091 $ 2,264,848

Preferred stock, par value $ 0.01 $ 0.01

Preferred stock, shares authorized 500,000 500,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value $ 0.01 $ 0.01

Common stock, shares authorized 20,000,000 20,000,000

Common stock, shares issued 13,598,909 13,596,409

Common stock, shares outstanding 7,510,884 7,800,833

Series A Junior Participating Preferred Stock [Member]

Preferred stock, par value $ 0.01 $ 0.01

Preferred stock, shares authorized 20,000 20,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

X

- Definition
Amount of allowance for credit loss on accounts receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 97 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Intangible Assets
12 Months Ended

Nov. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets
Note 4– Intangible Assets
The Company incurs certain legal and related costs in connection with patent and trademark applications. If a future economic benefit is anticipated from the resulting patent or trademark or an alternate future use is available to the Company, such costs are capitalized and amortized over the expected life of the patent or trademark. The Company’s assessment of future economic benefit involves considerable management judgment. A different conclusion could result in the reduction of the carrying value of these assets.
Intangible assets were as follows as of November 30, 2019 and 2018:

   Useful lives    November 30,
2019    November 30,
2018
Patents

10-20 years
   $ 234,570    $ 234,570
Less: Accumulated amortization
      (35,526 )    (23,663 )
License agreement
   10 years    470,000    470,000
Less: Intangible asset impairment
      (185,000 )    (185,000 )
Less: Accumulated amortization
      (155,194 )    (123,528 )
Customer relationships – Prepacyte
®
CB
   15 years    41,000    41,000
Less: Intangible asset impairment
      (26,267 )    (26,267 )
Less: Accumulated amortization
      (6,329 )    (5,276 )
Brand
   1 year    31,000    31,000
Less: Accumulated amortization
      (31,000 )    (15,500 )
Customer relationships – Cord:Use
   30 years    960,000    960,000
Less: Accumulated amortization
      (48,000 )    (16,000 )




Net Intangible Assets
   $ 1,249,254    $ 1,341,336




Expected amortization related to these intangible assets for each of the next five fiscal years and for periods thereafter is as follows:
Fiscal years ending November 30:

2020
   $ 67,667
2021
   $ 67,667
2022
   $ 67,667
2023
   $ 67,667
2024
   $ 67,667
Thereafter
   $ 910,919


Total
   $ 1,249,254


Amortization expense of intangibles was approximately $92,000 and $76,000 for the twelve months ended November 30, 2019 and November 30, 2018, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 98 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Allowance for Doubtful Accounts (Tables)
12 Months Ended

Nov. 30, 2019

Receivables [Abstract]

Allowance for Doubtful Accounts
The activity in the allowance for doubtful accounts is as follows for the years ended November 30, 2019 and 2018:

December 1, 2017
   $ 2,098,991
Bad Debt Expense
   727,483
Write-offs
   (907,263 )
Recoveries
   345,637


November 30, 2018
   2,264,848
Bad Debt Expense
   767,128
Write-offs
   (756,688 )
Recoveries
   308,803


November 30, 2019
   $ 2,584,091

X

- Definition
Tabular disclosure of allowance for credit loss on financing receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11B
-URI http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447
+ Details

Name: us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 99 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Stockholders' Equity (Tables)
12 Months Ended

Nov. 30, 2019

Fair Value of Options Granted
Variables used to determine the fair value of the options granted for the years ended November 30, 2019 and November 30, 2018 are as follows:

   2019 2018
Weighted average values:

Expected dividends
   0% 0%
Expected volatility
   64.02% 50.85%
Risk free interest rate
   1.55% 2.67%
Expected life
   8.4 years 5.0 years

Service-Based Vesting Condition Options [Member]

Stock Option Activity
Stock option activity for options with only service-based vesting conditions for the year ended November 30, 2019, was as follows:

   Options    Weighted
Average
Exercise
Price    Weighted
Average
Remaining
Contractual
Term (Years)    Aggregate
Intrinsic
Value
Outstanding at November 30, 2018
   1,001,365    $ 2.77    3.97    $ 4,580,967
Granted
   143,409    7.55    0    4,851
Exercised
   (2,500 )    2.28    0    14,175
Expired/forfeited
   (52,500 )    4.82    0    143,450



Outstanding at November 30, 2019
   1,089,774    3.30    3.91    $ 4,648,111




Exercisable at November 30, 2019
   964,540    2.75    3.33    $ 4,644,277




Significant Option Groups Exercisable Option and its Price and Contractual Life
Significant option groups outstanding and exercisable at November 30, 2019 and related price and contractual life information are as follows:

   Outstanding    Exercisable
      Weighted
Average
      Remaining    Weighted       Weighted
Range of Exercise Prices
   Outstanding    Contractual
Life (Years)    Average
Exercise Price    Outstanding    Average
Exercise Price
$1.01 to $2.00
   422,500    2.10    $ 1.73    422,500    $ 1.73
$2.01 to $3.00
   265,000    2.11    $ 2.72    265,000    $ 2.72
$3.01 to $4.00
   204,729    6.23    $ 3.14    204,729    $ 3.14
$6.01 to $7.00
   2,500    4.65    $ 6.50    1,667    $ 6.50
$7.01 to $8.00
   195,045    7.84    $ 7.63    70,644    $ 7.67







   1,089,774    3.91    $ 3.30    964,540    $ 2.75








Summary of Non-Vested Options
A summary of the status of the Company’s
non-vested
options as of November 30, 2019, and changes during the fiscal year then ended, is presented below:

      Weighted Average
      Grant-Date
   Options    Fair Value
Non-vested
at November 30, 2018
   40,254    $ 3.06
Granted
   143,409    5.02
Vested
   (58,429 )    4.36
Forfeited
   0    0



Non-vested
at November 30, 2019
   125,234    $ 4.70




X

- Definition
Tabular disclosure of the changes in outstanding nonvested shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=ccel_ServiceBasedVestingConditionOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)					1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 01, 2018 USD ($)	Jun. 01, 2017 USD ($)	Feb. 01, 2012 USD ($)	Oct. 10, 2001 USD ($) shares	Dec. 31, 2005 USD ($)	Feb. 28, 2019 USD ($)	May 31, 2019 USD ($)	Nov. 30, 2019 USD ($) CompensationPlan Unit shares	Nov. 30, 2018 USD ($)
Debt Securities, Available-for-sale [Line Items]
ASC 606 adoption adjustment, net of tax								$ 253,447
Cumulative effect on retained earnings, tax								94,192
Deferred revenue								32,508,511
Deferred revenue current								8,875,138
Warranty payment		$ 100,000	$ 75,000		$ 50,000
Offset personal expenses		10,000
Commission paid								35,300
Capitalized contract acquisition costs, net of amortization expense	$ 329,231
Cumulative amortization expense	66,533
Additional capitalized contract acquisition costs, net of amortization expense								87,518
Provisions for interest or penalties related to uncertain tax positions								0	$ 0
Uncertain tax provisions								0	0
Impairment on long lived assets								$ 0	0
Number of employee stock based compensation plan \| CompensationPlan								2
Unrealized holding gains, trading securities									28,000
Cumulative-effect adjustment from accumulated other comprehensive income to retained earnings						$ 341,000
Unrealized holding gain (losses), marketable securities								$ 28,000	300,000
Payment warranty					$ 50,000
Increased payment warranty		$ 100,000	75,000
Additional payment warranty			$ 10,000
Stock compensation expense reversed								$ 444,000
Stock compensation, number of shares opted to lump sum cash payment \| shares								30,000
Impairment charges							$ 2,332,763	$ 2,332,763
Concentration risk related to supplier								The Company depends on one supplier for the source of its collection kits
Advertising cost included in selling, general and administrative expenses								$ 981,448	986,664
Stock-based option compensation expense								$ 398,000	$ 478,000
Deferred revenue recognition period								12 months
Employee Stock Incentive Plan [Member]
Debt Securities, Available-for-sale [Line Items]
Number of outstanding options excluded from computation of diluted earnings per share \| shares								70,136
Saneron [Member]
Debt Securities, Available-for-sale [Line Items]
Ownership interest								33.00%	33.00%
Saneron [Member] \| CCEL Bio-Therapies, Inc. [Member]
Debt Securities, Available-for-sale [Line Items]
Non-Controlling interest after merger				43.42%
Saneron Therapeutics, Inc. [Member] \| CCEL Bio-Therapies, Inc. [Member]
Debt Securities, Available-for-sale [Line Items]
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary \| shares				260,000
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary				$ 1,924,000
Saneron Therapeutics, Inc. [Member] \| Stem Cell Preservation Technologies, Inc. [Member]
Debt Securities, Available-for-sale [Line Items]
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary \| shares				195,000
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary				$ 3,900
Accounting Standards Update 2014-09 [Member]
Debt Securities, Available-for-sale [Line Items]
Incremental contract acquisition cost	329,231
Reversed incremental acquisition cost	18,408
ASC 606 adoption adjustment, net of tax	253,447
Cumulative effect on retained earnings, tax	$ 94,192
Option One [Member]
Debt Securities, Available-for-sale [Line Items]
Contracted storage amortization period								21 years
Option Two [Member]
Debt Securities, Available-for-sale [Line Items]
Contracted storage amortization period								1 year
Option Three [Member]
Debt Securities, Available-for-sale [Line Items]
Contracted storage amortization period								life-time
Contracted storage amortization description								The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue
Accounts Receivables [Member]
Debt Securities, Available-for-sale [Line Items]
Period of doubtful for accounts receivable due from client								30 days
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] \| Duke University [Member]
Debt Securities, Available-for-sale [Line Items]
Inventory, in units \| Unit								6,000
Number of units, per month \| Unit								12
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] \| Duke University [Member] \| Maximum [Member]
Debt Securities, Available-for-sale [Line Items]
Inventory, in units \| Unit								144

Property and Equipment - Summary of Major Classes of Propery and Equipment (Detail) - USD ($)	Nov. 30, 2019	Nov. 30, 2018
Property, Plant and Equipment [Line Items]
Property and Equipment	$ 8,963,178	$ 8,300,883
Less: Accumulated Depreciation	(7,116,711)	(6,807,482)
Total Property and Equipment	1,846,467	1,493,401
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment	6,568,205	5,905,910
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment	1,200,934	1,200,934
Computer Software - internal use [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment	$ 1,194,039	$ 1,194,039

Acquisition - Additional Information (Detail) - USD ($)		12 Months Ended
Acquisition - Additional Information (Detail) - USD ($)	Jun. 11, 2018	Nov. 30, 2019	Nov. 30, 2018
Business Acquisition [Line Items]
Payment under asset purchase agreement			$ 10,500,000
Common stock par value		$ 0.01	$ 0.01
Brand [Member]
Business Acquisition [Line Items]
Useful lives		1 year
Customer Relationships [Member]
Business Acquisition [Line Items]
Useful lives		15 years
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member]
Business Acquisition [Line Items]
Aggregate consideration payable at closing under the Purchase Agreement	$ 14,000,000
Payment under asset purchase agreement	$ 10,500,000
Shares issued under asset purchase agreement	465,426
Common stock par value	$ 0.01
Sale of stock price per share	$ 7.52
Percentage of earn out to be paid from gross revenues	75.00%
Common stock deliver	$ 200,000
Common stock value	5,000,000
Costs associated with the acquisition	$ 580,000
Discount rate	19.00%
Long-term sustainable growth rate	3.00%
Market royalty rate	1.00%
Fair value of inventory	$ 16,037,957
Fair value of accounts receivable	188,019
Fair value of prepaid expenses	68,867
Short term deferred revenue	330,508
Long term deferred revenue	1,074,898
Amount of earn out to be paid from sale of public cord blood inventory	$ 500,000
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] \| Brand [Member]
Business Acquisition [Line Items]
Useful lives	1 year
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Useful lives	30 years

Inventory - Additional Information (Detail) - USD ($)	6 Months Ended	12 Months Ended
Inventory - Additional Information (Detail) - USD ($)	May 31, 2019	Nov. 30, 2019
Other Asset Impairment Charges	$ 2,332,763	$ 2,332,763

Notes Payable - Summary of Future Principal Payments under Note Payable Obligation (Detail) - USD ($)	Nov. 30, 2019	Nov. 30, 2018
Debt Disclosure [Abstract]
2020	$ 3,100,000
2021	3,100,000
2022	2,908,433
Total	$ 9,108,433	$ 13,208,433

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Finite-Lived Intangible Assets [Line Items]
Net Intangible Assets	$ 1,249,254	$ 1,341,336
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	234,570	234,570
Less: Accumulated amortization	$ (35,526)	(23,663)
Patents [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	10 years
Patents [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	20 years
License Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	10 years
Finite lived intangible assets, gross	$ 470,000	470,000
Less: Intangible asset impairment	(185,000)	(185,000)
Less: Accumulated amortization	$ (155,194)	(123,528)
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	15 years
Finite lived intangible assets, gross	$ 41,000	41,000
Less: Intangible asset impairment	(26,267)	(26,267)
Less: Accumulated amortization	$ (6,329)	(5,276)
Brand [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	1 year
Finite lived intangible assets, gross	$ 31,000	31,000
Less: Accumulated amortization	$ (31,000)	(15,500)
Customer Relationships One [Member]
Finite-Lived Intangible Assets [Line Items]
Useful lives	30 years
Finite lived intangible assets, gross	$ 960,000	960,000
Less: Accumulated amortization	$ (48,000)	$ (16,000)

Revenue Sharing Agreements ("RSAs") - Additional Information (Detail)	12 Months Ended
	Nov. 30, 2019 USD ($) Store	Nov. 30, 2018 USD ($)	Nov. 30, 2008	May 31, 2001 USD ($) Store	Feb. 09, 1999 USD ($) Store
Revenue Sharing Agreement [Line Items]
Total payments to RSA holders	$ 832,587	$ 671,245
Interest expense	950,300	864,676
Interest expense	1,703,446	1,546,900
Revenue Sharing Agreement ("RSA") [Member]
Revenue Sharing Agreement [Line Items]
Interest expense	909,765	798,292
Illinois [Member]
Revenue Sharing Agreement [Line Items]
Revenue sharing agreement price	$ 1,000,000
Number of storage spaces \| Store	33,000
Investors share in net storage revenues	50.00%
Billing and collection expense percentage	50.00%
Illinois and Its Contiguous States [Member]
Revenue Sharing Agreement [Line Items]
Percentage of 50% net storage revenue generated from specimens paid	75.00%
Texas [Member]
Revenue Sharing Agreement [Line Items]
Revenue sharing agreement price				$ 750,000
Number of storage spaces \| Store				33,000
Investors share in net storage revenues				37.50%
Variable interest entity, qualitative or quantitative information, ownership percentage			50.00%
Interest expense	$ 944,060	$ 848,024
Florida [Member]
Revenue Sharing Agreement [Line Items]
Revenue sharing agreement price					$ 1,000,000
Number of storage spaces \| Store					33,000

License Agreements - Summary of License Fees Earned (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
License Agreements [Line Items]
Revenue	$ 31,816,571	$ 29,218,490
Processing and Storage Royalties [Member]
License Agreements [Line Items]
Revenue	1,000,000	1,000,000
License and royalty income [Member]
License Agreements [Line Items]
Revenue	1,000,000	1,000,000
India [Member] \| Processing and Storage Royalties [Member]
License Agreements [Line Items]
Revenue	1,000,000	1,000,000
India [Member] \| License and royalty income [Member]
License Agreements [Line Items]
Revenue	$ 1,000,000	$ 1,000,000

Consolidated Statements of Stockholders' Deficit - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Other Comprehensive Income [Member]	Accumulated Deficit [Member]
Beginning balance at Nov. 30, 2017	$ (12,502,896)	$ 128,995	$ 31,373,048	$ (19,571,113)	$ 40,865	$ (24,474,691)
Beginning balance, shares at Nov. 30, 2017		12,899,517
Common stock issued	3,670,925	$ 6,969	3,663,956
Common stock issued, shares		696,892
Compensatory element of stock options	478,378		478,378
Unrealized loss on available for sale securities	300,119				300,119
Net income (loss)	(854,824)					(854,824)
Ending balance at Nov. 30, 2018	(8,908,298)	$ 135,964	35,515,382	(19,571,113)	340,984	(25,329,515)
Ending balance, shares at Nov. 30, 2018		13,596,409
Common stock issued	5,700	$ 25	5,675
Common stock issued, shares		2,500
Compensatory element of stock options	397,770		397,770
Cumulative-effect adjustment due to the adoption of ASU 2016-01 \| Accounting Standards Update 2016-01 [Member]					$ (340,984)	340,984
Unrealized loss on available for sale securities	0
ASC 606 adoption adjustment, net of tax	253,447					253,447
Treasury Stock	(992,244)			(992,244)
Net income (loss)	2,290,774					2,290,774
Ending balance at Nov. 30, 2019	$ (6,952,851)	$ 135,989	$ 35,918,827	$ (20,563,357)		$ (22,444,310)
Ending balance, shares at Nov. 30, 2019		13,598,909

Consolidated Balance Sheets - USD ($)	Nov. 30, 2019	Nov. 30, 2018
Current Assets
Cash and cash equivalents	$ 6,541,037	$ 6,040,033
Marketable securities	904,053	875,689
Accounts receivable (net of allowance for doubtful accounts of $2,584,091 and $2,264,848, respectively)	6,097,331	5,867,335
Prepaid expenses	500,260	461,815
Inventory, current portion	1,084,533	1,260,557
Other current assets	260,397	254,465
Total current assets	15,387,611	14,759,894
Property and Equipment-net	1,846,467	1,493,401
Other Assets
Intangible assets, net	1,249,254	1,341,336
Inventory, net of current portion	12,646,000	14,775,316
Goodwill	1,941,411	1,941,411
Deferred tax assets	9,079,994	7,656,897
Deposits and other assets, net	427,423	113,888
Total other assets	25,652,082	26,136,848
Total assets	42,886,160	42,390,143
Current Liabilities
Accounts payable	1,369,111	1,261,653
Accrued expenses	2,085,180	2,702,788
Current portion of note payable	3,100,000	3,100,000
Deferred revenue	8,875,138	8,365,284
Total current liabilities	15,429,429	15,429,725
Other Liabilities
Deferred revenue, net of current portion	23,633,373	20,317,231
Contingent Consideration	3,495,057	4,282,975
Note payable, net of current portion and debt issuance costs	5,856,152	9,843,510
Long-term liability - revenue sharing agreements	1,425,000	1,425,000
Total other liabilities	34,409,582	35,868,716
Total liabilities	49,839,011	51,298,441
Commitments and contingencies (Note 13)
Stockholders' Deficit
Preferred stock
Common stock ($.01 par value, 20,000,000 authorized; 13,598,909 issued and 7,510,884 outstanding as of November 30, 2019 and 13,596,409 issued and 7,800,833 outstanding as of November 30, 2018)	135,989	135,964
Additional paid-in capital	35,918,827	35,515,382
Treasury stock, at cost	(20,563,357)	(19,571,113)
Accumulated other comprehensive income		340,984
Accumulated deficit	(22,444,310)	(25,329,515)
Total stockholders' deficit	(6,952,851)	(8,908,298)
Total liabilities and stockholders' deficit	42,886,160	42,390,143
Series A Junior Participating Preferred Stock [Member]
Stockholders' Deficit
Preferred stock
Tianhe Stem Cell Biotechnologies Inc [Member]
Other Assets
Investment	$ 308,000	$ 308,000

Description of Business and Summary of Significant Accounting Policies - Calculation of Basic and Diluted Net (loss) Income per Common Share (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Denominator:
Weighted-average shares outstanding-basic	7,794,828	7,463,051
Dilutive common shares issuable upon exercise of stock options	617,586
Weighted-average shares-diluted	8,412,414	7,463,051
Income(Loss) per share:
Basic	$ 0.29	$ (0.11)
Diluted	$ 0.27	$ (0.11)
Net Income (Loss)	$ 2,290,774	$ (854,824)

Acquisition - Summary of Preliminary Allocation of Total Purchase Price (Detail) - USD ($)	Nov. 30, 2019	Nov. 30, 2018	Jun. 11, 2018
Business Acquisition [Line Items]
Goodwill	$ 1,941,411	$ 1,941,411
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member]
Business Acquisition [Line Items]
Accounts receivable			$ 188,019
Inventory			16,037,957
Prepaid expenses			68,867
Property and equipment			568,407
Other asset - Tianhe capital stock			308,000
Total identifiable net assets acquired			18,162,250
Less: Deferred revenue			(1,405,406)
Goodwill			1,941,411
Total			18,698,255
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] \| Brand [Member]
Business Acquisition [Line Items]
Intangible assets			31,000
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets			$ 960,000

Income Taxes - Summary of Deferred Tax Assets and Liabilities (Detail) - USD ($)	Nov. 30, 2019	Nov. 30, 2018
Tax Assets:
Deferred income (Net of Discounts)	$ 6,256,000	$ 5,157,000
Tax over book basis in unconsolidated affiliate	1,224,000	1,214,000
Accrued payroll	82,000	257,000
Reserves and other accruals	1,589,000	868,000
Stock compensation	411,000	330,000
Depreciation and Amortization	450,000	428,000
Transaction costs	18,000	18,000
RSA Buy-out	1,095,000	1,210,000
Total Assets:	11,125,000	9,482,000
Tax liabilities:
Unrealized gains on marketable securities	(117,000)	(112,000)
NOL's credits, and other carryforward items	(282,000)	(79,000)
Total Liabilities:	(399,000)	(191,000)
Deferred Tax Assets, Valuation Allowance	(1,646,000)	(1,634,000)
Net Deferred Tax Asset	$ 9,080,000	$ 7,657,000

Allowance for Doubtful Accounts - Allowance for Doubtful Accounts (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Beginning Balance	$ 2,264,848	$ 2,098,991
Bad Debt Expense	767,128	727,483
Write-offs	(756,688)	(907,263)
Recoveries	308,803	345,637
Ending Balance	$ 2,584,091	$ 2,264,848

Income Taxes - Summary of Open Tax Years and Ongoing Tax Examinations in Major Jurisdictions (Detail)	12 Months Ended
	Nov. 30, 2019
United States - Federal Income Tax [Member]
Income Tax Contingency [Line Items]
Examinations in Process	N/A
United States - Federal Income Tax [Member] \| Earliest Tax Year [Member]
Income Tax Contingency [Line Items]
Open Tax Years	2015
United States - Federal Income Tax [Member] \| Latest Tax Year [Member]
Income Tax Contingency [Line Items]
Open Tax Years	2018
United States - Various States [Member]
Income Tax Contingency [Line Items]
Examinations in Process	N/A
United States - Various States [Member] \| Earliest Tax Year [Member]
Income Tax Contingency [Line Items]
Open Tax Years	2013
United States - Various States [Member] \| Latest Tax Year [Member]
Income Tax Contingency [Line Items]
Open Tax Years	2018

Description of Business and Summary of Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 904,053	$ 875,689
Contingent consideration	3,495,057	4,282,975
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities	904,053
Trading Securities		68,816
Available-for-sale		806,873
Total	904,053	875,689
Contingent consideration	3,495,057	4,282,975
Total	3,495,057	4,282,975
Fair Value, Measurements, Recurring [Member] \| Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	4,282,975
Subtractions – Cord:Use earnout	(45,000)
Fair value adjustment	(742,918)
Ending balance	3,495,057
Level 1 [Member] \| Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities	904,053
Trading Securities		68,816
Available-for-sale		806,873
Total	904,053	875,689
Level 3 [Member] \| Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	3,495,057	4,282,975
Total	$ 3,495,057	$ 4,282,975

Stockholders' Equity - Additional Information (Detail) - USD ($)			1 Months Ended		12 Months Ended
	May 21, 2018	Mar. 08, 2018	Aug. 30, 2019	May 31, 2012	Dec. 31, 2019	Nov. 30, 2019	Nov. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares						143,409
Weighted average grant date fair value						$ 5.02	$ 3.23
Plan modification description and terms						The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019
Shares earned paid in cash							$ 444,000
Stock compensation, number of shares opted to lump sum cash payment						30,000
David Portnoy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares		23,636
Shares earned during period						304,946
Number of shares surrendered						157,472
Payments Of Cash In Surrender Of Shares In Share Based Compensation Activities						$ 534,917
Mark Portnoy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares		20,000
Shares earned during period						265,172
Number of shares surrendered						134,977
Payments Of Cash In Surrender Of Shares In Share Based Compensation Activities						$ 457,327
Oleg Mikulinksy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested options						15,000
Oleg Mikulinksy [Member] \| Second Amendment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares	8,000
Share based compensation options fair value						$ 18,000	$ 10,000
Shares granted during period						34,349
Optionee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares						1,500
2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in violation						75,000
Number of options not ratified						45,000
Number of options ratified						177,770
2006 Plan [Member] \| Employee Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock for issuance pursuant to stock options or restricted stock						1,000,000
Option issued						325,000	380,000
Shares issued under stock incentive plan						0
2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock for issuance pursuant to stock options or restricted stock						1,500,000
Shares issued under stock incentive plan						667,479
Options granted in violation						70,270
Number of options not ratified						45,000
Number of options ratified						177,770
2012 Plan [Member] \| Employee Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in common stock reserved for issuance				2,500,000
2000 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in violation						77,500
Number of options not ratified						45,000
Number of options ratified						177,770
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation options fair value						$ 77,000	$ 62,000
Selling, General and Administrative Expenses [Member] \| Performance And Market Based Vesting Condition Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements granted						172,000
Share based compensation options fair value						$ 86,000
Service Based Stock Options [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares						763,274	621,365
Service Based Restricted Shares [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares						129,729	129,729
Performance Based Options [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares						530,851	823,415
Market Based Options [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares						116,218	116,240
Service-Based Vesting Condition Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares						143,409
Service-Based Vesting Condition Options [Member] \| 2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements granted						$ 519,000
Service-Based Vesting Condition Options [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements granted						$ 519,000
Performance And Market Based Vesting Condition Options [Member] \| David Portnoy [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during period							47,273
Performance And Market Based Vesting Condition Options [Member] \| Mark Portnoy [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during period							40,000
Performance And Market Based Vesting Condition Options [Member] \| Mark Portnoy [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during period						8,000
Performance And Market Based Vesting Condition Options [Member] \| Selling, General and Administrative Expenses [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation options fair value						$ 18,200	$ 144,300
Performance And Market Based Vesting Condition Options [Member] \| Selling, General and Administrative Expenses [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation options fair value						$ 19,200	$ 13,500
Market-Based Vesting Condition Options [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares forfeited during period						4,444	2,666
Market-Based Vesting Condition Options [Member] \| David Portnoy [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares forfeited during period						15,756
Market-Based Vesting Condition Options [Member] \| Mark Portnoy [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares forfeited during period							13,332
Market-Based Vesting Condition Options [Member] \| Selling, General and Administrative Expenses [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation options fair value						$ 8,000
Performance Shares [Member] \| 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Other than options granted in violation						1,129,247
Other than options ratified					776,798
Other than options surrendered					352,449
Payments for surrender of shares					$ 1,436,244
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share issued to option holder						2,500	63,750
Options exercised						$ 5,700	$ 170,925
Stock Option [Member] \| Service-Based Vesting Condition Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period						1 year 1 month 27 days
Total fair value of shares vested						$ 255,000
Non Qualified Stock Options [Member] \| Performance And Market Based Vesting Condition Options [Member] \| David Portnoy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during period			26,243
Non Qualified Stock Options [Member] \| Performance And Market Based Vesting Condition Options [Member] \| Mark Portnoy [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted during period			22,222

Income Taxes - Summary of Income Tax Provision (Benefit) (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Current:
Federal	$ 1,637,000	$ 1,467,000
State	769,000	622,000
Foreign	108,000	108,000
Subtotal	2,514,000	2,197,000
Deferred:
Federal	(1,106,000)	2,716,000
State	(307,000)	(441,000)
Subtotal	(1,413,000)	2,275,000
Income Tax Expense	$ 1,100,641	$ 4,472,504

Property and Equipment - Additional Information (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 309,000	$ 241,000
Depreciation amount included in cost of sales	$ 195,000	$ 137,000

Note Payable - Summary of Interest Expense on Note Payable (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Interest Expense, Debt [Abstract]
Interest expense on notes payable	$ 646,744	$ 589,583
Debt issuance costs	112,642	109,293
Total interest expense	$ 759,386	$ 698,876

Intangible Assets - Schedule of Expected Amortization Expenses (Detail) - USD ($)	Nov. 30, 2019	Nov. 30, 2018
Finite-Lived Intangible Assets, Net [Abstract]
2020	$ 67,667
2021	67,667
2022	67,667
2023	67,667
2024	67,667
Thereafter	910,919
Net Intangible Assets	$ 1,249,254	$ 1,341,336

Share Repurchase Plan - Additional Information (Detail) - $ / shares			12 Months Ended
	Nov. 30, 2019	Mar. 31, 2018	Nov. 30, 2019	Nov. 30, 2018	Oct. 06, 2016	Apr. 08, 2015	Jun. 06, 2012	Dec. 31, 2011
Equity, Class of Treasury Stock [Line Items]
Number of shares authorized to repurchase					8,000,000	6,000,000	3,000,000	1,000,000
Share repurchase plan			open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
Treasury stock, shares	6,093,535		6,093,535	5,801,086
2012 Stock Incentive Plan [Member]
Equity, Class of Treasury Stock [Line Items]
Number of shares repurchased		292,449
Common Stock [Member]
Equity, Class of Treasury Stock [Line Items]
Treasury stock, shares	6,093,535		6,093,535
Repurchase agreement, purchase price per share	$ 3.37		$ 3.39	$ 0.00
Number of shares repurchased			292,449	0

Stockholders' Equity - Fair Value of Options Granted (Detail) - Service-Based Vesting Condition Options [Member]	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Weighted average values:
Expected life	8 years 4 months 24 days	5 years
Measurement Input, Expected Dividend Rate [Member]
Weighted average values:
Expected dividends	0	0
Measurement Input, Price Volatility [Member]
Weighted average values:
Expected dividends	64.02	50.85
Measurement Input, Risk Free Interest Rate [Member]
Weighted average values:
Expected dividends	1.55	2.67

License Agreements - Additional Information (Detail)	12 Months Ended
License Agreements - Additional Information (Detail)	Nov. 30, 2019 USD ($) Agreement	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)
License Agreements [Line Items]
Types of agreements \| Agreement	2
LifeCell License and Agreement [Member]
License Agreements [Line Items]
Royalty income since inception of license and royalty agreement	$ 9,300,000
Royalty collected since inception of license and royalty agreement	8,400,000
LifeCell License and Agreement [Member] \| Accounts Receivable [Member]
License Agreements [Line Items]
Royalties receivable	900,000
LifeCell License and Agreement [Member] \| Maximum [Member]
License Agreements [Line Items]
Royalties receivable	$ 1,000,000	$ 1,000,000	$ 1,000,000

Retirement Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Defined Benefit Plan [Abstract]
Amount allows under 401(k) retirement plan	15.00%
Contribution to 401(k) retirement plan	$ 205,000	$ 158,000

Consolidated Statements of Stockholders' Deficit (Parenthetical)	12 Months Ended
	Nov. 30, 2019 USD ($)
Statement of Stockholders' Equity [Abstract]
Cumulative Effect on Retained Earnings, Tax	$ 94,192

Consolidated Balance Sheets (Parenthetical) - USD ($)	Nov. 30, 2019	Nov. 30, 2018
Accounts receivable, allowance for doubtful accounts	$ 2,584,091	$ 2,264,848
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	13,598,909	13,596,409
Common stock, shares outstanding	7,510,884	7,800,833
Series A Junior Participating Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0